[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n* Acrokeratosis paraneoplastic\nNote: The term \"paraneoplastic\" refers to a condition that is associated with a specific type of cancer, in this case, acrokeratosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastic is a synonym for Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastic is a synonym for Acrokeratosis paraneoplastica."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\nWeaver syndrome and Sotos syndrome are both rare genetic disorders that affect the development of the brain and nervous system. While they share some similarities, they are distinct conditions with different causes and clinical features.\nSimilarities between Weaver syndrome and Sotos syndrome include:\n* Both disorders are caused by mutations in genes that are involved in the development and maintenance of the brain and nervous system.\n* Both disorders result in intellectual disability, developmental delays, and a variety of physical abnormalities.\n* Both disorders can affect the growth and development of the brain, leading to changes in brain structure and function.\nHowever, there are also some key differences between the two disorders:\n* Weaver syndrome is caused by mutations in the PRC1 gene, which is involved in the regulation of gene expression during neural development. Sotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which is involved in the regulation of chromatin structure and gene expression.\n* Weaver syndrome typically presents with more severe cognitive impairments and developmental delays compared to Sotos syndrome.\n* Weaver syndrome can also cause distinctive facial features, such as a narrow nasal bridge, a short philtrum, and a small jaw, which are not typically seen in Sotos syndrome.\n* Sotos syndrome can also cause distinctive physical features, such as a large head, coarse facial features, and short stature, which are not typically seen in Weaver syndrome.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct genetic disorders with different causes and clinical features. It is important to consider the specific symptoms and characteristics of each disorder when evaluating a patient for either condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both rare genetic disorders affecting brain and nervous system development.\n2. Weaver syndrome is caused by mutations in the PRC1 gene.\n3. Sotos syndrome is caused by mutations in the NSD1 gene.\n4. Weaver syndrome generally presents with more severe cognitive impairments and developmental delays than Sotos syndrome.\n5. Some distinctive facial features such as a narrow nasal bridge, a short philtrum, and a small jaw are associated with Weaver syndrome, while these are not typically seen in Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both rare genetic disorders affecting brain and nervous system development.",
      "Weaver syndrome is caused by mutations in the PRC1 gene.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Weaver syndrome generally presents with more severe cognitive impairments and developmental delays than Sotos syndrome.",
      "Some distinctive facial features such as a narrow nasal bridge, a short philtrum, and a small jaw are associated with Weaver syndrome, while these are not typically seen in Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PRC1 gene.\n3. TRUE\n4. UNKNOWN: While Weaver syndrome and Sotos syndrome both involve developmental issues, the severity can vary widely among individuals, and making general comparisons between the two syndromes on severity is not straightforward without specific studies or data to back up such a claim.\n5. FALSE [correction]: Some of the distinctive facial features such as a broad forehead and a prominent jaw are associated with Sotos syndrome. Facial features associated with Weaver syndrome include a broad face and a round chin, among others. The facial characteristics described in the statement are not specifically associated with Weaver syndrome nor are they typically differentiated from Sotos syndrome in the manner described.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Certainly! JASPAR is a popular database of transcription factor binding site (TFBS) profiles, which provide information on the DNA sequences that are recognized and bound by transcription factors (TFs). Here are the releases of the JASPAR database:\n1. JASPAR Release 1: This was the first release of the database, published in 2002. It contained a limited number of TFBS profiles for 15 TFs.\n2. JASPAR Release 2: Released in 2004, this update added more TFs and TFBS profiles, as well as improved the accuracy of the predictions.\n3. JASPAR Release 3: Published in 2007, this version included more than 100 TFs and over 1,000 TFBS profiles. It also introduced a new algorithm for predicting TFBSs.\n4. JASPAR Release 4: Released in 2010, this update expanded the number of TFs to over 150 and added more than 2,000 new TFBS profiles. It also improved the accuracy of the predictions using a new training set.\n5. JASPAR Release 5: Published in 2013, this version included over 200 TFs and more than 3,000 TFBS profiles. It also introduced a new feature for predicting the strength of TFBSs.\n6. JASPAR Release 6: Released in 2016, this update added more than 100 new TFs and over 1,000 new TFBS profiles. It also improved the accuracy of the predictions using a larger training set.\n7. JASPAR Release 7: Published in 2020, this version includes over 300 TFs and over 4,000 TFBS profiles. It also introduces a new algorithm for predicting TFBSs and improves the accuracy of the predictions using a larger and more diverse training set.\nThese are the releases of the JASPAR database, with each release adding more TFs, TFBS profiles, and improving the accuracy of the predictions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first release of the JASPAR database was published in 2002 with TFBS profiles for 15 TFs.\n2. JASPAR Release 2 was released in 2004 with additional TFs and TFBS profiles.\n3. By JASPAR Release 3 in 2007, the database contained more than 100 TFs and over 1,000 TFBS profiles.\n4. JASPAR Release 4 in 2010 expanded the number of TFs to over 150 and added over 2,000 new TFBS profiles.\n5. JASPAR Release 7 was published in 2020 and includes over 300 TFs and over 4,000 TFBS profiles.",
    "llama-2-7b-chat-hf_fact": [
      "The first release of the JASPAR database was published in 2002 with TFBS profiles for 15 TFs.",
      "JASPAR Release 2 was released in 2004 with additional TFs and TFBS profiles.",
      "By JASPAR Release 3 in 2007, the database contained more than 100 TFs and over 1,000 TFBS profiles.",
      "JASPAR Release 4 in 2010 expanded the number of TFs to over 150 and added over 2,000 new TFBS profiles.",
      "JASPAR Release 7 was published in 2020 and includes over 300 TFs and over 4,000 TFBS profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: JASPAR 2020 (Release 8) includes profiles for over 1,400 TFs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The function of the viral KP4 protein is to regulate the replication of the viral genome. KP4 is a protein encoded by the Kpu4 gene in the poxvirus, a double-stranded DNA virus that infects a wide range of hosts, including mammals and birds. The KP4 protein is involved in the late stages of the viral replication cycle and plays a critical role in the regulation of viral DNA synthesis and packaging.\nStudies have shown that KP4 protein functions as a negative regulator of viral DNA synthesis, meaning that it inhibits the activity of the viral polymerase and prevents the synthesis of new viral DNA. This is achieved through the interaction of KP4 with the viral polymerase, which leads to the inhibition of the enzyme's activity. Additionally, KP4 has been shown to play a role in the packaging of viral DNA into procapsids, which are the precursors to mature viral particles.\nIn summary, the function of the viral KP4 protein is to regulate the replication of the viral genome by inhibiting the activity of the viral polymerase and participating in the packaging of viral DNA into procapsids.",
    "llama-2-7b-chat-hf_fact_raw": "1. The viral KP4 protein regulates the replication of the viral genome.\n2. KP4 is a protein encoded by the Kpu4 gene in the poxvirus.\n3. Poxvirus is a double-stranded DNA virus that can infect mammals and birds.\n4. The KP4 protein functions as a negative regulator of viral DNA synthesis.\n5. KP4 is involved in the packaging of viral DNA into procapsids.",
    "llama-2-7b-chat-hf_fact": [
      "The viral KP4 protein regulates the replication of the viral genome.",
      "KP4 is a protein encoded by the Kpu4 gene in the poxvirus.",
      "Poxvirus is a double-stranded DNA virus that can infect mammals and birds.",
      "The KP4 protein functions as a negative regulator of viral DNA synthesis.",
      "KP4 is involved in the packaging of viral DNA into procapsids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: KP4 is a protein encoded by the Ustilago maydis (a type of fungus) virus. It is not associated with poxvirus.\n3. TRUE\n4. TRUE, assuming the statement is referring to KP4 from Ustilago maydis virus. KP4 is known to function as a viral killer toxin that can inhibit replication in other fungi, which may be considered a form of negative regulation.\n5. FALSE [correction]: KP4, as related to Ustilago maydis, is not involved in the packaging of viral DNA into procapsids. This function is not typically attributed to KP4; instead, KP4 acts as a killer toxin. Packaging of viral DNA is a function usually associated with structural proteins of a virus, which KP4 is not.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N,N-diethyl-N-methyl-5-amino-6-chloro-1,2,3,4-tetrahydroisoquinoline-3-ylamine) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a synthetic compound that mimics the action of thyroid hormones, such as triiodothyronine (T3) and thyroxine (T4), in the body. It has been shown to have a variety of biological activities, including the ability to stimulate metabolism, increase heart rate, and affect the growth and differentiation of cells.\nIn experimental studies, DITPA has been used to investigate the mechanisms of thyroid hormone action, to study the effects of thyroid hormone deficiency or excess, and to test the efficacy of new drugs that target the thyroid hormone system. For example, DITPA has been used to demonstrate the role of thyroid hormones in regulating metabolism, growth, and development, and to study the effects of thyroid hormone deficiency on these processes.\nIn clinical studies, DITPA has been used as a therapeutic agent in the treatment of certain thyroid disorders, such as hypothyroidism (underactive thyroid) and thyroid cancer. It has also been used as a diagnostic tool to assess thyroid function and to monitor the effectiveness of thyroid hormone therapy. However, it is important to note that DITPA is not a natural thyroid hormone and its use can have side effects, so it should only be used under the guidance of a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog utilized in both experimental and clinical studies.\n2. DITPA mimics the action of natural thyroid hormones like triiodothyronine (T3) and thyroxine (T4).\n3. DITPA has been used experimentally to investigate thyroid hormone mechanisms and study the effects of thyroid hormone deficiency or excess.\n4. In clinical studies, DITPA has been used as a therapeutic agent for certain thyroid disorders such as hypothyroidism and thyroid cancer.\n5. DITPA's use as a diagnostic tool includes assessing thyroid function and monitoring the effectiveness of thyroid hormone therapy.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog utilized in both experimental and clinical studies.",
      "DITPA mimics the action of natural thyroid hormones like triiodothyronine (T3) and thyroxine (T4).",
      "DITPA has been used experimentally to investigate thyroid hormone mechanisms and study the effects of thyroid hormone deficiency or excess.",
      "In clinical studies, DITPA has been used as a therapeutic agent for certain thyroid disorders such as hypothyroidism and thyroid cancer.",
      "DITPA's use as a diagnostic tool includes assessing thyroid function and monitoring the effectiveness of thyroid hormone therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DITPA has been studied for potential therapeutic application in conditions such as heart failure and metabolic disorders, not specifically for treating thyroid disorders such as hypothyroidism and thyroid cancer.\n5. FALSE [correction]: DITPA is not typically used as a diagnostic tool for assessing thyroid function or monitoring the effectiveness of thyroid hormone therapy; it is primarily investigated for its potential therapeutic effects.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! The COUGER tool is a computational tool for the analysis of RNA structure and function. It stands for \"Coupled OUrGine-based Exploration of RNA Genomes,\" and it was developed to help researchers study the structure and function of RNA molecules in a more efficient and accurate way.\nCOUGER tool uses a combination of computational methods, including molecular dynamics simulations, energy functions, and machine learning algorithms, to predict the 3D structure of RNA molecules and their interactions with other molecules. It can also be used to predict the stability of RNA molecules, their folding kinetics, and their binding affinity to other molecules.\nSome of the key features of COUGER tool include:\n1. Prediction of RNA structure: COUGER tool can predict the 3D structure of RNA molecules, including their secondary and tertiary structure, as well as their interactions with other molecules.\n2. Analysis of RNA stability: COUGER tool can predict the stability of RNA molecules under different conditions, such as changes in temperature, pH, or the presence of certain molecules.\n3. Prediction of RNA-protein interactions: COUGER tool can predict the binding affinity of RNA molecules to other molecules, such as proteins or small molecules.\n4. Analysis of RNA folding kinetics: COUGER tool can predict the folding kinetics of RNA molecules, including the rate of folding and the stability of the folded structure.\n5. Identification of functional sites: COUGER tool can identify functional sites in RNA molecules, such as binding sites or riboswitches, and predict their function.\nOverall, COUGER tool is a powerful tool for the analysis of RNA structure and function, and it can be used to study a wide range of RNA molecules, including messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA).",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool stands for \"Coupled OUrGine-based Exploration of RNA Genomes.\"\n2. The COUGER tool was developed to help researchers study the structure and function of RNA molecules.\n3. COUGER combines computational methods like molecular dynamics simulations, energy functions, and machine learning algorithms.\n4. The tool can predict the 3D structure of RNA molecules and their interactions with other molecules.\n5. The COUGER tool can be used to predict the stability, folding kinetics, and binding affinity of RNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool stands for \"Coupled OUrGine-based Exploration of RNA Genomes.\"",
      "The COUGER tool was developed to help researchers study the structure and function of RNA molecules.",
      "COUGER combines computational methods like molecular dynamics simulations, energy functions, and machine learning algorithms.",
      "The tool can predict the 3D structure of RNA molecules and their interactions with other molecules.",
      "The COUGER tool can be used to predict the stability, folding kinetics, and binding affinity of RNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The COUGER tool stands for \"COUpled clUster-GenERalized molecular fluid theory.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of Tick-borne Encephalitis (TBE). TBE is a viral infection transmitted to humans through the bite of an infected tick, and it can cause a range of symptoms including fever, headache, and neurological problems.\nThe most commonly used drugs for the treatment of TBE are:\n1. Ribavirin: This drug is an antiviral medication that has been shown to be effective in treating TBE. It works by reducing the replication of the virus in the body.\n2. Rimantadine: This drug is also an antiviral medication that has been used to treat TBE. It works by blocking the release of the virus from infected cells.\n3. Aztreonam: This drug is a type of antibiotic that is sometimes used to treat secondary bacterial infections that can occur in people with TBE.\n4. Corticosteroids: These drugs, such as prednisone, can be used to reduce inflammation in the brain and spinal cord, which can occur in some cases of TBE.\nIt's important to note that these drugs may not be effective in all cases of TBE, and the best treatment approach may depend on the severity and location of the infection, as well as the individual patient's medical history and overall health. In some cases, hospitalization may be necessary to provide appropriate treatment and monitoring.\nIt's also important to note that prevention is the best medicine, and taking steps to avoid tick bites, such as using insect repellents, wearing protective clothing, and conducting regular tick checks, can help prevent the infection in the first place.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tick-borne Encephalitis (TBE) is a viral infection transmitted to humans through the bite of an infected tick.\n2. Ribavirin is an antiviral medication used in treating Tick-borne Encephalitis.\n3. Rimantadine is an antiviral medication that has been used to treat Tick-borne Encephalitis.\n4. Aztreonam is an antibiotic used to treat secondary bacterial infections in people with Tick-borne Encephalitis.\n5. Corticosteroids like prednisone are used to reduce inflammation in the brain and spinal cord in some cases of TBE.",
    "llama-2-7b-chat-hf_fact": [
      "Tick-borne Encephalitis (TBE) is a viral infection transmitted to humans through the bite of an infected tick.",
      "Ribavirin is an antiviral medication used in treating Tick-borne Encephalitis.",
      "Rimantadine is an antiviral medication that has been used to treat Tick-borne Encephalitis.",
      "Aztreonam is an antibiotic used to treat secondary bacterial infections in people with Tick-borne Encephalitis.",
      "Corticosteroids like prednisone are used to reduce inflammation in the brain and spinal cord in some cases of TBE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no specific antiviral treatment for TBE. The primary treatment is supportive, and Ribavirin is not used to treat TBE.\n3. FALSE [correction]: Rimantadine is an antiviral drug primarily used to treat influenza A, not TBE.\n4. TRUE: While Aztreonam is an antibiotic and would not be used to treat a viral infection like TBE directly, it could be used to treat secondary bacterial infections in patients with TBE.\n5. TRUE: Corticosteroids like prednisone may be used to reduce inflammation in the central nervous system, which can be a part of the treatment for severe cases of TBE.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers available that provide DNA shape annotations, including:\n1. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser is a popular genome browser that provides a variety of features, including DNA shape annotations. The browser allows users to view genomic sequences, mRNA and other transcriptome data, and epigenetic marks, as well as visualize gene expression and other genomic features.\n2. Ensembl Genome Browser: Ensembl is a comprehensive and integrated genomic resource that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to view genomic sequences, gene models, and other genomic features, as well as visualize gene expression and other genomic data.\n3. GenomeView: GenomeView is a genome browser that provides a variety of features, including DNA shape annotations. The browser allows users to view genomic sequences, mRNA and other transcriptome data, and epigenetic marks, as well as visualize gene expression and other genomic features.\n4. OpenGenome Browser: OpenGenome Browser is an open-source genome browser that provides a variety of features, including DNA shape annotations. The browser allows users to view genomic sequences, gene models, and other genomic features, as well as visualize gene expression and other genomic data.\n5. HGNC Genome Browser: The HGNC (Human Genome Mutation Database) Genome Browser is a genome browser that provides a variety of features, including DNA shape annotations. The browser allows users to view genomic sequences, gene models, and other genomic features, as well as visualize gene expression and other genomic data.\nThese are some of the genome browsers that provide DNA shape annotations, and there may be others available depending on the specific needs of the researcher.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UCSC Genome Browser provides DNA shape annotations among other genomic features.\n2. Ensembl Genome Browser offers access to genomic data, including DNA shape annotations.\n3. GenomeView is a genome browser that includes DNA shape annotations in its variety of features.\n4. OpenGenome Browser is an open-source genome browser that provides DNA shape annotations.\n5. The HGNC Genome Browser includes DNA shape annotations as part of its features.",
    "llama-2-7b-chat-hf_fact": [
      "The UCSC Genome Browser provides DNA shape annotations among other genomic features.",
      "Ensembl Genome Browser offers access to genomic data, including DNA shape annotations.",
      "GenomeView is a genome browser that includes DNA shape annotations in its variety of features.",
      "OpenGenome Browser is an open-source genome browser that provides DNA shape annotations.",
      "The HGNC Genome Browser includes DNA shape annotations as part of its features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser offers a wide range of genomic data and annotations, but as of my knowledge cutoff in 2023, it does not specifically provide DNA shape annotations as part of its standard features.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nDNA shape annotations are a specific type of data concerning the three-dimensional structural aspects of DNA rather than the linear genetic sequence. While it is possible for genome browsers to provide such annotations, each specific browser's capabilities and the data it includes can vary significantly. Since the prior knowledge does not provide details on the specific capabilities of Ensembl Genome Browser, GenomeView, OpenGenome Browser, and HGNC Genome Browser regarding DNA shape annotations, the status of those statements remains unknown without further information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes a protein called enhancer of zest 2 (EZH2), which is a histone methyltransferase that plays a crucial role in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi syndrome: This is a rare genetic disorder that is characterized by intellectual disability, growth retardation, facial dysmorphism, and distinctive physical features. EZH2 mutations are found in approximately 50% of cases of Rubinstein-Taybi syndrome.\n2. Cdkn2a mutations: Cdkn2a is a gene that encodes a protein called p16INK4a, which is involved in the regulation of cell cycle progression and apoptosis. Mutations in the EZH2 gene can lead to the inactivation of p16INK4a, leading to uncontrolled cell growth and the development of cancer.\n3. Lymphedema breast cancer: EZH2 mutations have been found to be associated with aggressive breast cancer and poor prognosis in patients with lymphedema, a condition characterized by the abnormal accumulation of fluid in the tissues.\n4. Prostate cancer: EZH2 mutations have been identified in prostate cancer, and have been associated with more aggressive disease and poorer prognosis.\n5. Follicular lymphoma: EZH2 mutations have been found in a subset of follicular lymphoma, a type of B-cell non-Hodgkin lymphoma.\nThese are some of the syndromes associated with mutations in the EZH2 gene. It is important to note that the specific symptoms and severity of the disorder can vary depending on the location and type of mutation, as well as the individual's overall genetic background.",
    "llama-2-7b-chat-hf_fact_raw": "1. The EZH2 gene mutation is associated with approximately 50% of cases of Rubinstein-Taybi syndrome.\n2. Mutations in the EZH2 gene can lead to the inactivation of p16INK4a encoded by the Cdkn2a gene.\n3. EZH2 mutations have been found to be associated with aggressive breast cancer and poor prognosis in patients with lymphedema.\n4. EZH2 mutations have been identified in prostate cancer and are associated with more aggressive disease and poorer prognosis.\n5. A subset of follicular lymphoma, a type of B-cell non-Hodgkin lymphoma, has been found to have EZH2 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "The EZH2 gene mutation is associated with approximately 50% of cases of Rubinstein-Taybi syndrome.",
      "Mutations in the EZH2 gene can lead to the inactivation of p16INK4a encoded by the Cdkn2a gene.",
      "EZH2 mutations have been found to be associated with aggressive breast cancer and poor prognosis in patients with lymphedema.",
      "EZH2 mutations have been identified in prostate cancer and are associated with more aggressive disease and poorer prognosis.",
      "A subset of follicular lymphoma, a type of B-cell non-Hodgkin lymphoma, has been found to have EZH2 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The CREBBP gene mutation is associated with a majority of cases of Rubinstein-Taybi syndrome, not the EZH2 gene.\n2. UNKNOWN: The detailed interactions between EZH2 gene mutations and p16INK4a are specific and technical, and without further context, their relationship cannot be determined as true or false.\n3. FALSE [correction]: EZH2 mutations may be associated with aggressive forms of cancer, but the claim about poor prognosis in patients with lymphedema is not accurate as lymphedema is not typically caused by cancer mutations but rather is a condition often resulting from lymph node removal or damage.\n4. TRUE: Mutations in the EZH2 gene have been identified as a factor associated with more aggressive disease and poorer prognosis in prostate cancer.\n5. TRUE: Some cases of follicular lymphoma have been reported to present mutations in the EZH2 gene, which is associated with the pathogenesis of the disease.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some human proteins that are known to undergo a dimer-to-tetramer transition:\n1. p53: The tumor suppressor protein p53 is a transcription factor that regulates various cellular processes, including cell cycle arrest, apoptosis, and DNA repair. p53 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.\n2. HIF1A: Hypoxia-inducible factor 1 alpha (HIF1A) is a transcription factor that regulates the response to low oxygen levels in cells. HIF1A exists as a dimer in normoxic conditions but undergoes a dimer-to-tetramer transition in response to hypoxia, leading to its activation.\n3. STAT3: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that plays a role in immune responses and inflammation. STAT3 exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.\n4. c-Myc: c-Myc is a transcription factor that regulates cellular processes such as cell cycle progression, apoptosis, and DNA repair. c-Myc exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.\n5. NF-κB: Nuclear factor kappa B (NF-κB) is a transcription factor that regulates the expression of genes involved in inflammation and immune responses. NF-κB exists as a dimer in its inactive form and undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are many other proteins that exhibit this type of conformational change, and the specific details of the transition can vary depending on the protein and the stimulus that triggers it.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human protein p53 undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.\n2. Hypoxia-inducible factor 1 alpha (HIF1A) undergoes a dimer-to-tetramer transition in response to hypoxia.\n3. Signal transducer and activator of transcription 3 (STAT3) transitions from a dimer to a tetramer upon phosphorylation for activation.\n4. The c-Myc protein exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.\n5. Nuclear factor kappa B (NF-κB) changes from a dimer to a tetramer through phosphorylation, leading to its activation.",
    "llama-2-7b-chat-hf_fact": [
      "The human protein p53 undergoes a dimer-to-tetramer transition upon phosphorylation, leading to its activation.",
      "Hypoxia-inducible factor 1 alpha (HIF1A) undergoes a dimer-to-tetramer transition in response to hypoxia.",
      "Signal transducer and activator of transcription 3 (STAT3) transitions from a dimer to a tetramer upon phosphorylation for activation.",
      "The c-Myc protein exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation.",
      "Nuclear factor kappa B (NF-κB) changes from a dimer to a tetramer through phosphorylation, leading to its activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human protein p53 primarily functions as a tetramer when active, but its activation is not triggered by a dimer-to-tetramer transition upon phosphorylation. It is already a tetramer in its active form.\n2. FALSE [correction]: Hypoxia-inducible factor 1 alpha (HIF1A) does not undergo a dimer-to-tetramer transition in response to hypoxia. It forms a dimer with HIF1B (also known as ARNT) to become active.\n3. UNKNOWN: While STAT3 does form dimers upon phosphorylation, it's unclear from common knowledge whether phosphorylated STAT3 transitions to a tetramer for activation without specific context or current research data.\n4. FALSE [correction]: The c-Myc protein functions as a dimer in both its active and inactive forms. Phosphorylation can regulate its activity, but it does not involve a transition to a tetramer.\n5. FALSE [correction]: Nuclear factor kappa B (NF-κB) is activated through the degradation of its inhibitor IκB in response to various stimuli, which allows the NF-κB dimer to translocate to the nucleus. The activation does not involve changing from a dimer to a tetramer.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! Based on the information provided, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2 (B-cell lymphoma 2).",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 (B-cell lymphoma 2) has been found to interact with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 (B-cell lymphoma 2) has been found to interact with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older people (Harris et al., 2010).\n2. A 2012 meta-analysis of 10 randomized controlled trials found that vitamin D supplementation was associated with a 23% reduction in the risk of falls in older adults (Li et al., 2012).\n3. A 2014 randomized controlled trial found that vitamin D supplementation reduced the risk of falls by 43% in older adults with a history of falls (Shen et al., 2014).\n4. A 2017 Cochrane review of 18 randomized controlled trials found that vitamin D supplementation was associated with a 31% reduction in the risk of falls in older people (Bischoff-Ferrari et al., 2017).\nOverall, these studies suggest that vitamin D supplementation may be an effective strategy for reducing the risk of falls in older people, particularly in those who have a history of falls or who are at high risk of falling. However, it is important to note that the optimal dose and duration of vitamin D supplementation for fall prevention has not been definitively established, and more research is needed to determine the best approach.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older people.\n2. A 2012 meta-analysis of 10 randomized controlled trials found that vitamin D supplementation was associated with a 23% reduction in the risk of falls in older adults.\n3. A 2014 randomized controlled trial found that vitamin D supplementation reduced the risk of falls by 43% in older adults with a history of falls.\n4. A 2017 Cochrane review of 18 randomized controlled trials found that vitamin D supplementation was associated with a 31% reduction in the risk of falls in older people.",
    "llama-2-7b-chat-hf_fact": [
      "A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older people.",
      "A 2012 meta-analysis of 10 randomized controlled trials found that vitamin D supplementation was associated with a 23% reduction in the risk of falls in older adults.",
      "A 2014 randomized controlled trial found that vitamin D supplementation reduced the risk of falls by 43% in older adults with a history of falls.",
      "A 2017 Cochrane review of 18 randomized controlled trials found that vitamin D supplementation was associated with a 31% reduction in the risk of falls in older people."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN - The percentage reduction in the risk of falls and the number of studies included in the meta-analysis are specific details that would require access to the specified meta-analysis or related data to verify.\n3. UNKNOWN - Like statement 2, the percentage reduction and the specific details of the trial would need to be confirmed with the actual study.\n4. UNKNOWN - While later Cochrane reviews exist, the specific details such as the percentage reduction in risk of falls and the number of studies would need to be checked against the actual review for accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji domain-containing protein 2) is a histone demethylase that plays a crucial role in regulating gene expression by modifying histone methylation levels. MiR-155 (microRNA-155) is a small non-coding RNA molecule that regulates gene expression by binding to messenger RNA (mRNA) and preventing its translation.\nStudies have shown that Jarid2 and miR-155 are co-regulated in Th17 cells, which are a type of immune cell involved in the immune response. Specifically, Jarid2 has been shown to demethylate histone H3 lysine 4 (H3K4) in the promoter region of miR-155, leading to its activation and the regulation of Th17 cell differentiation and function. Conversely, miR-155 has been shown to target and degrade Jarid2, leading to its inhibition and the repression of histone demethylation.\nTherefore, there is a negative feedback loop between Jarid2 and miR-155 in Th17 cells, where the activation of Jarid2 leads to the repression of miR-155, and the activation of miR-155 leads to the inhibition of Jarid2. This loop plays a critical role in regulating the differentiation and function of Th17 cells and the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone demethylase involved in regulating gene expression by modifying histone methylation levels.\n2. MiR-155 is a small non-coding RNA molecule that regulates gene expression by binding to messenger RNA and preventing its translation.\n3. Both Jarid2 and miR-155 are co-regulated in Th17 cells, which are involved in the immune response.\n4. Jarid2 demethylates histone H3 lysine 4 in the promoter region of miR-155, leading to the activation of miR-155.\n5. MiR-155 can target and degrade Jarid2, which results in the repression of histone demethylation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone demethylase involved in regulating gene expression by modifying histone methylation levels.",
      "MiR-155 is a small non-coding RNA molecule that regulates gene expression by binding to messenger RNA and preventing its translation.",
      "Both Jarid2 and miR-155 are co-regulated in Th17 cells, which are involved in the immune response.",
      "Jarid2 demethylates histone H3 lysine 4 in the promoter region of miR-155, leading to the activation of miR-155.",
      "MiR-155 can target and degrade Jarid2, which results in the repression of histone demethylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone demethylase, but rather a member of the Jumonji family of proteins and a component of Polycomb repressive complex 2 (PRC2), which regulates histone methylation levels indirectly.\n2. TRUE\n3. UNKNOWN (Without specific scientific studies or context provided, it is unclear whether Jarid2 and miR-155 are co-regulated in Th17 cells.)\n4. FALSE [correction]: Jarid2 does not possess histone demethylase activity, so it does not directly demethylate histone H3 lysine 4 or any other histone site. Instead, its role is to regulate the activity of PRC2, which can modify histone methylation.\n5. UNKNOWN (The statement suggests a regulatory feedback loop; however, without specific context or research, we cannot ascertain the accuracy of miR-155 targeting and degrading Jarid2.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 8 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 8 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 8 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Certainly! Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. Here are some phosphorylation consensus motifs for CK1:\n1. Thr-Ser-Thr (TST) sequence: This is a common consensus motif for CK1 phosphorylation.\nExample: Thr-Ser-Thr-Ser-Pro-Gly-Gly-Gly (TSTSPGYGYG)\n2. Ser-Gly-X-Ser (SGS) sequence: This motif is also commonly recognized by CK1.\nExample: Ser-Gly-Ser-Gly-Gly-Gly-Gly (SGSGGG)\n3. Thr-X-Thr (TXT) sequence: CK1 can also phosphorylate threonine residues in the context of this motif.\nExample: Thr-Ser-Thr-Thr-Gly-Gly-Gly (TSTTGYGYG)\n4. Ser-X-Ser (SXS) sequence: This motif is another common target for CK1 phosphorylation.\nExample: Ser-Ser-Ser-Ser-Gly-Gly-Gly (SXSGSG)\n5. Pro-X-Pro (PXP) sequence: CK1 can also phosphorylate proline residues in this context.\nExample: Pro-Ser-Pro-Pro-Gly-Gly-Gly (PXPPGYGYG)\nThese consensus motifs are not exhaustive, and CK1 can phosphorylate other residues and motifs as well. However, these are some of the most common and well-conserved motifs recognized by CK1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. A common consensus motif for CK1 phosphorylation is the Thr-Ser-Thr (TST) sequence.\n3. CK1 recognizes the Ser-Gly-X-Ser (SGS) sequence for phosphorylation.\n4. The Thr-X-Thr (TXT) sequence is a motif that CK1 can phosphorylate.\n5. CK1 can phosphorylate proline residues in the context of the Pro-X-Pro (PXP) sequence.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "A common consensus motif for CK1 phosphorylation is the Thr-Ser-Thr (TST) sequence.",
      "CK1 recognizes the Ser-Gly-X-Ser (SGS) sequence for phosphorylation.",
      "The Thr-X-Thr (TXT) sequence is a motif that CK1 can phosphorylate.",
      "CK1 can phosphorylate proline residues in the context of the Pro-X-Pro (PXP) sequence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A common consensus motif for CK1 phosphorylation is Ser-X-X-Ser/Thr (where X can be any amino acid), not the Thr-Ser-Thr (TST) sequence.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: CK1 generally does not phosphorylate proline residues, and the Pro-X-Pro (PXP) sequence is not a typical consensus motif for phosphorylation by CK1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene, which is involved in the biosynthesis of the neurotransmitter serotonin.\n2. Tissue inhibitor of metalloproteinases 1 (TIMP1): This isoform is produced from the ASPH gene through alternative splicing and functions as a tissue inhibitor of metalloproteinases, which are enzymes involved in the breakdown of extracellular matrix proteins.\n3. Matrix metalloproteinase 9 (MMP9): This isoform is also produced through alternative splicing and is involved in the breakdown of extracellular matrix proteins, which is important for various physiological processes such as tissue remodeling and inflammation.\n4. Aspartate beta-hydroxylase 2 (ASPH2): This is a less well-studied isoform of the ASPH gene, but it has been shown to be involved in the regulation of cell proliferation and differentiation.\nIt is worth noting that the expression of these isoforms can be regulated by various factors, including developmental stage, tissue type, and cellular differentiation state, which can impact their functional roles in different biological processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes the primary isoform called aspartate beta-hydroxylase (ASPH).\n2. An isoform called tissue inhibitor of metalloproteinases 1 (TIMP1) is produced from the ASPH gene through alternative splicing.\n3. The ASPH gene also encodes an isoform known as matrix metalloproteinase 9 (MMP9) through alternative splicing.\n4. Aspartate beta-hydroxylase 2 (ASPH2) is another isoform encoded by the ASPH gene.\n\nNote: The statement regarding the involvement of the primary ASPH isoform in the biosynthesis of the neurotransmitter serotonin cannot be verified without additional context or evidence, as the known function of human ASPH is the hydroxylation of specific aspartyl and asparaginyl residues in proteins and it is not directly involved in serotonin biosynthesis. Therefore, the factual claim about its involvement in serotonin biosynthesis is not extracted.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes the primary isoform called aspartate beta-hydroxylase (ASPH).",
      "An isoform called tissue inhibitor of metalloproteinases 1 (TIMP1) is produced from the ASPH gene through alternative splicing.",
      "The ASPH gene also encodes an isoform known as matrix metalloproteinase 9 (MMP9) through alternative splicing.",
      "Aspartate beta-hydroxylase 2 (ASPH2) is another isoform encoded by the ASPH gene.",
      "te: The statement regarding the involvement of the primary ASPH isoform in the biosynthesis of the neurotransmitter serotonin cannot be verified without additional context or evidence, as the known function of human ASPH is the hydroxylation of specific aspartyl and asparaginyl residues in proteins and it is not directly involved in serotonin biosynthesis. Therefore, the factual claim about its involvement in serotonin biosynthesis is not extracted."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: An isoform called tissue inhibitor of metalloproteinases 1 (TIMP1) is not produced from the ASPH gene through alternative splicing. TIMP1 is encoded by its own distinct gene.\n3. FALSE [correction]: The ASPH gene does not encode an isoform known as matrix metalloproteinase 9 (MMP9) through alternative splicing. MMP9 is encoded by its own distinct gene.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Empagliflozin was FDA approved in 2014.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Loss of the protein Lon1 in the plant Arabidopsis has been shown to have several interesting effects. Here are some of the results that have been observed in studies:\n1. Impaired cell division and growth: Lon1 is involved in the regulation of the cell cycle and proliferation in Arabidopsis. Mutants lacking Lon1 have been shown to have reduced cell division and growth, leading to decreased plant size and biomass.\n2. Altered gene expression: Lon1 regulates the expression of many genes involved in various cellular processes, including DNA repair, metabolism, and stress response. Mutants lacking Lon1 have been found to have altered expression profiles of these genes, which can lead to changes in plant development and function.\n3. Increased sensitivity to stress: Lon1 has been shown to play a role in the response to various abiotic stresses, including oxidative stress, heat stress, and drought stress. Mutants lacking Lon1 are more sensitive to these stresses, which can lead to reduced plant survival and fitness.\n4. Changes in hormone signaling: Lon1 has been implicated in the regulation of plant hormone signaling, particularly the biosynthesis and degradation of the plant hormone auxin. Mutants lacking Lon1 have been found to have altered hormone profiles, which can lead to changes in plant growth and development.\n5. Altered leaf morphology: Lon1 has been shown to be involved in the regulation of leaf morphology, including leaf shape and size. Mutants lacking Lon1 have been found to have altered leaf morphology, which can affect plant growth and development.\nOverall, the loss of Lon1 in Arabidopsis has been shown to have significant effects on plant growth, development, and stress response, highlighting the importance of this protein in plant cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Loss of the protein Lon1 in the plant Arabidopsis is associated with impaired cell division and growth, leading to decreased plant size and biomass.\n2. Mutants lacking Lon1 in Arabidopsis have altered gene expression profiles.\n3. Arabidopsis mutants without Lon1 show increased sensitivity to various abiotic stresses, such as oxidative stress, heat stress, and drought stress.\n4. The absence of Lon1 in Arabidopsis affects the regulation of plant hormone signaling, particularly relating to the biosynthesis and degradation of auxin.\n5. Mutants of Arabidopsis lacking Lon1 exhibit altered leaf morphology, including changes in leaf shape and size.",
    "llama-2-7b-chat-hf_fact": [
      "Loss of the protein Lon1 in the plant Arabidopsis is associated with impaired cell division and growth, leading to decreased plant size and biomass.",
      "Mutants lacking Lon1 in Arabidopsis have altered gene expression profiles.",
      "Arabidopsis mutants without Lon1 show increased sensitivity to various abiotic stresses, such as oxidative stress, heat stress, and drought stress.",
      "The absence of Lon1 in Arabidopsis affects the regulation of plant hormone signaling, particularly relating to the biosynthesis and degradation of auxin.",
      "Mutants of Arabidopsis lacking Lon1 exhibit altered leaf morphology, including changes in leaf shape and size."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE – Loss of the protein Lon1 in Arabidopsis has been associated with defects in growth and development, which could result in decreased plant size and biomass due to impaired cell division and growth.\n2. TRUE – Mutants lacking Lon1 typically show changes in gene expression profiles, which is consistent with the role of proteases like Lon1 in protein quality control and regulation of various cellular processes.\n3. TRUE – Given that Lon1 plays a role in stress responses and mitochondrial function, Arabidopsis mutants without Lon1 could indeed show increased sensitivity to various abiotic stresses.\n4. TRUE – Lon1 can affect multiple cellular pathways, and plant hormone regulation is a complex network that can be influenced by changes in protein homeostasis and signaling pathways. The absence of Lon1 could affect the hormone signaling and homeostasis, such as auxin biosynthesis and degradation.\n5. TRUE – Altered leaf morphology, including changes in leaf shape and size, can be expected in mutants with growth and development impairments, such as those lacking Lon1 in Arabidopsis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone exists in the yeast genome. In fact, yeast has three linker histones: H3-linker, H4-linker, and H5-linker. These linker histones play a crucial role in the organization of chromatin in yeast cells, similar to their role in eukaryotic cells. They help to connect the DNA to the histone proteins and create a more compact and organized chromatin structure, which is important for various cellular processes such as transcription, replication, and repair.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone exists in the yeast genome.\n2. There are three types of linker histones in the yeast genome: H3-linker, H4-linker, and H5-linker.\n3. Linker histones are involved in the organization of chromatin in yeast cells.\n4. Linker histones in yeast play a role in connecting DNA to histone proteins.\n5. Linker histones contribute to the chromatin structure that is important for transcription, replication, and repair in yeast cells.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone exists in the yeast genome.",
      "There are three types of linker histones in the yeast genome: H3-linker, H4-linker, and H5-linker.",
      "Linker histones are involved in the organization of chromatin in yeast cells.",
      "Linker histones in yeast play a role in connecting DNA to histone proteins.",
      "Linker histones contribute to the chromatin structure that is important for transcription, replication, and repair in yeast cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Yeast, such as Saccharomyces cerevisiae, typically lack linker histones; their chromatin is organized differently compared to organisms with canonical linker histones.\n2. FALSE [correction]: Since yeast do not have canonical linker histones, they do not have H3-linker, H4-linker, and H5-linker types.\n3. UNKNOWN: While in general linker histones are involved in the organization of chromatin, the statement is misleading since yeast do not have canonical linker histones. If the statement refers to yeast-like Saccharomyces cerevisiae, it would be considered false; however, without more context on what is meant by 'linker histones' in yeast, it's hard to definitively classify this as true or false.\n4. UNKNOWN: Again, because yeast typically do not have canonical linker histones, they don't play a role in connecting DNA to histone proteins in the way that is typically understood in organisms with linker histones. The statement may be referring to other proteins that fulfill similar roles in yeast, but that is not clear from the context given.\n5. UNKNOWN: This statement would generally be true for eukaryotic cells with canonical linker histones, but as stated before, yeast (like Saccharomyces cerevisiae) lack these proteins. It's possible that other proteins contribute to chromatin structure important for these cellular processes in yeast, but without more context, the statement's accuracy is unclear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels. Tomatoes are rich in a compound called lycopene, which has been shown to have cholesterol-lowering properties. Studies have found that consuming tomato juice regularly can help reduce total cholesterol levels, as well as lower the levels of \"bad\" LDL cholesterol and increase the levels of \"good\" HDL cholesterol.\nOne study published in the Journal of Nutrition found that drinking 8 ounces of tomato juice daily for 12 weeks resulted in a significant decrease in total cholesterol and LDL cholesterol levels in healthy adults. Another study published in the American Journal of Clinical Nutrition found that consuming a diet rich in tomatoes and tomato-based products was associated with lower cholesterol levels in a population of postmenopausal women.\nIt's thought that the lycopene in tomato juice may help lower cholesterol levels by reducing the amount of cholesterol that is absorbed from the diet, as well as by increasing the breakdown of cholesterol in the body. Additionally, tomato juice contains other nutrients and compounds that may also contribute to its cholesterol-lowering effects, such as fiber, vitamins, and antioxidants.\nIt's important to note that while these studies suggest that tomato juice may have cholesterol-lowering effects, more research is needed to fully understand its potential benefits and how it compares to other cholesterol-lowering interventions. Additionally, it's important to consume tomato juice as part of a balanced diet and to talk to a healthcare provider before making any significant changes to your diet or medication regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomatoes contain a compound called lycopene which has cholesterol-lowering properties.\n2. A study published in the Journal of Nutrition reported that drinking 8 ounces of tomato juice daily for 12 weeks resulted in a significant decrease in total cholesterol and LDL cholesterol levels in healthy adults.\n3. Another study published in the American Journal of Clinical Nutrition found that a diet rich in tomatoes and tomato-based products was associated with lower cholesterol levels in a population of postmenopausal women.\n4. Lycopene may help lower cholesterol levels by reducing the absorption of cholesterol from the diet and increasing the breakdown of cholesterol in the body.\n5. Tomato juice contains other nutrients and compounds like fiber, vitamins, and antioxidants that may contribute to its cholesterol-lowering effects.",
    "llama-2-7b-chat-hf_fact": [
      "Tomatoes contain a compound called lycopene which has cholesterol-lowering properties.",
      "A study published in the Journal of Nutrition reported that drinking 8 ounces of tomato juice daily for 12 weeks resulted in a significant decrease in total cholesterol and LDL cholesterol levels in healthy adults.",
      "Another study published in the American Journal of Clinical Nutrition found that a diet rich in tomatoes and tomato-based products was associated with lower cholesterol levels in a population of postmenopausal women.",
      "Lycopene may help lower cholesterol levels by reducing the absorption of cholesterol from the diet and increasing the breakdown of cholesterol in the body.",
      "Tomato juice contains other nutrients and compounds like fiber, vitamins, and antioxidants that may contribute to its cholesterol-lowering effects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Tomato juice does contain vitamins and antioxidants that may contribute to its health benefits, but it is not a significant source of dietary fiber.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are heat shock proteins that play important roles in various cellular processes, including protein folding, protein degradation, and mRNA stability. Both Hsp70 and Hsp110 have been shown to influence mRNA stability by interacting with the 3' untranslated region (UTR) of target mRNAs and regulating their degradation.\nHsp70 has been shown to bind to the 3' UTR of target mRNAs and prevent the binding of the miRNA-induced silencing complex (miRISC), which is responsible for degrading the mRNA. By inhibiting the binding of miRISC, Hsp70 can stabilize the mRNA and promote its translation.\nHsp110, on the other hand, has been shown to interact with the 3' UTR of target mRNAs and recruit the deadenylase complex, which is responsible for removing the poly(A) tail from the mRNA. By removing the poly(A) tail, Hsp110 can destabilize the mRNA and promote its degradation.\nIn summary, both Hsp70 and Hsp110 can affect mRNA stability by interacting with the 3' UTR of target mRNAs and regulating the degradation of the mRNA. While Hsp70 promotes mRNA stability by inhibiting the binding of miRISC, Hsp110 promotes mRNA degradation by recruiting the deadenylase complex.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins involved in protein folding, protein degradation, and mRNA stability.\n2. Hsp70 binds to the 3' untranslated region (UTR) of target mRNAs to prevent the binding of the miRNA-induced silencing complex (miRISC).\n3. By inhibiting the binding of miRISC, Hsp70 stabilizes mRNA and promotes its translation.\n4. Hsp110 interacts with the 3' UTR of target mRNAs to recruit the deadenylase complex, which removes the poly(A) tail from the mRNA.\n5. While Hsp70 functions to stabilize mRNA, Hsp110 works to promote mRNA degradation.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are heat shock proteins involved in protein folding, protein degradation, and mRNA stability.",
      "Hsp70 binds to the 3' untranslated region (UTR) of target mRNAs to prevent the binding of the miRNA-induced silencing complex (miRISC).",
      "By inhibiting the binding of miRISC, Hsp70 stabilizes mRNA and promotes its translation.",
      "Hsp110 interacts with the 3' UTR of target mRNAs to recruit the deadenylase complex, which removes the poly(A) tail from the mRNA.",
      "While Hsp70 functions to stabilize mRNA, Hsp110 works to promote mRNA degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Hsp110 does not interact with the 3' UTR of target mRNAs to recruit the deadenylase complex for removing the poly(A) tail. Instead, Hsp110 typically acts as a nucleotide exchange factor that works together with Hsp70.\n5. FALSE [correction]: While Hsp70 has a role in stabilizing mRNA, it is not accurate to claim that Hsp110's function is to promote mRNA degradation. Hsp110 generally assists Hsp70 by facilitating the release of ADP to allow the binding of ATP, which is essential for the protein folding activity of Hsp70.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "In skeletal muscle, there are two types of deiodinases:\n1. Deiodinase type 1 (D1): This enzyme is responsible for converting T4 to T3 in the muscle cells. T3 is the active form of thyroid hormone that regulates muscle contraction and metabolism.\n2. Deiodinase type 2 (D2): This enzyme is responsible for converting T4 to reverse T3 (rT3) in the muscle cells. rT3 can inhibit the activity of T3 and reduce its ability to stimulate muscle contraction and metabolism.\nSo, to answer your question, there are two deiodinases present in skeletal muscle: deiodinase type 1 (D1) and deiodinase type 2 (D2).",
    "llama-2-7b-chat-hf_fact_raw": "1. There are two types of deiodinases present in skeletal muscle: deiodinase type 1 (D1) and deiodinase type 2 (D2).\n2. Deiodinase type 1 (D1) is responsible for converting T4 to T3 in muscle cells.\n3. Deiodinase type 2 (D2) is responsible for converting T4 to reverse T3 (rT3) in muscle cells.\n4. T3 is the active form of thyroid hormone that regulates muscle contraction and metabolism.\n5. Reverse T3 (rT3) can inhibit the activity of T3.",
    "llama-2-7b-chat-hf_fact": [
      "There are two types of deiodinases present in skeletal muscle: deiodinase type 1 (D1) and deiodinase type 2 (D2).",
      "Deiodinase type 1 (D1) is responsible for converting T4 to T3 in muscle cells.",
      "Deiodinase type 2 (D2) is responsible for converting T4 to reverse T3 (rT3) in muscle cells.",
      "T3 is the active form of thyroid hormone that regulates muscle contraction and metabolism.",
      "Reverse T3 (rT3) can inhibit the activity of T3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are actually three types of deiodinases present in humans: deiodinase type 1 (D1), deiodinase type 2 (D2), and deiodinase type 3 (D3).\n2. TRUE\n3. FALSE [correction]: Deiodinase type 2 (D2) is responsible for converting T4 to T3, not reverse T3 (rT3). Deiodinase type 3 (D3) is responsible for converting T4 to rT3.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Of course! Here are some inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme or ICE)\n2. Caspase-3 (also known as CPP32 or Yama/APOP-1)\n3. Caspase-7 (also known as ICELAP1 or CPP32L1)\n4. Caspase-8 (also known as Fas-associated protein with death domain or FADD)\n5. Caspase-9 (also known as BID or Bcl-2-associated X protein)\nThese caspases play a crucial role in the regulation of inflammation by promoting the cleavage of various inflammatory proteins, leading to the activation of downstream signaling pathways and the resolution of inflammation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta converting enzyme or ICE.\n2. Caspase-3 is also known as CPP32 or Yama/APOP-1.\n3. Caspase-7 is also known as ICELAP1 or CPP32L1.\n4. Caspase-8 is also known as Fas-associated protein with death domain or FADD.\n5. Caspase-9 is also known as BID or Bcl-2-associated X protein.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as interleukin-1 beta converting enzyme or ICE.",
      "Caspase-3 is also known as CPP32 or Yama/APOP-1.",
      "Caspase-7 is also known as ICELAP1 or CPP32L1.",
      "Caspase-8 is also known as Fas-associated protein with death domain or FADD.",
      "Caspase-9 is also known as BID or Bcl-2-associated X protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-7 is also known as CMH-1, ICE-LAP3, or LICE-1.\n4. FALSE [correction]: Caspase-8 is also known as FLICE or MACH, not Fas-associated protein with death domain (FADD); FADD is a different protein that interacts with caspase-8.\n5. FALSE [correction]: Caspase-9 is also known as APAF-3 or ICE-LAP6, not BID; BID is a different protein that interacts with caspases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between the aurora B kinase and the polycomb protein Ring1B. Aurora B kinase is a key regulator of mitosis and is involved in the proper separation of chromosomes during cell division. Ring1B, on the other hand, is a polycomb group protein that plays a critical role in the regulation of chromatin structure and gene expression, particularly during cellular differentiation and development.\nStudies have shown that Ring1B is a direct substrate of aurora B kinase, and that aurora B kinase phosphorylates and activates Ring1B during mitosis. This interaction is important for the proper progression of mitosis and the maintenance of genome stability.\nIn addition, Ring1B has been shown to play a role in the regulation of the aurora B kinase activity itself. For example, Ring1B has been shown to bind to and inhibit the activity of the aurora B kinase in certain contexts, suggesting that Ring1B may play a negative regulatory role in the aurora B kinase signaling pathway.\nOverall, the interaction between aurora B kinase and Ring1B is an important aspect of the complex regulation of mitosis and chromatin dynamics, and further research is needed to fully understand the molecular mechanisms underlying this interaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase is a key regulator of mitosis and is involved in the proper separation of chromosomes during cell division.\n2. Ring1B is a polycomb group protein that is involved in the regulation of chromatin structure and gene expression.\n3. Studies indicate that Ring1B is a direct substrate of aurora B kinase.\n4. Aurora B kinase phosphorylates and activates Ring1B during mitosis.\n5. Ring1B can bind to and inhibit the activity of the aurora B kinase in certain contexts.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase is a key regulator of mitosis and is involved in the proper separation of chromosomes during cell division.",
      "Ring1B is a polycomb group protein that is involved in the regulation of chromatin structure and gene expression.",
      "Studies indicate that Ring1B is a direct substrate of aurora B kinase.",
      "Aurora B kinase phosphorylates and activates Ring1B during mitosis.",
      "Ring1B can bind to and inhibit the activity of the aurora B kinase in certain contexts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific references or context, it is challenging to confirm the accuracy of the interactions between Aurora B kinase and Ring1B described in statements 3, 4, and 5. These statements involve complex biochemical processes that require scholarly citation for verification.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Thank you for the questions! In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice sites:\n* GU-rich sequences (e.g., GUG, GUU, GUC)\n* UG-rich sequences (e.g., UGU, UGC, UGA)\n* AU-rich sequences (e.g., AUU, AUC, AUA)\n* GAA/GAG sequences (found in introns of some genes, particularly those involved in the immune system)\nAcceptor splice sites:\n* AG-rich sequences (e.g., AGG, AGU, AGA)\n* GU-rich sequences (e.g., GUG, GUU, GUC)\n* UG-rich sequences (e.g., UGU, UGC, UGA)\n* AU-rich sequences (e.g., AUU, AUC, AUA)\nIt's worth noting that the frequency and distribution of these non-canonical motifs can vary across different organisms and tissues, and may also be influenced by various factors such as alternative splicing patterns and the presence of specific transcription factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. In vertebrates, GU-rich sequences are among the most frequent non-canonical sequence motifs at the donor splice sites.\n2. UG-rich sequences are also common non-canonical motifs at vertebrate donor splice sites.\n3. AU-rich sequences are prevalent non-canonical motifs at the donor splice sites in vertebrates.\n4. GAA/GAG sequences are found at donor splice sites in introns of some genes, particularly those involved in the immune system, in vertebrates.\n5. AG-rich sequences are one of the most frequent non-canonical motifs found at vertebrate acceptor splice sites.",
    "llama-2-7b-chat-hf_fact": [
      "In vertebrates, GU-rich sequences are among the most frequent non-canonical sequence motifs at the donor splice sites.",
      "UG-rich sequences are also common non-canonical motifs at vertebrate donor splice sites.",
      "AU-rich sequences are prevalent non-canonical motifs at the donor splice sites in vertebrates.",
      "GAA/GAG sequences are found at donor splice sites in introns of some genes, particularly those involved in the immune system, in vertebrates.",
      "AG-rich sequences are one of the most frequent non-canonical motifs found at vertebrate acceptor splice sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: AU-rich sequences are not typically described as prevalent non-canonical motifs at donor splice sites in vertebrates.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The event that results in the acetylation of S6K1 (p70 S6 kinase 1) is the activation of the PI3K (phosphatidylinositol 3-kinase) signaling pathway. PI3K is a lipid kinase that phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) at the 3-position, producing phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 then recruits and activates various signaling proteins, including S6K1, which is acetylated by histone acetyltransferases (HATs) in response to PI3K signaling. The acetylation of S6K1 leads to its activation and the subsequent regulation of various cellular processes, including protein synthesis and cell growth.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 (p70 S6 kinase 1) is triggered by the activation of the PI3K (phosphatidylinositol 3-kinase) signaling pathway.\n2. PI3K is a lipid kinase that phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3).\n3. PIP3 recruits and activates various signaling proteins, including S6K1.\n4. S6K1 is acetylated by histone acetyltransferases (HATs) in response to PI3K signaling.\n5. The acetylation of S6K1 leads to its activation and plays a role in the regulation of protein synthesis and cell growth.",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 (p70 S6 kinase 1) is triggered by the activation of the PI3K (phosphatidylinositol 3-kinase) signaling pathway.",
      "PI3K is a lipid kinase that phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3).",
      "PIP3 recruits and activates various signaling proteins, including S6K1.",
      "S6K1 is acetylated by histone acetyltransferases (HATs) in response to PI3K signaling.",
      "The acetylation of S6K1 leads to its activation and plays a role in the regulation of protein synthesis and cell growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While the specific acetylation of S6K1 triggered by PI3K activation is not a universally acknowledged fact in scientific literature, PI3K does activate various downstream signaling pathways which could potentially include post-translational modifications of certain proteins. However, without specific supporting evidence from the scientific literature, the veracity of this statement cannot be confirmed.\n\n2. TRUE: PI3K is indeed a lipid kinase that phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to produce phosphatidylinositol 3,4,5-trisphosphate (PIP3), which is a key step in the PI3K/Akt signaling pathway.\n\n3. TRUE: PIP3 indeed recruits and activates various signaling proteins, including AKT and other downstream effectors, which could potentially include S6K1, as part of the PI3K/Akt/mTOR signaling cascade.\n\n4. UNKNOWN: While S6K1 is a protein that can be phosphorylated and thus activated in response to signaling through the PI3K pathway, its acetylation by histone acetyltransferases (HATs) specifically in response to PI3K signaling is not a well-established fact and requires specific literature evidence to confirm.\n\n5. UNKNOWN: The role of S6K1 acetylation in its activation and function in protein synthesis and cell growth is not well-established in the context of general scientific knowledge. Typically, S6K1 is known to be phosphorylated for activation. The acetylation process is more commonly associated with gene regulation via histone modification rather than kinase activation. Therefore, without specific evidence, the truth of this statement is uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "The cause of episodic ataxia type 6 (EA6) is a genetic mutation that affects the FKBP52 gene. FKBP52 is a protein that plays a critical role in the regulation of calcium homeostasis in neurons, and mutations in this gene have been identified as the underlying cause of EA6. The mutations lead to an imbalance in calcium levels in neurons, which can disrupt normal neuronal function and lead to the symptoms of EA6, including episodes of ataxia (loss of coordination and balance), seizures, and cognitive decline.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by a genetic mutation.\n2. The genetic mutation that causes EA6 affects the FKBP52 gene.\n3. The FKBP52 gene is involved in the regulation of calcium homeostasis in neurons.\n4. Mutations in the FKBP52 gene lead to an imbalance in neuron calcium levels.\n5. Symptoms of EA6 include episodes of ataxia, seizures, and cognitive decline.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by a genetic mutation.",
      "The genetic mutation that causes EA6 affects the FKBP52 gene.",
      "The FKBP52 gene is involved in the regulation of calcium homeostasis in neurons.",
      "Mutations in the FKBP52 gene lead to an imbalance in neuron calcium levels.",
      "Symptoms of EA6 include episodes of ataxia, seizures, and cognitive decline."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The genetic mutation that causes EA6 typically affects the gene CACNA1A, not FKBP52.\n3. FALSE [correction]: FKBP52 gene is not typically associated with calcium homeostasis in neurons; it is more commonly associated with protein folding and steroid receptor regulation. The gene usually implicated in calcium regulation in neurons, related to episodic ataxia type 6, would be CACNA1A.\n4. FALSE [correction]: Since the FKBP52 gene is not the one associated with EA6, mutations in the FKBP52 gene are not known to lead to an imbalance in neuron calcium levels. It is mutations in the CACNA1A gene that can lead to such imbalances since it encodes a subunit of a voltage-dependent calcium channel.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify chromatin structure by adding or removing methyl groups to histone proteins, which are the chief proteins in chromatin. These enzymes play important roles in regulating gene expression, chromatin remodeling, and other cellular processes.\nIn animals, there are several types of chromomethylases that have been identified, including histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs). These enzymes are involved in various cellular processes, including transcriptional activation, repression, and maintenance of chromatin structure.\nFor example, histone H3 lysine 4 trimethylation (H3K4me3) is a mark that is typically associated with active gene promotion and transcriptional activation. HMTs such as SETDB1 (also known as EHMT2) and G9a (also known as KMT1E) are responsible for adding the H3K4me3 mark to histone H3.\nSimilarly, histone H3 lysine 27 trimethylation (H3K27me3) is a mark that is typically associated with gene repression and chromatin compaction. LSDs such as KDM5B (also known as LSD1) and KDM5C (also known as LSD2) are responsible for removing the H3K27me3 mark from histone H3.\nIn addition to these HMTs and LSDs, there are also other chromomethylases that are involved in various cellular processes, such as DNA damage response, cell cycle regulation, and stem cell maintenance.\nOverall, chromomethylases play important roles in regulating chromatin structure and gene expression in animal genomes, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes present in animal genomes that modify chromatin structure by methylation of histone proteins.\n2. Chromomethylases are involved in processes such as regulating gene expression, chromatin remodeling, and other cellular processes in animals.\n3. Histone methyltransferases and lysine-specific demethylases are types of chromomethylases identified in animals.\n4. SETDB1 (EHMT2) and G9a (KMT1E) are HMTs responsible for adding histone H3 lysine 4 trimethylation (H3K4me3) mark, which is associated with active gene promotion.\n5. KDM5B (also known as LSD1) and KDM5C (also known as LSD2) are LSDs responsible for removing histone H3 lysine 27 trimethylation (H3K27me3) mark, typically associated with gene repression.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes present in animal genomes that modify chromatin structure by methylation of histone proteins.",
      "Chromomethylases are involved in processes such as regulating gene expression, chromatin remodeling, and other cellular processes in animals.",
      "Histone methyltransferases and lysine-specific demethylases are types of chromomethylases identified in animals.",
      "SETDB1 (EHMT2) and G9a (KMT1E) are HMTs responsible for adding histone H3 lysine 4 trimethylation (H3K4me3) mark, which is associated with active gene promotion.",
      "KDM5B (also known as LSD1) and KDM5C (also known as LSD2) are LSDs responsible for removing histone H3 lysine 27 trimethylation (H3K27me3) mark, typically associated with gene repression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes present in plant genomes that modify chromatin structure by methylation of DNA, not histone proteins.\n2. FALSE [correction]: Given that chromomethylases are present in plants, not animals, the processes they are involved in would pertain to plants. However, enzymes in animals do perform similar functions as described but would be categorized differently, not as chromomethylases.\n3. FALSE [correction]: Histone methyltransferases (HMTs) and lysine-specific demethylases (LSDs) are different from chromomethylases. They are enzymes identified in both plant and animal genomes responsible for histone methylation and demethylation, respectively, not DNA methylation.\n4. FALSE [correction]: SETDB1 (EHMT2) and G9a (KMT1C) are indeed histone methyltransferases (HMTs), but they are responsible for the methylation of histone H3 lysine 9 (H3K9), not lysine 4. H3K4me3 is a mark associated with active gene transcription and is typically added by different HMTs like MLL/SET1 complexes.\n5. FALSE [correction]: KDM5B (also known as JARID1B) and KDM5C (also known as JARID1C) are indeed lysine-specific demethylases (LSDs), but they are responsible for the demethylation of histone H3 lysine 4 (H3K4), not lysine 27 (H3K27). LSD1 (KDM1A) is a demethylase that can remove methylation from H3K4 or H3K9, depending on the context, and KDM5B and KDM5C specifically demethylate di- and tri-methylated H3K4. H3K27me3 is typically demethylated by the UTX (KDM6A) or JMJD3 (KDM6B) enzymes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Certainly! There are several packages available in R/Bioconductor for analyzing transcription factor binding sites (TFBS). Here are some of the popular ones:\n1. TFBS: This package provides a comprehensive set of tools for the analysis of TFBS. It includes functions for motif discovery, motif visualization, and the prediction of TFBS.\n2. TRANSFAC: This package is a widely used tool for the prediction of TFBS in DNA sequences. It uses a database of known TFBS to predict the binding sites in a given DNA sequence.\n3. MatInspector: This package provides a comprehensive set of tools for the analysis of TFBS, including motif discovery, motif visualization, and the prediction of TFBS. It also includes functions for the analysis of ChIP-seq data.\n4. HISAT2: This package is a popular tool for the analysis of ChIP-seq data, which can also be used for the prediction of TFBS. It provides a comprehensive set of tools for the analysis of ChIP-seq data, including peak calling, motif discovery, and the analysis of DNA sequence nearby the binding sites.\n5. DeepSEA: This package provides a comprehensive set of tools for the analysis of TFBS in deep-sequencing data, including ChIP-seq and RNA-seq data. It includes functions for motif discovery, motif visualization, and the prediction of TFBS.\n6. TFTools: This package provides a comprehensive set of tools for the analysis of TFBS in DNA sequences. It includes functions for motif discovery, motif visualization, and the prediction of TFBS.\n7. GSEA: This package provides a comprehensive set of tools for the analysis of TFBS in gene expression data. It includes functions for motif discovery, motif visualization, and the prediction of TFBS.\n8. ARTE: This package provides a comprehensive set of tools for the analysis of TFBS in DNA sequences. It includes functions for motif discovery, motif visualization, and the prediction of TFBS.\n9. DREAM: This package provides a comprehensive set of tools for the analysis of TFBS in DNA sequences. It includes functions for motif discovery, motif visualization, and the prediction of T",
    "llama-2-7b-chat-hf_fact_raw": "1. The TFBS package is available in R/Bioconductor for analyzing transcription factor binding sites and includes motif discovery and visualization functions.\n2. TRANSFAC is an R/Bioconductor package used for predicting transcription factor binding sites using a database of known TFBS.\n3. MatInspector provides tools in R/Bioconductor for TFBS analysis, including ChIP-seq data analysis functions.\n4. HISAT2 is an R/Bioconductor package used for analyzing ChIP-seq data and predicting transcription factor binding sites.\n5. DeepSEA is a tool in R/Bioconductor designed for analyzing TFBS in deep-sequencing data, including ChIP-seq and RNA-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "The TFBS package is available in R/Bioconductor for analyzing transcription factor binding sites and includes motif discovery and visualization functions.",
      "TRANSFAC is an R/Bioconductor package used for predicting transcription factor binding sites using a database of known TFBS.",
      "MatInspector provides tools in R/Bioconductor for TFBS analysis, including ChIP-seq data analysis functions.",
      "HISAT2 is an R/Bioconductor package used for analyzing ChIP-seq data and predicting transcription factor binding sites.",
      "DeepSEA is a tool in R/Bioconductor designed for analyzing TFBS in deep-sequencing data, including ChIP-seq and RNA-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TRANSFAC is a database and not an R/Bioconductor package. It contains data on transcription factors, their binding sites, and regulated genes.\n3. FALSE [correction]: MatInspector is not an R/Bioconductor tool; it is part of the Genomatix Software Suite and is used for identifying transcription factor binding sites but does not specifically have ChIP-seq data analysis functions.\n4. FALSE [correction]: HISAT2 is not an R/Bioconductor package; it is a fast and sensitive alignment program for mapping next-generation sequencing reads (DNA and RNA) but is not used for predicting transcription factor binding sites.\n5. FALSE [correction]: DeepSEA is a deep learning-based algorithmic framework for predicting the effects of noncoding variants on DNA sequences, including TFBS, but it is not a tool within R/Bioconductor. It is a standalone tool that can be used with various types of sequencing data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Certainly, I'd be happy to help! Here are some clinical trials for the prevention of sarcopenia:\n1. A randomized controlled trial published in the Journal of the American Medical Directors Association in 2018 found that a 12-month exercise program consisting of resistance training and aerobic exercise improved muscle mass and strength in older adults.\n2. A systematic review and meta-analysis published in the journal Age in 2019 found that resistance training and protein supplementation were effective in preventing sarcopenia in older adults.\n3. A randomized controlled trial published in the Journal of the American Geriatrics Society in 2017 found that a 12-month exercise program consisting of resistance training and balance exercises improved muscle mass and functional ability in older adults.\n4. A randomized controlled trial published in the Journal of Gerontology in 2018 found that a 6-month exercise program consisting of resistance training and aerobic exercise improved muscle mass and strength in older adults with sarcopenia.\n5. A systematic review and meta-analysis published in the journal Nutrients in 2020 found that a combination of resistance training, aerobic exercise, and nutritional interventions (such as protein supplementation and caloric restriction) were effective in preventing sarcopenia in older adults.\n6. A randomized controlled trial published in the Journal of the American Geriatrics Society in 2019 found that a 12-month exercise program consisting of resistance training and balance exercises improved muscle mass and functional ability in older adults with mild cognitive impairment.\n7. A randomized controlled trial published in the Journal of Aging Research in 2018 found that a 6-month exercise program consisting of resistance training and aerobic exercise improved muscle mass and functional ability in older adults with chronic obstructive pulmonary disease (COPD).\n8. A systematic review and meta-analysis published in the journal Ageing Research Reviews in 2020 found that a combination of exercise and nutritional interventions (such as protein supplementation and caloric restriction) were effective in preventing sarcopenia in older adults.\nTh",
    "llama-2-7b-chat-hf_fact_raw": "1. A 12-month exercise program comprised of resistance training and aerobic exercise was found to improve muscle mass and strength in older adults, according to a trial published in the Journal of the American Medical Directors Association in 2018.\n2. Resistance training and protein supplementation have been proven effective in preventing sarcopenia in older adults, as per a systematic review and meta-analysis published in the journal Age in 2019.\n3. A trial published in the Journal of the American Geriatrics Society in 2017 found that resistance training and balance exercises, over a 12-month period, improved muscle mass and functional ability in older adults.\n4. A 6-month exercise program including resistance training and aerobic exercise improved muscle mass and strength in older adults with sarcopenia, as reported by a trial published in the Journal of Gerontology in 2018.\n5. A combination of resistance training, aerobic exercise, and nutritional interventions such as protein supplementation and caloric restriction was effective in preventing sarcopenia, according to a systematic review and meta-analysis published in the journal Nutrients in 2020.",
    "llama-2-7b-chat-hf_fact": [
      "A 12-month exercise program comprised of resistance training and aerobic exercise was found to improve muscle mass and strength in older adults, according to a trial published in the Journal of the American Medical Directors Association in 2018.",
      "Resistance training and protein supplementation have been proven effective in preventing sarcopenia in older adults, as per a systematic review and meta-analysis published in the journal Age in 2019.",
      "A trial published in the Journal of the American Geriatrics Society in 2017 found that resistance training and balance exercises, over a 12-month period, improved muscle mass and functional ability in older adults.",
      "A 6-month exercise program including resistance training and aerobic exercise improved muscle mass and strength in older adults with sarcopenia, as reported by a trial published in the Journal of Gerontology in 2018.",
      "A combination of resistance training, aerobic exercise, and nutritional interventions such as protein supplementation and caloric restriction was effective in preventing sarcopenia, according to a systematic review and meta-analysis published in the journal Nutrients in 2020."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the specific details included in each statement pertaining to the publication of the studies, the outcomes, and the publication years, these statements appear to be summaries of the findings of various studies. Without the ability to verify the exact contents of the journals and studies mentioned, the statements seem plausible and consistent based on common gerontological research themes. If any statement included incorrect information about the publication, date, or findings, that would require access to the respective journals and articles for verification.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "The database of molecular recognition features in membrane proteins is the \"Membrane Protein Structural Bioinformatics Resource (MPSBR)\" [1]. MPSBR is a comprehensive database that provides information on the structural and functional properties of membrane proteins, including their molecular recognition features.\nMPSBR contains a wide range of data types, including:\n1. Structure: 3D structures of membrane proteins, including both solved and predicted structures.\n2. Sequence: Amino acid sequences of membrane proteins, including both full-length and truncated forms.\n3. Function: Information on the functional domains and sites of membrane proteins, such as transmembrane helices, loops, and binding sites.\n4. Interactions: Information on the interactions between membrane proteins and other molecules, such as ligands, substrates, and other proteins.\n5. Energetics: Information on the energetics of membrane protein structure and function, including hydrophobic and hydrophilic interactions, electrostatic potential, and binding affinity.\n6. Machine learning models: Machine learning models that predict the structure, function, and interactions of membrane proteins based on their sequence and structural features.\nBy providing a comprehensive view of the molecular recognition features of membrane proteins, MPSBR is a valuable resource for researchers studying the structure, function, and dynamics of these important biomolecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. The database of molecular recognition features in membrane proteins is called the \"Membrane Protein Structural Bioinformatics Resource (MPSBR).\"\n2. MPSBR provides information on the structural and functional properties of membrane proteins.\n3. MPSBR contains 3D structures of membrane proteins, including solved and predicted structures.\n4. MPSBR includes amino acid sequences of membrane proteins, in full-length and truncated forms.\n5. The database has information on interactions between membrane proteins and other molecules, such as ligands and substrates.",
    "llama-2-7b-chat-hf_fact": [
      "The database of molecular recognition features in membrane proteins is called the \"Membrane Protein Structural Bioinformatics Resource (MPSBR).\"",
      "MPSBR provides information on the structural and functional properties of membrane proteins.",
      "MPSBR contains 3D structures of membrane proteins, including solved and predicted structures.",
      "MPSBR includes amino acid sequences of membrane proteins, in full-length and truncated forms.",
      "The database has information on interactions between membrane proteins and other molecules, such as ligands and substrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The database of molecular recognition features in membrane proteins is known as the \"Membrane Protein Data Bank (MPDB)\" or \"Membrane Proteins of Known 3D Structure.\" There is no widely recognized database specifically called the \"Membrane Protein Structural Bioinformatics Resource (MPSBR).\"\n\n2. TRUE: A database like the Membrane Protein Data Bank or similar resources would provide information on the structural and functional properties of membrane proteins.\n\n3. TRUE: Databases dedicated to membrane proteins usually include 3D structures of membrane proteins, both solved by experimental methods and predicted by computational techniques.\n\n4. UNKNOWN: While many bioinformatics databases include amino acid sequences, without specific reference to the MPSBR, which seems to be a fictional or incorrect name, it's unclear whether this statement is accurate for the database in question.\n\n5. TRUE: A comprehensive database for membrane proteins would typically have information on interactions between membrane proteins and other molecules such as ligands and substrates, which are crucial for understanding their biological functions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is a direct oral anticoagulant that is metabolized by the liver and kidneys. The main metabolic pathway of rivaroxaban involves the enzyme CYP2C9, which is primarily found in the liver, and to a lesser extent in the kidneys. The kidneys are responsible for about 20-30% of rivaroxaban metabolism, with the remaining metabolism occurring in the liver. The metabolites of rivaroxaban are further conjugated and excreted in the urine.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver and kidneys.\n2. The enzyme CYP2C9 is primarily found in the liver and is involved in the metabolism of rivaroxaban.\n3. The kidneys account for approximately 20-30% of rivaroxaban metabolism.\n4. The metabolites of rivaroxaban are excreted in the urine.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver and kidneys.",
      "The enzyme CYP2C9 is primarily found in the liver and is involved in the metabolism of rivaroxaban.",
      "The kidneys account for approximately 20-30% of rivaroxaban metabolism.",
      "The metabolites of rivaroxaban are excreted in the urine."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The enzyme CYP3A4 and CYP2J2, rather than CYP2C9, are primarily involved in the metabolism of rivaroxaban.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a nuclear receptor that plays a crucial role in regulating cardiac function and development. It is primarily expressed in the heart, where it regulates the expression of genes involved in cardiac contractility, hypertrophy, and fibrosis. Some of the genes known to be regulated by TRalpha2 in the heart include:\n1. beta-MHC (beta-myosin heavy chain): TRalpha2 regulates the expression of beta-MHC, which is a critical component of the cardiac contractile apparatus.\n2. ANF (alpha-myosin heavy chain): TRalpha2 also regulates the expression of ANF, another important component of the cardiac contractile apparatus.\n3. TNNI3 (troponin I3): TRalpha2 regulates the expression of TNNI3, a protein that plays a crucial role in the regulation of cardiac contractility.\n4. TNNT2 (troponin T2): TRalpha2 regulates the expression of TNNT2, another protein involved in the regulation of cardiac contractility.\n5. CTGF (connective tissue growth factor): TRalpha2 regulates the expression of CTGF, a protein that is involved in the regulation of cardiac fibrosis.\n6. Collagen type I: TRalpha2 regulates the expression of the gene encoding collagen type I, a critical component of the extracellular matrix that provides structural support to the heart.\n7. Fibrinogen: TRalpha2 regulates the expression of the gene encoding fibrinogen, a protein involved in blood clotting and cardiac remodeling.\n8. VEGF (vascular endothelial growth factor): TRalpha2 regulates the expression of VEGF, a protein involved in angiogenesis and cardiac remodeling.\n9. BNP (brain natriuretic peptide): TRalpha2 regulates the expression of the gene encoding BNP, a peptide hormone involved in the regulation of cardiac function and remodeling.\n10. NFAT (nuclear factor of activated T cells): TRalpha2 regulates the expression of the gene encoding NFAT, a transcription factor involved in the regulation of cardiac hypertro",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is a nuclear receptor that regulates cardiac function and development.\n2. TRalpha2 is primarily expressed in the heart.\n3. TRalpha2 regulates the expression of the beta-myosin heavy chain (beta-MHC) gene.\n4. TRalpha2 regulates the expression of the connective tissue growth factor (CTGF) gene.\n5. TRalpha2 regulates the expression of the vascular endothelial growth factor (VEGF) gene.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is a nuclear receptor that regulates cardiac function and development.",
      "TRalpha2 is primarily expressed in the heart.",
      "TRalpha2 regulates the expression of the beta-myosin heavy chain (beta-MHC) gene.",
      "TRalpha2 regulates the expression of the connective tissue growth factor (CTGF) gene.",
      "TRalpha2 regulates the expression of the vascular endothelial growth factor (VEGF) gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TRalpha2 is not exclusively or primarily expressed in the heart; it is expressed in several tissues, including brain, liver, and kidney.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several biomedical question answering systems available, including:\n1. PubMed: A comprehensive database of biomedical literature maintained by the National Library of Medicine.\nExample question: \"What are the latest research findings on the role of inflammation in Alzheimer's disease?\"\nAnswer: PubMed can provide a list of recent articles and studies on this topic, including the abstracts and summaries of the findings.\n2. Google Scholar: A search engine specifically designed for academic and scholarly research, providing access to a vast collection of articles, theses, books, and other publications.\nExample question: \"What are the potential side effects of taking statins for high cholesterol?\"\nAnswer: Google Scholar can provide a list of recent articles and studies on this topic, including the abstracts and summaries of the findings, as well as a way to filter the results by date, author, and more.\n3. BioMed Central: A publishing platform that provides open access to over 250 peer-reviewed, online journals in the life sciences, including medicine, biology, and genetics.\nExample question: \"What are the current treatments for Ebola virus disease?\"\nAnswer: BioMed Central can provide a list of recent articles and studies on this topic, including the abstracts and summaries of the findings, as well as links to the full text of the articles.\n4. DrugBank: A comprehensive online database of drugs, drug targets, and drug interactions, providing information on the pharmacology, pharmacokinetics, and pharmacodynamics of drugs.\nExample question: \"What are the potential drug interactions with methotrexate, a chemotherapy drug used to treat cancer?\"\nAnswer: DrugBank can provide a list of drugs that interact with methotrexate, including the mechanism of interaction, the severity of the interaction, and the recommended dosage adjustments.\n5. Gene Ontology: A resource that provides a standardized vocabulary for describing the functions of genes and the biological processes they are involved in.\nExample question: \"What are the genes involved in the development of the nervous system?\"\nAnswer: Gene Ontology can provide a list of genes that are involved in the development of the nerv",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed is a database of biomedical literature maintained by the National Library of Medicine.\n2. Google Scholar is a search engine designed for academic and scholarly research with access to various publications.\n3. BioMed Central is a publishing platform that offers over 250 peer-reviewed, open access online journals in life sciences.\n4. DrugBank is an online database that contains information on drugs, drug targets, and drug interactions.\n5. Gene Ontology provides a standardized vocabulary for describing gene functions and biological processes.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed is a database of biomedical literature maintained by the National Library of Medicine.",
      "Google Scholar is a search engine designed for academic and scholarly research with access to various publications.",
      "BioMed Central is a publishing platform that offers over 250 peer-reviewed, open access online journals in life sciences.",
      "DrugBank is an online database that contains information on drugs, drug targets, and drug interactions.",
      "Gene Ontology provides a standardized vocabulary for describing gene functions and biological processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! The trancription factor that activates the betalain pathway is:\nabetter regulator (ABR)",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! For global quantitative phosphoproteomic analyses, there are several technologies that are commonly used for enrichment of phosphorylated peptides. Here are some of the preferred technologies:\n1. TiO2-based enrichment: This is a widely used method for phosphoproteomics, which involves immunoprecipitating the protein of interest and then incubating it with a TiO2 matrix. The phosphorylated peptides are then enriched on the TiO2 surface and detected using mass spectrometry.\n2. IMAC (Immunomagnetic bead) enrichment: This method uses magnetic beads conjugated to an anti-phosphorylation antibody to capture phosphorylated peptides. The beads are then washed and analyzed by mass spectrometry.\n3. PD-10 enrichment: PD-10 is a column-based enrichment method that uses a matrix of aminocaproic acid to capture phosphorylated peptides. The captured peptides are then eluted and analyzed by mass spectrometry.\n4. Protocol-based enrichment: This method uses a combination of enzymes and chemicals to selectively cleave and capture phosphorylated peptides. The captured peptides are then analyzed by mass spectrometry.\n5. Microfluidic-based enrichment: This method uses microfluidics to isolate phosphorylated peptides from the rest of the sample. The isolated peptides are then analyzed by mass spectrometry.\n6. Enrichment using protein G beads: Protein G beads are used to capture phosphorylated peptides, which are then eluted and analyzed by mass spectrometry.\n7. Enrichment using metal-chelating beads: Metal-chelating beads are used to capture phosphorylated peptides, which are then eluted and analyzed by mass spectrometry.\n8. Enrichment using hydrazide-based beads: Hydrazide-based beads are used to capture phosphorylated peptides, which are then eluted and analyzed by mass",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment is a method used for the enrichment of phosphorylated peptides in phosphoproteomics.\n2. IMAC (Immunomagnetic bead) enrichment uses magnetic beads conjugated to an anti-phosphorylation antibody to capture phosphorylated peptides.\n3. PD-10 enrichment is a column-based method utilizing a matrix of aminocaproic acid to capture phosphorylated peptides.\n4. Protocol-based enrichment employs a combination of enzymes and chemicals to selectively capture phosphorylated peptides.\n5. Microfluidic-based enrichment uses microfluidics technology to isolate phosphorylated peptides for analysis.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment is a method used for the enrichment of phosphorylated peptides in phosphoproteomics.",
      "IMAC (Immunomagnetic bead) enrichment uses magnetic beads conjugated to an anti-phosphorylation antibody to capture phosphorylated peptides.",
      "PD-10 enrichment is a column-based method utilizing a matrix of aminocaproic acid to capture phosphorylated peptides.",
      "Protocol-based enrichment employs a combination of enzymes and chemicals to selectively capture phosphorylated peptides.",
      "Microfluidic-based enrichment uses microfluidics technology to isolate phosphorylated peptides for analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: IMAC (Immobilized Metal Affinity Chromatography) enrichment uses metal ions (usually Fe3+ or Ga3+) immobilized on a matrix to capture phosphorylated peptides, not magnetic beads conjugated to an anti-phosphorylation antibody.\n3. UNKNOWN \n4. UNKNOWN \n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is used to rate the severity of Rett syndrome, a neurodevelopmental disorder caused by mutations in the MECP2 gene. The Palmini classification system categorizes Rett syndrome into four levels of severity, based on the presence and severity of clinical features such as intellectual disability, seizures, and motor difficulties. The levels are:\n* Level 1: Mild Rett syndrome, with minimal clinical symptoms\n* Level 2: Moderate Rett syndrome, with moderate intellectual disability and seizures\n* Level 3: Severe Rett syndrome, with significant intellectual disability and multiple medical problems\n* Level 4: Profound Rett syndrome, with severe intellectual disability and significant motor and sensory impairments.\nIt is important to note that the Palmini classification system is not a diagnostic tool, but rather a way to categorize the severity of the disorder in individuals with Rett syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of Rett syndrome.\n2. Rett syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene.\n3. The Palmini classification system categorizes Rett syndrome into four levels of severity.\n4. The classification includes levels such as mild, moderate, severe, and profound Rett syndrome, based on clinical features.\n5. The Palmini classification is not a diagnostic tool for Rett syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of Rett syndrome.",
      "Rett syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene.",
      "The Palmini classification system categorizes Rett syndrome into four levels of severity.",
      "The classification includes levels such as mild, moderate, severe, and profound Rett syndrome, based on clinical features.",
      "The Palmini classification is not a diagnostic tool for Rett syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Rett Syndrome Severity Scale (RSSS), not the Palmini classification, is used to rate the severity of Rett syndrome.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and can cause pain, swelling, and difficulty swallowing. While the exact cause of subacute thyroiditis is not fully understood, several studies have suggested that viral infections may play a role in its development.\nOne of the most well-known viruses associated with subacute thyroiditis is the Epstein-Barr virus (EBV). EBV is a common herpesvirus that is known to infect over 90% of the global population, and it has been linked to the development of various diseases, including subacute thyroiditis. Studies have shown that EBV can infect thyroid cells and trigger an immune response that leads to inflammation and damage to the thyroid gland.\nOther viruses that have been linked to subacute thyroiditis include:\n* Human herpesvirus 6 (HHV-6): HHV-6 is a member of the herpesvirus family that has been implicated in the development of subacute thyroiditis.\n* Human adenovirus (HAdV): HAdV is a common double-stranded DNA virus that has been associated with subacute thyroiditis.\n* Respiratory viruses: Respiratory viruses, such as influenza and respiratory syncytial virus (RSV), have also been linked to subacute thyroiditis.\nIt is important to note that the exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not fully understood and may involve complex interactions between the virus, the immune system, and the thyroid gland. Further research is needed to determine the exact role of viruses in the etiology of subacute thyroiditis and to identify potential targets for therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is an inflammatory condition that can cause pain, swelling, and difficulty swallowing.\n3. The Epstein-Barr virus (EBV) has been linked to the development of subacute thyroiditis.\n4. Human herpesvirus 6 (HHV-6) has been implicated in the development of subacute thyroiditis.\n5. Human adenovirus (HAdV) has been associated with subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is an inflammatory condition that can cause pain, swelling, and difficulty swallowing.",
      "The Epstein-Barr virus (EBV) has been linked to the development of subacute thyroiditis.",
      "Human herpesvirus 6 (HHV-6) has been implicated in the development of subacute thyroiditis.",
      "Human adenovirus (HAdV) has been associated with subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While certain viruses like EBV and HHV-6 have been associated with subacute thyroiditis, there is no strong evidence implicating human adenovirus (HAdV) in the development of subacute thyroiditis as of my knowledge cutoff in 2023.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic translation initiation factor 2-alpha kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis and induction of autophagy. STAT3 is a transcription factor that regulates the expression of genes involved in various cellular processes, including inflammation, immune response, and cell survival.\nStudies have shown that STAT3 plays a critical role in regulating the expression of genes involved in autophagy, and that EIF2AK2-mediated phosphorylation of eIF2α can activate STAT3 and suppress autophagy. For example, one study found that EIF2AK2 phosphorylation of eIF2α leads to the activation of STAT3 and the suppression of autophagy in response to oxidative stress (1). Another study found that inhibition of STAT3 activity enhances autophagy in response to EIF2AK2 inhibition (2). These findings suggest that the interaction between EIF2AK2 and STAT3 plays a critical role in regulating the balance between protein synthesis and autophagy in response to cellular stress.\nReferences:\n1. Kim et al. (2015). EIF2AK2-mediated phosphorylation of eIF2α regulates the expression of genes involved in autophagy. Biochim Biophys Acta, 1852(11), 1939-1948.\n2. Li et al. (2013). STAT3 regulates the expression of genes involved in autophagy in response to EIF2AK2 inhibition. Biochem Biophys Res Commun, 430(2), 1042-1048.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.\n3. STAT3 is a transcription factor that regulates the expression of genes involved in inflammation, immune response, and cell survival.\n4. Phosphorylation of eIF2α by EIF2AK2 can activate STAT3 and suppress autophagy.\n5. Inhibition of STAT3 activity enhances autophagy in response to EIF2AK2 inhibition.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.",
      "STAT3 is a transcription factor that regulates the expression of genes involved in inflammation, immune response, and cell survival.",
      "Phosphorylation of eIF2α by EIF2AK2 can activate STAT3 and suppress autophagy.",
      "Inhibition of STAT3 activity enhances autophagy in response to EIF2AK2 inhibition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Phosphorylation of eIF2α by EIF2AK2 generally leads to an inhibition of global protein synthesis, which can affect various cellular processes, but there is no direct indication that it activates STAT3. Instead, this phosphorylation can be part of a stress response that may lead to autophagy.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool used for genomic analysis, specifically for the analysis of chromatin structure and gene regulation. It can be used to predict the 3D structure of chromosomes and the interactions between different regions of the genome, including the binding sites of transcription factors and other regulatory elements.\nTheatre can be used in a variety of ways, including:\n1. Chromatin structure prediction: Theatre can be used to predict the 3D structure of chromosomes based on the sequence of the genome. This can help researchers understand how the sequence of the genome is organized in 3D space and how this organization affects gene regulation.\n2. Transcription factor binding site prediction: Theatre can be used to predict the binding sites of transcription factors, which are proteins that regulate gene expression by binding to specific DNA sequences. By predicting the binding sites of transcription factors, researchers can gain insights into how gene expression is regulated and how different transcription factors interact with each other.\n3. Gene regulation analysis: Theatre can be used to analyze the regulation of genes at the level of chromatin structure. By predicting the 3D structure of chromosomes and the interactions between different regions of the genome, researchers can identify the regions of the genome that are involved in regulating specific genes.\n4. Epigenetic analysis: Theatre can be used to analyze the epigenetic marks that are associated with specific genes or regulatory elements. Epigenetic marks are chemical modifications to DNA or histone proteins that can affect gene expression without changing the underlying DNA sequence. By predicting the epigenetic marks associated with specific genes or regulatory elements, researchers can gain insights into how gene expression is regulated.\n5. Disease research: Theatre can be used to analyze the genomic structure and regulation in diseased cells, such as cancer cells. By identifying the changes in chromatin structure and gene regulation that occur in diseased cells, researchers can gain insights into the molecular mechanisms underlying disease and develop new therapeutic strategies.\nOverall, Theatre is a powerful tool for understanding the complex interactions between genes and their regulatory elements, and how these interactions are disrupted in disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for the analysis of chromatin structure and gene regulation.\n2. Theatre can predict the 3D structure of chromosomes based on the sequence of the genome.\n3. The software is capable of predicting the binding sites of transcription factors.\n4. Theatre can analyze epigenetic marks that affect gene expression without changing the underlying DNA sequence.\n5. Researchers can use Theatre for analyzing changes in chromatin structure and gene regulation in diseased cells.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for the analysis of chromatin structure and gene regulation.",
      "Theatre can predict the 3D structure of chromosomes based on the sequence of the genome.",
      "The software is capable of predicting the binding sites of transcription factors.",
      "Theatre can analyze epigenetic marks that affect gene expression without changing the underlying DNA sequence.",
      "Researchers can use Theatre for analyzing changes in chromatin structure and gene regulation in diseased cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The context does not provide enough information to conclude whether Theatre is a software tool used for the analysis of chromatin structure and gene regulation. Additionally, \"Theatre\" may not be the correct term for such a software; it could be a typographical error for a software name like \"Chromatin Theatre\" if such software exists.\n2. UNKNOWN: Without specific information about the capabilities of the software referred to as \"Theatre,\" it is not possible to determine the truth of this statement.\n3. UNKNOWN: Similarly, without additional context or confirmation, it is impossible to verify whether the software has this capability.\n4. UNKNOWN: The statement's correctness depends on specific features of the software, which are not provided in the context.\n5. UNKNOWN: Without further context about \"Theatre\" and its functionalities, the application of the software in analyzing diseased cells cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences and the similarity between them. The algorithm has a time complexity of O(n^2), where n is the length of the shorter sequence. This means that as the length of the sequences increases, the time required to perform the alignment also increases quadratically.\nFor example, if the two sequences are 100 nucleotides long, the algorithm will take approximately 10,000 times longer to align them than if they were 10 nucleotides long.\nIt's worth noting that there are faster and more efficient algorithms available for sequence alignment, such as the Needleman-Wunsch algorithm, which has a time complexity of O(n log n). However, the Smith-Waterman algorithm is still widely used in many applications due to its high accuracy and sensitivity.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm has a time complexity of O(n^2).\n2. The time required to perform the alignment with the Smith-Waterman algorithm increases quadratically with the length of the sequences.\n3. The Needleman-Wunsch algorithm has a time complexity of O(n log n).",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm has a time complexity of O(n^2).",
      "The time required to perform the alignment with the Smith-Waterman algorithm increases quadratically with the length of the sequences.",
      "The Needleman-Wunsch algorithm has a time complexity of O(n log n)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Needleman-Wunsch algorithm has a time complexity of O(n^2).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 is a member of the solute carrier (SLC) family of proteins. Specifically, it is a member of the SLC12 family, which is also known as the hydroxyl-carboxylate transporters.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the solute carrier (SLC) family of proteins.\n2. FLVCR1 belongs to the SLC12 family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the solute carrier (SLC) family of proteins.",
      "FLVCR1 belongs to the SLC12 family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is a member of the major facilitator superfamily (MFS) of transporters, not the solute carrier (SLC) family.\n2. FALSE [correction]: Since FLVCR1 does not belong to the SLC family of proteins, it cannot belong to the SLC12 family. It is actually part of a group of heme transporters.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Certainly! The biotinylation tagging approach is a technique used to identify protein-protein interaction partners by labeling a protein of interest with a biotin moiety, which can then be used to pull down and identify interacting proteins.\nUsing this approach, GATA-1 interacting partners have been identified as follows:\n1. KAT2A (also known as PRKAR1A): GATA-1 was shown to interact with KAT2A, a protein involved in protein kinase A (PKA) signaling, in a study published in the journal Nature Communications in 2017.\n2. TFIIA: GATA-1 was found to interact with TFIIA, a protein involved in transcription factor IIA, in a study published in the journal Molecular Cell in 2011.\n3. CBX3: GATA-1 was shown to interact with CBX3, a chromodomain-containing protein involved in chromatin remodeling, in a study published in the journal Cell Reports in 2016.\n4. RBBP4: GATA-1 was found to interact with RBBP4, a protein involved in RNA splicing and transcriptional elongation, in a study published in the journal Nature Communications in 2018.\n5. P53: GATA-1 was shown to interact with P53, a tumor suppressor protein, in a study published in the journal Oncogene in 2013.\nThese are just a few examples of the protein partners that have been identified through the use of the biotinylation tagging approach in the context of GATA-1 research. There may be additional partners that have been identified in other studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 was shown to interact with KAT2A in a study published in Nature Communications in 2017.\n2. GATA-1 was found to interact with TFIIA according to a study published in Molecular Cell in 2011.\n3. GATA-1 was shown to interact with CBX3 in a study published in Cell Reports in 2016.\n4. GATA-1 was found to interact with RBBP4 in a study published in Nature Communications in 2018.\n5. GATA-1 was shown to interact with P53 in a study published in Oncogene in 2013.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 was shown to interact with KAT2A in a study published in Nature Communications in 2017.",
      "GATA-1 was found to interact with TFIIA according to a study published in Molecular Cell in 2011.",
      "GATA-1 was shown to interact with CBX3 in a study published in Cell Reports in 2016.",
      "GATA-1 was found to interact with RBBP4 in a study published in Nature Communications in 2018.",
      "GATA-1 was shown to interact with P53 in a study published in Oncogene in 2013."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe veracity of these statements would require access to specific scientific literature published in the journals mentioned in the years specified. Without reviewing the actual publications or the latest research findings, it is not possible to confirm the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided, it seems that TAF10 interacting with the GATA1 transcription factor leads to the activation of transcription. GATA1 is a transcription factor that plays a crucial role in regulating gene expression in hematopoietic cells, and TAF10 is a component of the transcriptional elongation complex RNA polymerase II. When TAF10 interacts with GATA1, it helps to recruit RNA polymerase II to the promoter region of GATA1-regulated genes, leading to the initiation of transcription. This outcome is consistent with the role of TAF10 in facilitating the processivity of RNA polymerase II during transcription elongation.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interaction with the GATA1 transcription factor leads to the activation of transcription.\n2. GATA1 is a transcription factor that regulates gene expression in hematopoietic cells.\n3. TAF10 is a component of the transcriptional elongation complex RNA polymerase II.\n4. The interaction between TAF10 and GATA1 aids in recruiting RNA polymerase II to the promoter region of GATA1-regulated genes.\n5. TAF10 facilitates the processivity of RNA polymerase II during transcription elongation.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interaction with the GATA1 transcription factor leads to the activation of transcription.",
      "GATA1 is a transcription factor that regulates gene expression in hematopoietic cells.",
      "TAF10 is a component of the transcriptional elongation complex RNA polymerase II.",
      "The interaction between TAF10 and GATA1 aids in recruiting RNA polymerase II to the promoter region of GATA1-regulated genes.",
      "TAF10 facilitates the processivity of RNA polymerase II during transcription elongation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: TAF10 is a component of the general transcription factor complex TFIID, not specifically the transcriptional elongation complex.\n4. TRUE\n5. FALSE [correction]: TAF10 does not facilitate the processivity of RNA polymerase II during transcription elongation; it is involved in the formation of the TFIID complex which plays a role in the initiation of transcription.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare professionals with clinical decision-making support by analyzing patient data and providing recommendations for diagnosis, treatment, and management of chronic pain.\nSome examples of DSS for chronic pain management include:\n1. Chronic Pain Management Decision Support System (CPMDSS): This system was developed by the University of Washington and provides clinicians with evidence-based recommendations for managing chronic pain, including medication selection, dosing, and monitoring.\n2. Pain Management Pro (PMP): This DSS is designed for primary care physicians and provides recommendations for pain management based on the latest clinical guidelines and evidence. It also includes a decision-making algorithm that helps clinicians choose the most appropriate treatment for each patient.\n3. PainCare: This DSS is a comprehensive tool that provides clinicians with information on pain assessment, diagnosis, and treatment options. It also includes a decision support module that helps clinicians choose the most appropriate treatment for each patient based on their individual needs.\n4. Pain Management and Outcomes (PMO): This DSS is designed for use in hospitals and provides clinicians with real-time data and feedback on pain management practices. It also includes a decision support module that helps clinicians choose the most appropriate treatment for each patient based on their individual needs.\n5. Clinical Pain Management Decision Support System (CPMDSS): This system is designed for use in primary care and specialty pain clinics and provides clinicians with evidence-based recommendations for managing chronic pain. It also includes a decision-making algorithm that helps clinicians choose the most appropriate treatment for each patient.\nThese are just a few examples of the many DSS available for chronic pain management. By using these systems, clinicians can provide more effective and personalized care for their patients, leading to improved pain management outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. A Decision Support System (DSS) is a computer-based system that assists healthcare professionals with clinical decision-making by analyzing patient data and providing recommendations.\n2. The Chronic Pain Management Decision Support System (CPMDSS) was developed by the University of Washington.\n3. Pain Management Pro (PMP) is a DSS designed for primary care physicians to provide recommendations based on clinical guidelines and evidence.\n4. PainCare is a comprehensive DSS that includes a module for clinical decision support based on individual patient needs.\n5. Pain Management and Outcomes (PMO) is a DSS used in hospitals that provides real-time data and feedback on pain management practices.",
    "llama-2-7b-chat-hf_fact": [
      "A Decision Support System (DSS) is a computer-based system that assists healthcare professionals with clinical decision-making by analyzing patient data and providing recommendations.",
      "The Chronic Pain Management Decision Support System (CPMDSS) was developed by the University of Washington.",
      "Pain Management Pro (PMP) is a DSS designed for primary care physicians to provide recommendations based on clinical guidelines and evidence.",
      "PainCare is a comprehensive DSS that includes a module for clinical decision support based on individual patient needs.",
      "Pain Management and Outcomes (PMO) is a DSS used in hospitals that provides real-time data and feedback on pain management practices."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the nature of the statements provided, it seems they are related to specific healthcare technology tools, likely Decision Support Systems (DSS) aimed at assisting with pain management. These statements would require access to current specialized databases or resources specific to healthcare technology, which may include academic publications, industry reports, or databases related to hospital information systems, in order to verify the development origins and the functionalities of particular systems like CPMDSS, PMP, PainCare, and PMO. Without that information, the truthfulness of statements 2 through 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "The subcellular localization of the protein angiogenin is primarily cytoplasmic. Angiogenin is a pro-angiogenic factor that plays a key role in the regulation of angiogenesis, the process of blood vessel formation. It is secreted from endothelial cells and circulating cells, such as platelets and monocytes, and can diffuse into the extracellular space, where it can interact with other proteins and modulate their activity. Once inside the cytoplasm, angiogenin can interact with various signaling proteins and regulate their activity, leading to changes in gene expression and the formation of new blood vessels.",
    "llama-2-7b-chat-hf_fact_raw": "1. The subcellular localization of the protein angiogenin is primarily in the cytoplasm.\n2. Angiogenin is a pro-angiogenic factor involved in the regulation of angiogenesis.\n3. Angiogenin is secreted from endothelial cells.\n4. Angiogenin is secreted from circulating cells such as platelets and monocytes.\n5. Angiogenin can interact with various signaling proteins in the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "The subcellular localization of the protein angiogenin is primarily in the cytoplasm.",
      "Angiogenin is a pro-angiogenic factor involved in the regulation of angiogenesis.",
      "Angiogenin is secreted from endothelial cells.",
      "Angiogenin is secreted from circulating cells such as platelets and monocytes.",
      "Angiogenin can interact with various signaling proteins in the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided appear to be consistent with established knowledge about angiogenin, which is a pro-angiogenic factor that can be found in the cytoplasm, is secreted by various cell types including endothelial cells, platelets, and monocytes, and can interact with various signaling proteins within the cytoplasm to regulate angiogenesis. However, without specific scientific references, it's essential to note that there may be additional contexts or nuances not addressed by these broad statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Ranolazine is a drug that has been shown to affect kinase signaling activation in the heart. Specifically, it has been shown to inhibit the activation of the protein kinase Akt, which is a key regulator of cell survival and metabolism in the heart.\nAkt is activated downstream of the PI3K (phosphatidylinositol 3-kinase) signaling pathway, which is activated by a variety of growth factors and hormones. When PI3K is activated, it generates phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits and activates Akt. Akt then phosphorylates and activates a number of downstream targets, including the Ser/Thr kinase protein kinase B (PKB), which is also known as Akt.\nRanolazine has been shown to inhibit the activation of Akt in the heart by blocking the activity of PI3K. This can lead to decreased cell survival and metabolism in the heart, which can contribute to the development of heart failure.\nIn summary, ranolazine affects kinase signaling activation in the heart by inhibiting the activity of the PI3K signaling pathway and downstream targets, including Akt.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activation of the protein kinase Akt in the heart.\n2. Akt is a key regulator of cell survival and metabolism in the heart.\n3. Akt is activated downstream of the PI3K signaling pathway.\n4. PI3K activation leads to the generation of PIP3, which recruits and activates Akt.\n5. Ranolazine's inhibition of Akt in the heart occurs through blocking the activity of PI3K.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activation of the protein kinase Akt in the heart.",
      "Akt is a key regulator of cell survival and metabolism in the heart.",
      "Akt is activated downstream of the PI3K signaling pathway.",
      "PI3K activation leads to the generation of PIP3, which recruits and activates Akt.",
      "Ranolazine's inhibition of Akt in the heart occurs through blocking the activity of PI3K."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is primarily known to inhibit the late sodium current in the heart, not the activation of the protein kinase Akt.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While Ranolazine inhibits the late sodium current in the heart, there is no direct evidence suggesting that it blocks the activity of PI3K to inhibit Akt. Its primary mechanism is not through the PI3K/Akt pathway.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "No, the regulation of Vsr endonuclease is not entirely independent of the growth phase of bacteria. While Vsr is primarily regulated by the transcriptional activator Vfr, which is constitutively expressed in E. coli, the activity of Vfr is influenced by the growth phase of the bacteria.\nDuring the logarithmic growth phase, when bacterial cells are actively dividing, Vfr is bound to the operator region of the vsr gene and activates its transcription. As the bacteria enter the stationary phase, the availability of nutrients and the concentration of certain signaling molecules changes, leading to a decrease in Vfr activity and a decrease in vsr transcription.\nIn addition, the expression of other genes involved in DNA repair and recombination, such as RecA and RecB, is also regulated by the growth phase of the bacteria. For example, RecA expression is induced during the stationary phase, and RecB expression is induced during the early logarithmic phase.\nTherefore, while the regulation of Vsr endonuclease is not entirely dependent on the growth phase of bacteria, it is influenced by the overall growth cycle of the organism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is influenced by the growth phase of bacteria.\n2. Vsr endonuclease is primarily regulated by the transcriptional activator Vfr in E. coli.\n3. During the logarithmic growth phase, Vfr activates the transcription of the vsr gene by binding to the operator region.\n4. The availability of nutrients and concentration of certain signaling molecules can lead to a decrease in Vfr activity as bacteria enter the stationary phase.\n5. The expression of DNA repair and recombination genes such as RecA and RecB is regulated by the growth phase of bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is influenced by the growth phase of bacteria.",
      "Vsr endonuclease is primarily regulated by the transcriptional activator Vfr in E. coli.",
      "During the logarithmic growth phase, Vfr activates the transcription of the vsr gene by binding to the operator region.",
      "The availability of nutrients and concentration of certain signaling molecules can lead to a decrease in Vfr activity as bacteria enter the stationary phase.",
      "The expression of DNA repair and recombination genes such as RecA and RecB is regulated by the growth phase of bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The regulation of various enzymes, including endonucleases like Vsr, can be influenced by the growth phase of bacteria as their metabolic needs and environmental responses change.\n2. FALSE [correction]: Vsr endonuclease in E. coli is regulated by the DNA mismatch repair system and not by a transcriptional activator named Vfr. The endonuclease recognizes specific DNA mismatches and initiates repair mechanisms.\n3. FALSE [correction]: The described mechanism involving Vfr activating the transcription of the vsr gene by binding to the operator region does not apply to Vsr endonuclease regulation in E. coli, as Vfr is not the regulator for vsr.\n4. TRUE: Bacterial gene expression, including the expression of genes involved in DNA repair and recombination, can be influenced by environmental factors such as nutrient availability and signaling molecule concentrations. While this statement doesn't specifically mention Vsr endonuclease, it is generally true that such factors can lead to changes in gene regulatory protein activities and therefore would affect whether enzymes like Vsr are more or less active during different growth phases like the stationary phase.\n5. TRUE: The expression of DNA repair and recombination genes is known to be regulated by the growth phase of bacteria. For example, in E. coli, the RecA protein, which is essential for DNA repair and the SOS response, is regulated in part by the growth phase of the bacterial culture.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! For the prediction of beta-barrel transmembrane proteins, there are several computational tools that can be used. Here are some of the commonly used tools:\n1. BepiPred: BepiPred is a web server that predicts the topology of beta-barrel transmembrane proteins based on their amino acid sequence. It uses a combination of sequence-based features and structural information to predict the transmembrane helices and the orientation of the protein in the membrane.\n2. TMHMM: TMHMM is a tool that predicts the transmembrane helices in a protein based on its sequence. It uses a combination of sequence-based features and structural information to predict the transmembrane helices and their orientation in the membrane.\n3. TopPred: TopPred is a web server that predicts the topology of transmembrane proteins based on their amino acid sequence. It uses a combination of sequence-based features and structural information to predict the transmembrane helices and their orientation in the membrane.\n4. PredictProtein: PredictProtein is a web server that predicts the structure and function of proteins based on their amino acid sequence. It includes tools for predicting the topology of transmembrane proteins, including beta-barrel proteins.\n5. I-TASSER: I-TASSER is a web server that predicts the structure of transmembrane proteins based on their amino acid sequence. It uses a combination of sequence-based features and structural information to predict the transmembrane helices and their orientation in the membrane.\n6. TMPro: TMPro is a tool that predicts the transmembrane helices in a protein based on its amino acid sequence. It uses a combination of sequence-based features and structural information to predict the transmembrane helices and their orientation in the membrane.\n7. TM-align: TM-align is a tool that aligns multiple transmembrane protein structures to identify conserved features and predict the topology of new proteins. It can be used to predict the topology of beta-barrel transmembrane proteins.\n8. PHD-TOPO: PHD-TOPO is a tool that predicts the topology of transmembrane proteins based on",
    "llama-2-7b-chat-hf_fact_raw": "1. BepiPred is a web server that predicts the topology of beta-barrel transmembrane proteins using a combination of sequence-based features and structural information.\n2. TMHMM predicts the transmembrane helices in a protein based on its amino acid sequence.\n3. PredictProtein includes tools for predicting the topology of transmembrane proteins, such as beta-barrel proteins, based on their amino acid sequence.\n4. I-TASSER predicts the structure of transmembrane proteins and uses structural information to predict the orientation of transmembrane helices.\n5. TM-align is a tool designed to align transmembrane protein structures to predict the topology of new proteins, including beta-barrel transmembrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BepiPred is a web server that predicts the topology of beta-barrel transmembrane proteins using a combination of sequence-based features and structural information.",
      "TMHMM predicts the transmembrane helices in a protein based on its amino acid sequence.",
      "PredictProtein includes tools for predicting the topology of transmembrane proteins, such as beta-barrel proteins, based on their amino acid sequence.",
      "I-TASSER predicts the structure of transmembrane proteins and uses structural information to predict the orientation of transmembrane helices.",
      "TM-align is a tool designed to align transmembrane protein structures to predict the topology of new proteins, including beta-barrel transmembrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE - I-TASSER can predict the tertiary structure of proteins, including transmembrane proteins, but it is not specific about using structural information for orientation prediction; its methodology involves iterative threading and ab initio modeling.\n5. FALSE [correction]: TM-align is a tool designed to align protein structures based on their three-dimensional shapes, but it is not specifically used to predict the topology of new proteins. It is used for structural comparison and to identify similar structures.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify disorders related to the neurotransmitter dopamine, specifically those that affect the dopamine receptors. The Galassi classification system groups these disorders into three categories based on the type of dopamine receptor affected:\n1. D1-like receptors: Disorders that affect the D1-like receptors, such as schizophrenia and bipolar disorder.\n2. D2-like receptors: Disorders that affect the D2-like receptors, such as Parkinson's disease and Huntington's disease.\n3. D1-D2 intermediates: Disorders that affect both the D1-like and D2-like receptors, such as addiction and attention deficit hyperactivity disorder (ADHD).\nSo, to answer your last question, Galassi classification is used to classify disorders related to dopamine receptors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification system is used to classify disorders related to dopamine receptors.\n2. Disorders that affect the D1-like receptors include schizophrenia and bipolar disorder.\n3. Parkinson's disease and Huntington's disease are disorders that affect the D2-like receptors.\n4. Disorders that affect both the D1-like and D2-like receptors include addiction and attention deficit hyperactivity disorder (ADHD).",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification system is used to classify disorders related to dopamine receptors.",
      "Disorders that affect the D1-like receptors include schizophrenia and bipolar disorder.",
      "Parkinson's disease and Huntington's disease are disorders that affect the D2-like receptors.",
      "Disorders that affect both the D1-like and D2-like receptors include addiction and attention deficit hyperactivity disorder (ADHD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification system is used to classify types of internal brain herniation, not disorders related to dopamine receptors.\n2. FALSE [correction]: While schizophrenia and bipolar disorder are associated with dopamine dysregulation, they are not specifically classified by the receptors they affect using the Galassi classification system.\n3. TRUE: Parkinson's disease and Huntington's disease are indeed associated with dysfunction of D2-like dopamine receptors, although this statement simplifies the complex pathophysiology of these conditions.\n4. TRUE: Addiction and ADHD are disorders that are associated with dysfunction of both D1-like and D2-like receptors, among other factors. However, this statement is simplified and does not account for the complexity of these conditions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Here are some common features of Shapiro syndrome:\n1. Neonatal onset: Shapiro syndrome typically presents in the newborn period, often within the first few days of life.\n2. Hypotonia: Patients with Shapiro syndrome often have hypotonia, or decreased muscle tone, which can make them appear floppy or weak.\n3. Developmental delays: Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n4. Intellectual disability: Many individuals with Shapiro syndrome have intellectual disability, which can range from mild to severe.\n5. Distinctive facial features: People with Shapiro syndrome may have distinctive facial features, including a small head, narrow eyes, and a short nose.\n6. Congenital anomalies: Some individuals with Shapiro syndrome may be born with congenital anomalies, such as heart defects or cleft palate.\n7. Short stature: Patients with Shapiro syndrome often have short stature, which can be apparent from an early age.\n8. Increased risk of infections: Individuals with Shapiro syndrome may be more prone to infections, particularly respiratory infections, due to their immune system dysfunction.\n9. Autoimmune disorders: Some individuals with Shapiro syndrome may develop autoimmune disorders, such as type 1 diabetes or autoimmune thyroiditis.\n10. Increased risk of cancer: There is an increased risk of developing certain types of cancer, such as lymphoma, in individuals with Shapiro syndrome.\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome typically presents in the neonatal period, often within the first few days of life.\n2. Patients with Shapiro syndrome often have hypotonia, or decreased muscle tone.\n3. Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n4. Many individuals with Shapiro syndrome have intellectual disability, which can range from mild to severe.\n5. Patients with Shapiro syndrome often have short stature.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome typically presents in the neonatal period, often within the first few days of life.",
      "Patients with Shapiro syndrome often have hypotonia, or decreased muscle tone.",
      "Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.",
      "Many individuals with Shapiro syndrome have intellectual disability, which can range from mild to severe.",
      "Patients with Shapiro syndrome often have short stature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome typically presents in later childhood or adolescence, not in the neonatal period.\n2. TRUE\n3. TRUE\n4. UNKNOWN: While individuals with neurological conditions like Shapiro syndrome may have intellectual disabilities, the specificity of this condition to such a broad range of intellectual disability is not clear without additional context.\n5. UNKNOWN: Short stature may be associated with many different syndromes and conditions, but there is not enough information to affirm that it is commonly seen in patients with Shapiro syndrome specifically.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Mutations within the BRAG1 gene have been linked to a rare genetic disorder called BRAG1-related cerebellar ataxia. This is a neurodegenerative disorder that affects the cerebellum and can cause a range of symptoms including coordination problems, balance difficulties, and cognitive decline.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to BRAG1-related cerebellar ataxia.\n2. BRAG1-related cerebellar ataxia is a neurodegenerative disorder.\n3. The disorder affects the cerebellum.\n4. Symptoms of BRAG1-related cerebellar ataxia include coordination problems and balance difficulties.\n5. Cognitive decline is a symptom of BRAG1-related cerebellar ataxia.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to BRAG1-related cerebellar ataxia.",
      "BRAG1-related cerebellar ataxia is a neurodegenerative disorder.",
      "The disorder affects the cerebellum.",
      "Symptoms of BRAG1-related cerebellar ataxia include coordination problems and balance difficulties.",
      "Cognitive decline is a symptom of BRAG1-related cerebellar ataxia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within the BRCA1 gene are linked to hereditary breast and ovarian cancer, not BRAG1-related cerebellar ataxia. The correct gene associated with cerebellar ataxia is often SCA (Spinocerebellar Ataxia), but the specific gene depends on the type of ataxia.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called protein phosphatase 2A (PP2A).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process that occurs in bacteria such as Bacillus subtilis during stationary phase, where the bacterial population is no longer growing and is instead in a state of dormancy. During this phase, the bacteria undergo a series of genetic changes that allow them to adapt to their environment and survive until conditions improve.\nThere are several mechanisms that underlie adaptive mutagenesis in Bacillus subtilis, including:\n1. DNA damage response: During stationary phase, bacteria are exposed to a variety of stressors, including DNA-damaging agents, which can lead to mutations. The bacteria have evolved mechanisms to repair DNA damage, but in some cases, the damage can be irreparable, leading to mutations.\n2. Reactive oxygen species (ROS) production: ROS are highly reactive molecules that can damage DNA and other cellular components. Bacteria produce ROS as a byproduct of metabolism, and during stationary phase, the levels of ROS can increase, leading to mutations.\n3. Methylation-mediated mutagenesis: Bacteria can methylate their DNA, which can lead to mutations. During stationary phase, the levels of methylation can increase, leading to mutations.\n4. Transposon-mediated mutagenesis: Transposons are mobile genetic elements that can insert into different locations in the genome, leading to mutations. During stationary phase, the levels of transposon activity can increase, leading to mutations.\n5. Homologous recombination-mediated mutagenesis: Homologous recombination is a repair process that involves the exchange of genetic information between two identical or similar DNA molecules. During stationary phase, the levels of homologous recombination can increase, leading to mutations.\n6. Telomere shortening-mediated mutagenesis: Telomeres are repetitive DNA sequences that cap the ends of chromosomes. During stationary phase, telomeres can shorten, leading to mutations.\n7. Epigenetic modifications-mediated mutagenesis: Epigenetic modifications are chemical changes to DNA or histone proteins that can affect gene expression without alter",
    "llama-2-7b-chat-hf_fact_raw": "1. Adaptive mutagenesis occurs in Bacillus subtilis during the stationary phase when the bacterial population is no longer growing.\n2. The DNA damage response is a mechanism of adaptive mutagenesis where bacteria repair DNA damage, but sometimes mutations result from irreparable damage.\n3. Reactive oxygen species (ROS) production during stationary phase can lead to mutations as ROS can damage DNA and other cellular components.\n4. Methylation-mediated mutagenesis occurs when bacteria methylate their DNA, and increased levels of methylation can lead to mutations during stationary phase.\n5. Transposon-mediated mutagenesis involves mobile genetic elements inserting into different locations in the genome, which can increase during stationary phase and lead to mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Adaptive mutagenesis occurs in Bacillus subtilis during the stationary phase when the bacterial population is no longer growing.",
      "The DNA damage response is a mechanism of adaptive mutagenesis where bacteria repair DNA damage, but sometimes mutations result from irreparable damage.",
      "Reactive oxygen species (ROS) production during stationary phase can lead to mutations as ROS can damage DNA and other cellular components.",
      "Methylation-mediated mutagenesis occurs when bacteria methylate their DNA, and increased levels of methylation can lead to mutations during stationary phase.",
      "Transposon-mediated mutagenesis involves mobile genetic elements inserting into different locations in the genome, which can increase during stationary phase and lead to mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The DNA damage response is a cellular response to DNA damage. While this mechanism is crucial for repairing DNA, during adaptive mutagenesis the mutations result not necessarily from irreparable damage, but from a regulated process that involves induced errors by the DNA repair machinery.\n3. TRUE\n4. FALSE [correction]: Methylation-mediated mutagenesis is not a widely recognized form of adaptive mutagenesis. While DNA methylation is a process that occurs in bacteria, it primarily serves for the regulation of gene expression and protection against foreign DNA, rather than directly causing mutations.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucic acid syndrome, is a rare but potentially life-threatening condition that can occur in individuals consuming large amounts of erucic acid, which is a toxic compound found in the seeds of the rapeseed plant (Brassica napus). The main cause of erucism is the consumption of large amounts of erucic acid, typically through the consumption of large amounts of rapeseed oil or other products containing high levels of erucic acid.\nErucic acid can cause damage to the liver, kidneys, and other organs in the body, leading to a range of symptoms including nausea, vomiting, abdominal pain, diarrhea, and fatigue. In severe cases, erucism can progress to more serious complications such as liver failure, kidney failure, and even death.\nIt is important to note that the risk of developing erucism is generally low for individuals consuming small amounts of rapeseed products, such as cooking oils or foods containing trace amounts of erucic acid. However, individuals consuming large amounts of rapeseed products or those with pre-existing liver or kidney disease may be at higher risk of developing erucism.\nTo prevent erucism, it is important to consume rapeseed products in moderation and to avoid consuming large amounts of erucic acid. Additionally, individuals with pre-existing liver or kidney disease should consult with their healthcare provider before consuming any products containing high levels of erucic acid.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a condition that can occur from consuming large amounts of erucic acid.\n2. Erucic acid is a toxic compound found in the seeds of the rapeseed plant (Brassica napus).\n3. The consumption of large amounts of rapeseed oil or other products containing high levels of erucic acid can cause erucism.\n4. Symptoms of erucism include nausea, vomiting, abdominal pain, diarrhea, and fatigue.\n5. Severe cases of erucism can result in liver failure, kidney failure, and death.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a condition that can occur from consuming large amounts of erucic acid.",
      "Erucic acid is a toxic compound found in the seeds of the rapeseed plant (Brassica napus).",
      "The consumption of large amounts of rapeseed oil or other products containing high levels of erucic acid can cause erucism.",
      "Symptoms of erucism include nausea, vomiting, abdominal pain, diarrhea, and fatigue.",
      "Severe cases of erucism can result in liver failure, kidney failure, and death."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Hydrochlorothiazide is a medication that is commonly used to treat hypertension (high blood pressure) and edema (fluid retention) associated with conditions such as heart failure, liver disease, and kidney disease. It works by increasing the amount of urine produced by the kidneys, which helps to lower blood pressure and reduce fluid buildup in the body. Other potential indications for hydrochlorothiazide include:\n* Hyperlipidemia (elevated levels of fats in the blood)\n* Diabetes insipidus (a rare condition that causes the body to produce an excessive amount of urine)\n* Hypokalemia (low levels of potassium in the blood)\n* Anorexia nervosa (a condition characterized by a lack of appetite and weight loss)\n* X-linked hypophosphatemia (a rare genetic disorder that affects the body's ability to absorb phosphate)\nIt's important to note that hydrochlorothiazide can have side effects, so it's important to use it only as directed by a healthcare professional and to carefully monitor your health while taking this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat edema (fluid retention) associated with conditions such as heart failure, liver disease, and kidney disease.\n3. Hydrochlorothiazide is indicated for the treatment of hyperlipidemia (elevated levels of fats in the blood).\n4. Hydrochlorothiazide can be used to treat diabetes insipidus, a condition that causes the body to produce an excessive amount of urine.\n5. Hydrochlorothiazide can be prescribed for the treatment of hypokalemia (low levels of potassium in the blood).",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat edema (fluid retention) associated with conditions such as heart failure, liver disease, and kidney disease.",
      "Hydrochlorothiazide is indicated for the treatment of hyperlipidemia (elevated levels of fats in the blood).",
      "Hydrochlorothiazide can be used to treat diabetes insipidus, a condition that causes the body to produce an excessive amount of urine.",
      "Hydrochlorothiazide can be prescribed for the treatment of hypokalemia (low levels of potassium in the blood)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrochlorothiazide is not typically used to treat hyperlipidemia. It is a diuretic used for lowering blood pressure and treating edema but not for treating elevated levels of fats in the blood.\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide can actually cause hypokalemia as a side effect because it leads to an increased excretion of potassium in the urine. It is not prescribed to treat low levels of potassium in the blood; in fact, patients may need to take potassium supplements to prevent hypokalemia when using this medication.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials, such as silicon-based hydrogels, have been developed to create a supportive and protective layer around the urethra, helping to prevent leakage of urine. These materials can be used to create a urethral bulking agent, which can help to strengthen the urethral tissue and improve the continence of the individual. Additionally, silicon-based coatings have been applied to medical devices, such as catheters, to reduce the risk of irritation and infection. Overall, silicon has shown promise as a material for the treatment of urinary incontinence, offering a potential alternative to traditional treatments such as surgery.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon-based hydrogels have been developed to create a supportive layer around the urethra.\n3. Urethral bulking agents created from silicon-based materials can strengthen urethral tissue.\n4. Silicon-based coatings have been applied to catheters to reduce irritation and infection risks.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon-based hydrogels have been developed to create a supportive layer around the urethra.",
      "Urethral bulking agents created from silicon-based materials can strengthen urethral tissue.",
      "Silicon-based coatings have been applied to catheters to reduce irritation and infection risks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "The association between the moon cycle and the rupture risk of intracranial aneurysms is a topic of ongoing research and debate in the field of neuroscience and biomedicine. While some studies have suggested a possible link between the lunar cycle and the likelihood of aneurysm rupture, the evidence is not yet conclusive.\nOne study published in the journal \"Stroke\" in 2013 analyzed data from over 1,500 patients with ruptured intracranial aneurysms and found that the risk of rupture was significantly higher during the full moon phase compared to other phases of the moon cycle. However, the study also noted that the association between the moon cycle and aneurysm rupture was weak and may be influenced by other factors such as seasonal variations and changes in atmospheric pressure.\nAnother study published in the \"Journal of Neurosurgery\" in 2017 found that the risk of aneurysm rupture was higher during the full moon phase in patients with unruptured intracranial aneurysms, but the association was only significant in patients with larger aneurysms.\nDespite these findings, many experts believe that the association between the moon cycle and aneurysm rupture is likely due to chance or other factors, rather than a direct effect of the lunar cycle on the aneurysm itself. For example, some studies have suggested that changes in atmospheric pressure and barometric pressure during the full moon phase may play a role in aneurysm rupture, rather than the lunar cycle itself.\nIn summary, while there is some evidence to suggest a possible association between the moon cycle and the rupture risk of intracranial aneurysms, the evidence is not yet conclusive and more research is needed to fully understand the relationship between these two phenomena.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have suggested a possible link between the lunar cycle and the likelihood of intracranial aneurysm rupture.\n2. A study published in the journal \"Stroke\" in 2013 found a higher risk of aneurysm rupture during the full moon phase compared to other moon phases.\n3. The study in \"Stroke\" concluded that the association between the moon cycle and aneurysm rupture was weak.\n4. A 2017 study in the \"Journal of Neurosurgery\" found a higher risk of aneurysm rupture during the full moon phase, specifically in patients with larger unruptured intracranial aneurysms.\n5. Some studies have suggested that factors such as atmospheric pressure may play a role in aneurysm rupture rather than the lunar cycle itself.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have suggested a possible link between the lunar cycle and the likelihood of intracranial aneurysm rupture.",
      "A study published in the journal \"Stroke\" in 2013 found a higher risk of aneurysm rupture during the full moon phase compared to other moon phases.",
      "The study in \"Stroke\" concluded that the association between the moon cycle and aneurysm rupture was weak.",
      "A 2017 study in the \"Journal of Neurosurgery\" found a higher risk of aneurysm rupture during the full moon phase, specifically in patients with larger unruptured intracranial aneurysms.",
      "Some studies have suggested that factors such as atmospheric pressure may play a role in aneurysm rupture rather than the lunar cycle itself."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - There have been studies exploring the relationship between the lunar cycle and various health events, including intracranial aneurysm rupture.\n2. UNKNOWN - Without access to the specific contents of the article from the journal \"Stroke,\" the exact findings of the study cannot be confirmed.\n3. UNKNOWN - The conclusion regarding the strength of the association as mentioned in the statement cannot be verified without the specific study details.\n4. UNKNOWN - Without details from the 2017 study in the \"Journal of Neurosurgery,\" the finding about a higher risk of aneurysm rupture during the full moon cannot be confirmed.\n5. TRUE - Some research has indeed suggested that other factors like atmospheric pressure could be more influential on the risk of aneurysm rupture than the lunar cycle, though this area of study is complex and conclusions vary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein has been shown to regulate the splicing process. HuR, also known as ELAVL1, is a RNA-binding protein that plays a critical role in the regulation of mRNA splicing, particularly in the nucleus. It has been demonstrated that HuR can bind to specific splice sites and enhance or repress the splicing of certain pre-mRNAs, leading to changes in the expression of target genes.\nIn addition, HuR has been shown to regulate the stability of mRNAs and the localization of spliceosomes, which are the complexes responsible for catalyzing mRNA splicing. HuR can also modulate the activity of other splicing factors and influence the global splicing pattern in cells.\nOverall, HuR plays a multifaceted role in the regulation of mRNA splicing, and its dysregulation has been implicated in a variety of diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein, also known as ELAVL1, regulates the splicing process of mRNA.\n2. HuR can bind to specific splice sites and influence the splicing of certain pre-mRNAs.\n3. HuR affects the stability and localization of mRNAs.\n4. HuR plays a role in the regulation of spliceosome activity, which are complexes responsible for catalyzing mRNA splicing.\n5. Dysregulation of HuR protein has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein, also known as ELAVL1, regulates the splicing process of mRNA.",
      "HuR can bind to specific splice sites and influence the splicing of certain pre-mRNAs.",
      "HuR affects the stability and localization of mRNAs.",
      "HuR plays a role in the regulation of spliceosome activity, which are complexes responsible for catalyzing mRNA splicing.",
      "Dysregulation of HuR protein has been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HuR protein, also known as ELAVL1, does not regulate the splicing process of mRNA; instead, it is primarily involved in regulating mRNA stability and translation.\n2. FALSE [correction]: HuR is not known to bind directly to splice sites to influence splicing; it typically binds to AU-rich elements in the 3' UTR of mRNAs to affect their stability and translation.\n3. TRUE\n4. FALSE [correction]: HuR does not play a direct role in the regulation of spliceosome activity. The spliceosome is responsible for mRNA splicing, but HuR mainly influences mRNA stability and translation post-transcriptionally.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (PA) is a small protein that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of PA, also known as prothymosin alpha peptide (PTP), has been identified as a potential therapeutic agent for various diseases, including cancer and neurodegenerative disorders. Here are some of the known functions of PTP:\n1. Cell proliferation: PTP has been shown to promote cell proliferation by stimulating the activation of cyclin-dependent kinases (CDKs) and the phosphorylation of retinoblastoma protein (Rb), leading to the inhibition of cell cycle arrest and the progression of cells through the cell cycle.\n2. Cell survival: PTP has been shown to induce the expression of Bcl-2 family proteins, which are involved in the regulation of apoptosis, and to inhibit the activity of caspases, which are enzymes that play a role in programmed cell death (apoptosis).\n3. Differentiation: PTP has been shown to induce the expression of differentiation-related genes and to promote the differentiation of various cell types, including neurons and muscle cells.\n4. Neuroprotection: PTP has been shown to have neuroprotective effects in various models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, by reducing oxidative stress, inflammation, and the loss of neurons.\n5. Cancer treatment: PTP has been shown to have anti-tumor effects in various cancer models, including breast, lung, and colon cancer, by inhibiting the proliferation of cancer cells and inducing apoptosis.\nIn summary, PTP has a wide range of functions in various cellular processes, including cell proliferation, differentiation, survival, and neuroprotection, and has been identified as a potential therapeutic agent for various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha (PA) is involved in cellular processes such as cell proliferation, differentiation, and survival.\n2. The c-terminal peptide of prothymosin alpha (PTP) stimulates the activation of cyclin-dependent kinases (CDKs) and the phosphorylation of retinoblastoma protein (Rb).\n3. PTP induces the expression of Bcl-2 family proteins, which regulate apoptosis, and inhibits the activity of caspases.\n4. PTP promotes the differentiation of various cell types, including neurons and muscle cells.\n5. PTP has been shown to have anti-tumor effects in various cancer models and has been identified as a potential therapeutic agent for diseases like cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha (PA) is involved in cellular processes such as cell proliferation, differentiation, and survival.",
      "The c-terminal peptide of prothymosin alpha (PTP) stimulates the activation of cyclin-dependent kinases (CDKs) and the phosphorylation of retinoblastoma protein (Rb).",
      "PTP induces the expression of Bcl-2 family proteins, which regulate apoptosis, and inhibits the activity of caspases.",
      "PTP promotes the differentiation of various cell types, including neurons and muscle cells.",
      "PTP has been shown to have anti-tumor effects in various cancer models and has been identified as a potential therapeutic agent for diseases like cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Prothymosin alpha (PA) is known to be involved in various cellular processes, including cell proliferation, differentiation, and survival.\n\n2. UNKNOWN: Without specific scientific references, it's difficult to confirm whether the c-terminal peptide of prothymosin alpha (PTP) directly stimulates the activation of cyclin-dependent kinases (CDKs) and the phosphorylation of retinoblastoma protein (Rb). This statement requires detailed biological knowledge or research evidence to verify.\n\n3. UNKNOWN: The claim that PTP induces the expression of Bcl-2 family proteins, which regulate apoptosis, and inhibits the activity of caspases is specific and would require scientific literature or studies to verify its accuracy. Without such information, we cannot determine the truthfulness of this statement.\n\n4. UNKNOWN: The statement that PTP promotes the differentiation of various cell types, including neurons and muscle cells, is again very specific and would require scientific evidence to validate. Without access to relevant research, it's impossible to ascertain whether this is true or false.\n\n5. UNKNOWN: While the statement that PTP has anti-tumor effects and may be a potential therapeutic agent for diseases like cancer and neurodegenerative disorders is plausible, confirming its accuracy demands specific scientific studies or clinical trial results. Therefore, without supporting evidence available, the truthfulness of this statement remains undetermined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence Gly-Asp-Gly-Ala-Gly-Gly-Gly (GDGGA). This sequence is known as the \"fibrillization unit\" of cystatin C and is responsible for the formation of fibrillar aggregates in vitro and in vivo.",
    "llama-2-7b-chat-hf_fact_raw": "1. The amino acid sequence Gly-Asp-Gly-Ala-Gly-Gly-Gly (GDGGA) plays a pivotal role in human cystatin C fibrillization.\n2. The sequence referred to as \"fibrillization unit\" of cystatin C is responsible for the formation of fibrillar aggregates.\n3. Cystatin C fibrillar aggregates can form both in vitro and in vivo.",
    "llama-2-7b-chat-hf_fact": [
      "The amino acid sequence Gly-Asp-Gly-Ala-Gly-Gly-Gly (GDGGA) plays a pivotal role in human cystatin C fibrillization.",
      "The sequence referred to as \"fibrillization unit\" of cystatin C is responsible for the formation of fibrillar aggregates.",
      "Cystatin C fibrillar aggregates can form both in vitro and in vivo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The amino acid sequence Gly-Ala-Gly-Asp-Gly-Gly-Gly (GAGDGGG) plays a pivotal role in human cystatin C fibrillization.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (hypoxia-inducible factor-1 alpha) is expected to increase after the administration of the cytoprotective prodrug amifostine (ethyol).\nAmifostine is a prodrug that is converted into the active compound ethylene diamine (EDA) after administration. EDA is a potent inhibitor of the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PH), which is responsible for the degradation of HIF-1α. By inhibiting HIF-PH, EDA increases the stability and activity of HIF-1α, leading to an increase in the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, glucose metabolism, and cell survival.\nTherefore, administration of amifostine (ethyol) is expected to increase the concentration of HIF-1α in the body, which can have therapeutic effects in various conditions, including cancer, cardiovascular disease, and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The administration of amifostine (ethyol) is expected to increase the concentration of protein HIF-1α (hypoxia-inducible factor-1 alpha).\n2. Amifostine is a prodrug that is converted into the active compound ethylene diamine (EDA).\n3. Ethylene diamine (EDA) inhibits the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PH).\n4. Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) by EDA leads to increased stability and activity of HIF-1α.\n5. Increased HIF-1α levels lead to an increase in the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, glucose metabolism, and cell survival.",
    "llama-2-7b-chat-hf_fact": [
      "The administration of amifostine (ethyol) is expected to increase the concentration of protein HIF-1α (hypoxia-inducible factor-1 alpha).",
      "Amifostine is a prodrug that is converted into the active compound ethylene diamine (EDA).",
      "Ethylene diamine (EDA) inhibits the enzyme hypoxia-inducible factor prolyl hydroxylase (HIF-PH).",
      "Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) by EDA leads to increased stability and activity of HIF-1α.",
      "Increased HIF-1α levels lead to an increase in the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, glucose metabolism, and cell survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The impact of amifostine on HIF-1α concentration is not well-known without specific experimental context or data.\n2. FALSE [correction]: Amifostine is a prodrug that is dephosphorylated into the active compound WR-1065, not ethylene diamine (EDA).\n3. UNKNOWN: Without specific biochemical context, the role of ethylene diamine (EDA) on hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is not clear.\n4. UNKNOWN: Since the identity of the active compound was incorrect in statement 2, the action of EDA on HIF-PH is not corroborated, and the effect on HIF-1α's stability and activity remains unknown.\n5. TRUE: Increased levels of HIF-1α indeed lead to upregulated expression of genes that are involved in the body’s adaptive response to hypoxic conditions, which includes the promotion of angiogenesis, altered glucose metabolism, and mechanisms that support cell survival.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone marks, specifically histone 3 lysine 4 trimethylation (H3K4me3), on specific genomic regions. H3K4me3 is a mark of active gene expression and is involved in the regulation of various cellular processes, including cell proliferation, differentiation, and maintenance of chromatin structure. Set7 is known to be involved in the regulation of stem cell self-renewal, cell fate determination, and the maintenance of pluripotency in embryonic stem cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase that deposits the histone mark H3K4me3.\n2. H3K4me3 is associated with active gene expression.\n3. Set7 plays a role in regulating cell proliferation.\n4. Set7 is involved in the differentiation of cells.\n5. Set7 contributes to the maintenance of pluripotency in embryonic stem cells.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase that deposits the histone mark H3K4me3.",
      "H3K4me3 is associated with active gene expression.",
      "Set7 plays a role in regulating cell proliferation.",
      "Set7 is involved in the differentiation of cells.",
      "Set7 contributes to the maintenance of pluripotency in embryonic stem cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set7, also known as SETD7, is a histone methyltransferase that predominantly deposits the mono-methyl mark at lysine 4 on histone H3 (H3K4me1), not the tri-methyl mark (H3K4me3).\n2. TRUE\n3. TRUE: Set7 has been implicated in the regulation of cell proliferation in various contexts, although this can be cell-type and context-dependent.\n4. TRUE: Set7 has been demonstrated to be involved in the differentiation of several cell types, including its role in the differentiation of skeletal muscle cells and adipocytes among others.\n5. FALSE [correction]: Set7 is not usually associated with the maintenance of pluripotency in embryonic stem cells. Instead, it has been shown to be involved in the differentiation process, which is the opposite of maintaining pluripotency.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Thank you for your kind words! Hepcidin, the protein that regulates iron metabolism, has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a protein that regulates iron metabolism.\n2. Hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a protein that regulates iron metabolism.",
      "Hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin has 8 cysteine amino acid residues that form 4 disulfide bonds.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is localized primarily to the mitochondria. DNAJC11 is a mitochondrial-targeted protein that plays a critical role in regulating mitochondrial function and energy metabolism. It has been shown to interact with various mitochondrial proteins and enzymes, including complex I of the electron transport chain, and to regulate the activity of these proteins in order to maintain proper mitochondrial function and metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized primarily to the mitochondria.\n2. DNAJC11 plays a role in regulating mitochondrial function and energy metabolism.\n3. DNAJC11 interacts with various mitochondrial proteins and enzymes.\n4. DNAJC11 has been shown to interact with complex I of the electron transport chain.\n5. DNAJC11 regulates the activity of mitochondrial proteins to maintain proper mitochondrial function and metabolism.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized primarily to the mitochondria.",
      "DNAJC11 plays a role in regulating mitochondrial function and energy metabolism.",
      "DNAJC11 interacts with various mitochondrial proteins and enzymes.",
      "DNAJC11 has been shown to interact with complex I of the electron transport chain.",
      "DNAJC11 regulates the activity of mitochondrial proteins to maintain proper mitochondrial function and metabolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with scientific information typically known about genes encoding chaperone proteins involved in mitochondrial function, such as DNAJC11. DNAJC11 is known to localize to mitochondria, it interacts with mitochondrial proteins including those in the electron transport chain, and is implicated in the regulation of mitochondrial function and metabolism. Without more specific context challenging any of the statements, they would conventionally be accepted as true based on current general scientific understanding.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Thank you for the opportunity to help! To answer your last question, yes, ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs).\nUCEs are regions of the genome that are highly conserved across species and are thought to be involved in critical regulatory functions, such as gene expression and chromatin structure. CNVs, on the other hand, are genomic regions that contain more or fewer copies of a particular DNA sequence than the typical diploid number.\nStudies have shown that UCEs are frequently lost or reduced in size among CNVs, particularly in regions that are prone to deletions or duplications. This loss of UCEs can lead to changes in gene expression and disrupt normal cellular function, potentially contributing to the development of disease.\nFor example, a study published in the journal Nature Genetics found that UCEs were significantly depleted among CNVs in individuals with autism spectrum disorder (ASD). The study suggested that the loss of UCEs may contribute to the development of ASD by disrupting normal brain development and function.\nIn summary, UCEs are often depleted among CNVs, and this loss can have important consequences for normal cellular function and disease development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are highly conserved regions of the genome across different species.\n2. Copy number variants (CNVs) are genomic regions with a variable number of copies of a particular DNA sequence.\n3. UCEs are frequently lost or reduced in size among CNVs, especially in areas prone to deletions or duplications.\n4. The loss of UCEs among CNVs can lead to changes in gene expression and disrupt normal cellular function.\n5. A study in the journal Nature Genetics reported significant depletion of UCEs among CNVs in individuals with autism spectrum disorder (ASD).",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are highly conserved regions of the genome across different species.",
      "Copy number variants (CNVs) are genomic regions with a variable number of copies of a particular DNA sequence.",
      "UCEs are frequently lost or reduced in size among CNVs, especially in areas prone to deletions or duplications.",
      "The loss of UCEs among CNVs can lead to changes in gene expression and disrupt normal cellular function.",
      "A study in the journal Nature Genetics reported significant depletion of UCEs among CNVs in individuals with autism spectrum disorder (ASD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Ultraconserved elements (UCEs) are generally highly resistant to being lost or reduced in size among CNVs, precisely because they are so strongly conserved across species. They tend not to be included in regions prone to deletions or duplications.\n4. TRUE\n5. UNKNOWN (Without access to a specific study or reference, the truth of this statement cannot be assessed.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the histone H3. Haspin is a protein that plays a crucial role in regulating the progression of mitosis by phosphorylating and activating the histone H3, which is a key component of chromatin. The phosphorylation of histone H3 by Haspin helps to recruit and activate other proteins that are essential for the proper progression of mitosis, such as the Aurora kinase and the spindle assembly checkpoint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is the histone H3.\n2. Haspin kinase phosphorylates and activates the histone H3 during mitosis.\n3. Phosphorylation of histone H3 by Haspin is important for the recruitment and activation of other proteins involved in mitosis.\n4. The Aurora kinase is one of the proteins that is recruited and activated during mitosis as a result of histone H3 phosphorylation by Haspin.\n5. The spindle assembly checkpoint is another protein that is activated due to the phosphorylation of histone H3 by Haspin during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is the histone H3.",
      "Haspin kinase phosphorylates and activates the histone H3 during mitosis.",
      "Phosphorylation of histone H3 by Haspin is important for the recruitment and activation of other proteins involved in mitosis.",
      "The Aurora kinase is one of the proteins that is recruited and activated during mitosis as a result of histone H3 phosphorylation by Haspin.",
      "The spindle assembly checkpoint is another protein that is activated due to the phosphorylation of histone H3 by Haspin during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin kinase phosphorylates histone H3, but this modification does not activate the histone itself; rather, it creates a binding site for other proteins involved in mitosis.\n3. TRUE\n4. FALSE [correction]: While the Aurora kinase is involved in mitosis, it is not recruited and activated as a direct result of histone H3 phosphorylation by Haspin. Aurora kinase activation involves other regulatory mechanisms.\n5. FALSE [correction]: The spindle assembly checkpoint is not a protein; it is a regulatory checkpoint system that monitors the status of spindle assembly and chromosome attachment to the spindle. It is not directly activated by the phosphorylation of histone H3 by Haspin but is affected by the broader regulatory processes of mitosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "The mechanism of viroid replication is a complex process that involves the interaction of the viroid with the host cell's machinery. Viroids are small, single-stranded RNA molecules that replicate by using the host cell's RNA-dependent RNA polymerase (RdRP) enzyme. Here is a simplified explanation of the mechanism of viroid replication:\n1. Infection: Viroids infect host plants by penetrating the plasma membrane and entering the cytoplasm. Once inside the cytoplasm, they bind to a specific host protein called a viroid-binding protein (VBP).\n2. Unwinding: The viroid-VBP complex then unwinds the viroid RNA, creating a double-stranded RNA template.\n3. RdRP binding: The unwound viroid RNA then binds to the host cell's RdRP enzyme, which is responsible for synthesizing new RNA molecules from double-stranded RNA templates.\n4. RNA synthesis: The RdRP enzyme uses the viroid RNA template to synthesize new viroid RNA molecules, which are then released from the host cell.\n5. Replication: The newly synthesized viroid RNA molecules can then go on to infect other host cells, perpetuating the cycle of infection.\nIn summary, the mechanism of viroid replication involves the interaction of the viroid with the host cell's RdRP enzyme, which allows the viroid to use the host cell's machinery to synthesize new viroid RNA molecules. This process is essential for the survival and propagation of viroids, and it highlights the unique relationship between viroids and their host plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that use the host cell's RNA-dependent RNA polymerase (RdRP) enzyme for replication.\n2. Viroids penetrate the plasma membrane and enter the cytoplasm of host plants to infect them.\n3. Once inside the cytoplasm, viroids bind to a viroid-binding protein (VBP) which unwinds the viroid RNA.\n4. The host cell's RdRP enzyme binds to the unwound viroid RNA to synthesize new RNA molecules from double-stranded RNA templates.\n5. The newly synthesized viroid RNA molecules can infect other host cells, perpetuating a cycle of infection.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that use the host cell's RNA-dependent RNA polymerase (RdRP) enzyme for replication.",
      "Viroids penetrate the plasma membrane and enter the cytoplasm of host plants to infect them.",
      "Once inside the cytoplasm, viroids bind to a viroid-binding protein (VBP) which unwinds the viroid RNA.",
      "The host cell's RdRP enzyme binds to the unwound viroid RNA to synthesize new RNA molecules from double-stranded RNA templates.",
      "The newly synthesized viroid RNA molecules can infect other host cells, perpetuating a cycle of infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not penetrate the plasma membrane like viruses. Instead, they are often introduced into the plant cells through wounds or during agricultural practices.\n3. UNKNOWN\n4. FALSE [correction]: The host cell's RNA polymerase II, not RNA-dependent RNA polymerase (RdRP), is thought to be involved in viroids replication, by using the viroid's RNA as a template to synthesize new RNA molecules without the need for a double-stranded RNA intermediate.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Yes, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD). Studies have shown that levels of fibronectin in the blood of DMD patients are significantly lower than those in healthy individuals, which could serve as a diagnostic marker for the disease. Additionally, fibronectin levels have been found to decrease over time in DMD patients, providing a potential marker for disease progression.\nFurthermore, fibronectin has been shown to play a role in the pathogenesis of DMD, as it is involved in the regulation of muscle cell adhesion and migration, which are impaired in DMD patients. Therefore, measuring fibronectin levels in the blood of DMD patients may not only serve as a diagnostic marker but also provide insight into the underlying disease mechanisms.\nIn summary, fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy, offering a new opportunity for early diagnosis and monitoring of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Levels of fibronectin in the blood of DMD patients are significantly lower than those in healthy individuals.\n3. Fibronectin levels are found to decrease over time in patients with Duchenne muscular dystrophy.\n4. Fibronectin is involved in the regulation of muscle cell adhesion and migration.\n5. Measuring fibronectin levels in DMD patients may provide insight into the underlying disease mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been identified as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Levels of fibronectin in the blood of DMD patients are significantly lower than those in healthy individuals.",
      "Fibronectin levels are found to decrease over time in patients with Duchenne muscular dystrophy.",
      "Fibronectin is involved in the regulation of muscle cell adhesion and migration.",
      "Measuring fibronectin levels in DMD patients may provide insight into the underlying disease mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Levels of fibronectin in the blood of DMD patients are typically higher, not lower, than those in healthy individuals.\n3. FALSE [correction]: Fibronectin levels are found to increase over time in patients with Duchenne muscular dystrophy.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. The ENCODE (ENCyclopedia Of DNA Elements) project, which is a large-scale effort to map all of the functional elements in the human genome.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive map of epigenetic marks across multiple tissues and cell types in multiple organisms.\n3. The NIH Roadmap Epigenomics Mapping Center, which is focused on generating high-resolution maps of epigenetic marks in human tissues and cells.\n4. The Epigenomics of Human Disease Consortium, which is a collaborative effort to study the epigenetic changes that occur in response to disease and to identify new therapeutic targets for disease treatment.\n5. The Cancer Epigenome Project, which aims to generate a comprehensive map of epigenetic changes in cancer cells and to identify new therapeutic targets for cancer treatment.\nThese are just a few examples of the major epigenome projects that are represented in the DeepBlue data server. The server contains a wealth of information on the epigenetic landscape of various organisms, and it is a valuable resource for researchers studying epigenetics and its role in human health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.\n2. Data from the Roadmap Epigenomics Project is included in the DeepBlue epigenomic data server.\n3. The NIH Roadmap Epigenomics Mapping Center contributes high-resolution maps of epigenetic marks to the DeepBlue server.\n4. The Epigenomics of Human Disease Consortium's collaborative research data is available on the DeepBlue epigenomic data server.\n5. The DeepBlue epigenomic data server holds information from the Cancer Epigenome Project.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (ENCyclopedia Of DNA Elements) project.",
      "Data from the Roadmap Epigenomics Project is included in the DeepBlue epigenomic data server.",
      "The NIH Roadmap Epigenomics Mapping Center contributes high-resolution maps of epigenetic marks to the DeepBlue server.",
      "The Epigenomics of Human Disease Consortium's collaborative research data is available on the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server holds information from the Cancer Epigenome Project."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout more detail, it's challenging to verify the inclusion of specific projects like \"The Epigenomics of Human Disease Consortium\" and the \"Cancer Epigenome Project\" in the DeepBlue epigenomic data server. These details would require specific knowledge about the data sources and collaborations involved with the DeepBlue server that is not commonly available without direct reference to the server’s documentation or datasets.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is called \"CodonMapper\".\nCodonMapper is a bioinformatics tool that uses SOMs to analyze the codon usage patterns of a given gene or protein sequence and identify potential areas of functional importance. It can be used to identify synonymous codons that are more or less conserved among different species, or to identify specific codons that are enriched in functional regions of a protein.\nBy using SOMs to represent the codon usage patterns of a protein, Cowan and his colleagues (2003) were able to identify regions of the protein that are more functionally important and may be subject to positive selection. This approach can be useful for identifying potential functional regions of a protein that may be targeted by mutations or for identifying areas of the protein that are more conserved across different species.\nIn summary, the tool that employs self-organizing maps for analyzing synonymous codon usage is called \"CodonMapper\".",
    "llama-2-7b-chat-hf_fact_raw": "1. CodonMapper is a tool that uses self-organizing maps (SOMs) to analyze synonymous codon usage.\n2. CodonMapper can be used to identify synonymous codons that vary in conservation among different species.\n3. CodonMapper can help identify specific codons enriched in functional regions of a protein.\n4. Cowan and his colleagues utilized CodonMapper in 2003 for protein analysis.\n5. CodonMapper aims to identify regions of proteins that might be under positive selection.",
    "llama-2-7b-chat-hf_fact": [
      "CodonMapper is a tool that uses self-organizing maps (SOMs) to analyze synonymous codon usage.",
      "CodonMapper can be used to identify synonymous codons that vary in conservation among different species.",
      "CodonMapper can help identify specific codons enriched in functional regions of a protein.",
      "Cowan and his colleagues utilized CodonMapper in 2003 for protein analysis.",
      "CodonMapper aims to identify regions of proteins that might be under positive selection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microtubule-Associated Protein Dynamics Regulator 1) is a protein that plays a crucial role in regulating the dynamics of microtubules in cells. Microtubules are essential components of a cell's cytoskeleton, which provides structural support and plays a key role in cell division, intracellular transport, and cell signaling. MINDY-1 is a plus-end tracking protein that binds to the plus ends of microtubules and regulates their stability and dynamics.\nIn addition to its role in microtubule dynamics, MINDY-1 has been implicated in various cellular processes, including cell migration, invasion, and metastasis. For example, studies have shown that MINDY-1 is overexpressed in many types of cancer, where it promotes cancer cell migration and invasion by regulating microtubule dynamics.\nOverall, MINDY-1 is an important regulator of microtubule dynamics and cellular behavior, and its dysregulation has been implicated in a variety of diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a protein that regulates the dynamics of microtubules in cells.\n2. Microtubules are components of the cell's cytoskeleton, involved in cell division, intracellular transport, and cell signaling.\n3. MINDY-1 is a plus-end tracking protein, which binds to the plus ends of microtubules.\n4. MINDY-1 has been implicated in cell migration, invasion, and metastasis processes.\n5. MINDY-1 is overexpressed in many types of cancer and contributes to cancer cell migration and invasion.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a protein that regulates the dynamics of microtubules in cells.",
      "Microtubules are components of the cell's cytoskeleton, involved in cell division, intracellular transport, and cell signaling.",
      "MINDY-1 is a plus-end tracking protein, which binds to the plus ends of microtubules.",
      "MINDY-1 has been implicated in cell migration, invasion, and metastasis processes.",
      "MINDY-1 is overexpressed in many types of cancer and contributes to cancer cell migration and invasion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 refers to 'MInD Your own business-1,' a deubiquitinating enzyme connected to the regulation of mitophagy, not the regulation of microtubules.\n2. TRUE\n3. FALSE [correction]: The statement regarding MINDY-1 as a plus-end tracking protein applies to a different kind of protein known as +TIPs (plus-end tracking proteins), not MINDY-1.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The statements about MINDY-1 as it relates to cancer are uncertain without specific scientific evidence or context from reputable research. MINDY-1 might be related to other cellular processes, such as mitophagy, which could play a role in cancer dynamics. However, this statement would require specific literature to confirm or refute in the context of the given statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Great! I'm happy to help with your questions about biomedicine. To answer your last question, there are several software packages available for the analysis of conserved genomic loci. Some popular options include:\n1. PhyloBayes: PhyloBayes is a Bayesian phylogenetic software package that can be used to infer the evolutionary history of conserved genomic regions. It takes into account the phylogenetic relationships between organisms and the evolutionary history of the genes or genomic regions of interest.\n2. PhastCons: PhastCons is a software package that estimates the evolutionary conservation of genomic regions across different species. It uses a hidden Markov model to infer the probability of a given amino acid or nucleotide at a specific position in a protein or nucleotide sequence, based on the conservation of that position across different species.\n3. CONSER: CONSER is a database and software package that provides information on the conservation of protein and nucleotide sequences across different species. It includes a database of conserved domains, which are regions of protein or nucleotide sequences that are highly conserved across different species, as well as tools for searching and analyzing these sequences.\n4. MEME: MEME is a software package that can be used to identify and analyze conserved genomic regions. It uses a combination of sequence alignment and hidden Markov modeling to identify regions of high conservation across different species, and can also be used to identify functional elements within these regions.\n5. GERP: GERP is a software package that can be used to identify and analyze conserved genomic regions. It uses a combination of sequence alignment and hidden Markov modeling to identify regions of high conservation across different species, and can also be used to identify functional elements within these regions.\nThese are just a few examples of the many software packages available for the analysis of conserved genomic loci. Each package has its own strengths and limitations, and the choice of which package to use will depend on the specific research question and the characteristics of the data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a Bayesian phylogenetic software package used for inferring the evolutionary history of conserved genomic regions.\n2. PhastCons is a software package that estimates evolutionary conservation across different species using a hidden Markov model.\n3. CONSER is a database and software package that offers information on the conservation of protein and nucleotide sequences across species.\n4. MEME is a software package designed for identifying and analyzing conserved genomic regions through sequence alignment and hidden Markov modeling.\n5. GERP is a software package that identifies and analyzes conserved genomic regions, also using sequence alignment and hidden Markov modeling.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a Bayesian phylogenetic software package used for inferring the evolutionary history of conserved genomic regions.",
      "PhastCons is a software package that estimates evolutionary conservation across different species using a hidden Markov model.",
      "CONSER is a database and software package that offers information on the conservation of protein and nucleotide sequences across species.",
      "MEME is a software package designed for identifying and analyzing conserved genomic regions through sequence alignment and hidden Markov modeling.",
      "GERP is a software package that identifies and analyzes conserved genomic regions, also using sequence alignment and hidden Markov modeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CONSER is not known as a standard database or software package in the context of sequence conservation. Users might be referring to Consurf, which is a tool for estimating the evolutionary conservation of amino acids in protein sequences, or the CONSERTING software tool for conserved segment identification.\n4. FALSE [correction]: MEME is a software package designed for finding motifs in unaligned nucleotide or protein sequences, not specifically for identifying and analyzing conserved genomic regions through sequence alignment and hidden Markov modeling.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! The PIEZO2 gene is associated with several diseases, including:\n1. Autism Spectrum Disorder (ASD): Mutations in the PIEZO2 gene have been identified as a risk factor for autism spectrum disorder (ASD). Studies have shown that individuals with ASD are more likely to have mutations in the PIEZO2 gene than those without ASD.\n2. Intellectual Disability: PIEZO2 gene mutations have also been linked to intellectual disability, which is characterized by below-average intelligence and cognitive abilities.\n3. Sensory Processing Disorders: PIEZO2 gene mutations have been associated with sensory processing disorders, which can cause difficulties with processing and interpreting sensory information from the environment.\nThese are just a few examples of the diseases associated with the PIEZO2 gene. It's important to note that the PIEZO2 gene is a complex gene that is involved in many different biological processes, and mutations in this gene can have a wide range of effects on human health.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been identified as a risk factor for autism spectrum disorder (ASD).\n2. PIEZO2 gene mutations have been linked to intellectual disability.\n3. PIEZO2 gene mutations have been associated with sensory processing disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been identified as a risk factor for autism spectrum disorder (ASD).",
      "PIEZO2 gene mutations have been linked to intellectual disability.",
      "PIEZO2 gene mutations have been associated with sensory processing disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n\nExplanation:\nFor statements 1 and 2, without specific scientific evidence or references, it’s not possible to confirm whether PIEZO2 gene mutations have been identified as a risk factor for autism spectrum disorder (ASD) or have been linked to intellectual disability. These statements are specific claims that would need to be supported by current research data to be confirmed as true or false.\n\nFor statement 3, PIEZO2 is a gene that encodes a protein related to the mechanosensitive ion channels, and it is involved in the body's sense of touch and proprioception. It is known that mutations in PIEZO2 can lead to sensory processing issues, so this statement is considered true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the processing of double-stranded RNA (dsRNA) into small interfering RNA (siRNA) and microRNA (miRNA). This process is important for the RNA interference (RNAi) pathway, which is a natural mechanism of gene regulation in cells. By dimerizing with ERAP1, ERAP2 helps to facilitate the cleavage of dsRNA by the RNase III enzyme Dicer, leading to the production of siRNA and miRNA that can then be used to silence specific genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the processing of double-stranded RNA (dsRNA) into small interfering RNA (siRNA) and microRNA (miRNA).\n2. The processing of dsRNA to siRNA and miRNA is important for the RNA interference (RNAi) pathway.\n3. The RNAi pathway is a natural mechanism of gene regulation in cells.\n4. ERAP2 facilitates the cleavage of dsRNA by the RNase III enzyme Dicer when dimerized with ERAP1.\n5. The production of siRNA and miRNA through this process is used to silence specific genes.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the processing of double-stranded RNA (dsRNA) into small interfering RNA (siRNA) and microRNA (miRNA).",
      "The processing of dsRNA to siRNA and miRNA is important for the RNA interference (RNAi) pathway.",
      "The RNAi pathway is a natural mechanism of gene regulation in cells.",
      "ERAP2 facilitates the cleavage of dsRNA by the RNase III enzyme Dicer when dimerized with ERAP1.",
      "The production of siRNA and miRNA through this process is used to silence specific genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are not known to promote the processing of double-stranded RNA (dsRNA) into small interfering RNA (siRNA) and microRNA (miRNA). ERAP1 and ERAP2 are associated with the processing of antigenic peptides for presentation by MHC class I molecules and are not directly involved in RNA interference.\n2. TRUE: The processing of dsRNA to siRNA and miRNA is indeed important for the RNA interference (RNAi) pathway.\n3. TRUE: The RNAi pathway is a natural mechanism of gene regulation in eukaryotic cells that involves dsRNA leading to the regulation of gene expression.\n4. FALSE [correction]: ERAP2 is not responsible for cleaving dsRNA into siRNA and miRNA. The enzyme Dicer is the one that facilitates the cleavage of dsRNA into siRNA and miRNA, and there is no role of ERAP1-ERAP2 dimerization in this context.\n5. TRUE: The production of siRNA and miRNA through the action of Dicer and subsequent processes is indeed used to silence specific genes, which is one of the central mechanisms of RNA interference.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of embryonic development and tissue homeostasis. In non-damaged gallbladders, R-spondin 1 and Noggin have been shown to have the following functions:\nR-spondin 1:\n* Regulation of stem cell maintenance and proliferation: R-spondin 1 has been shown to promote the proliferation and maintenance of stem cells in the gallbladder, particularly in the bile ducts and epithelial cells.\n* Modulation of inflammation: R-spondin 1 has anti-inflammatory properties and can inhibit the activation of immune cells in the gallbladder, such as T cells and macrophages.\n* Maintenance of gallbladder architecture: R-spondin 1 helps maintain the normal architecture of the gallbladder, including the structure and organization of bile ducts and epithelial cells.\nNoggin:\n* Regulation of cell growth and differentiation: Noggin has been shown to inhibit the growth and differentiation of gallbladder epithelial cells, which can help maintain the normal function of the gallbladder.\n* Modulation of inflammation: Noggin has anti-inflammatory properties and can inhibit the activation of immune cells in the gallbladder, such as T cells and macrophages.\n* Maintenance of gallbladder barrier function: Noggin helps maintain the integrity of the epithelial barrier in the gallbladder, which is important for preventing bile and lipid leakage into the abdominal cavity.\nOverall, R-spondin 1 and Noggin play important roles in maintaining the normal function of the non-damaged gallbladder, including the regulation of stem cell maintenance and proliferation, modulation of inflammation, and maintenance of gallbladder architecture and barrier function.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 promotes the proliferation and maintenance of stem cells in the gallbladder.\n2. R-spondin 1 has anti-inflammatory properties and can inhibit the activation of immune cells in the gallbladder.\n3. R-spondin 1 helps to maintain the normal architecture of the gallbladder.\n4. Noggin inhibits the growth and differentiation of gallbladder epithelial cells.\n5. Noggin helps maintain the integrity of the epithelial barrier in the gallbladder.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 promotes the proliferation and maintenance of stem cells in the gallbladder.",
      "R-spondin 1 has anti-inflammatory properties and can inhibit the activation of immune cells in the gallbladder.",
      "R-spondin 1 helps to maintain the normal architecture of the gallbladder.",
      "Noggin inhibits the growth and differentiation of gallbladder epithelial cells.",
      "Noggin helps maintain the integrity of the epithelial barrier in the gallbladder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific context and references, it is difficult to verify whether R-spondin 1 promotes the proliferation and maintenance of stem cells specifically in the gallbladder, as it is generally known for its role in stem cell biology and tissue regeneration.\n2. UNKNOWN: The anti-inflammatory properties of R-spondin 1 and its specific effects on immune cells in the gallbladder would require specific scientific evidence to confirm. R-spondin is known to be involved in Wnt signaling, which can have various roles in inflammation, but the statement is too specific without supporting data.\n3. UNKNOWN: Again, the role of R-spondin 1 in maintaining the normal architecture of the gallbladder is very specific, and this statement would need to be supported by scientific studies to be verified as true or false.\n4. UNKNOWN: Noggin is known as a BMP (Bone Morphogenetic Protein) antagonist which plays roles in the regulation of development and growth in various tissues. However, without specific references, it's challenging to confirm whether noggin inhibits the growth and differentiation of gallbladder epithelial cells.\n5. UNKNOWN: Noggin's role in maintaining the integrity of the epithelial barrier specifically in the gallbladder would require evidence from scientific research. While it is involved in developmental processes, including epithelial development, the statement's specificity necessitates direct supporting evidence.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) requires a subunit to function. NOX5 is a membrane-bound enzyme that generates reactive oxygen species (ROS) in the cell through the transfer of electrons from NADPH to oxygen. The enzyme is composed of multiple subunits, including:\n* NOX5A: The catalytic subunit that binds NADPH and oxygen\n* NOX5B: A regulatory subunit that modulates the activity of NOX5A\n* NOX5C: A subunit that interacts with the cytoskeleton and regulates the localization of NOX5A and NOX5B\nTogether, these subunits work cooperatively to generate ROS in the cell, which play important roles in various cellular processes, including cell signaling, migration, and immune responses.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires a subunit to function.\n2. NOX5 is a membrane-bound enzyme that generates reactive oxygen species (ROS) in cells.\n3. The catalytic subunit of NOX5 is NOX5A, which binds NADPH and oxygen.\n4. NOX5B is a regulatory subunit that modulates the activity of the catalytic subunit NOX5A.\n5. NOX5C is a subunit that interacts with the cytoskeleton and regulates the localization of NOX5A and NOX5B.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires a subunit to function.",
      "NOX5 is a membrane-bound enzyme that generates reactive oxygen species (ROS) in cells.",
      "The catalytic subunit of NOX5 is NOX5A, which binds NADPH and oxygen.",
      "NOX5B is a regulatory subunit that modulates the activity of the catalytic subunit NOX5A.",
      "NOX5C is a subunit that interacts with the cytoskeleton and regulates the localization of NOX5A and NOX5B."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require a regulatory subunit to function. It has calcium-binding EF-hand motifs that allow it to be regulated by intracellular calcium levels. \n2. TRUE\n3. TRUE – While \"NOX5A\" is not a standard designation, the catalytic domain of NOX5 does indeed bind NADPH and oxygen to generate ROS.\n4. FALSE [correction]: There is no regulatory subunit \"NOX5B\" for NOX5. The NOX5 enzyme itself can be regulated by calcium levels without the need for a separate regulatory subunit.\n5. FALSE [correction]: There is no subunit \"NOX5C\" known to interact with the cytoskeleton and regulate the localization of NOX5 components. NOX5's interaction with the cytoskeleton and its localization are regulated by its own structural domains and not by a separate subunit designated as NOX5C.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are connected through their role in regulating iron metabolism. Furin is a protease enzyme that is involved in the processing and maturation of several proteins, including the iron-regulatory hormone hepcidin. Hepcidin is produced in the liver and plays a key role in regulating iron homeostasis in the body by inhibiting iron absorption in the duodenum and promoting iron recycling from transferrin-bound iron.\nFurin has been shown to be involved in the processing and maturation of hepcidin, particularly in the cleavage of hepcidin propeptides to generate the active form of the hormone. This processing is important for the proper regulation of iron metabolism, as the active form of hepcidin is more potent in inhibiting iron absorption.\nIn addition, furin has been implicated in the regulation of other iron-related genes, including the iron exporter ferroportin, and the iron-responsive gene transferrin.\nOverall, the connection between furin and hepcidin is through their shared role in regulating iron metabolism, with furin playing a key role in the processing and maturation of hepcidin, and both enzymes working together to maintain proper iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme that is involved in the processing and maturation of several proteins, including hepcidin.\n2. Hepcidin is an iron-regulatory hormone produced in the liver that plays a key role in regulating iron homeostasis.\n3. Active hepcidin inhibits iron absorption in the duodenum and promotes iron recycling from transferrin-bound iron.\n4. Furin is involved in the cleavage of hepcidin propeptides to generate the active form of the hormone.\n5. Furin has been implicated in the regulation of the iron exporter ferroportin and the iron-responsive gene transferrin.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme that is involved in the processing and maturation of several proteins, including hepcidin.",
      "Hepcidin is an iron-regulatory hormone produced in the liver that plays a key role in regulating iron homeostasis.",
      "Active hepcidin inhibits iron absorption in the duodenum and promotes iron recycling from transferrin-bound iron.",
      "Furin is involved in the cleavage of hepcidin propeptides to generate the active form of the hormone.",
      "Furin has been implicated in the regulation of the iron exporter ferroportin and the iron-responsive gene transferrin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While furin is a protease enzyme involved in the activation of several precursor proteins and pathogens, without specific information on hepcidin processing, the role of furin in hepcidin maturation cannot be determined from the statement alone.\n2. TRUE: Hepcidin is indeed an iron-regulatory hormone produced by the liver, and it is central to the regulation of iron homeostasis in the body.\n3. TRUE: Active hepcidin can bind to the iron exporter ferroportin, causing its internalization and degradation, which inhibits iron absorption in the duodenum and limits the release of iron from macrophages, thus promoting iron recycling.\n4. UNKNOWN: The statement asserts that furin processes hepcidin propeptides into their active form. However, the specifics of hepcidin maturation and which proteases are involved might vary, and without additional information, we cannot confirm the specific role of furin in this process.\n5. FALSE [correction]: The statement wrongly implies direct involvement of furin with ferroportin and transferrin regulation. While furin may be implicated in the regulatory pathways, ferroportin regulation is primarily by hepcidin binding, and transferrin regulation is part of systemic iron homeostasis. Furin's primary role does not directly regulate these proteins but may be indirectly involved through the activation of other regulatory proteins.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"Hxk1\" gene cluster. This gene cluster contains several genes involved in the breakdown and synthesis of glucose, including HXK1, PFK1, and GSY1. The Hxk1 gene cluster is responsible for the majority of glucose metabolism in yeast and is essential for cell growth and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. The glycolysis/gluconeogenesis gene cluster is also known as the \"Hxk1\" gene cluster.\n3. The Hxk1 gene cluster contains genes involved in the breakdown and synthesis of glucose.\n4. The genes HXK1, PFK1, and GSY1 are part of the Hxk1 gene cluster.\n5. The Hxk1 gene cluster is essential for yeast cell growth and survival.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster is also known as the \"Hxk1\" gene cluster.",
      "The Hxk1 gene cluster contains genes involved in the breakdown and synthesis of glucose.",
      "The genes HXK1, PFK1, and GSY1 are part of the Hxk1 gene cluster.",
      "The Hxk1 gene cluster is essential for yeast cell growth and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific data or sources, it is difficult to confirm whether the glycolysis/gluconeogenesis gene cluster is indeed the largest metabolic gene cluster in yeast.\n2. FALSE [correction]: The glycolysis/gluconeogenesis gene cluster is not generally referred to as the \"Hxk1\" gene cluster. HXK1 is a gene encoding hexokinase, which is involved in glycolysis, but the gene cluster itself would not typically be called \"Hxk1.\"\n3. TRUE: The glycolysis/gluconeogenesis gene cluster does contain genes involved in the breakdown (glycolysis) and synthesis (gluconeogenesis) of glucose.\n4. TRUE: HXK1 encodes for hexokinase, PFK1 encodes phosphofructokinase, which are important enzymes in glycolysis, and GSY1 encodes glycogen synthase involved in the synthesis of glycogen, a form of glucose storage. These genes play roles in glucose metabolism and may be part of or associated with related gene clusters.\n5. TRUE: The ability to metabolize glucose through glycolysis and gluconeogenesis is essential for yeast cell growth and survival because glucose is a primary source of energy and carbon for cellular processes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! The role of LMT lncRNA (LMT for short) is:\nLMT is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of gene expression, particularly in the context of cancer. LMT has been shown to act as a tumor suppressor by inhibiting the expression of oncogenes and pro-inflammatory genes, and by promoting the expression of tumor suppressor genes. LMT does this by binding to DNA and chromatin-modifying proteins, such as histone-modifying enzymes, to alter the structure of chromatin and recruit transcriptional regulators.\nIn addition, LMT has been shown to play a role in the regulation of stem cell pluripotency and differentiation, and has been implicated in the development of certain neurological disorders.\nOverall, LMT is a complex and multifaceted lncRNA that plays a critical role in the regulation of gene expression and cellular function, and its dysregulation has been implicated in a variety of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. LMT lncRNA plays a crucial role in the regulation of gene expression.\n2. LMT acts as a tumor suppressor by inhibiting the expression of oncogenes and pro-inflammatory genes.\n3. LMT promotes the expression of tumor suppressor genes.\n4. LMT binds to DNA and chromatin-modifying proteins to alter the structure of chromatin.\n5. LMT's dysregulation has been implicated in the development of certain neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "LMT lncRNA plays a crucial role in the regulation of gene expression.",
      "LMT acts as a tumor suppressor by inhibiting the expression of oncogenes and pro-inflammatory genes.",
      "LMT promotes the expression of tumor suppressor genes.",
      "LMT binds to DNA and chromatin-modifying proteins to alter the structure of chromatin.",
      "LMT's dysregulation has been implicated in the development of certain neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Great! I'd be happy to help with your questions about bioinformatics and R/Bioconductor packages.\nFor performing SNP (single nucleotide polymorphism) enrichment analysis, one popular R/Bioconductor package is \"plink\". Plink is a versatile tool for genome-wide association studies (GWAS) and can perform a variety of analyses, including SNP enrichment analysis.\nHere's an example of how to use plink to perform SNP enrichment analysis:\n1. Install plink:\nIf you haven't installed plink already, you can do so using the following command in R:\ninstall.packages(\"plink\")\n2. Load the SNP data:\n Load the SNP data into R using the following command:\ndata <- read.table(\"snp_data.txt\", header=TRUE, row.names=1)\nReplace \"snp_data.txt\" with the actual file name and path of your SNP data.\n3. Perform SNP enrichment analysis:\nUse the following command to perform SNP enrichment analysis:\nenrichment <- plink(data, \"--enrich\")\nThis will output the results of the enrichment analysis, including the P-value and the odds ratio for each gene.\n4. Interpret the results:\nInterpret the results of the enrichment analysis by looking at the P-value and odds ratio for each gene. A P-value less than 0.05 and an odds ratio greater than 1 indicate that the gene is enriched for SNPs.\nHere's an example of the output from plink:\nEnrichment results for the top 100 genes:\nGene ID  Odds Ratio P-value\n1 1234567890 3.45 0.001\nThis indicates that gene 1234567890 is enriched for SNPs, with an odds ratio of 3.45 and a P-value of 0.001.\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Plink is an R/Bioconductor package used for performing SNP (single nucleotide polymorphism) enrichment analysis.\n2. Plink is commonly utilized for genome-wide association studies (GWAS).\n3. The package can be installed in R using the command install.packages(\"plink\").\n4. SNP enrichment analysis results from Plink include P-value and odds ratio for each gene.\n5. A P-value less than 0.05 and an odds ratio greater than 1 indicate SNP enrichment for a gene according to the provided usage of Plink.",
    "llama-2-7b-chat-hf_fact": [
      "Plink is an R/Bioconductor package used for performing SNP (single nucleotide polymorphism) enrichment analysis.",
      "Plink is commonly utilized for genome-wide association studies (GWAS).",
      "The package can be installed in R using the command install.packages(\"plink\").",
      "SNP enrichment analysis results from Plink include P-value and odds ratio for each gene.",
      "A P-value less than 0.05 and an odds ratio greater than 1 indicate SNP enrichment for a gene according to the provided usage of Plink."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Plink is a free, open-source whole genome association analysis toolset, not an R/Bioconductor package.\n2. TRUE\n3. FALSE [correction]: Plink cannot be installed using install.packages(\"plink\") because it is not an R package; it is a standalone software tool.\n4. TRUE: While the statement is a bit broad, Plink does indeed provide results such as P-value and odds ratio which can be used to assess gene associations.\n5. UNKNOWN: The statement may generally be true in the context of statistical analysis associated with GWAS, but without specific reference to 'provided usage of Plink', it is difficult to determine the accuracy of the statement. In general, a P-value less than 0.05 can indicate statistical significance in many contexts, and an odds ratio greater than 1 can indicate an association between a trait and a gene, but usage of thresholds can vary by study or researcher.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! The key players involved in radial glial specification to ependymal cells are:\n1. Notch signaling pathway: The Notch signaling pathway is a critical regulator of radial glial specification and differentiation to ependymal cells. Notch ligands, such as Delta-like 1 (Dll1) and Dll4, are expressed on the ventricular surface of the neural tube, while the Notch receptor is expressed on the radial glial cells. The binding of Notch ligands to the receptor triggers a signaling cascade that regulates the expression of genes involved in radial glial specification and differentiation.\n2. Wnt signaling pathway: The Wnt signaling pathway is also involved in the regulation of radial glial specification and differentiation to ependymal cells. Wnt ligands, such as Wnt3a, are expressed in the neural tube and bind to the Frizzled receptor on radial glial cells, leading to the activation of the Wnt signaling pathway. This pathway regulates the expression of genes involved in radial glial specification and differentiation.\n3. Bone morphogenetic protein (BMP) signaling pathway: BMP signaling pathway is also involved in the regulation of radial glial specification and differentiation to ependymal cells. BMP ligands, such as BMP4, are expressed in the neural tube and bind to the BMP receptor on radial glial cells, leading to the activation of the BMP signaling pathway. This pathway regulates the expression of genes involved in radial glial specification and differentiation.\n4. Shh signaling pathway: The Shh signaling pathway is also involved in the regulation of radial glial specification and differentiation to ependymal cells. Shh ligand is expressed in the neural tube and binds to the Patched receptor on radial glial cells, leading to the activation of the Shh signaling pathway. This pathway regulates the expression of genes involved in radial glial specification and differentiation.\n5. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modifications, also play a crucial role in the regulation of radial glial specification and differentiation to",
    "llama-2-7b-chat-hf_fact_raw": "1. The Notch signaling pathway is a critical regulator of radial glial specification and differentiation to ependymal cells.\n2. The Wnt signaling pathway is involved in the regulation of radial glial specification and differentiation to ependymal cells.\n3. The Bone morphogenetic protein (BMP) signaling pathway is involved in regulating radial glial specification and differentiation to ependymal cells.\n4. The Shh signaling pathway is involved in the regulation of radial glial specification and differentiation to ependymal cells.\n5. Epigenetic modifications play a crucial role in the regulation of radial glial specification and differentiation to ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "The Notch signaling pathway is a critical regulator of radial glial specification and differentiation to ependymal cells.",
      "The Wnt signaling pathway is involved in the regulation of radial glial specification and differentiation to ependymal cells.",
      "The Bone morphogenetic protein (BMP) signaling pathway is involved in regulating radial glial specification and differentiation to ependymal cells.",
      "The Shh signaling pathway is involved in the regulation of radial glial specification and differentiation to ependymal cells.",
      "Epigenetic modifications play a crucial role in the regulation of radial glial specification and differentiation to ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIn developmental neuroscience, these signaling pathways (Notch, Wnt, BMP, Shh) and epigenetic modifications are known mechanisms that play a role in the regulation of various aspects of neurogenesis, which includes radial glial specification and differentiation. Each of these pathways can influence the fate of neural progenitor cells, including their differentiation to ependymal cells, which are involved in producing cerebrospinal fluid among other functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a type of brain tumor, that are characterized by the lack of expression of certain biomarkers, such as estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These biomarkers are typically used to guide treatment decisions for breast cancer, but in the context of gliomas, their absence can have important implications for diagnosis and treatment.\nTriple negative gliomas are typically fast-growing and aggressive, and they tend to have a poorer prognosis than other types of gliomas, such as those that are ER-positive or HER2-positive. They are also more likely to recur after initial treatment.\nSome of the key features of triple negative gliomas include:\n* Lack of expression of ER, PR, and HER2\n* High proliferation rate\n* Poor prognosis compared to other types of gliomas\n* Higher risk of recurrence after initial treatment\n* Aggressive growth pattern\n* Tendency to occur in younger patients\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the lack of expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).\n2. These biomarkers (ER, PR, HER2) are typically used to guide treatment decisions for breast cancer.\n3. Triple negative gliomas tend to have a poorer prognosis than other types of gliomas that are ER-positive or HER2-positive.\n4. Triple negative gliomas are more likely to recur after initial treatment.\n5. Triple negative gliomas are typically fast-growing and aggressive.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the lack of expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).",
      "These biomarkers (ER, PR, HER2) are typically used to guide treatment decisions for breast cancer.",
      "Triple negative gliomas tend to have a poorer prognosis than other types of gliomas that are ER-positive or HER2-positive.",
      "Triple negative gliomas are more likely to recur after initial treatment.",
      "Triple negative gliomas are typically fast-growing and aggressive."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple-negative gliomas are incorrectly mentioned here. The term \"triple-negative\" is typically used to refer to a subtype of breast cancer, not gliomas. Gliomas are a type of brain tumor characterized by their location and the type of cell from which they originate, not typically by the status of ER, PR, and HER2.\n\n2. TRUE: In the context of breast cancer, the biomarkers estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) are indeed used to guide treatment decisions.\n\n3. UNKNOWN: Because the first statement is incorrect and there is no such classification as triple negative gliomas in the context of brain tumors, we cannot accurately determine the prognosis relative to ER-positive or HER2-positive statuses as these biomarkers are not standard for classifying gliomas.\n\n4. UNKNOWN: Since the term \"triple-negative glioma\" is not accurate, we cannot assess the likelihood of recurrence after initial treatment compared to other gliomas based on ER, PR, and HER2 status.\n\n5. UNKNOWN: Without an accurate classification of \"triple-negative gliomas\", we cannot determine specific growth patterns or aggressiveness. However, gliomas as a group can range from slow-growing to fast-growing, and their aggressiveness varies widely depending on the type and grade of the glioma.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 is a gene that encodes for a protein involved in the regulation of gene expression.\nIn the context of biomedicine, TOPAZ1 has been found to be associated with various diseases, including cancer and neurological disorders. For example, studies have shown that TOPAZ1 is overexpressed in certain types of cancer, such as breast cancer, and that inhibition of TOPAZ1 can inhibit cancer cell growth and migration. Additionally, TOPAZ1 has been implicated in neurological disorders such as Alzheimer's disease, where it has been shown to play a role in the regulation of gene expression involved in the progression of the disease.\nIn summary, TOPAZ1 is a gene that plays a critical role in the regulation of gene expression and its dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a gene that encodes for a protein involved in the regulation of gene expression.\n2. TOPAZ1 has been associated with various diseases, including cancer and neurological disorders.\n3. Studies have shown that TOPAZ1 is overexpressed in certain types of cancer, such as breast cancer.\n4. Inhibition of TOPAZ1 can inhibit cancer cell growth and migration.\n5. TOPAZ1 has been implicated in neurological disorders such as Alzheimer's disease, where it is involved in the regulation of gene expression linked to the progression of the disease.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a gene that encodes for a protein involved in the regulation of gene expression.",
      "TOPAZ1 has been associated with various diseases, including cancer and neurological disorders.",
      "Studies have shown that TOPAZ1 is overexpressed in certain types of cancer, such as breast cancer.",
      "Inhibition of TOPAZ1 can inhibit cancer cell growth and migration.",
      "TOPAZ1 has been implicated in neurological disorders such as Alzheimer's disease, where it is involved in the regulation of gene expression linked to the progression of the disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements are specific and refer to the function and implications of a gene called TOPAZ1. Without access to current, detailed scientific literature or a specific passage containing these assertions, it's not possible to verify the accuracy of the statements. They may be true if they are accurately citing conclusions from peer-reviewed scientific studies, but without such context or data, their veracity remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. The GATA-1 gene contains multiple exons that are spliced together to produce different isoforms of the GATA-1 transcription factor. The expression of these exons is regulated by various factors, including transcription factors, histone modifications, and non-coding RNAs.\nIn particular, the expression of GATA-1 isoforms is regulated by the binding of transcription factors to specific DNA sequences in the GATA-1 promoter region. For example, the transcription factor GATA-1 itself binds to a specific sequence in the GATA-1 promoter to activate the transcription of GATA-1 isoforms. Other transcription factors, such as GATA-2 and GATA-3, can also bind to the GATA-1 promoter and regulate its expression.\nIn addition, the expression of GATA-1 isoforms is also influenced by histone modifications, such as histone 3 lysine 4 trimethylation (H3K4me3), which can recruit chromatin-modifying enzymes that activate the expression of GATA-1. Non-coding RNAs, such as microRNAs, can also regulate the expression of GATA-1 by binding to specific mRNAs and inhibiting their translation.\nOverall, the regulation of GATA-1 isoforms is a complex process that involves the interplay of multiple transcription factors, histone modifications, and non-coding RNAs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene itself controls the expression of GATA-1 isoforms.\n2. The GATA-1 gene contains multiple exons that can be spliced together to produce different isoforms.\n3. The expression of GATA-1 isoforms is regulated by the binding of transcription factors to specific DNA sequences in the GATA-1 promoter region.\n4. Histone modifications, such as H3K4me3, can influence the expression of GATA-1 isoforms.\n5. Non-coding RNAs, including microRNAs, can regulate the expression of GATA-1 by binding to specific mRNAs and inhibiting their translation.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene itself controls the expression of GATA-1 isoforms.",
      "The GATA-1 gene contains multiple exons that can be spliced together to produce different isoforms.",
      "The expression of GATA-1 isoforms is regulated by the binding of transcription factors to specific DNA sequences in the GATA-1 promoter region.",
      "Histone modifications, such as H3K4me3, can influence the expression of GATA-1 isoforms.",
      "Non-coding RNAs, including microRNAs, can regulate the expression of GATA-1 by binding to specific mRNAs and inhibiting their translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nExplanation regarding statement 5: While the statement is generally true in the context of gene expression regulation, it should be noted that non-coding RNAs, including microRNAs, typically regulate gene expression by binding to specific mRNAs which usually leads to the degradation or inhibition of those mRNAs, not by directly inhibiting their translation. This is a mechanistic subtlety that might be important when considering the precise mode of action. However, without further specific information about GATA-1 regulation by microRNAs, the statement is accepted as generally correct.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a genomic sequencing technique used to identify and characterize the expression of microRNAs (miRNAs) in a given sample. MicroRNAs are small non-coding RNAs that play a critical role in regulating gene expression by binding to messenger RNAs (mRNAs) and preventing their translation into proteins. By sequencing the miRNA transcriptome, MIRA-seq allows researchers to identify which miRNAs are active in a given cell or tissue type, and how their expression changes in response to different stimuli or diseases. This information can be used to better understand the role of miRNAs in various biological processes and to identify potential therapeutic targets for diseases such as cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a genomic sequencing technique designed specifically to profile the expression of microRNAs (miRNAs).\n2. MicroRNAs are small non-coding RNAs involved in the regulation of gene expression.\n3. MIRA-seq can identify which miRNAs are active in a given cell or tissue type.\n4. MIRA-seq measures how miRNA expression changes in response to different stimuli or diseases.\n5. MIRA-seq has applications in understanding biological processes and identifying therapeutic targets for diseases like cancer.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a genomic sequencing technique designed specifically to profile the expression of microRNAs (miRNAs).",
      "MicroRNAs are small non-coding RNAs involved in the regulation of gene expression.",
      "MIRA-seq can identify which miRNAs are active in a given cell or tissue type.",
      "MIRA-seq measures how miRNA expression changes in response to different stimuli or diseases.",
      "MIRA-seq has applications in understanding biological processes and identifying therapeutic targets for diseases like cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq, or Methylation Interference Assay sequencing, is not designed to profile the expression of microRNAs (miRNAs). Instead, it is a technique for analyzing protein-DNA interactions by identifying the methylation pattern on DNA that interferes with protein binding.\n2. TRUE\n3. FALSE [correction]: MIRA-seq does not identify which miRNAs are active in a given cell or tissue type; it is used for studying protein-DNA interactions.\n4. FALSE [correction]: MIRA-seq does not measure miRNA expression changes; its purpose is to assess protein-DNA binding specificities and affinities, not to monitor gene expression levels.\n5. FALSE [correction]: While the correction for MIRA-seq applications in understanding biological processes and potential therapeutic targets is true, it pertains to its role in analyzing protein-DNA interactions, not in miRNA profiling. It can contribute to the identification of crucial regulatory regions in the genome and the proteins that interact with them, which indeed has applications in disease research, but not specifically through miRNA targeting.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a medication used to treat a rare genetic disorder called cryopyrin-associated periodic syndrome (CAPS) and pyoderma gangrenosum, a chronic skin condition. It works by blocking the activity of a protein called interleukin-1 (IL-1) which is involved in the inflammation and immune response. By blocking the activity of IL-1, ARCALYST helps to reduce inflammation and alleviate symptoms associated with CAPS and pyoderma gangrenosum.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndrome (CAPS).\n2. ARCALYST is also used to treat pyoderma gangrenosum, a chronic skin condition.\n3. ARCALYST works by blocking the activity of interleukin-1 (IL-1).\n4. Interleukin-1 (IL-1) is involved in inflammation and immune response.\n5. By inhibiting IL-1, ARCALYST reduces inflammation and alleviates symptoms related to CAPS and pyoderma gangrenosum.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is used to treat cryopyrin-associated periodic syndrome (CAPS).",
      "ARCALYST is also used to treat pyoderma gangrenosum, a chronic skin condition.",
      "ARCALYST works by blocking the activity of interleukin-1 (IL-1).",
      "Interleukin-1 (IL-1) is involved in inflammation and immune response.",
      "By inhibiting IL-1, ARCALYST reduces inflammation and alleviates symptoms related to CAPS and pyoderma gangrenosum."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ARCALYST is not indicated for the treatment of pyoderma gangrenosum. It is used for the treatment of conditions such as CAPS.\n3. TRUE\n4. TRUE\n5. TRUE (in regards to CAPS, but not pyoderma gangrenosum as ARCALYST is not indicated for treating pyoderma gangrenosum)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Of the human acrocentric chromosomes, the following are involved in Robertsonian translocations:\n1. Chromosome 13: This is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all translocations.\n2. Chromosome 14: Chromosome 14 is the second most common chromosome involved in Robertsonian translocations, accounting for approximately 20% of all translocations.\n3. Chromosome 15: Chromosome 15 is involved in a smaller percentage of Robertsonian translocations, accounting for approximately 5% of all translocations.\n4. Chromosome 21: Chromosome 21 is the shortest acrocentric chromosome and is involved in a very small percentage of Robertsonian translocations.\nIt is important to note that Robertsonian translocations are typically balanced translocations, meaning that the abnormal chromosome material is present in both copies of the chromosome. This can lead to a balanced translocation, where the individual has a normal diploid number of chromosomes (46), but with a rearrangement of the chromosome material.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is involved in Robertsonian translocations, accounting for approximately 70% of all translocations.\n2. Chromosome 14 is involved in Robertsonian translocations, accounting for approximately 20% of all translocations.\n3. Chromosome 15 is involved in Robertsonian translocations, accounting for approximately 5% of all translocations.\n4. Chromosome 21, which is the shortest acrocentric chromosome, is involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is involved in Robertsonian translocations, accounting for approximately 70% of all translocations.",
      "Chromosome 14 is involved in Robertsonian translocations, accounting for approximately 20% of all translocations.",
      "Chromosome 15 is involved in Robertsonian translocations, accounting for approximately 5% of all translocations.",
      "Chromosome 21, which is the shortest acrocentric chromosome, is involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: It is not accurate to state that Chromosome 14 accounts for approximately 20% of all Robertsonian translocations without specific data or sources that confirm this percentage.\n3. FALSE [correction]: Just like statement 2, it is not accurate to assign a specific percentage to the involvement of Chromosome 15 in Robertsonian translocations without supporting data.\n4. TRUE (with a note) [correction]: While Chromosome 21 is an acrocentric chromosome and can be involved in Robertsonian translocations, it is not accurate to specifically label it as the shortest without a comparison to other acrocentric chromosomes, which include Chromosomes 13, 14, 15, and 22. Further clarification is needed to confirm it is the shortest.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "For the identification of pediatric brain tumors, the R package \"brainTumor\" could be used. This package provides a set of tools for the analysis of brain tumor genomics data, including RNA sequencing (RNA-seq) data. It can be used to identify mutations, copy number variations, and other genomic features that are associated with pediatric brain tumors.\nHere is an example of how to use the \"brainTumor\" package to identify mutations in pediatric brain tumors:\n1. Install the \"brainTumor\" package by running the following command in the R console:\ninstall.packages(\"brainTumor\")\n2. Load the \"brainTumor\" package by running the following command:\nlibrary(brainTumor)\n3. Load the genomic data for the pediatric brain tumors by running the following command:\ndata(brainTumorData)\n4. Identify mutations in the tumor genomes by running the following command:\nmutations(brainTumorData)\n5. Visualize the mutations using a Circos plot by running the following command:\ncircosPlot(brainTumorData, type = \"mutations\")\nThis will create a Circos plot showing the locations and types of mutations in the pediatric brain tumors.\nNote: The \"brainTumor\" package requires the \"limma\" package to be installed. Therefore, you may need to install both packages simultaneously.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"brainTumor\" package is an R package used for the analysis of brain tumor genomics data.\n2. The \"brainTumor\" package can be used to identify mutations, copy number variations, and other genomic features associated with pediatric brain tumors.\n3. RNA sequencing data (RNA-seq) can be analyzed using the \"brainTumor\" package.\n4. The \"brainTumor\" package allows for the visualization of mutations in pediatric brain tumors using a Circos plot.\n5. The \"brainTumor\" package requires the \"limma\" package to be installed in order to function properly.",
    "llama-2-7b-chat-hf_fact": [
      "The \"brainTumor\" package is an R package used for the analysis of brain tumor genomics data.",
      "The \"brainTumor\" package can be used to identify mutations, copy number variations, and other genomic features associated with pediatric brain tumors.",
      "RNA sequencing data (RNA-seq) can be analyzed using the \"brainTumor\" package.",
      "The \"brainTumor\" package allows for the visualization of mutations in pediatric brain tumors using a Circos plot.",
      "The \"brainTumor\" package requires the \"limma\" package to be installed in order to function properly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or access to a definitive source (like a package repository or documentation), it's not possible to verify the existence or purpose of a software package named \"brainTumor.\"\n\n2. UNKNOWN: Assuming the \"brainTumor\" package exists, it's plausible that it could be used for such purposes, but without specific documentation or a description of the package's capabilities, this cannot be confirmed.\n\n3. UNKNOWN: The ability to analyze RNA sequencing data (RNA-seq) using the \"brainTumor\" package would be contingent on the package's features. Without documentation of the package, this cannot be verified.\n\n4. UNKNOWN: A Circos plot is a common method for visualizing genomic data, and it's plausible that a genomics data analysis package might offer this feature. However, without definitive information about the capabilities of the \"brainTumor\" package, the truth of this statement cannot be determined.\n\n5. UNKNOWN: The requirement of the \"limma\" package, which is used for analyzing gene expression data, would depend on the specific functionalities of the \"brainTumor\" package. Again, without access to the package's documentation, the dependency cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Thank you for your kind words! I'm here to help you with your biomedicine questions.\nTo answer your last question, NEMO (Nuclear Envelope-Associated Membrane Protein) is not a zinc finger protein. Zinc finger proteins are a class of proteins that contain one or more zinc ions bind to specific DNA sequences and play a role in regulating gene expression.\nNEMO, on the other hand, is a protein that plays a critical role in the immune system, particularly in the activation of the NF-κB (nuclear factor kappa B) transcription factor. NF-κB is a transcription factor that regulates the expression of genes involved in inflammation and immune responses. NEMO is a key component of the IκB kinase complex, which phosphorylates and degrades the inhibitory protein IκB, leading to the activation of NF-κB.\nSo, while NEMO is not a zinc finger protein, it plays a crucial role in regulating the immune response and inflammation through its interaction with NF-κB.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (Nuclear Envelope-Associated Membrane Protein) is not a zinc finger protein.\n2. Zinc finger proteins contain one or more zinc ions and bind to specific DNA sequences to regulate gene expression.\n3. NEMO plays a critical role in the immune system.\n4. NEMO is involved in the activation of the NF-κB (nuclear factor kappa B) transcription factor.\n5. NEMO is a key component of the IκB kinase complex, which is involved in the phosphorylation and degradation of the protein IκB, leading to NF-κB activation.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (Nuclear Envelope-Associated Membrane Protein) is not a zinc finger protein.",
      "Zinc finger proteins contain one or more zinc ions and bind to specific DNA sequences to regulate gene expression.",
      "NEMO plays a critical role in the immune system.",
      "NEMO is involved in the activation of the NF-κB (nuclear factor kappa B) transcription factor.",
      "NEMO is a key component of the IκB kinase complex, which is involved in the phosphorylation and degradation of the protein IκB, leading to NF-κB activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: NEMO, which stands for NF-kappaB essential modulator, is indeed not classified as a zinc finger protein. It is an essential component of the IκB kinase (IKK) complex, which is critical for NF-κB activation.\n2. TRUE: Zinc finger proteins are a family of proteins that contain zinc ion(s) and typically bind to specific DNA sequences to regulate gene expression, among other functions.\n3. TRUE: NEMO does play a critical role in the immune system as part of the signaling pathways that lead to the activation of NF-κB, a transcription factor involved in immune and inflammatory responses.\n4. TRUE: NEMO is involved in the activation of the NF-κB transcription factor by being a part of the IKK complex which is necessary for the NF-κB signaling pathway.\n5. TRUE: NEMO is indeed a key component of the IκB kinase complex (IKK), and is involved in the phosphorylation and degradation of IκB, which leads to the activation of NF-κB.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a transcriptional elongation factor that plays a crucial role in regulating the transcription of genes, particularly those involved in DNA repair and replication. It has been shown to interact with nucleosomes and affect their positioning on the DNA, thereby influencing gene expression.\nStudies have shown that TFIIS can recognize and bind to specific nucleosome sequences, and this binding can either enhance or repress the recruitment of other transcription factors and coregulators to the promoter region. By modulating the positioning of nucleosomes, TFIIS can alter the accessibility of the DNA to transcriptional machinery, thereby controlling gene expression.\nIn addition, TFIIS has been shown to be involved in the regulation of chromatin structure and dynamics, including the formation of higher-order chromatin structures such as topologically associated domains (TADs) and chromatin loops. These structures can also influence gene expression by bringing distant regulatory elements and their target genes into close proximity.\nIn summary, TFIIS plays a crucial role in regulating nucleosome positioning and gene expression by modulating the accessibility of the DNA to transcriptional machinery and influencing the formation of higher-order chromatin structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS stands for Transcription Factor IIS.\n2. TFIIS can affect nucleosome positioning on the DNA.\n3. TFIIS plays a role in regulating the transcription of genes, particularly those involved in DNA repair and replication.\n4. TFIIS can influence gene expression by interacting with nucleosomes.\n5. TFIIS is involved in the regulation of chromatin structure and dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS stands for Transcription Factor IIS.",
      "TFIIS can affect nucleosome positioning on the DNA.",
      "TFIIS plays a role in regulating the transcription of genes, particularly those involved in DNA repair and replication.",
      "TFIIS can influence gene expression by interacting with nucleosomes.",
      "TFIIS is involved in the regulation of chromatin structure and dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! To answer your last question, origins of replication in yeast centromeres typically fire late in the cell cycle.\nDuring the G1 phase of the cell cycle, the origin of replication on the light chain of the centromere is inactive and not actively transcribed. It remains in this state until the cell enters the S phase, when the origin on the heavy chain becomes active and initiates DNA replication. This late firing of the origin of replication is thought to be due to the presence of a repressive complex called the CCCTC-binding factor (CBF) which binds to the origin and prevents it from firing until the cell is ready to enter the S phase.\nSo, to summarize, origins of replication in yeast centromeres fire late in the cell cycle, specifically during the S phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication in yeast centromeres typically fire late in the cell cycle.\n2. During the G1 phase of the cell cycle, the origin of replication on the light chain of the centromere is inactive.\n3. The origin of replication on the heavy chain becomes active and initiates DNA replication in the S phase.\n4. The presence of a repressive complex called the CCCTC-binding factor (CBF) prevents origins of replication from firing early.\n5. The CCCTC-binding factor (CBF) binds to the origin of replication on the centromere.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication in yeast centromeres typically fire late in the cell cycle.",
      "During the G1 phase of the cell cycle, the origin of replication on the light chain of the centromere is inactive.",
      "The origin of replication on the heavy chain becomes active and initiates DNA replication in the S phase.",
      "The presence of a repressive complex called the CCCTC-binding factor (CBF) prevents origins of replication from firing early.",
      "The CCCTC-binding factor (CBF) binds to the origin of replication on the centromere."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication typically fire early in the cell cycle, not late.\n2. TRUE\n3. FALSE [correction]: There is no distinction between a \"light chain\" and a \"heavy chain\" for the origin of replication in yeast; this terminology is more associated with antibodies. Origins of replication become active and initiate DNA replication in the S phase.\n4. FALSE [correction]: The CCCTC-binding factor (also known as CTCF) is not known to be a repressive complex that prevents origins of replication from firing; instead, it's typically involved in chromosome organization and regulation of gene expression. It is the Origin Recognition Complex (ORC), along with other proteins, that regulates the firing of origins of replication.\n5. FALSE [correction]: The CCCTC-binding factor (CBF or CTCF) is not known to specifically bind to origins of replication on the centromere; it is involved in chromatin organization and transcriptional regulation. The specific protein complex that binds at origins of replication to initiate DNA replication is the Origin Recognition Complex (ORC).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! Mammalian GA-sequences are a type of non-coding RNA that have been found to play important roles in various cellular processes, including gene regulation, RNA processing, and cell signaling. Some of the properties of mammalian GA-sequences include:\n1. Structure: Mammalian GA-sequences are composed of a conserved 7-nucleotide sequence (GACGAGA) repeated multiple times, with a variable number of repeats.\n2. Distribution: GA-sequences are found in the nucleus and cytoplasm of mammalian cells, and are particularly enriched in certain tissues, such as brain and muscle.\n3. Transcriptional regulation: GA-sequences are transcribed from the sense and antisense strands of DNA, and their expression is regulated by a variety of transcription factors.\n4. RNA processing: GA-sequences are subject to RNA processing, including splicing, editing, and degradation, which can affect their stability and function.\n5. Function: Mammalian GA-sequences have been implicated in a variety of cellular processes, including gene regulation, RNA processing, and cell signaling. They have been shown to bind to and regulate the activity of transcription factors, and to influence the stability of mRNAs and their translation into protein.\n6. Regulation of gene expression: GA-sequences can regulate the expression of specific genes by binding to and modulating the activity of transcription factors, or by affecting the stability of mRNAs.\n7. Cellular localization: GA-sequences are found in the nucleus and cytoplasm of mammalian cells, and their localization can affect their function.\n8. Interaction with other molecules: GA-sequences can interact with other molecules, such as transcription factors, RNA-binding proteins, and chromatin-modifying enzymes, to modulate their function.\n9. Evolutionary conservation: GA-sequences are conserved across species, indicating their importance in cellular function.\n10. Disease association: GA-sequences have been implicated in a variety of dise",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are composed of a conserved 7-nucleotide sequence (GACGAGA) repeated multiple times.\n2. GA-sequences are found in the nucleus and cytoplasm of mammalian cells and are enriched in brain and muscle tissues.\n3. GA-sequences are subject to RNA processing, which includes splicing, editing, and degradation.\n4. Mammalian GA-sequences are involved in cellular processes such as gene regulation, RNA processing, and cell signaling.\n5. GA-sequences have been implicated in the regulation of the expression of specific genes through their interaction with transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are composed of a conserved 7-nucleotide sequence (GACGAGA) repeated multiple times.",
      "GA-sequences are found in the nucleus and cytoplasm of mammalian cells and are enriched in brain and muscle tissues.",
      "GA-sequences are subject to RNA processing, which includes splicing, editing, and degradation.",
      "Mammalian GA-sequences are involved in cellular processes such as gene regulation, RNA processing, and cell signaling.",
      "GA-sequences have been implicated in the regulation of the expression of specific genes through their interaction with transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In mammals, GA-sequences, often referred to as GA-rich sequences, do not typically have a conserved 7-nucleotide sequence repeated multiple times as described. These sequences can be rich in guanine (G) and adenine (A) nucleotides, but their exact composition and repeats can vary.\n2. TRUE\n3. TRUE: RNA sequences, including GA-rich sequences, can indeed be subject to various RNA processing mechanisms, but the specific details of these processes for GA-sequences may vary and are not universally established.\n4. TRUE: GA-rich sequences can be involved in cellular processes such as gene regulation, RNA processing, and cell signaling, but the direct involvement and mechanisms may vary and are areas of ongoing research.\n5. TRUE: GA-sequences can play a role in gene regulation and may interact with transcription factors, but the specificity and detailed mechanisms of these interactions can be complex and are subject to scientific investigation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "According to the Ensembl Gene database, the mouse genome contains 6 Groucho-related genes (GRG):\n1. Grm1 (Groucho-related gene 1)\n2. Grm2 (Groucho-related gene 2)\n3. Grm3 (Groucho-related gene 3)\n4. Grm4 (Groucho-related gene 4)\n5. Grm5 (Groucho-related gene 5)\n6. Grm6 (Groucho-related gene 6)\nThese genes are also known as Groucho-like genes or GRL genes and are involved in various cellular processes, including transcriptional regulation, cell signaling, and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 6 Groucho-related genes (GRG).\n2. The genes are identified as Grm1, Grm2, Grm3, Grm4, Grm5, and Grm6.\n3. These genes are also referred to as Groucho-like genes or GRL genes.\n4. GRG genes are involved in transcriptional regulation.\n5. GRG genes play a role in cell signaling and development.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 6 Groucho-related genes (GRG).",
      "The genes are identified as Grm1, Grm2, Grm3, Grm4, Grm5, and Grm6.",
      "These genes are also referred to as Groucho-like genes or GRL genes.",
      "GRG genes are involved in transcriptional regulation.",
      "GRG genes play a role in cell signaling and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse genome does not contain 6 Groucho-related genes (GRG); instead, it contains genes for Groucho/TLE family members, which are homologs to the Drosophila Groucho gene, but they are typically not numbered in this fashion.\n2. FALSE [correction]: The genes Grm1 through Grm6 refers to the metabotropic glutamate receptors, not Groucho-related genes.\n3. UNKNOWN: Without specific literature to state this exact terminology it's difficult to determine the truth of this statement. However, 'Groucho-like genes' typically would refer to genes similar to the Drosophila Groucho gene, which are more commonly known as TLE genes in mammals.\n4. TRUE: Groucho/TLE genes (homologs of the Drosophila Groucho gene) are indeed involved in transcriptional regulation.\n5. TRUE: Groucho/TLE family members, as transcriptional co-repressors, play a critical role in various aspects of cell signaling and development.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Thank you for the opportunity to assist you! To answer your last question, the RNA polymerase II subunit that carries RNA cleavage activity is the RNA polymerase II subunit alpha (RPA). RPA is responsible for recognizing and binding to the 3' end of the RNA transcript during transcription, and it plays a crucial role in the processing of RNA transcripts, including RNA cleavage.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS\n\nThe response appears to be based on a misunderstanding or an error; there is no RNA polymerase II subunit known as \"RNA polymerase II subunit alpha (RPA)\" that is responsible for RNA cleavage activity. RNA cleavage is a function generally associated with other factors involved in RNA processing, not a specific subunit of RNA polymerase II. Therefore, the information provided does not correspond to verifiable facts.",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PHF6 gene. The PHF6 gene provides instructions for making a protein called Pumilio and Heterochromatin-binding factor 6 (PHF6), which plays a critical role in the regulation of gene expression and chromatin structure. Mutations in the PHF6 gene can lead to changes in the way genes are expressed, resulting in the characteristic features of Ohdo syndrome, including intellectual disability, delayed speech and language development, and a distinctive facial appearance.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder.\n2. Mutations in the PHF6 gene cause Ohdo syndrome.\n3. The PHF6 gene is responsible for making a protein called Pumilio and Heterochromatin-binding factor 6 (PHF6).\n4. The PHF6 protein is involved in the regulation of gene expression and chromatin structure.\n5. Mutations in the PHF6 gene can lead to characteristic features of Ohdo syndrome, such as intellectual disability, delayed speech and language development, and a distinctive facial appearance.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder.",
      "Mutations in the PHF6 gene cause Ohdo syndrome.",
      "The PHF6 gene is responsible for making a protein called Pumilio and Heterochromatin-binding factor 6 (PHF6).",
      "The PHF6 protein is involved in the regulation of gene expression and chromatin structure.",
      "Mutations in the PHF6 gene can lead to characteristic features of Ohdo syndrome, such as intellectual disability, delayed speech and language development, and a distinctive facial appearance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the SALL1 or MED12 gene cause Ohdo syndrome. The PHF6 gene has been associated with other conditions, such as Borjeson-Forssman-Lehmann syndrome.\n3. UNKNOWN\n4. UNKNOWN: Although the role of PHF6 suggests involvement in gene expression and chromatin structure, without specific information about Ohdo syndrome and the role of PHF6 in this context, it is difficult to confirm the statement as true or false.\n5. TRUE: The statement accurately describes common features of Ohdo syndrome which are indeed associated with mutations in relevant genes, including SALL1 or MED12, not the PHF6 gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "For the analysis of psychiatric disease genes, the \"psychgen\" package in R/Bioconductor is commonly used. This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, including mood disorders, anxiety disorders, and schizophrenia. It allows researchers to perform genome-wide association studies (GWAS), gene-set enrichment analysis, and pathway analysis, among other functions.\nSome of the key features of the \"psychgen\" package include:\n1. GWAS analysis: The package provides a range of tools for performing GWAS, including imputation of missing genotypes, testing for association between genetic variants and disease status, and estimation of effect sizes.\n2. Gene-set enrichment analysis: The package includes tools for identifying gene sets that are overrepresented among genetic variants associated with disease, allowing researchers to identify potential pathways or biological processes that may be implicated in the disorder.\n3. Pathway analysis: The package provides tools for identifying pathways and networks that are enriched among genetic variants associated with disease, allowing researchers to identify potential therapeutic targets or biomarkers.\n4. Fine-mapping: The package includes tools for fine-mapping genetic variants to identify the specific genetic variant or variants that are most strongly associated with disease.\n5. Machine learning: The package includes tools for using machine learning algorithms to predict disease status based on genetic data, including support vector machines, random forests, and neural networks.\nOverall, the \"psychgen\" package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, allowing researchers to identify genetic variants associated with disease and to explore their functional implications.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"psychgen\" package is used for the analysis of psychiatric disease genes in R/Bioconductor.\n2. \"Psychgen\" allows researchers to perform genome-wide association studies (GWAS).\n3. The package includes tools for gene-set enrichment analysis.\n4. Pathway analysis can be conducted using the \"psychgen\" package to identify potential therapeutic targets or biomarkers.\n5. \"Psychgen\" incorporates machine learning algorithms to predict disease status based on genetic data.",
    "llama-2-7b-chat-hf_fact": [
      "The \"psychgen\" package is used for the analysis of psychiatric disease genes in R/Bioconductor.",
      "\"Psychgen\" allows researchers to perform genome-wide association studies (GWAS).",
      "The package includes tools for gene-set enrichment analysis.",
      "Pathway analysis can be conducted using the \"psychgen\" package to identify potential therapeutic targets or biomarkers.",
      "\"Psychgen\" incorporates machine learning algorithms to predict disease status based on genetic data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence and functionality of the \"psychgen\" package cannot be verified without the appropriate context or a reliable source due to the ever-evolving nature of software and packages within computational biology.\n2. UNKNOWN: Similarly, the ability of the \"psychgen\" package to perform GWAS is unclear without specific details about the package's features or access to its documentation.\n3. UNKNOWN: The statement regarding gene-set enrichment analysis tools within the \"psychgen\" package cannot be confirmed without further information.\n4. UNKNOWN: The capability for pathway analysis within the \"psychgen\" package cannot be validated without more context or evidence.\n5. UNKNOWN: Whether \"psychgen\" incorporates machine learning algorithms for disease status prediction is not verifiable without additional details or references.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Certainly! I'd be happy to help. The \"swirl sign\" is a term used in the context of intracerebral hemorrhage (ICH), which refers to a specific type of brain injury caused by bleeding within the brain tissue.\nThe swirl sign is characterized by a specific pattern of swirling or twisting of the brain tissue on a CT or MRI scan. It is typically seen in the early stages of ICH, and is thought to represent the movement of blood within the brain due to the bleeding. The swirl sign can be an important diagnostic marker for ICH, as it can help doctors identify the location and severity of the bleeding.\nIn summary, the swirl sign is a specific pattern of brain tissue swirling or twisting seen on a CT or MRI scan in the early stages of intracerebral hemorrhage, which is thought to represent the movement of blood within the brain due to the bleeding.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign is used in the context of intracerebral hemorrhage (ICH).\n2. The swirl sign represents a pattern of swirling or twisting of the brain tissue visible on a CT or MRI scan.\n3. It is typically observed in the early stages of intracerebral hemorrhage.\n4. The swirl sign can help doctors identify the location and severity of the bleeding within the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign is used in the context of intracerebral hemorrhage (ICH).",
      "The swirl sign represents a pattern of swirling or twisting of the brain tissue visible on a CT or MRI scan.",
      "It is typically observed in the early stages of intracerebral hemorrhage.",
      "The swirl sign can help doctors identify the location and severity of the bleeding within the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign actually represents a pattern of blood at different stages of clotting within a hematoma on a CT scan, not a twisting of the brain tissue.\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! Here's my answer to the last question:\nArabidopsis ROF1 (RNA binding protein 1) expression is induced by various factors, including:\n1. Light: Light exposure can induce ROF1 expression in Arabidopsis plants, suggesting a role in photomorphogenesis.\n2. Abiotic stress: ROF1 expression is also induced by abiotic stressors such as drought, high temperature, and salinity, indicating a role in stress response.\n3. Hormones: ROF1 expression is regulated by plant hormones, particularly auxin and ethylene, which play important roles in plant growth and development.\n4. Developmental cues: ROF1 expression is also regulated by developmental cues, such as cell division and cell expansion, which are important for plant growth and development.\n5. Genetic mutations: Mutations in genes encoding ROF1-interacting proteins or in the ROF1 gene itself can also affect ROF1 expression and function.\nOverall, ROF1 expression is regulated by a complex interplay of environmental and genetic factors, and its function is critical for plant growth and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by light exposure.\n2. Arabidopsis ROF1 expression is induced by abiotic stressors such as drought, high temperature, and salinity.\n3. Plant hormones, particularly auxin and ethylene, regulate Arabidopsis ROF1 expression.\n4. Arabidopsis ROF1 expression is regulated by developmental cues, including cell division and cell expansion.\n5. Genetic mutations in genes encoding ROF1-interacting proteins or in the ROF1 gene itself can affect ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by light exposure.",
      "Arabidopsis ROF1 expression is induced by abiotic stressors such as drought, high temperature, and salinity.",
      "Plant hormones, particularly auxin and ethylene, regulate Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 expression is regulated by developmental cues, including cell division and cell expansion.",
      "Genetic mutations in genes encoding ROF1-interacting proteins or in the ROF1 gene itself can affect ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWhile I can confirm that genetic mutations in genes encoding interacting proteins or in the gene itself (statement 5) can affect expression levels as a general principle of genetics, I cannot claim the specific statements regarding Arabidopsis ROF1 expression (statements 1-4) without specific evidence or academic references relating to these aspects of the plant's physiology. Such details would typically require subject-matter expertise or access to current scientific research on the topic.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M).",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is a proteinase inhibitor, and mutations in the A2M gene are not the most common cause of hereditary renal amyloidosis. The most common cause of hereditary renal amyloidosis is mutations in the gene encoding fibrinogen A alpha-chain (AFib), transthyretin (ATTR), apolipoprotein A-I (AApoAI), and lysozyme (ALys).",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed. The hippocampus is a region of the brain that plays a critical role in memory formation and spatial navigation, and changes in the proteins present in this region have been implicated in various neurological disorders, including Alzheimer's disease and epilepsy.\nStudies have used various proteomic techniques, such as two-dimensional gel electrophoresis (2DGE) and mass spectrometry (MS), to identify and quantify the proteins present in the mouse hippocampus. These studies have identified thousands of proteins present in the hippocampus, including structural proteins, enzymes, receptors, and regulatory proteins.\nSome examples of proteins that have been identified in the mouse hippocampus include:\n* Synaptic proteins, such as synaptotagmin and neuroligin, which are involved in the formation and regulation of synapses\n* Neurotransmitter receptors, such as NMDA and AMPA receptors, which are involved in the transmission of signals between neurons\n* Enzymes involved in the synthesis and degradation of neurotransmitters, such as acetylcholinesterase and butyrylcholinesterase\n* Proteins involved in the regulation of gene expression, such as histones and transcription factors\n* Proteins involved in the maintenance of neuronal structure and function, such as tubulin and actin\nThese studies have provided a comprehensive view of the proteins present in the mouse hippocampus and have identified potential targets for the development of new treatments for neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using proteomic techniques.\n2. The hippocampus is involved in memory formation and spatial navigation.\n3. Proteomic studies of the mouse hippocampus have identified thousands of proteins.\n4. Techniques such as two-dimensional gel electrophoresis (2DGE) and mass spectrometry (MS) have been employed in the analysis of the mouse hippocampus proteome.\n5. Identified proteins in the mouse hippocampus include synaptic proteins, neurotransmitter receptors, and enzymes involved in neurotransmitter synthesis and degradation.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using proteomic techniques.",
      "The hippocampus is involved in memory formation and spatial navigation.",
      "Proteomic studies of the mouse hippocampus have identified thousands of proteins.",
      "Techniques such as two-dimensional gel electrophoresis (2DGE) and mass spectrometry (MS) have been employed in the analysis of the mouse hippocampus proteome.",
      "Identified proteins in the mouse hippocampus include synaptic proteins, neurotransmitter receptors, and enzymes involved in neurotransmitter synthesis and degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll of these statements are consistent with current scientific understanding. Proteomic studies typically identify a large number of proteins, including those mentioned in statement 5, and techniques like 2DGE and MS are commonly used in proteomic analysis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Great, I'm glad to help! Acrocentric chromosomes are characterized by a large centromere region and a small acrocentric arm. In mice, all chromosomes are acrocentric, meaning they have a large centromere region and short arms. This is in contrast to the human chromosomes, where some chromosomes are acrocentric, while others are metacentric or telocentric. The acrocentric chromosomes in mice are typically found in the autosomal chromosomes (chromosomes 1-16), while the sex chromosomes (chromosomes X and Y) are metacentric.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes are characterized by a large centromere region and a small acrocentric arm.\n2. In mice, all chromosomes are acrocentric.\n3. Mice have acrocentric autosomal chromosomes (chromosomes 1-16).\n4. The sex chromosomes in mice are metacentric.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes are characterized by a large centromere region and a small acrocentric arm.",
      "In mice, all chromosomes are acrocentric.",
      "Mice have acrocentric autosomal chromosomes (chromosomes 1-16).",
      "The sex chromosomes in mice are metacentric."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Acrocentric chromosomes are characterized by a centromere that is situated close to one end, creating a long arm and a very short (or sometimes indistinguishable) other arm.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The sex chromosomes in mice are not metacentric. The Y chromosome is acrocentric, while the X chromosome is submetacentric.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! For the last question, the siRNA-based drug in clinical trials for the treatment of pancreatic cancer is:\nOlysio (simeprevir) is a nucleotide NS5B polymerase inhibitor that is currently in clinical trials for the treatment of pancreatic cancer. It works by targeting the NS5B polymerase enzyme, which is essential for the replication of the hepatitis C virus (HCV). By inhibiting this enzyme, Olysio can reduce the amount of HCV in the body, which can help to slow the progression of liver disease and improve treatment outcomes.\nI hope this information is helpful! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Olysio (simeprevir) is a nucleotide NS5B polymerase inhibitor.\n2. Olysio is in clinical trials for the treatment of pancreatic cancer.\n3. Olysio targets the NS5B polymerase enzyme.\n4. Olysio aims to reduce the amount of hepatitis C virus (HCV) in the body.\n5. By inhibiting the NS5B polymerase enzyme, Olysio helps to slow the progression of liver disease.",
    "llama-2-7b-chat-hf_fact": [
      "Olysio (simeprevir) is a nucleotide NS5B polymerase inhibitor.",
      "Olysio is in clinical trials for the treatment of pancreatic cancer.",
      "Olysio targets the NS5B polymerase enzyme.",
      "Olysio aims to reduce the amount of hepatitis C virus (HCV) in the body.",
      "By inhibiting the NS5B polymerase enzyme, Olysio helps to slow the progression of liver disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Olysio (simeprevir) is a protease inhibitor, not a nucleotide NS5B polymerase inhibitor.\n2. UNKNOWN\n3. FALSE [correction]: Olysio targets the NS3/4A protease enzyme, not the NS5B polymerase enzyme.\n4. TRUE\n5. UNKNOWN (Although Olysio does help to treat hepatitis C, which can lead to liver disease, the statement is vague as it doesn't specify that Olysio is for HCV, not liver disease in general, and \"slow the progression of liver disease\" might not be accurate without the context of hepatitis C).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore, also known as the H+/Pge pore, is a transmembrane protein complex found in the plasma membrane of certain cells, including pancreatic beta cells and neurons. The HPG pore is a proton-selective channel that allows the passage of protons (hydrogen ions) across the membrane, while maintaining a strict selectivity for other ions and molecules.\nThe HPG pore is composed of four subunits: H+, Pge, Pti, and Ptia. These subunits form a tetrameric structure that spans the plasma membrane and is anchored to the lipid bilayer by hydrophobic interactions. The HPG pore is gated by changes in the concentration of intracellular calcium ions, which can open or close the channel by altering the conformation of the subunits.\nThe HPG pore plays a crucial role in regulating the activity of pancreatic beta cells, which are responsible for producing insulin and glucagon, the two hormones that control blood sugar levels. When blood glucose levels are high, the HPG pore opens, allowing protons to flow into the beta cell, which in turn activates the enzyme ATP-sensitive potassium channels and leads to the secretion of insulin. Conversely, when blood glucose levels are low, the HPG pore closes, preventing the entry of protons and inhibiting the secretion of insulin.\nIn addition to its role in pancreatic beta cells, the HPG pore has been implicated in the regulation of neuronal activity and the control of appetite and metabolism. Dysfunction of the HPG pore has been linked to a number of diseases, including type 2 diabetes, obesity, and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a transmembrane protein complex found in the plasma membrane of certain cells, including pancreatic beta cells and neurons.\n2. It is a proton-selective channel that allows the passage of protons across the membrane while selectively blocking other ions and molecules.\n3. The HPG pore is composed of four subunits: H+, Pge, Pti, and Ptia, forming a tetrameric structure.\n4. It is gated by changes in the concentration of intracellular calcium ions, which can open or close the channel.\n5. Dysfunction of the HPG pore has been linked to a number of diseases, including type 2 diabetes, obesity, and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a transmembrane protein complex found in the plasma membrane of certain cells, including pancreatic beta cells and neurons.",
      "It is a proton-selective channel that allows the passage of protons across the membrane while selectively blocking other ions and molecules.",
      "The HPG pore is composed of four subunits: H+, Pge, Pti, and Ptia, forming a tetrameric structure.",
      "It is gated by changes in the concentration of intracellular calcium ions, which can open or close the channel.",
      "Dysfunction of the HPG pore has been linked to a number of diseases, including type 2 diabetes, obesity, and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements refer to a structure called the \"HPG pore,\" which is not a recognized or standard term in cellular biology or medicine as of my knowledge cutoff in early 2023. Due to the lack of publicly available information on the \"HPG pore\" and its characteristics, it is not possible to accurately verify or correct these statements. They may refer to a hypothetical or less commonly known protein complex, or it could be a mix-up with some other factual information. Without more context or specific scientific references, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale effort to sequence the genomes of 959 species of nematodes, which are a group of microscopic worms that are important model organisms in biomedical research. The initiative was launched in 2015 and is funded by the National Institutes of Health (NIH) in the United States.\nThe goal of the 959 Nematode Genomes initiative is to generate high-quality genomic data for a wide range of nematode species, including those that are important for human health and disease, such as parasitic nematodes that cause diseases like elephantiasis and river blindness. By sequencing the genomes of these nematodes, researchers hope to gain a better understanding of their biology and identify new targets for drug development and other interventions.\nThe initiative involves a collaborative effort between researchers at multiple institutions, including universities, research institutes, and biotechnology companies. The project involves a range of techniques, including DNA sequencing, assembly, and analysis, as well as the development of new computational tools and methods to analyze the large amounts of data generated by the project.\nOverall, the 959 Nematode Genomes initiative is an important effort to advance our understanding of nematode biology and to identify new opportunities for improving human health through the study of these fascinating organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. The initiative was launched in 2015.\n3. The National Institutes of Health (NIH) in the United States funds the initiative.\n4. One of the goals is to gain a better understanding of nematodes that cause diseases like elephantiasis and river blindness.\n5. The initiative is a collaborative effort between researchers at multiple institutions, including universities, research institutes, and biotechnology companies.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "The initiative was launched in 2015.",
      "The National Institutes of Health (NIH) in the United States funds the initiative.",
      "One of the goals is to gain a better understanding of nematodes that cause diseases like elephantiasis and river blindness.",
      "The initiative is a collaborative effort between researchers at multiple institutions, including universities, research institutes, and biotechnology companies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the commonly used packages include:\n1. NIPTpack: This package provides a set of tools for the analysis of NIPT data, including quality control, sample classification, and statistical analysis. It also includes functions for visualizing the results.\n2. Prenat: This package provides a comprehensive set of tools for the analysis of NIPT data, including statistical analysis, visualization, and interpretation of results. It also includes functions for handling missing data and outliers.\n3. PrenatalGenetics: This package provides a set of tools for the analysis of NIPT data, including statistical analysis, visualization, and interpretation of results. It also includes functions for handling missing data and outliers, as well as functions for estimating the probability of a positive test result.\n4. NIPTAnalysis: This package provides a set of tools for the analysis of NIPT data, including statistical analysis, visualization, and interpretation of results. It also includes functions for handling missing data and outliers, as well as functions for estimating the probability of a positive test result.\n5. PrenatalTesting: This package provides a set of tools for the analysis of NIPT data, including statistical analysis, visualization, and interpretation of results. It also includes functions for handling missing data and outliers, as well as functions for estimating the probability of a positive test result.\nThese packages can be used to analyze various types of NIPT data, including DNA from maternal blood, plasma, or serum, and can be used to detect various genetic conditions, such as trisomies 21, 18, and 13, as well as other genetic abnormalities.",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTpack is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. Prenat is an R package that offers comprehensive tools for the analysis of NIPT data.\n3. PrenatalGenetics is an R package that includes functions for estimating the probability of a positive NIPT test result.\n4. NIPTAnalysis is an R package designed for handling missing data and outliers in NIPT data analysis.\n5. PrenatalTesting is an R package that can be used to detect various genetic conditions, such as trisomies 21, 18, and 13, through the analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTpack is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "Prenat is an R package that offers comprehensive tools for the analysis of NIPT data.",
      "PrenatalGenetics is an R package that includes functions for estimating the probability of a positive NIPT test result.",
      "NIPTAnalysis is an R package designed for handling missing data and outliers in NIPT data analysis.",
      "PrenatalTesting is an R package that can be used to detect various genetic conditions, such as trisomies 21, 18, and 13, through the analysis of NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without a specific reference to the \"NIPTpack\" as an R package in the R community or repositories, the existence and specific functionalities of this package cannot be determined. It's necessary to refer to reliable sources such as CRAN (Comprehensive R Archive Network) or other repositories to verify this information.\n2. UNKNOWN: As with the previous statement, without specific reference or documentation, we cannot validate if \"Prenat\" is an R package or its capabilities in analyzing NIPT data. Verification from authoritative sources is needed.\n3. UNKNOWN: The statement about \"PrenatalGenetics\" as an R package and its functions also requires confirmation from trusted sources to determine its validity.\n4. UNKNOWN: The existence and purpose of \"NIPTAnalysis\" as an R package for handling missing data and outliers in NIPT data analysis are not verifiable without further information or documentation.\n5. UNKNOWN: Similarly, \"PrenatalTesting\" being an R package capable of detecting genetic conditions through NIPT data analysis cannot be validated without additional evidence or source information. \n\nFor all the above statements, actual knowledge of the R package ecosystem or documentation for the mentioned packages would be necessary for a definitive answer. In the absence of that, the existence or features of these packages remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare genetic disorder characterized by a range of developmental and behavioral abnormalities. It is caused by mutations in the PTEN gene, which encodes a protein that plays a critical role in regulating cell growth and division.\nThe main features of Achenbach's syndrome include:\n1. Intellectual disability: Individuals with Achenbach's syndrome typically have mild to moderate intellectual disability, which can range from mild to moderate.\n2. Autism spectrum disorder: Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD), which is characterized by difficulties in social interaction and communication.\n3. Distinctive facial features: People with Achenbach's syndrome may have distinctive facial features, such as a small head, narrow eyes, and a flat nasal bridge.\n4. Growth delays: Children with Achenbach's syndrome may experience delays in their growth and development, including short stature and delayed puberty.\n5. Increased risk of cancer: Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, including breast, ovarian, and thyroid cancer.\n6. Other medical problems: Achenbach's syndrome can also cause a range of other medical problems, including seizures, vision and hearing loss, and heart defects.\nOverall, Achenbach's syndrome is a complex and rare genetic disorder that can have significant impacts on an individual's quality of life. Early diagnosis and appropriate management can help to minimize the severity of these effects and improve outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by a range of developmental and behavioral abnormalities.\n2. The PTEN gene mutation is the cause of Achenbach's syndrome.\n3. Individuals with Achenbach's syndrome typically have mild to moderate intellectual disability.\n4. Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD).\n5. Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, such as breast, ovarian, and thyroid cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by a range of developmental and behavioral abnormalities.",
      "The PTEN gene mutation is the cause of Achenbach's syndrome.",
      "Individuals with Achenbach's syndrome typically have mild to moderate intellectual disability.",
      "Many individuals with Achenbach's syndrome have been diagnosed with autism spectrum disorder (ASD).",
      "Individuals with Achenbach's syndrome have an increased risk of developing certain types of cancer, such as breast, ovarian, and thyroid cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by bruising to the hands or fingers without any identified cause, not developmental or behavioral abnormalities.\n2. FALSE [correction]: Achenbach's syndrome is not caused by the PTEN gene mutation. It is not currently associated with specific genetic mutations.\n3. FALSE [correction]: Achenbach's syndrome does not typically involve intellectual disability as it is primarily characterized by spontaneous bruising.\n4. FALSE [correction]: There is no established connection between Achenbach's syndrome and the diagnosis of autism spectrum disorder (ASD).\n5. FALSE [correction]: Achenbach's syndrome does not have a known association with an increased risk of developing cancer. It is predominantly associated with paroxysmal hand hematoma.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "For the detection of long repeat expansions, a variety of algorithms have been developed and used in bioinformatics. Some of the commonly used algorithms for detecting long repeat expansions include:\n1. RepeatMasker: This algorithm is a widely used tool for identifying repetitive elements in a DNA sequence. It uses a combination of heuristics and statistical models to identify potential repeat regions and can be used to detect both short and long repeat expansions.\n2. GATAware: This algorithm is specifically designed to detect GATA-like transcription factor binding sites, which are often associated with long repeat expansions in genomic DNA. GATAware uses a combination of sequence motif discovery and machine learning techniques to identify potential GATA binding sites.\n3. LRE-Finder: This algorithm is a more recent tool that is specifically designed for detecting long repeat expansions (LREs) in genomic DNA. LRE-Finder uses a combination of sequence alignment and machine learning techniques to identify LREs and can be used to detect both known and novel repeat regions.\n4. REPEAT-Finder: This algorithm is another widely used tool for detecting repetitive elements in genomic DNA, including long repeat expansions. REPEAT-Finder uses a combination of sequence alignment and machine learning techniques to identify potential repeat regions and can be used to detect both known and novel repeat elements.\n5. Primer3: This algorithm is a widely used tool for designing PCR primers, but it can also be used for detecting long repeat expansions. Primer3 uses a combination of sequence alignment and machine learning techniques to identify potential repeat regions and can be used to detect both known and novel repeat elements.\nThese are some of the commonly used algorithms for detecting long repeat expansions in bioinformatics. The choice of algorithm will depend on the specific research question and the characteristics of the DNA sequence being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm that identifies repetitive elements in DNA sequences and can detect both short and long repeat expansions.\n2. GATAware is an algorithm designed to detect GATA-like transcription factor binding sites associated with long repeat expansions in genomic DNA.\n3. LRE-Finder is an algorithm specifically designed for detecting long repeat expansions in genomic DNA.\n4. REPEAT-Finder is an algorithm that detects repetitive elements in genomic DNA, including long repeat expansions.\n5. Primer3 is an algorithm that, while primarily used for designing PCR primers, can also detect long repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm that identifies repetitive elements in DNA sequences and can detect both short and long repeat expansions.",
      "GATAware is an algorithm designed to detect GATA-like transcription factor binding sites associated with long repeat expansions in genomic DNA.",
      "LRE-Finder is an algorithm specifically designed for detecting long repeat expansions in genomic DNA.",
      "REPEAT-Finder is an algorithm that detects repetitive elements in genomic DNA, including long repeat expansions.",
      "Primer3 is an algorithm that, while primarily used for designing PCR primers, can also detect long repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized algorithm called GATAware associated with detecting transcription factor binding sites or long repeat expansions. GATA-related algorithms might be designed to detect GATA binding sites, but there is no standard reference to an algorithm named GATAware for the purpose stated.\n3. TRUE\n4. UNKNOWN: Without further context, it is unclear whether there is an algorithm specifically called REPEAT-Finder that does what is described. Commonly known tools for detecting repetitive elements in genomic DNA include RepeatMasker and Tandem Repeats Finder, but not REPEAT-Finder.\n5. FALSE [correction]: Primer3 is an algorithm used for designing PCR primers. It does not have the functionality to detect long repeat expansions in genomic DNA. Its primary purpose is to design forward and reverse primers for polymerase chain reactions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Medulloblastoma: Neuroligin-3 has been found to be overexpressed in medulloblastoma, a type of pediatric brain cancer that arises in the cerebellum. Overexpression of neuroligin-3 has been linked to aggressive disease and poor prognosis in this tumor type.\n2. Glioblastoma: Neuroligin-3 has also been implicated in the development and progression of glioblastoma, the most common and aggressive type of primary brain cancer. High levels of neuroligin-3 have been detected in glioblastoma tumors and are associated with poorer prognosis.\n3. Meningioma: Neuroligin-3 has been found to be overexpressed in some types of meningioma, a type of brain tumor that arises in the meninges, the protective coverings of the brain and spinal cord.\nOverall, the overexpression of neuroligin-3 has been linked to the development and progression of several types of brain tumors, and may play a role in their malignant behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 has been found to be overexpressed in medulloblastoma, a pediatric brain cancer.\n2. Overexpression of neuroligin-3 is associated with aggressive disease and poor prognosis in medulloblastoma.\n3. Neuroligin-3 has been implicated in the progression of glioblastoma, the most common type of primary brain cancer.\n4. High levels of neuroligin-3 in glioblastoma tumors are associated with poorer prognosis.\n5. Neuroligin-3 is overexpressed in some types of meningioma, which is a tumor that arises from the meninges.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 has been found to be overexpressed in medulloblastoma, a pediatric brain cancer.",
      "Overexpression of neuroligin-3 is associated with aggressive disease and poor prognosis in medulloblastoma.",
      "Neuroligin-3 has been implicated in the progression of glioblastoma, the most common type of primary brain cancer.",
      "High levels of neuroligin-3 in glioblastoma tumors are associated with poorer prognosis.",
      "Neuroligin-3 is overexpressed in some types of meningioma, which is a tumor that arises from the meninges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nSince glioblastoma and medulloblastoma are indeed types of brain cancers where neuroligin-3 can play a role, the statements provided are consistent with scientific findings up to the point of my knowledge cutoff. However, for the statement about meningioma, the connection between neuroligin-3 and this type of tumor is less clear without specific literature or studies to reference, hence the response is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Thank you for the opportunity to help! Gas vesicles are small, membrane-bound structures found in some bacteria and archaea. The size of gas vesicles can vary depending on the species and the specific function of the vesicle, but they are generally in the range of 10-100 nanometers (nm) in diameter.\nFor example, in the bacterium Escherichia coli, gas vesicles are typically around 20-30 nm in diameter. In contrast, gas vesicles in the archaeon Halorubrum sodomense can be up to 100 nm in diameter.\nIt's worth noting that the size of gas vesicles can also vary depending on the concentration of gas inside the vesicle. When the vesicle is depleted of gas, it may collapse or become smaller in size.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. The diameter of gas vesicles generally ranges from 10-100 nanometers (nm).\n3. In the bacterium Escherichia coli, gas vesicles are typically around 20-30 nm in diameter.\n4. Gas vesicles in the archaeon Halorubrum sodomense can be up to 100 nm in diameter.\n5. The size of gas vesicles can vary depending on the concentration of gas inside the vesicle.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "The diameter of gas vesicles generally ranges from 10-100 nanometers (nm).",
      "In the bacterium Escherichia coli, gas vesicles are typically around 20-30 nm in diameter.",
      "Gas vesicles in the archaeon Halorubrum sodomense can be up to 100 nm in diameter.",
      "The size of gas vesicles can vary depending on the concentration of gas inside the vesicle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The diameter of gas vesicles generally ranges from 45-200 nanometers (nm).\n3. FALSE [correction]: The bacterium Escherichia coli does not typically have gas vesicles; they are more commonly found in buoyant bacteria like some cyanobacteria.\n4. UNKNOWN\n5. FALSE [correction]: The size of gas vesicles can vary depending on environmental conditions and the organism, but it is the rigidity and impermeability of the vesicle walls that maintain their size, not the concentration of gas inside the vesicle.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Of course! BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are some examples of BET proteins:\n1. BRD2 (Bromodomain and Extra-Terminal Domain Factor 2)\n2. BRD3 (Bromodomain and Extra-Terminal Domain Factor 3)\n3. BRDT (Bromodomain-Containing Protein T)\n4. BET1 (Bromodomain-Containing Protein 1)\n5. BET4 (Bromodomain-Containing Protein 4)\nThese proteins contain a bromodomain, a specific structural motif that recognizes and binds to acetylated lysine residues on histone proteins, leading to changes in chromatin structure and gene expression. BET proteins play a role in various cellular processes, including transcriptional activation, repression, and maintenance of chromatin structure, and have been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are involved in regulating gene expression by modifying chromatin structure.\n2. BRD2 is an example of a BET protein and stands for Bromodomain and Extra-Terminal Domain Factor 2.\n3. BRD3, another BET protein, stands for Bromodomain and Extra-Terminal Domain Factor 3.\n4. BRDT is an example of a BET protein and stands for Bromodomain-Containing Protein T.\n5. BET proteins contain a bromodomain that recognizes and binds to acetylated lysine residues on histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are involved in regulating gene expression by modifying chromatin structure.",
      "BRD2 is an example of a BET protein and stands for Bromodomain and Extra-Terminal Domain Factor 2.",
      "BRD3, another BET protein, stands for Bromodomain and Extra-Terminal Domain Factor 3.",
      "BRDT is an example of a BET protein and stands for Bromodomain-Containing Protein T.",
      "BET proteins contain a bromodomain that recognizes and binds to acetylated lysine residues on histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRDT is an example of a BET protein but it stands for Bromodomain Testis-Specific Protein.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "One algorithm that has been developed for prediction of protein subcellular localization using deep learning is the \"DeepLoc\" algorithm.\nDeepLoc is a deep learning-based method that uses a convolutional neural network (CNN) to predict the subcellular localization of proteins based on their amino acid sequences. The algorithm was developed by researchers at the University of California, San Diego and the University of California, Los Angeles, and was published in the journal Nature Methods in 2018.\nDeepLoc uses a large dataset of protein sequences and their corresponding subcellular localization annotations to train the CNN. The algorithm learns to identify features in the protein sequences that are associated with different subcellular localizations, and can predict the localization of new proteins with high accuracy.\nDeepLoc has been shown to outperform other machine learning-based methods for protein localization prediction, and has potential applications in a variety of fields, including drug discovery and personalized medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.\n2. DeepLoc utilizes a convolutional neural network (CNN) to analyze amino acid sequences of proteins.\n3. The algorithm was collectively developed by researchers at the University of California, San Diego and the University of California, Los Angeles.\n4. The results and description of DeepLoc were published in the journal Nature Methods in 2018.\n5. DeepLoc has exhibited superior performance compared to other machine learning-based methods for protein localization prediction.",
    "llama-2-7b-chat-hf_fact": [
      "The \"DeepLoc\" algorithm is a deep learning-based method for predicting protein subcellular localization.",
      "DeepLoc utilizes a convolutional neural network (CNN) to analyze amino acid sequences of proteins.",
      "The algorithm was collectively developed by researchers at the University of California, San Diego and the University of California, Los Angeles.",
      "The results and description of DeepLoc were published in the journal Nature Methods in 2018.",
      "DeepLoc has exhibited superior performance compared to other machine learning-based methods for protein localization prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The results and description of DeepLoc were published in the journal \"Bioinformatics\" in 2017.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but I couldn't find any information on \"MULTOVL\" in the context of biomedicine. It's possible that it's a misspelling or an obscure term, or it may not be a widely used term in the field. Can you please provide more context or clarify the question? I'll do my best to help you with any other questions you may have.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment. Metformin is a commonly used medication for type 2 diabetes, and research has shown that GDF15 levels may be altered in response to metformin therapy.\nStudies have shown that GDF15 levels are increased in individuals with type 2 diabetes, and that metformin treatment can decrease GDF15 levels in these individuals. Additionally, GDF15 levels have been shown to be elevated in response to other insulin-sensitizing medications, such as thiazolidinediones, suggesting that GDF15 may be a useful biomarker for identifying individuals who are likely to respond to these treatments.\nFurthermore, GDF15 has been shown to have a role in the regulation of glucose metabolism, and alterations in GDF15 levels have been linked to insulin resistance and type 2 diabetes. Therefore, GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment and for identifying individuals who may benefit from alternative treatments.\nIn summary, GDF15 has been identified as a potential biomarker for metformin treatment, and further research is needed to fully understand its role in this context.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.\n2. Metformin is a medication commonly used for treating type 2 diabetes.\n3. Research has indicated that levels of GDF15 may change in response to metformin therapy.\n4. Studies have found that GDF15 levels are higher in individuals with type 2 diabetes and that metformin treatment can decrease these levels.\n5. GDF15 is involved in the regulation of glucose metabolism, and its altered levels have been linked to insulin resistance and type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.",
      "Metformin is a medication commonly used for treating type 2 diabetes.",
      "Research has indicated that levels of GDF15 may change in response to metformin therapy.",
      "Studies have found that GDF15 levels are higher in individuals with type 2 diabetes and that metformin treatment can decrease these levels.",
      "GDF15 is involved in the regulation of glucose metabolism, and its altered levels have been linked to insulin resistance and type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nResearch on GDF15 has indicated its potential role in various physiological and pathological processes, including as a biomarker for different treatments like metformin. Metformin is indeed commonly used to treat type 2 diabetes and can affect GDF15 levels. Studies have found associations between GDF15 levels and metabolic disorders such as type 2 diabetes. GDF15 is known to be involved in the regulation of energy balance and has been linked to insulin action, although the exact mechanisms are still being researched.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as iterative splicing, is a process where a single intron is spliced multiple times, resulting in the production of multiple mRNA isoforms. This type of splicing is more frequent in introns that are shorter in length, as the splicing machinery can more easily cycle back and forth through the intron.\nIn contrast, long introns are less likely to undergo recursive splicing, as the splicing machinery has more distance to travel and is less likely to cycle back through the intron multiple times. As a result, long introns are more likely to be spliced once and produce a single mRNA isoform.\nSo, to summarize, recursive splicing is more common in short introns, while long introns are less likely to undergo this type of splicing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing involves a single intron being spliced multiple times.\n3. Multiple mRNA isoforms result from recursive splicing.\n4. Long introns are less likely to undergo recursive splicing.\n5. Long introns tend to produce a single mRNA isoform after splicing.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing involves a single intron being spliced multiple times.",
      "Multiple mRNA isoforms result from recursive splicing.",
      "Long introns are less likely to undergo recursive splicing.",
      "Long introns tend to produce a single mRNA isoform after splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Long introns are more likely to undergo recursive splicing due to their length and complexity.\n5. FALSE [correction]: Long introns, which may undergo recursive splicing, can give rise to multiple mRNA isoforms after splicing.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Great, I'm here to help! The TALE-iD method is a biotechnology tool used for targeted gene editing and regulation. It is a genome-editing platform that allows for the precise modification of genes by introducing a DNA-binding protein called a TALE (TAL effector) that recognizes a specific DNA sequence. The TALE protein is engineered to carry a DNA-cutting enzyme, such as a nuclease, which cuts the DNA at the targeted location, leading to either gene knockout or gene editing.\nThe TALE-iD method is used for a variety of applications, including basic research, biotechnology, and medicine. Some of the specific uses of TALE-iD include:\n1. Gene knockout: By introducing a TALE protein that recognizes a specific DNA sequence, researchers can delete or \"knock out\" a particular gene, allowing them to study the function of that gene.\n2. Gene editing: TALE-iD can be used to introduce specific mutations or changes into a gene, allowing researchers to study the effect of those changes on gene function.\n3. Gene regulation: TALE-iD can be used to regulate the expression of a gene by modifying its DNA sequence, leading to changes in the level of gene expression.\n4. Cancer therapy: TALE-iD can be used to target and delete cancer-causing genes, leading to the development of new cancer therapies.\n5. Gene therapy: TALE-iD can be used to introduce healthy copies of a gene into cells to replace a faulty or missing gene, leading to the treatment of genetic diseases.\nOverall, the TALE-iD method is a powerful tool for targeted gene editing and regulation, with a wide range of potential applications in biotechnology and medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is a biotechnology tool used for targeted gene editing and regulation.\n2. It involves a DNA-binding protein called TAL effector (TALE) that recognizes specific DNA sequences.\n3. TALEs can be engineered to carry a DNA-cutting enzyme to modify genes at targeted locations.\n4. The TALE-iD method can be used for gene knockout to study the function of specific genes.\n5. TALE-iD has applications in cancer therapy by targeting and deleting cancer-causing genes.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is a biotechnology tool used for targeted gene editing and regulation.",
      "It involves a DNA-binding protein called TAL effector (TALE) that recognizes specific DNA sequences.",
      "TALEs can be engineered to carry a DNA-cutting enzyme to modify genes at targeted locations.",
      "The TALE-iD method can be used for gene knockout to study the function of specific genes.",
      "TALE-iD has applications in cancer therapy by targeting and deleting cancer-causing genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct term is TALEN, which stands for Transcription Activator-Like Effector Nuclease, not TALE-iD.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Thank you for your kind words! I'm happy to help you with your questions about biomedicine.\nTo answer your last question, there are several Lisp frameworks that have been developed for image processing, including:\n1. CL-IMAGINE: CL-IMAGINE is a Lisp image processing framework that provides a comprehensive set of tools for image analysis, processing, and visualization. It includes a wide range of algorithms for image filtering, thresholding, segmentation, and feature extraction, as well as tools for 3D image processing and analysis.\n2. Lisp-MRI: Lisp-MRI is a Lisp framework for medical image analysis and processing. It provides a set of tools for image reconstruction, processing, and visualization, as well as support for a wide range of image formats.\n3. OpenLisp-MRI: OpenLisp-MRI is an open-source Lisp framework for medical image analysis and processing. It includes a range of tools for image reconstruction, processing, and visualization, as well as support for a variety of image formats.\n4. BioLisp: BioLisp is a Lisp framework for biomedical image analysis and processing. It provides a set of tools for image analysis, processing, and visualization, as well as support for a wide range of image formats.\n5. Lisp-based Image Processing Toolkit (LIPIT): LIPIT is a Lisp-based toolkit for image processing and analysis. It includes a range of algorithms for image filtering, thresholding, segmentation, and feature extraction, as well as tools for image registration and recognition.\nThese are just a few examples of the many Lisp frameworks available for image processing. Each framework has its own strengths and weaknesses, and the choice of which one to use will depend on the specific needs of your project.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-IMAGINE is a Lisp image processing framework that includes algorithms for image filtering, thresholding, segmentation, and feature extraction.\n2. Lisp-MRI is a Lisp framework designed for medical image analysis and processing.\n3. OpenLisp-MRI is an open-source Lisp framework for medical image analysis and processing.\n4. BioLisp is a Lisp framework for biomedical image analysis and processing.\n5. Lisp-based Image Processing Toolkit (LIPIT) is designed for image processing and analysis, with features such as image registration and recognition.",
    "llama-2-7b-chat-hf_fact": [
      "CL-IMAGINE is a Lisp image processing framework that includes algorithms for image filtering, thresholding, segmentation, and feature extraction.",
      "Lisp-MRI is a Lisp framework designed for medical image analysis and processing.",
      "OpenLisp-MRI is an open-source Lisp framework for medical image analysis and processing.",
      "BioLisp is a Lisp framework for biomedical image analysis and processing.",
      "Lisp-based Image Processing Toolkit (LIPIT) is designed for image processing and analysis, with features such as image registration and recognition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN \n2. UNKNOWN \n3. UNKNOWN \n4. UNKNOWN \n5. UNKNOWN\n\nWithout additional context for each of these statements, it's not possible to definitively determine whether each statement is true or false. The specific names of Lisp frameworks given (CL-IMAGINE, Lisp-MRI, OpenLisp-MRI, BioLisp, LIPIT) may be actual frameworks with the described functionalities or fabricated for this task. Therefore, it's necessary to research individual frameworks or have reliable references to validate each statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The answer to the last question is:\nApproximately 60% of the genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication. This event occurred around 1,000 million years ago and resulted in the duplication of nearly half of the yeast genome. This duplication event has been referred to as the \"yeast whole genome duplication\" (WGD) and has been studied extensively in the field of evolutionary genomics. The remaining 40% of genes in S. cerevisiae are thought to have evolved through a process of gene loss and gene innovation since the WGD event.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 60% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.\n2. The whole genome duplication event in Saccharomyces cerevisiae occurred around 1,000 million years ago.\n3. Nearly half of the yeast genome was duplicated during the whole genome duplication event.\n4. The duplication event in Saccharomyces cerevisiae is known as the \"yeast whole genome duplication\" (WGD).\n5. Since the whole genome duplication event, 40% of the genes in Saccharomyces cerevisiae have evolved through gene loss and gene innovation.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 60% of the genes in Saccharomyces cerevisiae are the result of an ancient whole genome duplication.",
      "The whole genome duplication event in Saccharomyces cerevisiae occurred around 1,000 million years ago.",
      "Nearly half of the yeast genome was duplicated during the whole genome duplication event.",
      "The duplication event in Saccharomyces cerevisiae is known as the \"yeast whole genome duplication\" (WGD).",
      "Since the whole genome duplication event, 40% of the genes in Saccharomyces cerevisiae have evolved through gene loss and gene innovation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Approximately 60% of the genes in Saccharomyces cerevisiae are indeed a result of an ancient whole genome duplication, according to current scientific understanding.\n2. FALSE [correction]: The whole genome duplication event in Saccharomyces cerevisiae is estimated to have occurred around 100 million years ago, not 1,000 million years ago.\n3. TRUE: The statement \"Nearly half of the yeast genome was duplicated during the whole genome duplication event\" aligns with the information given in the first statement, assuming that approximately 60% can be rounded to \"nearly half.\"\n4. TRUE: The duplication event in Saccharomyces cerevisiae is commonly referred to as the \"yeast whole genome duplication\" (WGD).\n5. TRUE: After the whole genome duplication event, a significant portion of the Saccharomyces cerevisiae genes have evolved, and the stated 40% accounts for gene loss and gene innovation, which is consistent with the dynamics observed in genomic evolution following such events.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is bound by the complex of estrogen and its cognate ligand binding protein, known as the estrogen receptor-β (ERβ) complex.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is a nuclear receptor.\n2. Esrrb is bound by a complex of estrogen and its cognate ligand binding protein.\n3. The complex that binds to Esrrb is known as the estrogen receptor-β (ERβ) complex.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is a nuclear receptor.",
      "Esrrb is bound by a complex of estrogen and its cognate ligand binding protein.",
      "The complex that binds to Esrrb is known as the estrogen receptor-β (ERβ) complex."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not bound by a complex of estrogen and its cognate ligand binding protein; instead, it is an orphan receptor, which means it has no known endogenous ligand.\n3. FALSE [correction]: The complex known as the estrogen receptor-β (ERβ) complex refers to a different receptor that binds estrogen, whereas Esrrb is an orphan receptor that is related to the estrogen receptor but does not bind the hormone estrogen itself.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a gene that codes for a protein called zinc finger CCHC-type histone chaperone 17 (ZCCHC17). The protein is involved in various cellular processes, including:\n1. Chromatin remodeling: ZCCHC17 helps to remodel chromatin structure by altering the positioning of nucleosomes along DNA strands, which can affect gene expression.\n2. Transcriptional regulation: ZCCHC17 can bind to specific DNA sequences and either enhance or repress transcriptional activity, depending on the context.\n3. RNA metabolism: ZCCHC17 has been implicated in the splicing and stability of specific RNA molecules, including microRNAs and long non-coding RNAs.\n4. Cell cycle regulation: ZCCHC17 has been shown to play a role in the progression of the cell cycle, particularly in the G1/S phase transition.\n5. Apoptosis: ZCCHC17 has been implicated in the regulation of programmed cell death (apoptosis), with both pro- and anti-apoptotic functions depending on the context.\nIn summary, ZCCHC17 is a multifunctional protein that plays a complex role in various cellular processes, including chromatin remodeling, transcriptional regulation, RNA metabolism, cell cycle regulation, and apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a gene that codes for a protein called zinc finger CCHC-type histone chaperone 17.\n2. The ZCCHC17 protein is involved in chromatin remodeling by altering the positioning of nucleosomes along DNA strands.\n3. ZCCHC17 can bind to specific DNA sequences to influence transcriptional activity.\n4. ZCCHC17 is implicated in the splicing and stability of specific RNA molecules, including microRNAs and long non-coding RNAs.\n5. ZCCHC17 plays a role in the regulation of the cell cycle, particularly in the G1/S phase transition.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a gene that codes for a protein called zinc finger CCHC-type histone chaperone 17.",
      "The ZCCHC17 protein is involved in chromatin remodeling by altering the positioning of nucleosomes along DNA strands.",
      "ZCCHC17 can bind to specific DNA sequences to influence transcriptional activity.",
      "ZCCHC17 is implicated in the splicing and stability of specific RNA molecules, including microRNAs and long non-coding RNAs.",
      "ZCCHC17 plays a role in the regulation of the cell cycle, particularly in the G1/S phase transition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While the ZCCHC17 protein is indeed associated with nucleic acids, its role in chromatin remodeling specifically by altering the positioning of nucleosomes along DNA strands is not well-established or widely known. It is more commonly associated with other functions such as RNA metabolism.\n3. UNKNOWN: Without specific literature references, it is difficult to confirm whether ZCCHC17 binds to specific DNA sequences to influence transcriptional activity.\n4. FALSE [correction]: ZCCHC17, also known as nuclear zinc finger protein, NIZP, or ZNF828, is primarily known for its role in pre-mRNA processing and other RNA-related processes. It is not specifically known for binding or affecting microRNAs and long non-coding RNAs unless specific literature suggests otherwise.\n5. UNKNOWN: The role of ZCCHC17 in cell cycle regulation, particularly in the G1/S phase transition, is not well-documented without further context or research literature.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, connecting the nucleus to the cytoplasm. The NPC is composed of several proteins, including:\n1. Nucleoporins: These are the main components of the NPC, and they form a series of channels and strands that make up the structure. There are 33 known nucleoporins in human cells, including Nup107, Nup153, and Nup50.\n2. Spectrin: Spectrin is a cytoskeletal protein that helps to stabilize the NPC and maintain its structure.\n3. Emerin: Emerin is a protein that is specifically involved in the formation and maintenance of the NPC. It is found primarily in the nucleus and is important for the proper functioning of the NPC.\n4. Nup153: Nup153 is a nucleoporin that is involved in the transport of proteins and RNAs across the NPC. It is also important for the proper folding and stability of the NPC.\n5. Nup50: Nup50 is another nucleoporin that is involved in the transport of proteins and RNAs across the NPC. It is also important for the proper folding and stability of the NPC.\nThese proteins work together to form a complex that regulates the movement of molecules between the nucleus and cytoplasm, and plays a critical role in maintaining the proper functioning of the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) connects the nucleus to the cytoplasm in eukaryotic cells.\n2. There are 33 known nucleoporins that are components of the NPC in human cells, including Nup107, Nup153, and Nup50.\n3. Spectrin is a cytoskeletal protein that contributes to stabilizing the nuclear pore complex.\n4. Emerin is a protein involved in the formation and maintenance of the nuclear pore complex.\n5. Nup153 and Nup50 are nucleoporins involved in the transport of proteins and RNAs across the NPC and are important for its proper folding and stability.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) connects the nucleus to the cytoplasm in eukaryotic cells.",
      "There are 33 known nucleoporins that are components of the NPC in human cells, including Nup107, Nup153, and Nup50.",
      "Spectrin is a cytoskeletal protein that contributes to stabilizing the nuclear pore complex.",
      "Emerin is a protein involved in the formation and maintenance of the nuclear pore complex.",
      "Nup153 and Nup50 are nucleoporins involved in the transport of proteins and RNAs across the NPC and are important for its proper folding and stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are around 30 known nucleoporins in human cells that are components of the NPC, not specifically 33. The exact number may vary between sources, but it is typically cited to be around 30 or just over 30.\n3. FALSE [correction]: Spectrin is a cytoskeletal protein, but it is not known to contribute to the stabilization of the nuclear pore complex. Instead, spectrin plays a role in maintaining cell shape and the organization of membrane proteins.\n4. FALSE [correction]: Emerin is a protein associated with the nuclear lamina and is involved in the organization of the nuclear architecture rather than the formation and maintenance of the nuclear pore complex itself.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! Gepotidacin is a topoisomerase II inhibitor. Topoisomerase II is an enzyme that relaxes supercoiled DNA, and Gepotidacin binds to and inhibits the activity of this enzyme, leading to the accumulation of supercoiled DNA and the inhibition of DNA replication and transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. Topoisomerase II is an enzyme that relaxes supercoiled DNA.\n3. Gepotidacin binds to and inhibits the activity of topoisomerase II.\n4. The inhibition of topoisomerase II by Gepotidacin leads to the accumulation of supercoiled DNA.\n5. Gepotidacin's action results in the inhibition of DNA replication and transcription.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "Topoisomerase II is an enzyme that relaxes supercoiled DNA.",
      "Gepotidacin binds to and inhibits the activity of topoisomerase II.",
      "The inhibition of topoisomerase II by Gepotidacin leads to the accumulation of supercoiled DNA.",
      "Gepotidacin's action results in the inhibition of DNA replication and transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is a topoisomerase II inhibitor in Gram-positive bacteria and a topoisomerase IV inhibitor in Gram-negative bacteria.\n2. TRUE\n3. TRUE, given that statement 1 has been corrected to specify the enzyme's action in Gram-positive bacteria.\n4. FALSE [correction]: The inhibition of topoisomerase II by Gepotidacin would lead to the accumulation of DNA breaks, not supercoiled DNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! Canvas SPW is a software tool used in the field of biomedicine for the analysis of single-cell RNA sequencing (scRNA-seq) data. It is designed to facilitate the analysis of gene expression at the single-cell level, allowing researchers to identify and characterize different cell populations and understand the molecular mechanisms underlying various biological processes.\nHere is an example of how Canvas SPW can be used:\nQuestion: How does Canvas SPW help in the analysis of scRNA-seq data?\nAnswer: Canvas SPW is a powerful tool for the analysis of scRNA-seq data, as it allows researchers to identify and characterize different cell populations based on their gene expression profiles. By using Canvas SPW, researchers can:\n1. Cluster cells into distinct populations based on their gene expression profiles, revealing novel cell types and states.\n2. Identify key genes and pathways that are differentially expressed between different cell populations, providing insights into the molecular mechanisms underlying cellular heterogeneity.\n3. Visualize the expression of genes and proteins across different cell populations, allowing researchers to identify correlations and patterns of gene expression that may not be apparent through other methods.\n4. Integrate scRNA-seq data with other types of genomic data, such as DNA methylation or ChIP-seq, to gain a more comprehensive understanding of cellular heterogeneity and its relationship to disease.\nBy providing these functionalities, Canvas SPW enables researchers to gain a deeper understanding of cellular heterogeneity and its role in various biological processes, which can ultimately lead to the development of new therapeutic strategies for diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a software tool used for the analysis of single-cell RNA sequencing (scRNA-seq) data.\n2. The software is designed to facilitate the analysis of gene expression at the single-cell level.\n3. Canvas SPW helps researchers to cluster cells into distinct populations based on their gene expression profiles.\n4. It enables identification of key genes and pathways that are differentially expressed between different cell populations.\n5. Canvas SPW can integrate scRNA-seq data with other types of genomic data such as DNA methylation or ChIP-seq.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a software tool used for the analysis of single-cell RNA sequencing (scRNA-seq) data.",
      "The software is designed to facilitate the analysis of gene expression at the single-cell level.",
      "Canvas SPW helps researchers to cluster cells into distinct populations based on their gene expression profiles.",
      "It enables identification of key genes and pathways that are differentially expressed between different cell populations.",
      "Canvas SPW can integrate scRNA-seq data with other types of genomic data such as DNA methylation or ChIP-seq."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized software tool specifically named \"Canvas SPW\" for the analysis of single-cell RNA sequencing (scRNA-seq) data. A known software for scRNA-seq data analysis is \"Seurat\" or \"Scanpy\".\n2. TRUE, with a caveat [correction]: Given that \"Canvas SPW\" is not a recognized scRNA-seq analysis tool, this statement is not accurate in naming the software tool. However, the purpose of the statement is true in a general sense, as software designed for scRNA-seq data analysis does indeed facilitate the analysis of gene expression at the single-cell level.\n3. TRUE, with a caveat [correction]: Again, since \"Canvas SPW\" is not a recognized software tool, the statement is technically false. However, the statement correctly describes a common feature of scRNA-seq analysis tools, which is to help researchers cluster cells into distinct populations based on gene expression profiles.\n4. TRUE, with a caveat [correction]: Although there is a misnomer in the name of the software tool, the function described is characteristic of scRNA-seq analysis tools, which can enable the identification of key genes and pathways differentially expressed between different cell populations.\n5. UNKNOWN: Without specific knowledge of \"Canvas SPW\", which is not recognised, it is not possible to confirm whether it can integrate scRNA-seq data with other types of genomic data. However, some scRNA-seq analysis platforms do have this capability.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Here are some STING agonists:\n1. Poly IC: Poly IC is a synthetic agonist of STING that is commonly used to stimulate an immune response in vitro and in vivo.\n2. CpG ODN: CpG ODN (Cytosine-guanine dinucleotide with palindromic repeats) is a type of DNA molecule that can activate STING and induce an immune response.\n3. MMK-236: MMK-236 is a small molecule agonist of STING that has been shown to activate STING-dependent immune responses in vitro and in vivo.\n4. Vaccinia virus: Vaccinia virus, a poxvirus, can also activate STING and induce an immune response.\n5. Cutting edge: Cutting edge is a synthetic agonist of STING that is currently being developed as a potential therapeutic agent for the treatment of cancer.\nThese are just a few examples of STING agonists, and there are likely many more being researched and developed.",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly IC is a synthetic agonist of STING.\n2. CpG ODN is a type of DNA molecule that can activate STING.\n3. MMK-236 is a small molecule agonist of STING.\n4. Vaccinia virus can activate STING.\n5. Cutting edge is a synthetic agonist of STING being developed as a potential cancer therapy.",
    "llama-2-7b-chat-hf_fact": [
      "Poly IC is a synthetic agonist of STING.",
      "CpG ODN is a type of DNA molecule that can activate STING.",
      "MMK-236 is a small molecule agonist of STING.",
      "Vaccinia virus can activate STING.",
      "Cutting edge is a synthetic agonist of STING being developed as a potential cancer therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly IC is a synthetic analogue of double-stranded RNA (dsRNA) and is not an agonist of STING, but rather is recognized by pattern recognition receptors such as TLR3.\n2. FALSE [correction]: CpG ODN is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs, which can activate TLR9, not STING.\n3. UNKNOWN\n4. TRUE: Vaccinia virus can indeed activate STING as part of the host immune response to viral DNA.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Cross-linking and Immunoprecipitation with Capture of Aggregated Genomic Ends) is a powerful tool for studying the three-dimensional (3D) structure of chromosomes and their interactions with proteins. Here is how it works:\n1. Chromatin is first fixed, denatured, and sheared into smaller fragments using various enzymes, such as sonication or enzymatic digestion.\n2. The fragmented chromatin is then incubated with a specialized probe, called a capture probe, which selectively binds to the 3' end of the fragmented DNA.\n3. The chromatin-capture probe complex is then immunoprecipitated using an antibody or other immunoprecipitation agent.\n4. The immunoprecipitated complex is then subjected to a second round of shearing, which generates even smaller fragments.\n5. The resulting fragments are then analyzed using next-generation sequencing technologies, such as Illumina or PacBio, to determine the sequence of the fragments.\n6. The resulting data is then analyzed using specialized software to reconstruct the 3D structure of the chromosome and identify the regions of the chromatin that are in close proximity to each other.\n7. The final step is to compare the 3D structure of the chromosome to the gene expression data to identify regions of the chromosome that are associated with specific gene expression patterns.\nBy using SLIC-CAGE, researchers can gain insights into the 3D structure of chromosomes and how it relates to gene expression, which can help them understand the mechanisms underlying various biological processes and diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is used to study the three-dimensional structure of chromosomes and their interactions with proteins.\n2. During SLIC-CAGE, chromatin is first fixed, denatured, and sheared into smaller fragments.\n3. A capture probe in the SLIC-CAGE process selectively binds to the 3' end of the fragmented DNA.\n4. Next-generation sequencing technologies, such as Illumina or PacBio, are used to analyze the resulting fragments from the SLIC-CAGE process.\n5. SLIC-CAGE data is analyzed to reconstruct the 3D structure of chromosomes and identify chromatin regions in close proximity.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is used to study the three-dimensional structure of chromosomes and their interactions with proteins.",
      "During SLIC-CAGE, chromatin is first fixed, denatured, and sheared into smaller fragments.",
      "A capture probe in the SLIC-CAGE process selectively binds to the 3' end of the fragmented DNA.",
      "Next-generation sequencing technologies, such as Illumina or PacBio, are used to analyze the resulting fragments from the SLIC-CAGE process.",
      "SLIC-CAGE data is analyzed to reconstruct the 3D structure of chromosomes and identify chromatin regions in close proximity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: Without the passage text to verify details against, the responses are based on the general knowledge of chromosome conformation capture techniques and the assumption that SLIC-CAGE is a specific technique within this field. Chromosome conformation capture methods often study the 3D structure of chromosomes and their interactions. These methods typically include fixing and fragmenting chromatin, using sequence-specific probes (which could feasibly bind to the 3' end of DNA, as in typical capture methods), and analyzing data with next-generation sequencing to reconstruct 3D structures and ascertain chromatin interactions. However, since the specifics of SLIC-CAGE as a method are not common knowledge, and the technique's details may vary, without the passage, there's no way to fact-check the exact procedures or aims.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Lemur-3) is a protein that plays a crucial role in various cellular processes, including:\n1. Nuclear transport: LEM-3 is involved in the transport of proteins and RNA molecules between the cytoplasm and nucleus of cells. It helps to regulate the localization and activity of these molecules within the cell.\n2. Chromatin remodeling: LEM-3 is involved in the remodeling of chromatin, the complex of DNA and proteins that make up chromosomes. It helps to alter the structure of chromatin to allow for various cellular processes, such as transcription and DNA repair.\n3. Cell cycle regulation: LEM-3 has been shown to play a role in regulating the cell cycle, particularly in the G1/S checkpoint. It helps to ensure that cells progress through the cell cycle in an orderly and regulated manner.\n4. Cancer: LEM-3 has been implicated in various types of cancer, including breast, lung, and colon cancer. It is thought to play a role in tumorigenesis and cancer progression.\n5. Neurodegeneration: LEM-3 has been linked to various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is thought to play a role in the regulation of protein aggregation and the clearance of misfolded proteins in the brain.\nIn summary, LEM-3 is a multifunctional protein that plays a crucial role in various cellular processes, including nuclear transport, chromatin remodeling, cell cycle regulation, cancer, and neurodegeneration.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 (Lemur-3) is involved in the transport of proteins and RNA molecules between the cytoplasm and nucleus of cells.\n2. LEM-3 participates in the remodeling of chromatin.\n3. LEM-3 plays a role in regulating the G1/S checkpoint of the cell cycle.\n4. LEM-3 has been implicated in various types of cancer, such as breast, lung, and colon cancer.\n5. LEM-3 has been linked to neurodegenerative diseases like Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 (Lemur-3) is involved in the transport of proteins and RNA molecules between the cytoplasm and nucleus of cells.",
      "LEM-3 participates in the remodeling of chromatin.",
      "LEM-3 plays a role in regulating the G1/S checkpoint of the cell cycle.",
      "LEM-3 has been implicated in various types of cancer, such as breast, lung, and colon cancer.",
      "LEM-3 has been linked to neurodegenerative diseases like Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LEM-3 (Lemur Tyrosine Kinase-3) does not transport proteins and RNA molecules between the cytoplasm and nucleus; instead, it is involved in DNA damage response and repair.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! Please provide the questions related to biomedicine, and I will do my best to assist you.\nAs for the last question, the answer is:\nLY294002 inhibits the PI3K (phosphoinositide 3-kinase) signaling pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. LY294002 inhibits the PI3K (phosphoinositide 3-kinase) signaling pathway.",
    "llama-2-7b-chat-hf_fact": [
      "LY294002 inhibits the PI3K (phosphoinositide 3-kinase) signaling pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Thank you for the question! There are several databases that contain information on somatic mutations in normal cells. Here are a few examples:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. As part of this effort, TCGA has generated comprehensive datasets of genomic and transcriptomic changes in thousands of cancer samples, including information on somatic mutations in normal cells.\n2. The ExAC (Expert Analysis of Variation in the Human Genome) database: ExAC is a large-scale collaboration that aims to catalogue all known genetic variants in the human genome, including single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations. ExAC includes information on the frequency and distribution of these variants in both cancer and normal tissues.\n3. The COSMIC (Catalogue of Somatic Mutations in Cancer) database: COSMIC is a comprehensive database of somatic mutations in cancer, including information on the frequency and distribution of mutations in different cancer types. COSMIC also includes information on the functional impact of these mutations, as well as information on the drugs and therapies that target these mutations.\n4. The MutSig database: MutSig is a database of somatic mutations in normal tissues, including information on the frequency and distribution of mutations in different tissues and cell types. MutSig also includes information on the functional impact of these mutations and their potential role in disease.\n5. The METABRIC (Mutational Dynamics in Cancer) database: METABRIC is a database of somatic mutations in cancer, including information on the frequency and distribution of mutations in different cancer types. METABRIC also includes information on the functional impact of these mutations and their potential role in disease.\nThese are just a few examples of the many databases that contain information on somatic mutations in normal cells. Each of these databases has its own strengths and limitations, and they may be used in different contexts depending on the research question and the specific goals of the analysis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. TCGA's datasets include genomic and transcriptomic changes in thousands of cancer samples and contain information on somatic mutations in normal cells.\n3. The ExAC database aims to catalogue all known genetic variants in the human genome, such as SNPs, insertions, deletions, and copy number variations.\n4. The COSMIC database is a comprehensive source of somatic mutations in cancer, including data on the frequency and distribution of these mutations across different cancer types.\n5. The METABRIC database contains information on somatic mutations in cancer, their frequency, distribution, and functional impact, as well as their potential roles in disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "TCGA's datasets include genomic and transcriptomic changes in thousands of cancer samples and contain information on somatic mutations in normal cells.",
      "The ExAC database aims to catalogue all known genetic variants in the human genome, such as SNPs, insertions, deletions, and copy number variations.",
      "The COSMIC database is a comprehensive source of somatic mutations in cancer, including data on the frequency and distribution of these mutations across different cancer types.",
      "The METABRIC database contains information on somatic mutations in cancer, their frequency, distribution, and functional impact, as well as their potential roles in disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TCGA's datasets include genomic and transcriptomic changes in thousands of cancer samples, but they generally contain information on somatic mutations in cancer cells, not normal cells.\n3. FALSE [correction]: The ExAC (Exome Aggregation Consortium) database primarily focuses on cataloguing variation in human exomes, which is a subset of the genome. It includes information on variants such as single-nucleotide polymorphisms (SNPs) from the exomes of a large number of individuals but does not catalogue all known genetic variants in the entire human genome.\n4. TRUE\n5. FALSE [correction]: The METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) database contains information specifically related to breast cancer, including genomic and transcriptomic data, which can be used to understand the molecular subtypes and prognostic signatures of breast cancers. While it does contain information on somatic mutations and their potential roles in disease, METABRIC is particularly focused on breast cancer rather than all cancer types.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are some examples:\n1. JGraphT: JGraphT is a Java library for graph theory, which provides a simple and efficient way to manipulate and analyze graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n2. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple and efficient way to perform graph-based computations. It supports a wide range of graph algorithms and can be used for both small and large-scale graph processing.\n3. GraphMol: GraphMol is a Java library for molecular graph analysis that provides a simple and efficient way to perform graph-based computations on molecular graphs. It supports a wide range of graph algorithms and can be used for both small and large-scale graph processing.\n4. JGraph: JGraph is a Java library for graph theory that provides a simple and efficient way to manipulate and analyze graphs. It supports a wide range of graph algorithms and can be used for both directed and undirected graphs.\n5. GraphBLAS: GraphBLAS is a Java library for graph-based linear algebra that provides a simple and efficient way to perform graph-based computations. It supports a wide range of graph algorithms and can be used for both small and large-scale graph processing.\nThese libraries can be used for a wide range of applications in bioinformatics and biomedical research, such as protein structure prediction, gene expression analysis, and drug discovery.\nPlease let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library designed for graph theory.\n2. GraphCrunch is a Java library that can perform graph-based computations.\n3. GraphMol is a Java library for molecular graph analysis.\n4. JGraph supports the manipulation and analysis of both directed and undirected graphs.\n5. GraphBLAS is a Java library for graph-based linear algebra.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library designed for graph theory.",
      "GraphCrunch is a Java library that can perform graph-based computations.",
      "GraphMol is a Java library for molecular graph analysis.",
      "JGraph supports the manipulation and analysis of both directed and undirected graphs.",
      "GraphBLAS is a Java library for graph-based linear algebra."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GraphCrunch is not a Java library; it is a software tool for graph-based structural comparison of protein structures in different species, and it is generally used for biological network analysis.\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: GraphBLAS is not specifically a Java library; it is a set of specifications for building graph algorithms in the language of linear algebra. However, it can be used within Java programs via bindings or implementations that adapt it for Java.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! The SHERLOCKv2 platform is a next-generation diagnostic tool that integrates several advances in biotechnology to enable rapid, sensitive, and accurate detection of pathogens. Here are the four advances integrated into the SHERLOCKv2 platform:\n1. CRISPR-Cas13: The SHERLOCKv2 platform utilizes the CRISPR-Cas13 system, a type of RNA-guided DNA endonuclease, to cleave specific DNA sequences in the pathogen's genome. This creates a detectable signal that can be used to identify the pathogen.\n2. Single-molecule FRET: The platform employs single-molecule FRET (fluorescence resonance energy transfer) to measure the distance between the CRISPR-Cas13 complex and the target DNA. This allows for sensitive and accurate detection of the pathogen.\n3. Nucleic acid amplification: SHERLOCKv2 uses a nucleic acid amplification technique called self-templated amplification (STA) to amplify the target DNA sequence, which improves the sensitivity of the assay.\n4. Microfluidics: The platform utilizes microfluidics to mix the sample with the CRISPR-Cas13 complex and the FRET probe in a precise and controlled manner, allowing for rapid and efficient detection of the pathogen.\nBy integrating these four advances, the SHERLOCKv2 platform offers a highly sensitive and accurate diagnostic tool for detecting pathogens in a variety of settings, including resource-poor environments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform incorporates the CRISPR-Cas13 system for cleaving specific DNA sequences in a pathogen's genome.\n2. The SHERLOCKv2 platform employs single-molecule FRET for measuring the distance between the CRISPR-Cas13 complex and the target DNA.\n3. Self-templated amplification (STA) is used on the SHERLOCKv2 platform to amplify the target DNA sequence.\n4. Microfluidics is utilized on the SHERLOCKv2 platform for mixing the sample with the CRISPR-Cas13 complex and the FRET probe.\n5. The SHERLOCKv2 platform is designed for rapid, sensitive, and accurate detection of pathogens.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform incorporates the CRISPR-Cas13 system for cleaving specific DNA sequences in a pathogen's genome.",
      "The SHERLOCKv2 platform employs single-molecule FRET for measuring the distance between the CRISPR-Cas13 complex and the target DNA.",
      "Self-templated amplification (STA) is used on the SHERLOCKv2 platform to amplify the target DNA sequence.",
      "Microfluidics is utilized on the SHERLOCKv2 platform for mixing the sample with the CRISPR-Cas13 complex and the FRET probe.",
      "The SHERLOCKv2 platform is designed for rapid, sensitive, and accurate detection of pathogens."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The SHERLOCKv2 platform incorporates the CRISPR-Cas13 system for cleaving specific RNA sequences in a pathogen's genome, not DNA sequences.\n2. FALSE [correction]: The SHERLOCKv2 platform does not employ single-molecule FRET for measuring distance; it uses a reporter system that releases a signal when RNA is cleaved by Cas13.\n3. TRUE: Self-templating amplification (or a similar amplification technique like recombinase polymerase amplification) is used on the SHERLOCKv2 platform to amplify the target RNA sequence.\n4. UNKNOWN: The use of microfluidics with the SHERLOCKv2 platform isn't commonly detailed as a central feature, so this may vary depending on the specific setup or assay.\n5. TRUE: The SHERLOCKv2 platform is designed for rapid, sensitive, and accurate detection of pathogens, including those with RNA genomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "Of course! I'd be happy to help you with your questions about biomedicine. Here's my answer to the last question you provided:\nThe Bartender Algorithm is a machine learning algorithm used in bioinformatics to predict the binding affinity of a protein to a specific DNA sequence. The algorithm was developed by researchers at the University of California, San Diego and is designed to identify the most important amino acids in a protein that contribute to its binding affinity.\nThe Bartender Algorithm works by first identifying a set of \"bartenders\" in the protein, which are amino acids that are most highly conserved across different species. These bartenders are then used to predict the binding affinity of the protein to a specific DNA sequence. The algorithm uses a machine learning approach to identify the amino acids in the protein that are most important for binding and to predict their binding affinity.\nTo use the Bartender Algorithm, researchers typically start by identifying a set of bartenders in the protein of interest. These bartenders are typically identified by comparing the amino acid sequences of different species and identifying the amino acids that are most highly conserved. Once the bartenders have been identified, the algorithm can be used to predict the binding affinity of the protein to a specific DNA sequence.\nThe Bartender Algorithm has been shown to be effective in predicting the binding affinity of proteins to specific DNA sequences, and it has been used in a variety of applications, including the design of new drugs and the study of gene regulation.\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender Algorithm is a machine learning algorithm used in bioinformatics.\n2. The algorithm predicts the binding affinity of a protein to a specific DNA sequence.\n3. It was developed by researchers at the University of California, San Diego.\n4. The algorithm identifies a set of \"bartenders\" which are amino acids most highly conserved across different species.\n5. The Bartender Algorithm has been applied to the design of new drugs and the study of gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender Algorithm is a machine learning algorithm used in bioinformatics.",
      "The algorithm predicts the binding affinity of a protein to a specific DNA sequence.",
      "It was developed by researchers at the University of California, San Diego.",
      "The algorithm identifies a set of \"bartenders\" which are amino acids most highly conserved across different species.",
      "The Bartender Algorithm has been applied to the design of new drugs and the study of gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Bartender Algorithm does not appear to be a known machine learning algorithm used in bioinformatics. This might be a confusion with a real algorithm, but without additional context, a correct name or purpose cannot be provided.\n\n2. UNKNOWN\n\n3. UNKNOWN\n\n4. FALSE [correction]: If the Bartender Algorithm is not a recognized algorithm in bioinformatics, then the statement regarding the identification of \"bartenders\" and their characteristics is also false or based on a misunderstanding.\n\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree Resource File (PRF): This is a widely used web-based tool for creating and sharing human pedigrees. It allows users to create and edit pedigrees, as well as to search and download existing pedigrees.\n2. HUGO Gene Nomenclature Committee (HGNC): This is a web-based tool that provides a standardized system for naming genes and genetic variants. It also includes a pedigree editor for creating and sharing human pedigrees.\n3. Online Mendelian Inheritance in Man (OMIM): This is a comprehensive online database of genetic disorders and their associated genes. It also includes a pedigree editor for creating and sharing human pedigrees.\n4. University of California, San Diego (UCSD) Pedigree Editor: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n5. Pedigree Draw: This is a web-based tool that allows users to create and edit simple or complex pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n6. Family Inheritance: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n7. Pedigree Builder: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n8. GenoLogics Pedigree Editor: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n9. Pedigree Creator: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as the ability to add and remove individuals, as well as to edit the relationships between them.\n10. Family Tree Builder: This is a web-based tool that allows users to create and edit human pedigrees. It includes features such as",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Resource File (PRF) is a web-based tool used for creating and sharing human pedigrees.\n2. The HUGO Gene Nomenclature Committee (HGNC) offers a pedigree editor for creating and sharing human pedigrees.\n3. Online Mendelian Inheritance in Man (OMIM) includes a pedigree editor in its online database of genetic disorders.\n4. The University of California, San Diego (UCSD) Pedigree Editor is a web-based tool for creating and editing human pedigrees.\n5. Pedigree Draw is a web-based tool that allows for the creation and editing of simple or complex human pedigrees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Resource File (PRF) is a web-based tool used for creating and sharing human pedigrees.",
      "The HUGO Gene Nomenclature Committee (HGNC) offers a pedigree editor for creating and sharing human pedigrees.",
      "Online Mendelian Inheritance in Man (OMIM) includes a pedigree editor in its online database of genetic disorders.",
      "The University of California, San Diego (UCSD) Pedigree Editor is a web-based tool for creating and editing human pedigrees.",
      "Pedigree Draw is a web-based tool that allows for the creation and editing of simple or complex human pedigrees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Pedigree Resource File (PRF) is a genealogical database that provides access to family trees submitted by users, but is not specifically a tool for creating and sharing human pedigrees like a pedigree editor.\n2. FALSE [correction]: The HUGO Gene Nomenclature Committee (HGNC) is responsible for approving unique symbols and names for human genes, not offering a pedigree editor.\n3. UNKNOWN: While Online Mendelian Inheritance in Man (OMIM) is a comprehensive compendium of human genes and genetic phenotypes, it is not clear if they offer a specific tool for creating pedigrees as part of their online database.\n4. UNKNOWN: Without specific current information, it is unclear whether the University of California, San Diego (UCSD) offers a web-based tool known as the \"UCSD Pedigree Editor\" for creating and editing human pedigrees.\n5. UNKNOWN: Pedigree Draw might be a web-based tool as described, but without specific reference or current knowledge about it, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, which are toxins produced by spiders for defense purposes. Here are some examples:\n1. ToxinDB: ToxinDB is a comprehensive database of toxins from various sources, including spider venom. It contains information on the structure, function, and biological activity of toxins, as well as their potential applications in medicine and biotechnology.\n2. SpiderBase: SpiderBase is a database of spider venom peptides and toxins, including their sequences, structures, and biological activities. It also provides information on the species of spiders that produce these toxins and their potential uses in medicine and biotechnology.\n3. Venom-DB: Venom-DB is a database of venom peptides and proteins from various animals, including spiders. It contains information on the structure, function, and evolution of these peptides and proteins, as well as their potential uses in medicine and biotechnology.\n4. Natural Products Alliance: The Natural Products Alliance is a database of natural products, including spider venom toxins, that are derived from plants, animals, and microorganisms. It contains information on the structure, function, and biological activity of these natural products, as well as their potential applications in medicine and biotechnology.\n5. ToxinTeach: ToxinTeach is a database of toxins from various sources, including spider venom. It contains information on the structure, function, and biological activity of toxins, as well as their potential applications in medicine and biotechnology.\nThese are just a few examples of the many curated databases available for spider-venom toxins. Each database provides valuable information on the structure, function, and biological activity of these toxins, as well as their potential applications in medicine and biotechnology.",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a database that includes information on toxins from various sources, including spider venom.\n2. SpiderBase is a database specifically for spider venom peptides and toxins.\n3. Venom-DB is a database that involves venom peptides and proteins from various animals, including spiders.\n4. The Natural Products Alliance is a database that contains information on natural products such as spider venom toxins.\n5. ToxinTeach is a database that provides information on toxins from a variety of sources, including those from spider venom.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a database that includes information on toxins from various sources, including spider venom.",
      "SpiderBase is a database specifically for spider venom peptides and toxins.",
      "Venom-DB is a database that involves venom peptides and proteins from various animals, including spiders.",
      "The Natural Products Alliance is a database that contains information on natural products such as spider venom toxins.",
      "ToxinTeach is a database that provides information on toxins from a variety of sources, including those from spider venom."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib has been shown to have potential as a treatment for pancreatic cancer, but its effect on survival is still being studied and debated.\nA systematic review and meta-analysis of clinical trials published in 2020 found that axitinib may have a positive impact on overall survival (OS) and progression-free survival (PFS) in patients with advanced pancreatic cancer. The analysis suggested that axitinib may improve OS by 3.4 months compared to standard chemotherapy, and PFS by 2.8 months. However, the study also noted that the evidence is based on a limited number of patients and that further research is needed to confirm these findings.\nAnother study published in 2019 found that axitinib improved OS in patients with metastatic pancreatic cancer who had progressed after previous treatment with gemcitabine and nab-paclitaxel. The study found that the median OS was 10.6 months in the axitinib group compared to 7.4 months in the control group.\nHowever, it's important to note that not all studies have shown a survival benefit with axitinib. A phase III clinical trial conducted by the National Cancer Institute (NCI) found that axitinib did not improve OS in patients with advanced pancreatic cancer compared to standard chemotherapy.\nOverall, while some studies suggest that axitinib may have a positive impact on survival in patients with pancreatic cancer, the evidence is still emerging and more research is needed to confirm these findings.",
    "llama-2-7b-chat-hf_fact_raw": "1. A systematic review and meta-analysis of clinical trials published in 2020 suggested that axitinib may improve overall survival by 3.4 months in patients with advanced pancreatic cancer compared to standard chemotherapy.\n2. The same 2020 meta-analysis indicated axitinib may enhance progression-free survival (PFS) by 2.8 months for patients with advanced pancreatic cancer.\n3. A study published in 2019 found that the median overall survival was 10.6 months for patients with metastatic pancreatic cancer treated with axitinib, in comparison to 7.4 months in the control group.\n4. The National Cancer Institute conducted a phase III clinical trial that found axitinib did not improve overall survival in patients with advanced pancreatic cancer when compared to standard chemotherapy.\n5. The evidence for axitinib's effect on survival in pancreatic cancer patients is based on a limited number of patients and additional research is necessary to confirm these findings.",
    "llama-2-7b-chat-hf_fact": [
      "A systematic review and meta-analysis of clinical trials published in 2020 suggested that axitinib may improve overall survival by 3.4 months in patients with advanced pancreatic cancer compared to standard chemotherapy.",
      "The same 2020 meta-analysis indicated axitinib may enhance progression-free survival (PFS) by 2.8 months for patients with advanced pancreatic cancer.",
      "A study published in 2019 found that the median overall survival was 10.6 months for patients with metastatic pancreatic cancer treated with axitinib, in comparison to 7.4 months in the control group.",
      "The National Cancer Institute conducted a phase III clinical trial that found axitinib did not improve overall survival in patients with advanced pancreatic cancer when compared to standard chemotherapy.",
      "The evidence for axitinib's effect on survival in pancreatic cancer patients is based on a limited number of patients and additional research is necessary to confirm these findings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without access to the specific review and its findings, we cannot determine the accuracy of this statement.\n2. UNKNOWN: As with the first statement, the accuracy is dependent on the specific meta-analysis, which we cannot verify.\n3. UNKNOWN: Again, without access to the 2019 study itself, we have no way to confirm the accuracy of the survival rates reported here.\n4. UNKNOWN: Without specific reference to this trial results, it's not possible to confirm the accuracy of the statement regarding the National Cancer Institute's findings.\n5. TRUE: This statement reflects a common situation in clinical research. New treatments often require more extensive research to establish their efficacy broadly, and the statement is logically consistent with clinical research practices.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through its interaction with F-actin and other regulatory proteins. MLP is a negative regulator of actin dynamics, and it interacts with F-actin through its N-terminal domain. This interaction leads to the dephosphorylation and inactivation of myosin light chain kinase (MLCK), which is responsible for phosphorylating and activating myosin heavy chains, thereby regulating actin dynamics. By inhibiting MLCK, MLP reduces the actin-myosin contractility and allows for the relaxation of F-actin networks, thereby regulating cell migration, cell signaling, and other cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Myosin Light Chain Phosphatase) interacts with F-actin through its N-terminal domain.\n2. The interaction between MLP and F-actin leads to dephosphorylation and inactivation of myosin light chain kinase (MLCK).\n3. MLCK is responsible for phosphorylating and activating myosin heavy chains, which regulate actin dynamics.\n4. By inhibiting MLCK, MLP reduces actin-myosin contractility.\n5. Inhibition of MLCK by MLP allows for the relaxation of F-actin networks.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Myosin Light Chain Phosphatase) interacts with F-actin through its N-terminal domain.",
      "The interaction between MLP and F-actin leads to dephosphorylation and inactivation of myosin light chain kinase (MLCK).",
      "MLCK is responsible for phosphorylating and activating myosin heavy chains, which regulate actin dynamics.",
      "By inhibiting MLCK, MLP reduces actin-myosin contractility.",
      "Inhibition of MLCK by MLP allows for the relaxation of F-actin networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The interaction between MLP and myosin light chain leads to dephosphorylation, but it does not inactivate myosin light chain kinase (MLCK); rather, it reverses the action of MLCK.\n3. FALSE [correction]: MLCK is responsible for phosphorylating and activating myosin light chains, not myosin heavy chains, which in turn regulate actin-myosin contractility in smooth muscle cells.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Thank you for your kind words! There are approximately 500-600 protein kinases in the human kinome. Pseudokinases are proteins that have some structural features of kinases but lack their catalytic activity. While they do not phosphorylate proteins, pseudokinases can still play important roles in cellular signaling pathways. Examples of pseudokinases include protein kinase-like proteins and pseudokinase-like proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 500-600 protein kinases in the human kinome.\n2. Pseudokinases are proteins that have some structural features of kinases.\n3. Pseudokinases lack catalytic activity associated with kinases.\n4. Despite lacking catalytic activity, pseudokinases can play important roles in cellular signaling pathways.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 500-600 protein kinases in the human kinome.",
      "Pseudokinases are proteins that have some structural features of kinases.",
      "Pseudokinases lack catalytic activity associated with kinases.",
      "Despite lacking catalytic activity, pseudokinases can play important roles in cellular signaling pathways."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! Here are three apoE mimetics:\n1. GW2801: This is a small molecule inhibitor of apoE-binding proteins, such as apolipoprotein A-I (apoA-I) and apolipoprotein E (apoE). GW2801 has been shown to reduce liver inflammation and improve insulin sensitivity in mouse models of non-alcoholic fatty liver disease (NAFLD).\n2. RX-0201: This is a small molecule inhibitor of apoE-binding proteins, including apoA-I and apoE. RX-0201 has been shown to improve insulin sensitivity and reduce inflammation in mouse models of NAFLD.\n3. BMS-986177: This is a small molecule inhibitor of apoE-binding proteins, including apoA-I and apoE. BMS-986177 has been shown to improve insulin sensitivity and reduce inflammation in mouse models of NAFLD.\nNote: These are just a few examples of apoE mimetics, and there are likely many more compounds that have been identified and studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. GW2801 is a small molecule inhibitor of apoE-binding proteins.\n2. GW2801 has been shown to reduce liver inflammation and improve insulin sensitivity in mouse models of non-alcoholic fatty liver disease.\n3. RX-0201 is a small molecule inhibitor of apoE-binding proteins.\n4. RX-0201 has been shown to improve insulin sensitivity and reduce inflammation in mouse models of NAFLD.\n5. BMS-986177 is a small molecule inhibitor of apoE-binding proteins and has been studied for its effects in mouse models of NAFLD.",
    "llama-2-7b-chat-hf_fact": [
      "GW2801 is a small molecule inhibitor of apoE-binding proteins.",
      "GW2801 has been shown to reduce liver inflammation and improve insulin sensitivity in mouse models of non-alcoholic fatty liver disease.",
      "RX-0201 is a small molecule inhibitor of apoE-binding proteins.",
      "RX-0201 has been shown to improve insulin sensitivity and reduce inflammation in mouse models of NAFLD.",
      "BMS-986177 is a small molecule inhibitor of apoE-binding proteins and has been studied for its effects in mouse models of NAFLD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: RX-0201 is an Akt1 antisense oligonucleotide, not a small molecule inhibitor of apoE-binding proteins.\n4. UNKNOWN\n5. FALSE [correction]: BMS-986177 is an oral, reversible, direct inhibitor of factor XIa, not a small molecule inhibitor of apoE-binding proteins. Its effects have been studied in the context of reducing the risk of thrombosis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help! Sex differences in SAMHD1 activity have been observed in various studies.\nSAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. It is a deacetylase that targets and deacetylates the histone H3 lysine 9 (H3K9) residue, leading to the repression of viral gene expression.\nStudies have shown that there are sex differences in SAMHD1 activity, with females generally having higher levels of SAMHD1 enzyme activity compared to males. For example, a study published in the journal Nature Communications in 2017 found that female mice had higher levels of SAMHD1 activity in their livers compared to male mice, which made them more resistant to viral infection.\nAnother study published in the journal Cell Reports in 2019 found that female human cells had higher levels of SAMHD1 activity compared to male cells, which made them more effective at restricting the replication of certain viruses.\nThese sex differences in SAMHD1 activity may contribute to the observed differences in susceptibility to viral infections between males and females. For example, males are more susceptible to certain viral infections, such as HIV and HCV, while females are more susceptible to other viral infections, such as influenza and HPV.\nOverall, these studies suggest that sex differences in SAMHD1 activity may play a role in the differences in immune responses between males and females, and may have important implications for the development of novel therapeutic strategies for viral infections.",
    "llama-2-7b-chat-hf_fact_raw": "1. Sex differences in SAMHD1 activity have been observed, with females generally having higher levels of this enzyme activity compared to males.\n2. SAMHD1 is an enzyme that plays a crucial role in regulating the innate immune response to viral infections.\n3. A study published in Nature Communications in 2017 reported that female mice had higher levels of SAMHD1 activity in their livers than male mice.\n4. Research from a 2019 Cell Reports study found that female human cells exhibited higher levels of SAMHD1 activity compared to male cells.\n5. Studies suggest that these differences in SAMHD1 activity contribute to variations in susceptibility to viral infections between males and females.",
    "llama-2-7b-chat-hf_fact": [
      "Sex differences in SAMHD1 activity have been observed, with females generally having higher levels of this enzyme activity compared to males.",
      "SAMHD1 is an enzyme that plays a crucial role in regulating the innate immune response to viral infections.",
      "A study published in Nature Communications in 2017 reported that female mice had higher levels of SAMHD1 activity in their livers than male mice.",
      "Research from a 2019 Cell Reports study found that female human cells exhibited higher levels of SAMHD1 activity compared to male cells.",
      "Studies suggest that these differences in SAMHD1 activity contribute to variations in susceptibility to viral infections between males and females."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile it is true that SAMHD1 plays a crucial role in regulating the innate immune response to viral infections, without access to the specific studies or scientific data mentioned in statements 1, 3, 4, and 5, the claims about sex differences in SAMHD1 activity and their potential implications for susceptibility to viral infections cannot be verified and therefore remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit astrocyte differentiation. RUNX2 is a transcription factor that plays a crucial role in the regulation of cell fate decisions, including the differentiation of neural stem cells into astrocytes. Studies have shown that RUNX2 can repress the expression of genes involved in astrocyte differentiation and inhibit the process of astrocyte maturation.\nFor example, one study found that RUNX2 knockout mice exhibited an increase in the number of astrocytes in the brain, suggesting that RUNX2 is required for the proper regulation of astrocyte differentiation (1). Another study found that overexpression of RUNX2 in neural stem cells inhibited their differentiation into astrocytes, while knockdown of RUNX2 promoted astrocyte differentiation (2). These findings suggest that RUNX2 plays a negative role in regulating astrocyte differentiation.\nReferences:\n1. Li et al. (2010). Runx2 regulates the proliferation and differentiation of neural stem cells. Journal of Neuroscience Research, 88(8), 1743-1753.\n2. Zhang et al. (2013). Runx2 regulates the maintenance of neural stem cell self-renewal and proliferation by modulating the expression of key stem cell genes. Stem Cells, 31(6), 953-964.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.\n2. RUNX2 represses the expression of genes involved in astrocyte differentiation.\n3. A study indicated that RUNX2 knockout mice showed an increased number of astrocytes, suggesting its role in astrocyte differentiation.\n4. Overexpression of RUNX2 in neural stem cells inhibited their differentiation into astrocytes.\n5. Knockdown of RUNX2 promoted astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.",
      "RUNX2 represses the expression of genes involved in astrocyte differentiation.",
      "A study indicated that RUNX2 knockout mice showed an increased number of astrocytes, suggesting its role in astrocyte differentiation.",
      "Overexpression of RUNX2 in neural stem cells inhibited their differentiation into astrocytes.",
      "Knockdown of RUNX2 promoted astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIn general, the statements consistently suggest that RUNX2 plays a role in inhibiting astrocyte differentiation, which aligns with scientific findings related to the gene's functions. However, without access to the specific study mentioned in statement 3, I cannot fact-check the specific results described, but the statement follows the logic set by the other statements and general knowledge about RUNX2's functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Certainly! The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the shoulder joint. It is a procedure used to treat advanced stages of rotator cuff tears, where the damaged tissue and bone spurs have caused significant degeneration and pain in the shoulder joint. The procedure involves removing the damaged tissue and bone spurs, and replacing them with a prosthetic implant to restore function and reduce pain in the shoulder joint. The surgery is typically performed under general anesthesia and may require a hospital stay of a few days.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the shoulder joint.\n2. It is used to treat advanced stages of rotator cuff tears.\n3. The procedure involves removing damaged tissue and bone spurs from the shoulder joint.\n4. A prosthetic implant is used to replace the removed tissue and bone spurs in the shoulder joint.\n5. The surgery usually is conducted under general anesthesia and may require a hospital stay.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the shoulder joint.",
      "It is used to treat advanced stages of rotator cuff tears.",
      "The procedure involves removing damaged tissue and bone spurs from the shoulder joint.",
      "A prosthetic implant is used to replace the removed tissue and bone spurs in the shoulder joint.",
      "The surgery usually is conducted under general anesthesia and may require a hospital stay."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the shoulder joint.\n2. FALSE [correction]: It is used to treat advanced stages of osteoarthritis or other degenerative diseases in the hip, not rotator cuff tears.\n3. TRUE\n4. FALSE [correction]: A prosthetic implant is not used to replace the removed tissue and bone spurs in the Cobb-Stainsby excision arthroplasty. Instead, the procedure typically involves the creation of a false joint by placing a fascial flap or other soft tissue between the bone ends.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 (Growth Hormone-Releasing Hormone 2) has been shown to lead to Epithelial-to-Mesenchymal Transition (EMT), which is a process that involves the loss of epithelial characteristics and the acquisition of mesenchymal properties. EMT is a key step in the development of cancer and other diseases, and GRHL2 has been implicated in the regulation of this process.\nIn general, GRHL2 is a secreted protein that plays a role in regulating cell growth, differentiation, and survival. However, when GRHL2 is over-expressed, it can promote the activation of signaling pathways that lead to EMT. This can involve the inhibition of the epithelial marker E-cadherin and the activation of mesenchymal markers such as vimentin and N-cadherin.\nOverall, the over-expression of GRHL2 can contribute to the development of a more aggressive and invasive cancer phenotype by promoting EMT, and it is a potential therapeutic target for the treatment of cancer and other diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 leads to Epithelial-to-Mesenchymal Transition (EMT).\n2. EMT is characterized by the loss of epithelial characteristics and the acquisition of mesenchymal properties.\n3. GRHL2 is implicated in the regulation of EMT, which is a key step in the development of cancer and other diseases.\n4. Over-expression of GRHL2 can promote the activation of signaling pathways that lead to the inhibition of the epithelial marker E-cadherin.\n5. Over-expression of GRHL2 can activate mesenchymal markers such as vimentin and N-cadherin.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 leads to Epithelial-to-Mesenchymal Transition (EMT).",
      "EMT is characterized by the loss of epithelial characteristics and the acquisition of mesenchymal properties.",
      "GRHL2 is implicated in the regulation of EMT, which is a key step in the development of cancer and other diseases.",
      "Over-expression of GRHL2 can promote the activation of signaling pathways that lead to the inhibition of the epithelial marker E-cadherin.",
      "Over-expression of GRHL2 can activate mesenchymal markers such as vimentin and N-cadherin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 is usually associated with the suppression of Epithelial-to-Mesenchymal Transition (EMT).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Over-expression of GRHL2 typically leads to the activation of signaling pathways that maintain or enhance the expression of the epithelial marker E-cadherin.\n5. FALSE [correction]: Over-expression of GRHL2 is generally associated with the suppression of mesenchymal markers such as vimentin and N-cadherin, not their activation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Certainly! Lung cancer is a common type of cancer that affects the respiratory system, and several T-UCRs (transcription factors) have been implicated in its development and progression. Here are some examples:\n1. E2F1: E2F1 is a transcription factor that regulates the expression of genes involved in cell cycle progression and apoptosis. Studies have shown that E2F1 is overexpressed in many types of lung cancer, and its overexpression is associated with poor prognosis.\n2. c-Myc: c-Myc is a transcription factor that regulates cell proliferation, differentiation, and apoptosis. c-Myc is overexpressed in many types of cancer, including lung cancer, and its overexpression is associated with poor prognosis.\n3. HIF1A: HIF1A (hypoxia-inducible factor 1-alpha) is a transcription factor that regulates the expression of genes involved in adapting to hypoxia. HIF1A is overexpressed in many types of lung cancer, and its overexpression is associated with poor prognosis.\n4. NF-κB: NF-κB (nuclear factor kappa B) is a transcription factor that regulates the expression of genes involved in inflammation and immune response. NF-κB is overexpressed in many types of lung cancer, and its overexpression is associated with poor prognosis.\n5. SP1: SP1 (specificity protein 1) is a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and survival. SP1 is overexpressed in many types of lung cancer, and its overexpression is associated with poor prognosis.\nThese are just a few examples of T-UCRs that have been implicated in lung cancer. There are likely many other T-UCRs that play a role in lung cancer development and progression, and further research is needed to fully understand the complex molecular mechanisms involved in this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. E2F1 is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.\n2. c-Myc is overexpressed in lung cancer and its overexpression is associated with poor prognosis.\n3. HIF1A (hypoxia-inducible factor 1-alpha) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.\n4. NF-κB (nuclear factor kappa B) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.\n5. SP1 (specificity protein 1) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.",
    "llama-2-7b-chat-hf_fact": [
      "E2F1 is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.",
      "c-Myc is overexpressed in lung cancer and its overexpression is associated with poor prognosis.",
      "HIF1A (hypoxia-inducible factor 1-alpha) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.",
      "NF-κB (nuclear factor kappa B) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis.",
      "SP1 (specificity protein 1) is overexpressed in many types of lung cancer and its overexpression is associated with poor prognosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: E2F1 is known to be overexpressed in various types of lung cancer, and studies have linked its overexpression to poor prognosis.\n2. TRUE: c-Myc is frequently overexpressed in lung cancer, and its overexpression has been associated with poor prognosis in patients.\n3. TRUE: HIF1A is often overexpressed in lung cancers, particularly under hypoxic conditions that are common in tumor microenvironments, and its overexpression has been associated with poor prognosis.\n4. TRUE: NF-κB is known to be overexpressed in many types of cancers, including lung cancer, and has been implicated in promoting cancer progression and poor prognosis.\n5. TRUE: SP1 has been reported to be overexpressed in various cancers, including lung cancer, and its overexpression can contribute to tumorigenesis and might be associated with poor prognosis. However, the specificity of SP1 overexpression and its direct association with prognosis in lung cancer may be less established and more research might be needed to unequivocally confirm this relationship.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! GPR151 is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. However, recent studies have shown that GPR151 is involved in the regulation of various cellular processes, including inflammation, immune response, and cancer.\nGPR151 is a G protein-coupled receptor (GPCR) that is primarily expressed in the brain, but it is also found in other tissues, including the immune system and cancer cells. Activation of GPR151 has been shown to modulate the activity of multiple signaling pathways, including the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway.\nGPR151 has been implicated in a number of diseases, including:\n* Inflammatory disorders: GPR151 has been shown to play a role in the regulation of inflammation in various tissues, including the brain, where it can modulate the activity of microglia and astrocytes.\n* Cancer: GPR151 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer, where it can promote tumor growth and progression.\n* Neurodegenerative diseases: GPR151 has been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\nOverall, GPR151 is a complex and multifunctional receptor that plays a critical role in the regulation of various cellular processes, and its dysregulation has been implicated in a number of diseases. Further research is needed to fully understand the mechanisms of GPR151 and its potential as a therapeutic target for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan receptor, which means that its endogenous ligand or physiological function is not well-defined.\n2. GPR151 is a G protein-coupled receptor (GPCR) that is expressed primarily in the brain as well as in other tissues like the immune system and cancer cells.\n3. Activation of GPR151 modulates the activity of multiple signaling pathways, including the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway.\n4. GPR151 is implicated in the regulation of inflammation and is involved in the activity of microglia and astrocytes in the brain.\n5. GPR151 is overexpressed in various types of cancer, including breast, lung, and colon cancer, and is associated with promoting tumor growth and progression.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan receptor, which means that its endogenous ligand or physiological function is not well-defined.",
      "GPR151 is a G protein-coupled receptor (GPCR) that is expressed primarily in the brain as well as in other tissues like the immune system and cancer cells.",
      "Activation of GPR151 modulates the activity of multiple signaling pathways, including the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway.",
      "GPR151 is implicated in the regulation of inflammation and is involved in the activity of microglia and astrocytes in the brain.",
      "GPR151 is overexpressed in various types of cancer, including breast, lung, and colon cancer, and is associated with promoting tumor growth and progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - GPR151 is a G protein-coupled receptor (GPCR), and while it is primarily expressed in the brain, without specific information in the statement about its expression in other tissues like the immune system and cancer cells, the statement can be considered true. The \"as well as in other tissues\" part is vague without specifics.\n3. UNKNOWN - Without specific information to confirm or refute whether activation of GPR151 modulates these particular signaling pathways, we cannot determine the truthfulness of this statement.\n4. UNKNOWN - The role of GPR151 in the regulation of inflammation and its specific involvement in the activity of microglia and astrocytes in the brain cannot be determined without specific information. \n5. UNKNOWN - Like the previous statements, without specific evidence or sources to confirm the overexpression of GPR151 in various types of cancer and its association with promoting tumor growth and progression, the truthfulness of this statement is uncertain.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n1. FluA (H1N1)\n2. FluA (H3N2)\n3. FluB (Victoria)\n4. FluB (Yamagata)\nNote: The Fluzone intradermal vaccine is designed to protect against four different strains of the flu virus, including two strains of Influenza A (H1N1 and H3N2) and two strains of Influenza B (Victoria and Yamagata). The vaccine is administered via an intradermal injection, which delivers a smaller dose of the vaccine to the skin than a traditional intramuscular injection. This can help to stimulate a stronger immune response to the vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains FluA (H1N1).\n2. The Fluzone intradermal quadrivalent vaccine contains FluA (H3N2).\n3. The Fluzone intradermal quadrivalent vaccine contains FluB (Victoria).\n4. The Fluzone intradermal quadrivalent vaccine contains FluB (Yamagata).\n5. The Fluzone intradermal vaccine is administered via an intradermal injection.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains FluA (H1N1).",
      "The Fluzone intradermal quadrivalent vaccine contains FluA (H3N2).",
      "The Fluzone intradermal quadrivalent vaccine contains FluB (Victoria).",
      "The Fluzone intradermal quadrivalent vaccine contains FluB (Yamagata).",
      "The Fluzone intradermal vaccine is administered via an intradermal injection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIntradermal quadrivalent influenza vaccines like Fluzone are designed to protect against four different flu viruses: two influenza A viruses (H1N1 and H3N2) and two influenza B viruses (Victoria and Yamagata lineages). They are administered via an intradermal injection, which means they are injected into the skin rather than the muscle.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, which encodes the tumor necrosis factor receptor 2 (TNFR2), has been genetically associated with Systemic Lupus Erythematosus (SLE). Specifically, mutations in the TNFR2 gene have been identified as a risk factor for the development of SLE. The genetic association is thought to be due to the role of TNFR2 in the regulation of immune responses and the development of autoantibodies, which are antibodies that target the body's own tissues.\nOne specific mutation in the TNFR2 gene that has been associated with SLE is a point mutation in the TNFR2 gene that results in the substitution of the amino acid glutamine for arginine at position 205 (Q205R). This mutation has been found to be more common in individuals with SLE compared to the general population, and has been associated with an increased risk of developing SLE.\nOther genetic variations in the TNFR2 gene, such as copy number variations and single nucleotide polymorphisms (SNPs), have also been identified as risk factors for SLE. These variations may affect the expression or function of the TNFR2 protein, leading to an imbalance in immune responses and the development of autoantibodies.\nOverall, the genetic association between the TNFR2 gene and SLE highlights the complex interplay between genetic and environmental factors in the development of this autoimmune disease. Further research is needed to fully understand the role of genetic variations in the TNFR2 gene and other genes in the etiology of SLE, and to identify new targets for therapeutic intervention.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene encodes the tumor necrosis factor receptor 2.\n2. Mutations in the TNFR2 gene have been identified as a risk factor for the development of Systemic Lupus Erythematosus (SLE).\n3. A specific mutation in the TNFR2 gene (Q205R) has been associated with an increased risk of developing SLE.\n4. The point mutation Q205R results in the substitution of the amino acid arginine for glutamine at position 205.\n5. Genetic variations in the TNFR2 gene that can contribute to SLE include copy number variations and single nucleotide polymorphisms (SNPs).",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene encodes the tumor necrosis factor receptor 2.",
      "Mutations in the TNFR2 gene have been identified as a risk factor for the development of Systemic Lupus Erythematosus (SLE).",
      "A specific mutation in the TNFR2 gene (Q205R) has been associated with an increased risk of developing SLE.",
      "The point mutation Q205R results in the substitution of the amino acid arginine for glutamine at position 205.",
      "Genetic variations in the TNFR2 gene that can contribute to SLE include copy number variations and single nucleotide polymorphisms (SNPs)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The point mutation Q205R results in the substitution of the amino acid glutamine for arginine at position 205.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help!\nThere is currently no FDA-approved vaccine available for the prevention of peanut allergy. Peanut allergy is a complex and severe immune-mediated disorder that is caused by an abnormal response to peanut proteins. While researchers have been working on developing a vaccine for peanut allergy, the development of a safe and effective vaccine has been challenging due to the complexity of the allergy and the need to precisely mimic the natural allergenic components of peanuts.\nHowever, there are ongoing clinical trials investigating the safety and efficacy of various vaccine candidates for the prevention of peanut allergy. These trials are using different approaches, such as using small peptides or protein fragments of peanut allergens, or delivering these allergens using different carriers, such as viral vectors or nanoparticles. While these trials are still in their early stages, they offer hope for the development of a vaccine that could potentially prevent or treat peanut allergy in the future.\nIt's important to note that even if a vaccine for peanut allergy is developed, it may not be effective for everyone and could have potential side effects. Therefore, it's crucial to continue researching and developing new treatments for peanut allergy, including avoidance strategies and emergency treatment options.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no FDA-approved vaccine for the prevention of peanut allergy.\n2. Peanut allergy is caused by an abnormal immune response to peanut proteins.\n3. Clinical trials are ongoing to investigate vaccine candidates for the prevention of peanut allergy.\n4. Different approaches in vaccine development for peanut allergies include using small peptides or protein fragments of peanut allergens.\n5. The clinical trials for peanut allergy vaccines are still considered to be in the early stages.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no FDA-approved vaccine for the prevention of peanut allergy.",
      "Peanut allergy is caused by an abnormal immune response to peanut proteins.",
      "Clinical trials are ongoing to investigate vaccine candidates for the prevention of peanut allergy.",
      "Different approaches in vaccine development for peanut allergies include using small peptides or protein fragments of peanut allergens.",
      "The clinical trials for peanut allergy vaccines are still considered to be in the early stages."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the knowledge cutoff date is in 2023 and there is no specific context provided about the dates or outcomes of clinical trials, I cannot verify the current status of FDA approvals or the stages of clinical trials without up-to-date information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene is located on the X chromosome at position Xp11.2. This means that the Fxy gene is located on the long arm of the X chromosome at position 11.2, from the centromere towards the telomere.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. The specific position of the mouse Fxy gene on the X chromosome is Xp11.2.\n3. The Fxy gene is located on the long arm of the X chromosome.\n4. The position 11.2 indicates a location from the centromere towards the telomere.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "The specific position of the mouse Fxy gene on the X chromosome is Xp11.2.",
      "The Fxy gene is located on the long arm of the X chromosome.",
      "The position 11.2 indicates a location from the centromere towards the telomere."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: The Fxy gene, if referencing the typical human gene naming convention, would be on the short arm of the X chromosome, as 'p' denotes the short arm. However, gene naming conventions can differ in organisms, so without specific knowledge of mouse genetics, this could vary.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of a specific chemical probe, methidiumpropyl-EDTA (MPE), to selectively bind to and label the 5' ends of RNA molecules in a sample. This allows for the isolation and analysis of the 5' ends of RNA molecules, which can provide information about the transcriptome of a cell or organism.\nIn the MPE-seq method, the sample is first treated with MPE, which selectively binds to the 5' ends of RNA molecules. The sample is then separated by size using gel electrophoresis, and the RNA molecules are visualized using a DNA-binding dye. The resulting gel image shows the distribution of the RNA molecules based on their size, with the 5' ends of the RNA molecules being more visible due to the binding of the MPE probe.\nThe MPE-seq method is a powerful tool for analyzing the transcriptome, as it allows for the sensitive and specific detection of RNA molecules in a sample. It has been used to study a variety of biological processes, including gene expression, cell differentiation, and disease progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method employs methidiumpropyl-EDTA (MPE) as a chemical probe to bind the 5' ends of RNA molecules.\n2. Methidiumpropyl-EDTA (MPE) selectively labels the 5' ends of RNA molecules for isolation and analysis.\n3. After treatment with MPE, RNA molecules in a sample are separated by size using gel electrophoresis.\n4. A DNA-binding dye is used to visualize RNA molecules in the gel after electrophoresis.\n5. The MPE-seq method has applications in studying gene expression, cell differentiation, and disease progression.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method employs methidiumpropyl-EDTA (MPE) as a chemical probe to bind the 5' ends of RNA molecules.",
      "Methidiumpropyl-EDTA (MPE) selectively labels the 5' ends of RNA molecules for isolation and analysis.",
      "After treatment with MPE, RNA molecules in a sample are separated by size using gel electrophoresis.",
      "A DNA-binding dye is used to visualize RNA molecules in the gel after electrophoresis.",
      "The MPE-seq method has applications in studying gene expression, cell differentiation, and disease progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The MPE-seq method employs methidiumpropyl-EDTA (MPE) as a chemical probe, but it binds to the 3' ends of RNA molecules, not the 5' ends.\n2. FALSE [correction]: Methidiumpropyl-EDTA (MPE) selectively labels the 3' ends of RNA molecules for isolation and analysis, not the 5' ends.\n3. TRUE\n4. FALSE [correction]: A DNA-binding dye would not be used to visualize RNA molecules. RNA visualization typically requires RNA-specific stains such as ethidium bromide that also binds to DNA but can be used in different context or SYBR Green II which is more selective for RNA in the presence of DNA.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genomic Workbench for Analysis and Reconstruction) is a bioinformatics tool for reconstructing and analyzing genomes from high-throughput sequencing data. As far as I know, GWAR is not implemented in any specific programming language. It is built using a combination of software tools and libraries, including Python, C++, and Java, to provide a comprehensive platform for genomic analysis.\nTherefore, the answer to the last question is:\nGWAR is implemented using a combination of programming languages, including Python, C++, and Java.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAR stands for Genomic Workbench for Analysis and Reconstruction.\n2. GWAR is a bioinformatics tool used for reconstructing and analyzing genomes from high-throughput sequencing data.\n3. GWAR is implemented using a combination of programming languages, including Python, C++, and Java.",
    "llama-2-7b-chat-hf_fact": [
      "GWAR stands for Genomic Workbench for Analysis and Reconstruction.",
      "GWAR is a bioinformatics tool used for reconstructing and analyzing genomes from high-throughput sequencing data.",
      "GWAR is implemented using a combination of programming languages, including Python, C++, and Java."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GWAR does not stand for Genomic Workbench for Analysis and Reconstruction. GWAR is actually a rock band known for its elaborate science fiction-themed costumes and performances.\n2. FALSE [correction]: Since GWAR is not a bioinformatics tool but a rock band, it is not used for reconstructing and analyzing genomes from high-throughput sequencing data.\n3. FALSE [correction]: As GWAR is a band and not a software application, it is not implemented using any programming languages like Python, C++, or Java.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden is an investigational drug that has been shown to have neuroprotective effects in preclinical studies for the treatment of amyotrophic lateral sclerosis (ALS). While there is currently no cure for ALS, xaliproden has been found to slow down the progression of motor function decline in people with ALS.\nA phase II clinical trial published in 2018 found that xaliproden treatment resulted in a slower decline in motor function compared to placebo in patients with ALS. Specifically, the study found that the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was slower in the xaliproden group compared to the placebo group over a 24-week treatment period.\nWhile these findings are promising, it is important to note that the study was small and more research is needed to confirm these results and determine the long-term safety and efficacy of xaliproden for the treatment of ALS. Additionally, xaliproden has not been approved by regulatory authorities for the treatment of ALS, and it is important to discuss the potential benefits and risks of any new treatment with a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an investigational drug with neuroprotective effects studied for the treatment of amyotrophic lateral sclerosis (ALS).\n2. There is currently no cure for ALS.\n3. A phase II clinical trial published in 2018 found that xaliproden slowed down the progression of motor function decline in patients with ALS.\n4. In the aforementioned trial, the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was slower in the xaliproden group compared to the placebo group over a 24-week treatment period.\n5. Xaliproden has not been approved by regulatory authorities for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an investigational drug with neuroprotective effects studied for the treatment of amyotrophic lateral sclerosis (ALS).",
      "There is currently no cure for ALS.",
      "A phase II clinical trial published in 2018 found that xaliproden slowed down the progression of motor function decline in patients with ALS.",
      "In the aforementioned trial, the mean rate of decline in the ALS Functional Rating Scale (ALSFRS-R) was slower in the xaliproden group compared to the placebo group over a 24-week treatment period.",
      "Xaliproden has not been approved by regulatory authorities for the treatment of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (There is not enough information provided to verify the results of a specific phase II clinical trial from 2018.)\n4. UNKNOWN (Due to the lack of sufficient detail regarding the 2018 phase II clinical trial, the outcome pertaining to the ALSFRS-R cannot be confirmed.)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "In the case of the LiPS-A3S line, the transgenes are inserted into chromosome 16.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transgenes are inserted into chromosome 16 in the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact": [
      "Transgenes are inserted into chromosome 16 in the LiPS-A3S line."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nWithout the proper context or specific details regarding the LiPS-A3S line and the chromosomal location of the transgenes, it is not possible to determine the accuracy of the statement.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several tools and techniques that exist for predicting drug synergy with deep learning. Some of the popular ones include:\n1. DeepSynth: This is a deep learning-based tool that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes. It uses a convolutional neural network (CNN) to identify potential drug targets and predict their combinations for synergy.\n2. DrugCombo: This tool uses a combination of machine learning and graph-based methods to predict drug synergy. It analyzes the chemical structures of drugs and their targets, as well as their interactions with other proteins in the cell, to identify potential combinations for synergy.\n3. Synergizer: This tool uses a deep learning-based approach to predict drug synergy by analyzing the genomic and transcriptomic data of cancer cells. It identifies potential drug targets and predicts their combinations for synergy based on the expression levels of these targets.\n4. DrugNet: This tool uses a Bayesian network-based approach to predict drug synergy by analyzing the protein-protein interaction networks of cancer genes. It identifies potential drug targets and predicts their combinations for synergy based on their connectivity in the network.\n5. DeepDrug: This tool uses a deep learning-based approach to predict drug synergy by analyzing the genomic and transcriptomic data of cancer cells. It identifies potential drug targets and predicts their combinations for synergy based on the expression levels of these targets.\nThese are just a few examples of the many tools and techniques that exist for predicting drug synergy with deep learning. Each tool has its own strengths and limitations, and the choice of which tool to use will depend on the specific research question and data available.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a tool that predicts drug synergy using a convolutional neural network to analyze protein-protein interaction networks of cancer genes.\n2. DrugCombo is a tool that predicts drug synergy by analyzing the chemical structures of drugs and their targets, as well as their interaction with other proteins.\n3. Synergizer is a tool that predicts drug synergy by analyzing genomic and transcriptomic data of cancer cells, and it predicts combinations for synergy based on target expression levels.\n4. DrugNet is a Bayesian network-based tool that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes, focusing on connectivity.\n5. DeepDrug uses deep learning to predict drug synergy by analyzing genomic and transcriptomic data of cancer cells, focusing on potential drug targets and their expression levels.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a tool that predicts drug synergy using a convolutional neural network to analyze protein-protein interaction networks of cancer genes.",
      "DrugCombo is a tool that predicts drug synergy by analyzing the chemical structures of drugs and their targets, as well as their interaction with other proteins.",
      "Synergizer is a tool that predicts drug synergy by analyzing genomic and transcriptomic data of cancer cells, and it predicts combinations for synergy based on target expression levels.",
      "DrugNet is a Bayesian network-based tool that predicts drug synergy by analyzing the protein-protein interaction networks of cancer genes, focusing on connectivity.",
      "DeepDrug uses deep learning to predict drug synergy by analyzing genomic and transcriptomic data of cancer cells, focusing on potential drug targets and their expression levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truth or falsehood of these statements cannot be determined without additional context or information about the specific tools mentioned (DeepSynth, DrugCombo, Synergizer, DrugNet, and DeepDrug). These tools have specific functions in drug synergy prediction, but without access to reliable information about their methodology or functions, it is not possible to verify the accuracy of the descriptions provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS (Genome-Wide Association Studies) is called \"GWASdb\" (Genome-Wide Association Study Database). GWASdb is a user-friendly, web-based platform that allows researchers to compare and integrate data from multiple GWAS studies, facilitating the identification of novel associations and the replication of known findings. GWASdb was developed by the National Center for Biotechnology Information (NCBI) and is freely accessible to researchers worldwide.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWASdb stands for Genome-Wide Association Study Database.\n2. GWASdb is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).\n3. The platform is designed to allow researchers to compare and integrate data from multiple GWAS studies.\n4. GWASdb was developed by the National Center for Biotechnology Information (NCBI).\n5. GWASdb is freely accessible to researchers around the world.",
    "llama-2-7b-chat-hf_fact": [
      "GWASdb stands for Genome-Wide Association Study Database.",
      "GWASdb is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).",
      "The platform is designed to allow researchers to compare and integrate data from multiple GWAS studies.",
      "GWASdb was developed by the National Center for Biotechnology Information (NCBI).",
      "GWASdb is freely accessible to researchers around the world."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: GWASdb was developed by various groups and maintained by the Human Genome Center at the University of Tokyo, not the National Center for Biotechnology Information (NCBI).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a small molecule inhibitor of the protein kinase B (PKB, also known as Akt). It has been shown to have antitumor activity against various types of cancer, including sarcomas. In fact, CMB305 has been investigated as a potential treatment for soft tissue sarcoma, a type of cancer that affects connective tissue in the body.\nSarcomas are a diverse group of cancers that arise from the mesenchyme, a type of connective tissue that supports and connects other tissues in the body. They can occur in any part of the body and can be challenging to treat due to their location and aggressive nature.\nCMB305 has been shown to inhibit the activation of PKB, which is a key regulator of cell survival and proliferation. In sarcomas, PKB is often overactive, promoting cell growth and survival. By inhibiting PKB with CMB305, researchers have found that it can slow the growth of sarcoma cells and induce cell death in these cancer cells.\nWhile the results are promising, it's important to note that CMB305 is still a preclinical drug, and further studies are needed to determine its efficacy and safety in humans. However, the current evidence suggests that CMB305 may be a potential therapeutic option for the treatment of sarcomas, and clinical trials are currently underway to evaluate its use in this indication.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is an inhibitor of the protein kinase B (PKB, also known as Akt).\n2. CMB305 has shown antitumor activity against various types of cancer, including sarcomas.\n3. Sarcomas are cancers that arise from mesenchymal connective tissues.\n4. CMB305 inhibits the activation of PKB, which is often overactive in sarcomas.\n5. CMB305 is currently a preclinical drug and is undergoing clinical trials to evaluate its efficacy and safety in humans.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is an inhibitor of the protein kinase B (PKB, also known as Akt).",
      "CMB305 has shown antitumor activity against various types of cancer, including sarcomas.",
      "Sarcomas are cancers that arise from mesenchymal connective tissues.",
      "CMB305 inhibits the activation of PKB, which is often overactive in sarcomas.",
      "CMB305 is currently a preclinical drug and is undergoing clinical trials to evaluate its efficacy and safety in humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the latest research or specific scientific literature, it is not possible to verify the accuracy of the statements regarding CMB305, such as its inhibition properties, antitumor activity, or current stage in drug development. Therefore, a review of current scientific literature is necessary to assess those statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the St. Vital triad, is a clinical syndrome that consists of three key manifestations that are commonly observed in patients with mitochondrial disorders. The three manifestations are:\n1. Myopathy: Muscle weakness and wasting, leading to muscle weakness and loss of muscle mass.\n2. Encephalopathy: Cognitive impairment, including confusion, disorientation, and changes in behavior.\n3. Retinitis: Vision loss or blindness, often due to degeneration of the retina.\nThese three manifestations are often seen together in patients with mitochondrial disorders, such as Kearns-Sayre syndrome, and can be used to help diagnose and monitor the progression of these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad consists of three key manifestations: myopathy, encephalopathy, and retinitis.\n2. Myopathy in the context of the Saint's Triad involves muscle weakness and wasting.\n3. Encephalopathy in the Saint's Triad encompasses cognitive impairment, including confusion, disorientation, and changes in behavior.\n4. Retinitis as a part of the Saint's Triad leads to vision loss or blindness due to degeneration of the retina.\n5. The Saint's Triad is commonly observed in patients with mitochondrial disorders such as Kearns-Sayre syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad consists of three key manifestations: myopathy, encephalopathy, and retinitis.",
      "Myopathy in the context of the Saint's Triad involves muscle weakness and wasting.",
      "Encephalopathy in the Saint's Triad encompasses cognitive impairment, including confusion, disorientation, and changes in behavior.",
      "Retinitis as a part of the Saint's Triad leads to vision loss or blindness due to degeneration of the retina.",
      "The Saint's Triad is commonly observed in patients with mitochondrial disorders such as Kearns-Sayre syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Saint's Triad does not exist as a medical term. The symptoms listed are more indicative of Kearns-Sayre syndrome, which includes external ophthalmoplegia, retinitis pigmentosa, and heart block. If the term was intended to refer to a triad of symptoms found in a particular disorder, the correct name for the disorder and its associated triad would need to be provided.\n2. TRUE: Myopathy typically involves muscle weakness and wasting, and while myopathy itself isn't specifically part of the so-called \"Saint's Triad,\" these are indeed characteristics of myopathic diseases.\n3. TRUE: Encephalopathy does encompass symptoms such as cognitive impairment, including confusion, disorientation, and changes in behavior. These symptoms can be associated with various diseases, including mitochondrial disorders.\n4. TRUE: Retinitis typically leads to vision problems and can potentially cause vision loss or blindness due to degeneration of the retina. This symptom, specifically retinitis pigmentosa, is observed in Kearns-Sayre syndrome.\n5. TRUE: The symptoms described, although incorrectly associated with a non-existent \"Saint's Triad,\" are indeed commonly observed in patients with mitochondrial disorders such as Kearns-Sayre syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Overexpression of LY6K has been associated with improved prognosis in non-small cell lung cancer (NSCLC) patients. LY6K is a member of the LY6 kinase family and has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion.\nStudies have found that high levels of LY6K expression are associated with better overall survival and disease-free survival in NSCLC patients. For example, a study published in the journal Oncogene found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in a cohort of NSCLC patients. Another study published in the journal Clinical Cancer Research found that high levels of LY6K expression were associated with improved overall survival in a cohort of NSCLC patients treated with chemotherapy.\nThe mechanisms by which LY6K promotes a better prognosis in NSCLC are not fully understood, but it is thought to involve its role in regulating cellular processes such as cell adhesion and migration. LY6K has been shown to promote the adhesion of cancer cells to the extracellular matrix and to inhibit the migration of cancer cells, which may help to prevent the spread of cancer cells and improve the effectiveness of cancer therapy.\nIn summary, overexpression of LY6K is associated with improved prognosis in non-small cell lung cancer patients, and further research is needed to fully understand the mechanisms by which LY6K promotes a better prognosis in this disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with improved prognosis in non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are correlated with better overall survival and disease-free survival in NSCLC patients.\n3. A study published in the journal Oncogene found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in a cohort of NSCLC patients.\n4. Another study in the journal Clinical Cancer Research reported that high levels of LY6K expression were linked to improved overall survival in NSCLC patients treated with chemotherapy.\n5. LY6K has been shown to promote the adhesion of cancer cells to the extracellular matrix and to inhibit the migration of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with improved prognosis in non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are correlated with better overall survival and disease-free survival in NSCLC patients.",
      "A study published in the journal Oncogene found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in a cohort of NSCLC patients.",
      "Another study in the journal Clinical Cancer Research reported that high levels of LY6K expression were linked to improved overall survival in NSCLC patients treated with chemotherapy.",
      "LY6K has been shown to promote the adhesion of cancer cells to the extracellular matrix and to inhibit the migration of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with poor prognosis in non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: High levels of LY6K expression are usually correlated with poorer overall survival and disease-free survival in NSCLC patients.\n3. FALSE [correction]: Studies typically find that high levels of LY6K expression are associated with poorer overall survival and disease-free survival in NSCLC patients. However, without access to the specific study from the journal Oncogene, this statement's accuracy is based on general knowledge and might not reflect the findings of that particular study.\n4. UNKNOWN: Without access to the specific article in the journal Clinical Cancer Research, it's not possible to verify this statement.\n5. UNKNOWN: The role of LY6K in cancer cell adhesion and migration can vary, and without specific information from a study or publication, its exact function in these processes in the context of NSCLC cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Here are some Cdk targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (Cdk1): Cdk1 is a key regulator of the cell cycle and is dephosphorylated during cytokinesis to promote the separation of daughter cells.\n2. Cyclin-dependent kinase 2 (Cdk2): Cdk2 is also involved in the regulation of the cell cycle and is dephosphorylated during cytokinesis to facilitate the proper separation of daughter cells.\n3. Cyclin-dependent kinase 5 (Cdk5): Cdk5 is involved in the regulation of various cellular processes, including cell adhesion and migration, and is dephosphorylated during cytokinesis to promote proper cell separation.\n4. Membrane-associated guanylate kinase (MAGUK): MAGUK is a family of proteins that are involved in cell adhesion and signaling, and are dephosphorylated during cytokinesis to promote proper cell separation.\n5. Protein phosphatase 1 (PP1): PP1 is a serine/threonine protein phosphatase that dephosphorylates various cellular proteins, including Cdk1, Cdk2, and Cdk5, during cytokinesis to promote proper cell separation.\nThese are just a few examples of Cdk targets that are dephosphorylated during cytokinesis. There are likely many other targets that are also dephosphorylated during this process, and further research is needed to fully understand the mechanisms of cytokinesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (Cdk1) is dephosphorylated during cytokinesis.\n2. Cyclin-dependent kinase 2 (Cdk2) is dephosphorylated during cytokinesis.\n3. Cyclin-dependent kinase 5 (Cdk5) is dephosphorylated during cytokinesis.\n4. Membrane-associated guanylate kinase (MAGUK) proteins are dephosphorylated during cytokinesis.\n5. Protein phosphatase 1 (PP1) dephosphorylates various cellular proteins, including Cdk1, Cdk2, and Cdk5, during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (Cdk1) is dephosphorylated during cytokinesis.",
      "Cyclin-dependent kinase 2 (Cdk2) is dephosphorylated during cytokinesis.",
      "Cyclin-dependent kinase 5 (Cdk5) is dephosphorylated during cytokinesis.",
      "Membrane-associated guanylate kinase (MAGUK) proteins are dephosphorylated during cytokinesis.",
      "Protein phosphatase 1 (PP1) dephosphorylates various cellular proteins, including Cdk1, Cdk2, and Cdk5, during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Cyclin-dependent kinase 1 (Cdk1) is indeed regulated by phosphorylation and dephosphorylation at different stages of the cell cycle, including during cytokinesis.\n2. FALSE [correction]: Cyclin-dependent kinase 2 (Cdk2) is primarily involved in the regulation of the cell cycle at the G1-S transition and its activity depends on phosphorylation status, but it is not typically associated with dephosphorylation during cytokinesis.\n3. UNKNOWN: Cyclin-dependent kinase 5 (Cdk5) is not involved in the cell cycle regulation in the same way that Cdk1 and Cdk2 are. Cdk5 is primarily involved in neuronal cell functions, and its role in cytokinesis is not well-defined or may not be relevant. Therefore, without specific context or evidence, its dephosphorylation status during cytokinesis is unclear.\n4. UNKNOWN: Membrane-associated guanylate kinase (MAGUK) proteins are a family of proteins involved in numerous processes, including the organization of membrane domains and signal transduction. Their phosphorylation status during cytokinesis is not well-established in this statement, and thus the truth of the statement cannot be determined without additional context.\n5. TRUE: Protein phosphatase 1 (PP1) is known to be involved in dephosphorylating various cellular proteins, including Cdk1. It can regulate the cell cycle and indeed has roles in dephosphorylation events during cytokinesis. Whether it specifically dephosphorylates Cdk2 and Cdk5 during cytokinesis might depend on the cell type and context, but the statement is generally true regarding its dephosphorylation activity.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a drug used to treat a rare genetic disorder called Danon disease, which affects the heart and muscles. It works by reducing the amount of triglycerides in the blood, which can help improve the function of the heart and muscles in people with this condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a drug used to treat Danon disease.\n2. Danon disease is a rare genetic disorder that affects the heart and muscles.\n3. Xanamem works by reducing the amount of triglycerides in the blood.\n4. Lowering triglycerides can help improve the function of the heart and muscles in those with Danon disease.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a drug used to treat Danon disease.",
      "Danon disease is a rare genetic disorder that affects the heart and muscles.",
      "Xanamem works by reducing the amount of triglycerides in the blood.",
      "Lowering triglycerides can help improve the function of the heart and muscles in those with Danon disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n\nRationale:\n- Xanamem is not a well-known medication, and as such, its use for treating Danon disease cannot be confirmed without further context or medical literature.\n- Danon disease is indeed a rare genetic condition that principally affects the heart and skeletal muscles.\n- The mechanism of action of Xanamem (if it is an actual drug) and its impact on triglycerides are not provided in common knowledge databases as of my last update and would require specific pharmacological knowledge or research to verify.\n- The statement regarding the lowering of triglycerides helping heart and muscle function in Danon disease is a plausible hypothesis but without data on Xanamem or knowing if this is its actual mechanism, it remains unverified thus UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "The Hof1-Cyk3 interaction plays a crucial role in the regulation of the spindle positioning checkpoint in yeast. The Hof1 protein is a protein kinase that phosphorylates the Cyk3 protein, which is a key regulator of the spindle positioning checkpoint. The spindle positioning checkpoint ensures that the spindle fibers that separate the chromosomes during cell division are properly positioned and aligned with the chromosomes.\nWhen the spindle fibers are not properly positioned, the checkpoint is activated, and the cell cycle is delayed until the spindle fibers are properly aligned. The Hof1-Cyk3 interaction is essential for the activation of the spindle positioning checkpoint, as it allows Hof1 to phosphorylate and activate Cyk3, which then triggers the checkpoint.\nIn addition to its role in the spindle positioning checkpoint, the Hof1-Cyk3 interaction has been implicated in other cellular processes, including the regulation of the G1/S checkpoint and the maintenance of genome stability.\nOverall, the Hof1-Cyk3 interaction is a critical component of the cellular machinery that ensures proper chromosome segregation and genome stability in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the spindle positioning checkpoint in yeast.\n2. Hof1 is a protein kinase that phosphorylates the Cyk3 protein.\n3. The spindle positioning checkpoint ensures the proper positioning and alignment of spindle fibers with chromosomes during cell division.\n4. The activation of the spindle positioning checkpoint by the Hof1-Cyk3 interaction delays the cell cycle when spindle fibers are improperly positioned.\n5. The Hof1-Cyk3 interaction is implicated in the regulation of the G1/S checkpoint and the maintenance of genome stability in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the spindle positioning checkpoint in yeast.",
      "Hof1 is a protein kinase that phosphorylates the Cyk3 protein.",
      "The spindle positioning checkpoint ensures the proper positioning and alignment of spindle fibers with chromosomes during cell division.",
      "The activation of the spindle positioning checkpoint by the Hof1-Cyk3 interaction delays the cell cycle when spindle fibers are improperly positioned.",
      "The Hof1-Cyk3 interaction is implicated in the regulation of the G1/S checkpoint and the maintenance of genome stability in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a protein kinase. It is a protein involved in cytokinesis; it does not phosphorylate Cyk3 protein itself but instead interacts with it during cell division.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Hof1-Cyk3 interaction is primarily associated with cytokinesis and the cell division process. It is not directly implicated in the regulation of the G1/S checkpoint, which is associated with the initiation of DNA synthesis and genome stability.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including gastric cancer. Some T-UCRs that have been studied in gastric cancer include:\n1. TARDBP-AS1: This T-UCR is overexpressed in gastric cancer and promotes cancer cell proliferation and migration.\n2. MALAT1: This T-UCR is overexpressed in gastric cancer and regulates the epithelial-to-mesenchymal transition (EMT) and cancer cell migration.\n3. HOTAIR: This T-UCR is overexpressed in gastric cancer and promotes cancer cell proliferation and migration by repressing the expression of the tumor suppressor gene, PTEN.\n4. XBP1-AS1: This T-UCR is overexpressed in gastric cancer and regulates the expression of genes involved in cell proliferation and survival.\n5. Circular RNA (circRNA-002): This T-UCR is overexpressed in gastric cancer and regulates the expression of genes involved in cell proliferation and survival.\nThese T-UCRs play important roles in the development and progression of gastric cancer, and their expression levels can be used as potential biomarkers for early diagnosis and therapeutic targeting.",
    "llama-2-7b-chat-hf_fact_raw": "1. TARDBP-AS1 is overexpressed in gastric cancer and is associated with cancer cell proliferation and migration.\n2. MALAT1 is overexpressed in gastric cancer and is involved in regulating the epithelial-to-mesenchymal transition (EMT) and cancer cell migration.\n3. HOTAIR is overexpressed in gastric cancer and promotes cancer cell proliferation and migration by repressing the expression of the PTEN tumor suppressor gene.\n4. XBP1-AS1 is overexpressed in gastric cancer and affects the expression of genes related to cell proliferation and survival.\n5. circRNA-002 is overexpressed in gastric cancer and influences the expression of genes involved in cell proliferation and survival.",
    "llama-2-7b-chat-hf_fact": [
      "TARDBP-AS1 is overexpressed in gastric cancer and is associated with cancer cell proliferation and migration.",
      "MALAT1 is overexpressed in gastric cancer and is involved in regulating the epithelial-to-mesenchymal transition (EMT) and cancer cell migration.",
      "HOTAIR is overexpressed in gastric cancer and promotes cancer cell proliferation and migration by repressing the expression of the PTEN tumor suppressor gene.",
      "XBP1-AS1 is overexpressed in gastric cancer and affects the expression of genes related to cell proliferation and survival.",
      "circRNA-002 is overexpressed in gastric cancer and influences the expression of genes involved in cell proliferation and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\n- Statements about the overexpression of non-coding RNAs (such as TARDBP-AS1, XBP1-AS1, and circRNA-002) in gastric cancer and their role in regulation of various cancer-related processes are specific claims that would require access to recent scientific research for verification. Without direct access to up-to-date studies or articles discussing these specific non-coding RNAs in the context of gastric cancer, the truth of these statements cannot be reliably determined.\n- Statement 2 is true as MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1) is known to be overexpressed in various cancers including gastric cancer, and it has been reported to play a role in regulating EMT and cancer cell migration.\n- Statement 3 is true as HOTAIR (HOX Transcript Antisense RNA) is known to be overexpressed in multiple cancers including gastric cancer and can promote cancer progression partly by epigenetic mechanisms that may involve repression of tumor suppressor genes such as PTEN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects multiple organ systems. The LSI is a composite score that takes into account various organ manifestations, such as joint inflammation, serositis (inflammation of the lining of the heart and lungs), neuropsychiatric symptoms, and renal involvement. The score ranges from 0 to 100, with higher scores indicating greater disease severity.\nThe LSI is calculated by assigning weights to each organ manifestation based on its clinical significance, and then adding the scores for each manifestation. The weights are as follows:\n* Joint inflammation: 20 points\n* Serositis: 15 points\n* Neuropsychiatric symptoms: 10 points\n* Renal involvement: 15 points\nThe LSI has been widely used in clinical trials and cohort studies to evaluate the effectiveness of treatments for SLE and to monitor disease activity over time. It is a useful tool for clinicians to assess the overall severity of SLE and to identify areas of organ involvement that may require more aggressive treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI takes into account various organ manifestations like joint inflammation, serositis, neuropsychiatric symptoms, and renal involvement.\n3. The LSI score ranges from 0 to 100, with higher scores indicating greater disease severity.\n4. The weights assigned in the LSI for joint inflammation, serositis, neuropsychiatric symptoms, and renal involvement are 20 points, 15 points, 10 points, and 15 points, respectively.\n5. The LSI is utilized in clinical trials and cohort studies to evaluate treatment effectiveness for SLE and monitor disease activity over time.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI takes into account various organ manifestations like joint inflammation, serositis, neuropsychiatric symptoms, and renal involvement.",
      "The LSI score ranges from 0 to 100, with higher scores indicating greater disease severity.",
      "The weights assigned in the LSI for joint inflammation, serositis, neuropsychiatric symptoms, and renal involvement are 20 points, 15 points, 10 points, and 15 points, respectively.",
      "The LSI is utilized in clinical trials and cohort studies to evaluate treatment effectiveness for SLE and monitor disease activity over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The Lupus Severity Index does not assign fixed point values for various organ manifestations as the statement describes. The LSI uses a complex scoring system that takes into account various factors, and this system does not simplify the weighting of manifestations to a fixed-point scale.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several rare genetic disorders, including:\n1. Nephrogenic diabetes insipidus (NDI): De novo mutations in ZSWIM6 have been identified as a cause of NDI, a rare disorder characterized by the inability to regulate fluid levels in the body.\n2. Bartter syndrome: ZSWIM6 mutations have been found to cause Bartter syndrome, a rare kidney disorder that can lead to electrolyte imbalances, kidney damage, and other complications.\n3. Hypokalemic periodic paralysis: Some studies have suggested that ZSWIM6 mutations may contribute to the development of hypokalemic periodic paralysis, a rare disorder characterized by muscle weakness and paralysis triggered by changes in potassium levels.\n4. Other rare disorders: ZSWIM6 mutations have also been identified in other rare disorders, including autism spectrum disorder, intellectual disability, and congenital anomalies.\nIt is important to note that the frequency and distribution of ZSWIM6 mutations in these disorders are not well understood and may vary depending on the population and the specific disorder. Further research is needed to determine the full range of disorders associated with ZSWIM6 mutations and to improve diagnostic testing and treatment options.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified as a cause of Nephrogenic diabetes insipidus (NDI).\n2. ZSWIM6 mutations have been found to cause Bartter syndrome.\n3. ZSWIM6 mutations may contribute to the development of hypokalemic periodic paralysis.\n4. ZSWIM6 mutations have been identified in individuals with autism spectrum disorder, intellectual disability, and congenital anomalies.\n5. The frequency and distribution of ZSWIM6 mutations vary depending on the population and the specific disorder.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified as a cause of Nephrogenic diabetes insipidus (NDI).",
      "ZSWIM6 mutations have been found to cause Bartter syndrome.",
      "ZSWIM6 mutations may contribute to the development of hypokalemic periodic paralysis.",
      "ZSWIM6 mutations have been identified in individuals with autism spectrum disorder, intellectual disability, and congenital anomalies.",
      "The frequency and distribution of ZSWIM6 mutations vary depending on the population and the specific disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in ZSWIM6 have been identified as a cause of developmental disorders including intellectual disability and autism spectrum disorder, not Nephrogenic diabetes insipidus (NDI).\n2. FALSE [correction]: ZSWIM6 mutations are not known to cause Bartter syndrome. Bartter syndrome is typically associated with mutations in genes that affect salt reabsorption in the kidneys, such as SLC12A1, KCNJ1, CLCNKB, BSND, CASR, and MAGED2.\n3. UNKNOWN: Without specific literature to either support or refute the statement about hypokalemic periodic paralysis, the relation between ZSWIM6 mutations and this condition cannot be determined.\n4. TRUE: ZSWIM6 mutations have been identified in individuals with autism spectrum disorder, intellectual disability, and congenital anomalies.\n5. TRUE: In general, the frequency and distribution of genetic mutations, including those in ZSWIM6, can vary depending on the population studied and the specific disorder being considered.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify neurodegenerative diseases based on the type of protein aggregates that are present in the brain. The classification system was developed by Dr. George Koos and colleagues and includes the following categories:\n1. Alzheimer's disease: This is the most common type of neurodegenerative disease and is characterized by the presence of amyloid-β (Aβ) peptide aggregates.\n2. Parkinson's disease: This is a neurodegenerative disorder that is characterized by the presence of α-synuclein protein aggregates.\n3. Huntington's disease: This is an autosomal dominant disorder that is caused by an expansion of a CAG repeat in the Huntingtin gene and is characterized by the presence of Huntingtin protein aggregates.\n4. Prion diseases: These are infectious diseases caused by the misfolding of the prion protein and the formation of amyloid fibrils. Examples include bovine spongiform encephalopathy (BSE) or \"mad cow disease\" and Creutzfeldt-Jakob disease (CJD) in humans.\n5. Other neurodegenerative diseases: This category includes a group of diseases that do not fit into any of the other categories, such as frontotemporal dementia, progressive supranuclear palsy, and multiple system atrophy.\nSo, to answer your question, a disease can be classified using the Koos Classification based on the type of protein aggregate that is present in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is a system used for classifying neurodegenerative diseases.\n2. Alzheimer's disease is characterized by amyloid-β (Aβ) peptide aggregates and is categorized under the Koos Classification.\n3. Parkinson's disease is characterized by α-synuclein protein aggregates according to the Koos Classification.\n4. Huntington's disease is caused by an expansion of a CAG repeat in the Huntingtin gene and involves Huntingtin protein aggregates.\n5. Prion diseases, like bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD), involve the misfolding of prion protein and are included in the Koos Classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is a system used for classifying neurodegenerative diseases.",
      "Alzheimer's disease is characterized by amyloid-β (Aβ) peptide aggregates and is categorized under the Koos Classification.",
      "Parkinson's disease is characterized by α-synuclein protein aggregates according to the Koos Classification.",
      "Huntington's disease is caused by an expansion of a CAG repeat in the Huntingtin gene and involves Huntingtin protein aggregates.",
      "Prion diseases, like bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease (CJD), involve the misfolding of prion protein and are included in the Koos Classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is a system used for grading cerebellar vestibular schwannomas (acoustic neuromas), not neurodegenerative diseases.\n2. FALSE [correction]: While Alzheimer's disease is characterized by amyloid-β (Aβ) peptide aggregates, it is not categorized under the Koos Classification which is for schwannomas, not neurodegenerative diseases.\n3. FALSE [correction]: Parkinson's disease is characterized by the aggregation of the α-synuclein protein, but this fact is not related to the Koos Classification as this classification system does not pertain to neurodegenerative diseases.\n4. TRUE\n5. FALSE [correction]: Prion diseases do involve the misfolding of prion protein, but they are not included in the Koos Classification, which is for grading vestibular schwannomas, not classifying prion or other neurodegenerative diseases.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase). In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Anti-tumor activity: AZD8601 has been shown to inhibit the growth of various types of cancer cells, including breast, lung, and colon cancer cells, both in vitro and in vivo.\n2. Anti-inflammatory activity: AZD8601 has been shown to inhibit the activation of immune cells, such as macrophages and T cells, and reduce the production of pro-inflammatory cytokines in various animal models of inflammation.\n3. Neuroprotective activity: AZD8601 has been shown to protect against neuronal damage and degeneration in animal models of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.\n4. Cardiovascular protective activity: AZD8601 has been shown to reduce inflammation and improve cardiovascular function in animal models of cardiovascular disease, such as heart failure and atherosclerosis.\nOverall, AZD8601 has a broad range of in vivo effects, and further research is needed to fully understand its therapeutic potential in various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).\n2. AZD8601 has demonstrated anti-tumor activity by inhibiting the growth of breast, lung, and colon cancer cells both in vitro and in vivo.\n3. AZD8601 has shown anti-inflammatory activity by inhibiting the activation of immune cells and reducing the production of pro-inflammatory cytokines in animal models.\n4. AZD8601 has exhibited neuroprotective activity in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\n5. AZD8601 has displayed cardiovascular protective activity by reducing inflammation and improving cardiovascular function in animal models of diseases such as heart failure and atherosclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of the enzyme PI3K (phosphatidylinositol 3-kinase).",
      "AZD8601 has demonstrated anti-tumor activity by inhibiting the growth of breast, lung, and colon cancer cells both in vitro and in vivo.",
      "AZD8601 has shown anti-inflammatory activity by inhibiting the activation of immune cells and reducing the production of pro-inflammatory cytokines in animal models.",
      "AZD8601 has exhibited neuroprotective activity in animal models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.",
      "AZD8601 has displayed cardiovascular protective activity by reducing inflammation and improving cardiovascular function in animal models of diseases such as heart failure and atherosclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the enzyme PI3K; it is a developmental drug for a modified mRNA encoding for VEGF-A, which is used for regenerative medicine, particularly in cardiovascular diseases.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! SAHFS (SINE/ALU histone fold-containing RNA fragments) are created through a process called alternative splicing.\nAlternative splicing is a mechanism by which cells can generate multiple different forms of a protein from a single gene. This is achieved by splicing together different combinations of exons (expressed regions of the gene) and introns (non-expressed regions). The resulting RNA molecule is then translated into a protein.\nIn the case of SAHFS, the gene encoding these RNA fragments is called the SINE/ALU gene. This gene contains repeated sequences of short, simple repeat elements called SINEs (short interspersed nuclear elements) and ALUs (ALU repeats). These repeats are interspersed with other regions of the gene that are involved in splicing.\nDuring alternative splicing, the SINE/ALU repeats are recognized by the splicing machinery and excised from the RNA molecule. The resulting RNA fragment is then spliced to another RNA molecule, creating a new RNA molecule that contains a different combination of exons and introns. This process is repeated multiple times, resulting in the creation of multiple different SAHFS.\nThe specific combination of SINE/ALU repeats that are included in the final RNA molecule determines the identity of the SAHFS that are created. Different combinations of repeats can give rise to different SAHFS, each with its own unique function or properties.\nI hope that helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS (SINE/ALU histone fold-containing RNA fragments) are created through a process called alternative splicing.\n2. Alternative splicing allows cells to generate multiple different forms of a protein from a single gene.\n3. The gene encoding SAHFS is called the SINE/ALU gene, which contains repeated sequences called SINEs (short interspersed nuclear elements) and ALUs (ALU repeats).\n4. During alternative splicing, SINE/ALU repeats are excised from the RNA molecule.\n5. Different combinations of SINE/ALU repeats determine the identity and function of the SAHFS created.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS (SINE/ALU histone fold-containing RNA fragments) are created through a process called alternative splicing.",
      "Alternative splicing allows cells to generate multiple different forms of a protein from a single gene.",
      "The gene encoding SAHFS is called the SINE/ALU gene, which contains repeated sequences called SINEs (short interspersed nuclear elements) and ALUs (ALU repeats).",
      "During alternative splicing, SINE/ALU repeats are excised from the RNA molecule.",
      "Different combinations of SINE/ALU repeats determine the identity and function of the SAHFS created."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SAHFS (SINE/ALU histone fold-containing RNA fragments) are not created through alternative splicing, but rather they are a type of non-coding RNA fragment derived from repeat regions within the genome.\n2. TRUE\n3. FALSE [correction]: There isn't a specific \"SINE/ALU gene.\" Instead, SINEs (such as ALU repeats) are dispersed throughout the genome rather than being part of a specific gene.\n4. UNKNOWN: Without additional context, it is hard to determine whether SINE/ALU repeats are specifically excised during alternative splicing as the statement generalizes the process. Alternative splicing can involve various exons and introns, which may or may not include SINE/ALU repeats.\n5. UNKNOWN: While different combinations of exons determine the identity and function of proteins created through alternative splicing, there is not enough information to confirm that this process specifically determines the identity and function of the SAHFS mentioned, especially since SAHFS themselves are not products of alternative splicing.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ domain is a protein domain that plays a crucial role in the function of SATB1 (Steroidogenic factor 1). SATB1 is a transcription factor that regulates the expression of genes involved in steroid hormone biosynthesis and other cellular processes. The PDZ domain of SATB1 is responsible for its ability to interact with other proteins and modulate their function.\nIn particular, the PDZ domain of SATB1 binds to and regulates the activity of G-protein-coupled receptors (GPCRs), which are involved in a wide range of physiological processes, including signal transduction and regulation of gene expression. By interacting with GPCRs, SATB1 can modulate their activity and affect downstream signaling pathways.\nAdditionally, the PDZ domain of SATB1 has been shown to interact with other proteins, such as the cytoskeleton and nuclear import factors, which are involved in the regulation of SATB1 localization and activity.\nIn summary, the PDZ domain of SATB1 plays a crucial role in regulating the function of SATB1 by modulating the activity of GPCRs and other proteins, and thereby affecting the regulation of gene expression and other cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein domain that contributes to the function of SATB1 (Steroidogenic factor 1).\n2. SATB1 is a transcription factor involved in the regulation of gene expression for steroid hormone biosynthesis.\n3. The PDZ domain in SATB1 enables it to interact with other proteins and modulate their function.\n4. The PDZ domain of SATB1 binds to and regulates the activity of G-protein-coupled receptors (GPCRs).\n5. The PDZ domain of SATB1 has been shown to interact with the cytoskeleton and nuclear import factors.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein domain that contributes to the function of SATB1 (Steroidogenic factor 1).",
      "SATB1 is a transcription factor involved in the regulation of gene expression for steroid hormone biosynthesis.",
      "The PDZ domain in SATB1 enables it to interact with other proteins and modulate their function.",
      "The PDZ domain of SATB1 binds to and regulates the activity of G-protein-coupled receptors (GPCRs).",
      "The PDZ domain of SATB1 has been shown to interact with the cytoskeleton and nuclear import factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is a common structural domain of signaling proteins, but it is not a domain that contributes to the function of SATB1 (Special AT-rich Sequence-binding Protein 1). Instead, SATB1 is known for its role in chromatin remodeling and regulation of gene expression.\n2. FALSE [correction]: SATB1 is not involved in the regulation of gene expression for steroid hormone biosynthesis. Instead, it is a matrix-attachment region (MAR)-binding protein that regulates chromatin structure and gene expression. Steroidogenic factor 1 (SF-1), not SATB1, is involved in steroid hormone biosynthesis regulation.\n3. UNKNOWN: Without specific context to SATB1 having a PDZ domain, this statement cannot be determined to be true or false. SATB1 does interact with other proteins but whether it features a PDZ domain in that interaction is not specified in common scientific literature regarding SATB1.\n4. FALSE [correction]: SATB1 does not have a PDZ domain that binds to and regulates the activity of G-protein-coupled receptors (GPCRs). This function is not associated with SATB1, which is known for its role in chromatin organization and gene regulation rather than direct interaction with GPCRs.\n5. UNKNOWN: There is limited specific information provided to verify SATB1's interaction with the cytoskeleton and nuclear import factors. SATB1 is known to interact with various nuclear proteins and has roles in the organization of chromatin, but specific interactions with the cytoskeleton and nuclear import factors would require more context to evaluate.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Bayesian Linear Inverse Scattering) technique is a statistical method used to analyze and model complex biological systems, such as gene regulatory networks. The basis of the BLISS technique is to use Bayesian inference to estimate the parameters of a linear inverse scattering (LIS) model, which describes the relationships between the inputs and outputs of a system.\nIn the context of gene regulatory networks, the inputs are typically the concentrations of transcription factors and other regulatory molecules, and the outputs are the expression levels of target genes. The BLISS technique uses Bayesian inference to estimate the parameters of the LIS model, which can then be used to predict the behavior of the gene regulatory network under different conditions.\nThe BLISS technique has several advantages over other methods for analyzing gene regulatory networks, including:\n1. Non-linear modeling: The BLISS technique can handle non-linear relationships between the inputs and outputs of the system, which is important for modeling complex gene regulatory networks.\n2. Bayesian inference: The BLISS technique uses Bayesian inference to estimate the parameters of the LIS model, which provides a probabilistic framework for making predictions about the behavior of the system.\n3. Scalability: The BLISS technique can be applied to large-scale gene regulatory networks, making it a useful tool for analyzing complex systems.\n4. Interpretability: The BLISS technique provides a interpretable model of the gene regulatory network, which can be used to identify key regulatory elements and their interactions.\n5. Robustness: The BLISS technique is robust to noise and missing data, which is important for analyzing complex biological systems.\nOverall, the BLISS technique is a powerful tool for analyzing and modeling complex gene regulatory networks, and it has many potential applications in fields such as drug discovery and personalized medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique uses Bayesian inference to estimate the parameters of a linear inverse scattering (LIS) model.\n2. The inputs in the BLISS technique for gene regulatory networks are typically the concentrations of transcription factors and other regulatory molecules.\n3. The outputs in the BLISS technique for gene regulatory networks are the expression levels of target genes.\n4. The BLISS technique can handle non-linear relationships between inputs and outputs of gene regulatory networks.\n5. The BLISS technique provides an interpretable model of gene regulatory networks, useful for identifying key regulatory elements and interactions.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique uses Bayesian inference to estimate the parameters of a linear inverse scattering (LIS) model.",
      "The inputs in the BLISS technique for gene regulatory networks are typically the concentrations of transcription factors and other regulatory molecules.",
      "The outputs in the BLISS technique for gene regulatory networks are the expression levels of target genes.",
      "The BLISS technique can handle non-linear relationships between inputs and outputs of gene regulatory networks.",
      "The BLISS technique provides an interpretable model of gene regulatory networks, useful for identifying key regulatory elements and interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without the specific context or detailed information about the BLISS technique, it is not possible to ascertain the accuracy of this statement. BLISS could be an acronym for a specific scientific technique, but without further information, the relationship to Bayesian inference and a linear inverse scattering model cannot be confirmed.\n\n2. UNKNOWN: Although it is common for gene regulatory network models to use concentrations of transcription factors and regulatory molecules as inputs, it is not possible to verify whether this applies to the BLISS technique specifically without additional context.\n\n3. UNKNOWN: Similarly to (2), it is typical for gene regulatory network models to output the expression levels of target genes, but without more information about the BLISS technique, this statement cannot be confirmed or denied.\n\n4. UNKNOWN: This statement suggests that the BLISS technique can handle non-linear relationships. However, the earlier statement referenced a \"linear\" inverse scattering model. This is potentially contradictory, but without further context, it cannot be determined if this statement is true, false, or if there is a nuanced interpretation that reconciles the linearity with the handling of non-linear relationships.\n\n5. UNKNOWN: The claim that the BLISS technique provides an interpretable model of gene regulatory networks and is useful for identifying key regulatory elements and interactions is plausible in the context of computational biology. However, without specific information about the BLISS technique, the veracity of this statement cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! Here are three NK3R antagonists:\n1. GR 113691: This is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including nausea and vomiting associated with chemotherapy, as well as anxiety and depression.\n2. MK-8628: This is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of gastrointestinal disorders, including irritable bowel syndrome (IBS) and functional dyspepsia.\n3. BI 10773: This is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including nausea and vomiting associated with chemotherapy, as well as anxiety and depression.\nPlease let me know if you have any other questions!",
    "llama-2-7b-chat-hf_fact_raw": "1. GR 113691 is a potent and selective NK3R antagonist.\n2. MK-8628 is a potent and selective NK3R antagonist that may be used in the treatment of IBS and functional dyspepsia.\n3. BI 10773 is a potent and selective NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "GR 113691 is a potent and selective NK3R antagonist.",
      "MK-8628 is a potent and selective NK3R antagonist that may be used in the treatment of IBS and functional dyspepsia.",
      "BI 10773 is a potent and selective NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: BI 10773 is not an NK3R antagonist; it is an SGLT2 inhibitor used in the treatment of type 2 diabetes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is rimegepant.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "The protective efficacy of Vaxchora against moderate to severe cholera has been shown to be high in clinical trials. In a phase 3 clinical trial published in The Lancet in 2018, Vaxchora was found to provide 77% protection against moderate to severe cholera in individuals who received a single dose of the vaccine, compared to 23% protection in the placebo group. Additionally, the vaccine was found to provide 90% protection against severe cholera, which is the most severe form of the disease. These results suggest that Vaxchora is effective in preventing moderate to severe cholera and may be a valuable tool in controlling outbreaks of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora has been shown to provide 77% protection against moderate to severe cholera in a phase 3 clinical trial.\n2. The same phase 3 clinical trial indicated that the placebo group had a protection rate of 23% against moderate to severe cholera.\n3. Vaxchora was found to provide 90% protection against severe cholera.\n4. The phase 3 clinical trial results of Vaxchora were published in The Lancet in 2018.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora has been shown to provide 77% protection against moderate to severe cholera in a phase 3 clinical trial.",
      "The same phase 3 clinical trial indicated that the placebo group had a protection rate of 23% against moderate to severe cholera.",
      "Vaxchora was found to provide 90% protection against severe cholera.",
      "The phase 3 clinical trial results of Vaxchora were published in The Lancet in 2018."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nFor these statements, without specific data or a reference to the actual study and its results, it is not possible to determine the accuracy of the outcomes reported in the phase 3 clinical trial for Vaxchora, including the protection rates against cholera or the publication details in The Lancet.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine (OCV) developed by the World Health Organization (WHO). It was approved in 1989 and has been used extensively in developing countries to control and prevent cholera outbreaks. The OCV is a live, attenuated vaccine made from the Vibrio cholerae strain Inaba, which is the most common cause of cholera. It is given orally and provides protection against cholera for several years.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).\n2. The OCV was developed by the World Health Organization (WHO).\n3. This vaccine was approved in the US in 1989.\n4. The OCV has been used in developing countries to control and prevent cholera outbreaks.\n5. The vaccine is made from the Vibrio cholerae strain Inaba and is given orally.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).",
      "The OCV was developed by the World Health Organization (WHO).",
      "This vaccine was approved in the US in 1989.",
      "The OCV has been used in developing countries to control and prevent cholera outbreaks.",
      "The vaccine is made from the Vibrio cholerae strain Inaba and is given orally."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The OCV was not developed by the World Health Organization (WHO). The WHO plays a role in prequalification and recommends the use of oral cholera vaccines for control and prevention, but the development of the vaccines is typically carried out by pharmaceutical companies or research institutions.\n3. FALSE [correction]: The first oral cholera vaccine (OCV) approved for use in the United States was not approved in 1989. Vaxchora, which is a live, attenuated oral cholera vaccine, was approved by the U.S. Food and Drug Administration (FDA) on June 10, 2016.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the CD40 ligand gene (CD40LG). CVID is a primary immunodeficiency disorder characterized by a variable and unpredictable immune response to infections, and it is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals in the general population. Mutations in the CD40LG gene are found in approximately 70% of CVID patients of European descent, making it the most common genetic cause of this disorder in this population.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the CD40 ligand gene (CD40LG).\n2. Common variable immunodeficiency (CVID) is characterized by a variable and unpredictable immune response to infections.\n3. CVID is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals in the general population.\n4. Mutations in the CD40LG gene are found in approximately 70% of CVID patients of European descent.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is mutations in the CD40 ligand gene (CD40LG).",
      "Common variable immunodeficiency (CVID) is characterized by a variable and unpredictable immune response to infections.",
      "CVID is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals in the general population.",
      "Mutations in the CD40LG gene are found in approximately 70% of CVID patients of European descent."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not mutations in the CD40 ligand gene (CD40LG). Mutations in TNFRSF13B, which encodes TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor), are more commonly associated with CVID.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mutations in the CD40LG gene are found in a minority of CVID patients, not 70%. Mutations in this gene actually cause a different primary immunodeficiency known as X-linked hyper-IgM syndrome. The precise percentage of CVID patients with mutations in CD40LG is not well-defined but is significantly lower than 70%.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene plays a crucial role in the development and progression of Systemic Lupus Erythematosus (SLE), a complex and multifactorial autoimmune disease. SLE is characterized by the production of autoantibodies and the occurrence of various clinical manifestations, including joint inflammation, skin rashes, and kidney damage.\nStudies have shown that the IFIT1 gene is a critical regulator of the immune response and plays a key role in the suppression of autoreactive T cell responses in SLE. Mutations in the IFIT1 gene have been identified as a risk factor for the development of SLE, and variations in the IFIT1 gene have been associated with an increased risk of disease progression.\nIFIT1 gene mutations can lead to the overexpression of the IFIT1 protein, which can disrupt the normal functioning of the immune system and contribute to the development of autoimmune diseases such as SLE. Additionally, IFIT1 gene variations have been shown to affect the expression of genes involved in the regulation of inflammation and immune response, further contributing to the development of SLE.\nIn summary, the IFIT1 gene plays a critical role in the regulation of the immune response and the development of SLE, and mutations or variations in this gene can contribute to the development of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is a critical regulator of the immune response involved in the development and progression of Systemic Lupus Erythematosus (SLE).\n2. Mutations in the IFIT1 gene have been identified as a risk factor for the development of SLE.\n3. Variations in the IFIT1 gene are associated with an increased risk of SLE disease progression.\n4. Mutations in the IFIT1 gene can lead to the overexpression of the IFIT1 protein, which may disrupt the normal functioning of the immune system.\n5. IFIT1 gene variations can affect the expression of genes involved in regulating inflammation and immune response, contributing to the development of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is a critical regulator of the immune response involved in the development and progression of Systemic Lupus Erythematosus (SLE).",
      "Mutations in the IFIT1 gene have been identified as a risk factor for the development of SLE.",
      "Variations in the IFIT1 gene are associated with an increased risk of SLE disease progression.",
      "Mutations in the IFIT1 gene can lead to the overexpression of the IFIT1 protein, which may disrupt the normal functioning of the immune system.",
      "IFIT1 gene variations can affect the expression of genes involved in regulating inflammation and immune response, contributing to the development of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene is involved in the regulation of the immune response, and it has been studied in the context of various autoimmune diseases, including Systemic Lupus Erythematosus (SLE).\n2. UNKNOWN: While the IFIT1 gene might be studied in the context of autoimmune diseases like SLE, without specific research evidence provided here, it is unclear whether mutations in the IFIT1 gene have been identified as a risk factor specifically for the development of SLE.\n3. UNKNOWN: There may be associations between variations in the IFIT1 gene and an increased risk of disease progression in SLE. However, the statement's veracity would require reference to specific scientific findings, which are not provided here.\n4. UNKNOWN: While IFIT1 gene mutations could theoretically lead to overexpression of the IFIT1 protein, affecting the immune system's functioning, this statement would need to be supported by specific research to be verified.\n5. UNKNOWN: The statement suggests a possible mechanistic pathway by which IFIT1 gene variations could contribute to the development of SLE due to changes in gene expression related to inflammation and immune regulation. However, without concrete research evidence, this remains speculation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow osteoarthritis (OA). It is a self-reported questionnaire that assesses the patient's symptoms, function, and quality of life related to their elbow OA. The LES is based on a 50-item questionnaire that covers six domains:\n1. Pain\n2. Stiffness\n3. Function\n4. Grip strength\n5. Activities of daily living\n6. Sports and recreational activities\nThe LES scores are calculated based on the patient's responses to each question, and the total score ranges from 0 to 100. A higher score indicates more severe elbow OA. The LES has been found to be reliable and valid in measuring the severity of elbow OA and can be used to monitor the effectiveness of treatment interventions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow osteoarthritis.\n2. The LES is a self-reported questionnaire.\n3. The questionnaire that makes up the LES has 50 items.\n4. The LES questionnaire covers six domains including pain, stiffness, function, grip strength, activities of daily living, and sports and recreational activities.\n5. LES scores range from 0 to 100, with a higher score indicating more severe elbow osteoarthritis.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow osteoarthritis.",
      "The LES is a self-reported questionnaire.",
      "The questionnaire that makes up the LES has 50 items.",
      "The LES questionnaire covers six domains including pain, stiffness, function, grip strength, activities of daily living, and sports and recreational activities.",
      "LES scores range from 0 to 100, with a higher score indicating more severe elbow osteoarthritis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) questionnaire does not have 50 items; it consists of 20 items.\n4. FALSE [correction]: The LES questionnaire covers five domains: pain, function, social-psychological, work, and recreational activities, but not stiffness, grip strength specifically, or activities of daily living as separate domains.\n5. FALSE [correction]: LES scores range from 0 to 100, with a higher score indicating better elbow function, not more severe elbow osteoarthritis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! The 100,000 Genomes Project is a large-scale genomics initiative launched in 2012 to sequence the genomes of 100,000 individuals in the UK, including those with rare and aggressive cancers such as sarcoma. Here are some efforts related to sarcoma from the 100,000 Genomes Project:\n1. Whole-genome sequencing: The project aimed to sequence the entire genome of sarcoma tumors to identify genetic mutations and variations that may contribute to the development and progression of the disease.\n2. Transcriptome analysis: In addition to genome sequencing, the project also analyzed the transcriptome (the set of RNA molecules present in a cell) of sarcoma tumors to identify differences in gene expression between normal and cancerous cells.\n3. Epigenetic analysis: Epigenetic modifications, such as DNA methylation and histone modification, play a crucial role in the development and progression of cancer. The project investigated epigenetic changes in sarcoma tumors to better understand their role in the disease.\n4. Copy number variation analysis: Copy number variations (CNVs) are changes in the number of copies of a particular gene or genetic region. The project identified CNVs in sarcoma tumors to understand their contribution to the development and progression of the disease.\n5. Mutational analysis: The project identified genetic mutations in sarcoma tumors using whole-genome sequencing and exome sequencing. These mutations were analyzed to identify potential driver mutations that may be targeted for therapy.\n6. Functional validation: Once potential driver mutations were identified, the project functionally validated them using in vitro and in vivo experiments to determine their role in the development and progression of sarcoma.\n7. Identification of new therapeutic targets: The project identified new therapeutic targets for sarcoma treatment based on the genetic and epigenetic changes identified in the disease. These targets may be used in future clinical trials to develop new therapies for sarcoma.\n8. Development of personalized medicine approaches: The project aimed to develop personalized medicine approaches for",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project launched in 2012 aims to sequence the genomes of 100,000 individuals in the UK.\n2. The project undertook whole-genome sequencing of sarcoma tumors to identify genetic mutations and variations.\n3. Transcriptome analysis of sarcoma tumors was performed to study differences in gene expression between normal and cancerous cells.\n4. The 100,000 Genomes Project investigated epigenetic changes in sarcoma tumors.\n5. Copy number variations (CNVs) in sarcoma tumors were identified to understand their contribution to cancer development and progression.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project launched in 2012 aims to sequence the genomes of 100,000 individuals in the UK.",
      "The project undertook whole-genome sequencing of sarcoma tumors to identify genetic mutations and variations.",
      "Transcriptome analysis of sarcoma tumors was performed to study differences in gene expression between normal and cancerous cells.",
      "The 100,000 Genomes Project investigated epigenetic changes in sarcoma tumors.",
      "Copy number variations (CNVs) in sarcoma tumors were identified to understand their contribution to cancer development and progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project launched in 2013, not 2012, with the aim of sequencing the genomes of 100,000 individuals in the UK.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Thank you for the opportunity to assist you!\nTo answer your last question, no, protein ALEX1 does not contain armadillo repeats.\nArmadillo repeats are a type of protein structural motif found in some proteins, characterized by a repeating pattern of amino acids resembling the shell of an armadillo. These repeats are often found in proteins involved in protein-protein interactions, and are thought to play a role in the formation of protein complexes and the regulation of signaling pathways.\nALEX1, on the other hand, is a protein that has been implicated in the regulation of gene expression, particularly in the context of cancer. It is a transcriptional repressor that binds to specific DNA sequences and inhibits the activity of transcription factors, leading to decreased gene expression. While ALEX1 has been shown to interact with a number of other proteins and molecules, it does not contain armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.\n2. Armadillo repeats are a protein structural motif characterized by a repeating pattern of amino acids.\n3. Proteins with armadillo repeats are often involved in protein-protein interactions.\n4. ALEX1 is a protein implicated in the regulation of gene expression.\n5. ALEX1 acts as a transcriptional repressor by binding to DNA sequences and inhibiting the activity of transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats.",
      "Armadillo repeats are a protein structural motif characterized by a repeating pattern of amino acids.",
      "Proteins with armadillo repeats are often involved in protein-protein interactions.",
      "ALEX1 is a protein implicated in the regulation of gene expression.",
      "ALEX1 acts as a transcriptional repressor by binding to DNA sequences and inhibiting the activity of transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: ALEX1 does not directly bind to DNA to repress transcription; instead, it is involved in the alternative splicing of mRNA which can impact gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some enzymes that remove histone modifications:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to changes in chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC3.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from histone H3 lysine 4, leading to changes in chromatin structure and gene expression.\n5. Jumonji H3K4 demethylase (JMJD1A): This enzyme removes methyl groups from histone H3 lysine 4, leading to changes in chromatin structure and gene expression.\nThese enzymes play important roles in regulating chromatin structure and gene expression, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases remove methyl groups from histone proteins.\n2. Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.\n3. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n4. Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.\n5. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases remove methyl groups from histone proteins.",
      "Examples of histone demethylases include KDM4B, KDM5A, and KDM5B.",
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the provided statements about histone-modifying enzymes are accurate. Histone demethylases do indeed remove methyl groups from histone proteins, and the examples given (KDM4B, KDM5A, KDM5B) are indeed histone demethylases. Histone deacetylases remove acetyl groups from histones, and the examples listed (HDAC1, HDAC2, HDAC3) are correct. Lastly, LSD1 is known for demethylating histone H3 on lysine 4.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Thank you for the opportunity to help! To answer your last question, head circumference (HC) is not directly associated with an increased risk of brain tumors. While there is some evidence to suggest that certain head and neck characteristics, such as increased HC, may be associated with an increased risk of certain neurological conditions, such as epilepsy or migraines, there is no established link between HC and brain tumors.\nIt's important to note that brain tumors can occur in anyone, regardless of their head circumference or any other physical characteristic. The exact causes of brain tumors are not yet fully understood, but they are believed to involve a complex interplay of genetic and environmental factors.\nIf you have any concerns about your health or the health of a loved one, it's always a good idea to consult with a qualified healthcare professional. They can provide personalized advice and recommendations based on your individual situation and medical history.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is not directly associated with neural pluripotency. Instead, it is a homeobox gene that plays a role in brain and sensory organ development. Pluripotency is typically associated with genes like SOX2, OCT4, and NANOG.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The number of DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region can vary depending on the specific cell type and experimental conditions. However, in general, there are several DHS sites scattered throughout the beta globin locus region.\nAccording to a study published in the journal Genomics, there are at least 14 DHS sites identified in the beta globin locus region of mouse cells (Liu et al., 2009). These sites are located upstream of the beta globin gene cluster, as well as within the gene cluster itself.\nAnother study found that there are approximately 20 DHS sites in the beta globin locus region of mouse cells, including both constitutive and regulated sites (Zhang et al., 2013).\nIt is important to note that the number of DHS sites can vary depending on the specific cell type and experimental conditions, and the exact number of sites may be influenced by factors such as the method used to identify them and the level of resolution of the mapping.\nIn summary, there are multiple DNaseI hypersensitive sites (DHS) scattered throughout the beta globin locus region of the mouse genome, with the exact number varying depending on the specific cell type and experimental conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are several DNaseI hypersensitive sites (DHS) scattered throughout the murine beta globin locus region.\n2. At least 14 DHS sites have been identified in the beta globin locus region of mouse cells, according to a study published in the journal Genomics (Liu et al., 2009).\n3. These 14 DHS sites are located upstream of the beta globin gene cluster as well as within the gene cluster itself.\n4. Approximately 20 DHS sites have been found in the beta globin locus region of mouse cells, as per a study referenced (Zhang et al., 2013).\n5. The number of DHS sites can vary with the specific cell type and experimental conditions.",
    "llama-2-7b-chat-hf_fact": [
      "There are several DNaseI hypersensitive sites (DHS) scattered throughout the murine beta globin locus region.",
      "At least 14 DHS sites have been identified in the beta globin locus region of mouse cells, according to a study published in the journal Genomics (Liu et al., 2009).",
      "These 14 DHS sites are located upstream of the beta globin gene cluster as well as within the gene cluster itself.",
      "Approximately 20 DHS sites have been found in the beta globin locus region of mouse cells, as per a study referenced (Zhang et al., 2013).",
      "The number of DHS sites can vary with the specific cell type and experimental conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - It is well established in the field of genomics that DNaseI hypersensitive sites are typically associated with areas of active chromatin and gene regulation, and they are known to exist in the regions of various gene loci, including the murine (mouse) beta globin locus.\n2. TRUE - Since the statement references a specific study, assuming this is a factual reference, we can accept that at least 14 DHS sites have been identified as per the findings of Liu et al., published in 2009.\n3. TRUE - DHS sites are often found both upstream and within gene clusters as they are associated with regulatory regions of genes, so this statement is consistent with our understanding of gene regulation.\n4. FALSE [correction]: The statement directly contradicts the previous one regarding the number of DHS sites. As it also cites a study, which may or may not exist, this creates uncertainty. Assuming Liu et al. (2009) is accurate, the correct number would be 14 DHS sites, not 20. However, without knowing the contents of Zhang et al. (2013), it is difficult to make a definitive correction.\n5. TRUE - It is a well-documented phenomenon in genomics that the presence and number of regulatory elements, such as DHS sites, can indeed vary depending on the cell type and the conditions under which the experiment is conducted.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Of course! Here are some European influenza vaccines:\n1. Fluad (quadrivalent): produced by GSK, this vaccine is designed for adults 65 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n2. Fluarix Tetra (quadrivalent): produced by GSK, this vaccine is designed for adults and children aged 4 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n3. Flulaval Quadrivalent (quadrivalent): produced by Sanofi, this vaccine is designed for adults and children aged 4 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n4. Fluvirin Quadrivalent (quadrivalent): produced by Novartis, this vaccine is designed for adults and children aged 4 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n5. Afluria Quadrivalent (quadrivalent): produced by CSL, this vaccine is designed for adults and children aged 4 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n6. Vaxigrip Tetra (quadrivalent): produced by Sanofi, this vaccine is designed for adults and children aged 6 months and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n7. Fluad Quadrivalent (quadrivalent): produced by GSK, this vaccine is designed for adults 65 years and older and contains four strains: two influenza A strains (H1N1 and H3N2) and two influenza B strains.\n8. Flulaval Quadrivalent (quadrivalent): produced by Sanofi, this vaccine is designed for",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad (quadrivalent) is a vaccine produced by GSK for adults 65 years and older.\n2. Fluarix Tetra (quadrivalent) is a vaccine produced by GSK for adults and children aged 4 years and older.\n3. Flulaval Quadrivalent (quadrivalent) is a vaccine produced by Sanofi for adults and children aged 4 years and older.\n4. Fluvirin Quadrivalent (quadrivalent) is a vaccine produced by Novartis for adults and children aged 4 years and older.\n5. Vaxigrip Tetra (quadrivalent) is a vaccine produced by Sanofi for adults and children aged 6 months and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad (quadrivalent) is a vaccine produced by GSK for adults 65 years and older.",
      "Fluarix Tetra (quadrivalent) is a vaccine produced by GSK for adults and children aged 4 years and older.",
      "Flulaval Quadrivalent (quadrivalent) is a vaccine produced by Sanofi for adults and children aged 4 years and older.",
      "Fluvirin Quadrivalent (quadrivalent) is a vaccine produced by Novartis for adults and children aged 4 years and older.",
      "Vaxigrip Tetra (quadrivalent) is a vaccine produced by Sanofi for adults and children aged 6 months and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluad (quadrivalent) is a vaccine produced by Seqirus, not GSK, for adults 65 years and older.\n2. TRUE\n3. FALSE [correction]: Flulaval Quadrivalent (quadrivalent) is a vaccine produced by GSK for adults and children aged 6 months and older.\n4. FALSE [correction]: Fluvirin was previously produced by Novartis, but as of my knowledge cutoff in 2023, the influenza vaccines previously under Novartis have been acquired by other companies such as Seqirus. It's important to verify the current manufacturer as such affiliations can change.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the measles virus, mumps virus, and Nipah virus, among others. These viruses have a genome composed of several segmented, negative-sense RNA segments, each of which encodes a different protein. The segments are named according to their position in the genome, such as segment 1, segment 2, etc. The negative-sense RNA means that the RNA molecule has a complementary DNA (cDNA) strand, rather than the usual RNA strand. This is in contrast to positive-sense RNA viruses, which have a single, continuous RNA molecule that encodes all the genes needed for virus replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is composed of negative-sense RNA.\n2. Paramyxoviruses include the measles virus, mumps virus, and Nipah virus among others.\n3. The genome of Paramyxoviruses is segmented with each segment encoding a different protein.\n4. The segments of the Paramyxovirus genome are named according to their position, such as segment 1, segment 2, etc.\n5. Negative-sense RNA implies that the RNA molecule is complementary to a DNA strand (cDNA). \n\nNote: The answer provided claims that the Paramyxovirus genome is segmented. However, this statement is incorrect; Paramyxovirus genomes are not segmented but are single continuous molecules of negative-sense RNA. Please consult current and reliable scientific sources for accurate information on Paramyxovirus genomes.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is composed of negative-sense RNA.",
      "Paramyxoviruses include the measles virus, mumps virus, and Nipah virus among others.",
      "The genome of Paramyxoviruses is segmented with each segment encoding a different protein.",
      "The segments of the Paramyxovirus genome are named according to their position, such as segment 1, segment 2, etc.",
      "Negative-sense RNA implies that the RNA molecule is complementary to a DNA strand (cDNA).",
      "te: The answer provided claims that the Paramyxovirus genome is segmented. However, this statement is incorrect; Paramyxovirus genomes are not segmented but are single continuous molecules of negative-sense RNA. Please consult current and reliable scientific sources for accurate information on Paramyxovirus genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The genome of Paramyxoviruses is not segmented; it consists of a single continuous molecule of negative-sense RNA.\n4. FALSE [correction]: Since the Paramyxovirus genome is not segmented, it does not have segments named according to their position. Instead, there are different genes along the single molecule of RNA.\n5. TRUE\n6. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for treating topical psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat topical psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat topical psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is known as an oral medication used to treat the symptoms of chronic obstructive pulmonary disease (COPD). Topical formulations may exist for other conditions, but traditionally, roflumilast is not recognized as a treatment for psoriasis. However, without current data up to my knowledge cutoff date in 2023, I cannot confirm the status of roflumilast cream and its uses as of now.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "For identifying and visualizing ncRNA promoters, several tools have been developed. Some of the commonly used tools are:\n1. CpG Island Finder: This tool can identify regions of the genome with high CG dinucleotide content, which are often associated with ncRNA promoters.\n2. RNAhybrid: This tool can predict the secondary and tertiary structure of RNA molecules, including ncRNAs, based on their sequence.\n3. RNAProtomer: This tool can predict the secondary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n4. PICTAR: This tool can predict the secondary and tertiary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n5. RNAfold: This tool can predict the secondary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n6. Infernal: This tool can predict the secondary and tertiary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n7. RNAzif: This tool can predict the secondary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n8. RNAPro: This tool can predict the secondary and tertiary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n9. RNAProspector: This tool can predict the secondary and tertiary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\n10. RNA-Pro: This tool can predict the secondary and tertiary structure of RNA molecules and identify potential promoter regions based on their secondary structure.\nThese tools can be used to identify potential ncRNA promoters in a genome or transcriptome and visualize their location and structure. They can also be used to predict the expression level of ncRNAs and their potential functional roles in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies regions with high CG dinucleotide content, often associated with ncRNA promoters.\n2. RNAhybrid is a tool designed to predict the secondary and tertiary structure of RNA molecules, including ncRNAs, from their sequence.\n3. PICTAR is a tool used to predict both the secondary and tertiary structure of RNA molecules and to identify potential promoter regions based on structure.\n4. RNAfold is a tool that predicts the secondary structure of RNA molecules and identifies potential promoter regions.\n5. Infernal is a tool for predicting secondary and tertiary structures of RNA molecules and identifying potential promoter regions.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies regions with high CG dinucleotide content, often associated with ncRNA promoters.",
      "RNAhybrid is a tool designed to predict the secondary and tertiary structure of RNA molecules, including ncRNAs, from their sequence.",
      "PICTAR is a tool used to predict both the secondary and tertiary structure of RNA molecules and to identify potential promoter regions based on structure.",
      "RNAfold is a tool that predicts the secondary structure of RNA molecules and identifies potential promoter regions.",
      "Infernal is a tool for predicting secondary and tertiary structures of RNA molecules and identifying potential promoter regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CpG Island Finder is a tool that identifies regions with high CG dinucleotide content, which are often associated with gene promoters, not specifically non-coding RNA (ncRNA) promoters.\n2. FALSE [correction]: RNAhybrid is a tool designed to find the minimum free energy hybridization of a long and a short RNA, not to predict the secondary and tertiary structures of RNA molecules. It is often used to predict microRNA targets.\n3. FALSE [correction]: PICTAR is a tool used to predict microRNA targets, not to predict the secondary and tertiary structure of RNA molecules or to identify potential promoter regions.\n4. TRUE [correction]: While RNAfold does predict the secondary structure of RNA molecules, it does not directly identify potential promoter regions. This statement appears to be true with the caveat that the tool's primary function is to predict RNA secondary structure.\n5. FALSE [correction]: Infernal is a tool that searches DNA sequence databases for RNA structure and sequence similarities and is particularly good at identifying homologs of small, structured RNAs like ribosomal RNAs, not specifically predicting secondary and tertiary structures or identifying potential promoter regions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Certainly! SWIM (SWI/SNF Chromatin Modification) tool is a computational pipeline that can identify potential chromatin modifications and their associated genes in a given dataset. Here are some example genes that SWIM tool has identified as down-regulated in glioblastoma, based on a study published in the journal Nature Communications:\n1. TP53: TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM tool has identified TP53 as a down-regulated gene in glioblastoma.\n2. CDKN2A: CDKN2A is a tumor suppressor gene that encodes a protein that inhibits the activity of cyclin-dependent kinases. SWIM tool has identified CDKN2A as a down-regulated gene in glioblastoma.\n3. BRCA1: BRCA1 is a tumor suppressor gene that plays a role in DNA repair. SWIM tool has identified BRCA1 as a down-regulated gene in glioblastoma.\n4. PTEN: PTEN is a tumor suppressor gene that inhibits the activity of the PI3K/Akt signaling pathway. SWIM tool has identified PTEN as a down-regulated gene in glioblastoma.\n5. ATR: ATR is a protein that plays a role in the DNA damage response. SWIM tool has identified ATR as a down-regulated gene in glioblastoma.\n6. CHEK1: CHEK1 is a protein that plays a role in the DNA damage response. SWIM tool has identified CHEK1 as a down-regulated gene in glioblastoma.\n7. MLH1: MLH1 is a protein that plays a role in DNA mismatch repair. SWIM tool has identified MLH1 as a down-regulated gene in glioblastoma.\n8. MSH2: MSH2 is a protein that plays a role in DNA mismatch repair. SWIM tool has identified MSH2 as a down-regulated gene in glioblastoma.\n9. MSH6: MSH6 is a protein that plays a role in DNA mismatch repair. SWIM tool has identified MSH6 as a down-regulated gene in glioblastoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. SWIM tool has identified the TP53 gene as down-regulated in glioblastoma.\n2. SWIM tool has identified the CDKN2A gene as down-regulated in glioblastoma.\n3. SWIM tool has identified the BRCA1 gene as down-regulated in glioblastoma.\n4. SWIM tool has identified the PTEN gene as down-regulated in glioblastoma.\n5. SWIM tool has identified the ATR gene as down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "SWIM tool has identified the TP53 gene as down-regulated in glioblastoma.",
      "SWIM tool has identified the CDKN2A gene as down-regulated in glioblastoma.",
      "SWIM tool has identified the BRCA1 gene as down-regulated in glioblastoma.",
      "SWIM tool has identified the PTEN gene as down-regulated in glioblastoma.",
      "SWIM tool has identified the ATR gene as down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific reference to the data and results generated by the SWIM tool (Survival Weighted by Interactive Models), it is impossible to verify the accuracy of these statements regarding gene regulation in glioblastoma. The statements would require validation through research literature or direct access to the SWIM tool's output data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Topologically Associating Domains (TADs), which are three-dimensional nuclear substructures that are involved in the regulation of gene expression. Here are some of the commonly used R packages for TAD analysis:\n1. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the detection of TAD boundaries, the identification of TAD-associated genes, and the analysis of TAD-mediated gene regulation.\n2. TADeep: This package uses a deep learning approach to predict TAD boundaries and identify TAD-associated genes. It also provides tools for the analysis of TAD-mediated gene regulation.\n3. ChromHMM: This package uses a hidden Markov model (HMM) to model the three-dimensional structure of chromatin and predict TAD boundaries. It also provides tools for the analysis of TAD-mediated gene regulation.\n4. Chromatin3D: This package provides a comprehensive set of tools for the analysis of three-dimensional chromatin structure, including the detection of TADs, the analysis of chromatin loops, and the prediction of gene expression.\n5. H3K27ac ChIP-seq Peak Finder: This package uses a machine learning approach to identify regions of active gene expression, including TADs, based on histone H3 lysine 27 acetylation (H3K27ac) ChIP-seq data.\n6. TAD-seq: This package provides a comprehensive set of tools for the analysis of TADs, including the detection of TAD boundaries, the identification of TAD-associated genes, and the analysis of TAD-mediated gene regulation.\n7. Chromatin Interaction Network (CIN): This package provides a comprehensive set of tools for the analysis of chromatin interactions, including the detection of TADs, the analysis of chromatin loops, and the prediction of gene expression.\n8. Topologically Associating Domain (TAD) Analyzer: This package provides a comprehensive set of tools for the analysis of TADs, including the detection of TAD boundaries, the identification of TAD-associated genes, and the analysis of TAD-mediated gene regulation.\n9. Ch",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package designed for the analysis of Topologically Associating Domains (TADs) that includes tools for detecting TAD boundaries and identifying associated genes.\n2. TADeep is an R package that uses a deep learning approach to predict TAD boundaries and to identify TAD-associated genes.\n3. ChromHMM is an R package that employs a hidden Markov model to model chromatin's three-dimensional structure and to predict TAD boundaries.\n4. Chromatin3D is an R package that offers tools for analyzing three-dimensional chromatin structure, including the detection of TADs and the prediction of gene expression.\n5. H3K27ac ChIP-seq Peak Finder is an R package that uses machine learning to identify active gene expression regions, such as TADs, based on H3K27ac ChIP-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package designed for the analysis of Topologically Associating Domains (TADs) that includes tools for detecting TAD boundaries and identifying associated genes.",
      "TADeep is an R package that uses a deep learning approach to predict TAD boundaries and to identify TAD-associated genes.",
      "ChromHMM is an R package that employs a hidden Markov model to model chromatin's three-dimensional structure and to predict TAD boundaries.",
      "Chromatin3D is an R package that offers tools for analyzing three-dimensional chromatin structure, including the detection of TADs and the prediction of gene expression.",
      "H3K27ac ChIP-seq Peak Finder is an R package that uses machine learning to identify active gene expression regions, such as TADs, based on H3K27ac ChIP-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TADeep is not specifically an R package; the name might be fictional or confused with a different tool. To the best of my knowledge, no widely-recognized R package named TADeep exists for predicting TAD boundaries and associated genes.\n3. FALSE [correction]: ChromHMM is a tool to analyze chromatin states based on histone modification data and utilizes a hidden Markov model. While it is used to understand chromatin structure, it is not specifically described as an R package nor primarily used for modeling chromatin's three-dimensional structure or predicting TAD boundaries.\n4. UNKNOWN: While Chromatin3D seems to imply a focus on three-dimensional chromatin structure potentially including TADs, without more specific information it's unclear whether this is an actual R package or accurately represents such capabilities.\n5. FALSE [correction]: H3K27ac ChIP-seq Peak Finder does not seem to be a recognized R package. Furthermore, H3K27ac ChIP-seq is a technique to identify regions of active gene expression (often enhancers), but it does not directly relate to the identification of TADs. Identification of TADs usually involves Hi-C data rather than ChIP-seq data, and the effective tools for TADs analysis are not narrowly focused on H3K27ac or described as peak finders.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is called \"RulesMiner\". RulesMiner is a tool for analyzing and interpreting gene regulation in bacteria, particularly in the model organism Escherichia coli (E. coli). It allows users to mine regulatory rules from large-scale gene expression data and to predict the behavior of genes in response to different environmental conditions or genetic perturbations. RulesMiner can be used to identify key regulators, predict gene expression patterns, and understand the underlying regulatory mechanisms that control gene expression in bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"RulesMiner\" is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. \"RulesMiner\" is designed for analyzing and interpreting gene regulation in bacteria.\n3. Escherichia coli (E. coli) is a model organism for which \"RulesMiner\" can be used.\n4. \"RulesMiner\" allows users to mine regulatory rules from large-scale gene expression data.\n5. The tool can predict the behavior of genes in response to different environmental conditions or genetic perturbations.",
    "llama-2-7b-chat-hf_fact": [
      "\"RulesMiner\" is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "\"RulesMiner\" is designed for analyzing and interpreting gene regulation in bacteria.",
      "Escherichia coli (E. coli) is a model organism for which \"RulesMiner\" can be used.",
      "\"RulesMiner\" allows users to mine regulatory rules from large-scale gene expression data.",
      "The tool can predict the behavior of genes in response to different environmental conditions or genetic perturbations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The shikimate pathway is a metabolic pathway that produces aromatic amino acids and other compounds in cells. The end products of the shikimate pathway are:\n1. Aromatic amino acids: The shikimate pathway produces several aromatic amino acids, including phenylalanine, tyrosine, and tryptophan.\n2. Quinates: The shikimate pathway produces quinates, which are used in the synthesis of other compounds, such as coenzyme Q.\n3. Ergothioneine: The shikimate pathway produces ergothioneine, a sulfur-containing amino acid that has antioxidant properties.\n4. Kynurenine: The shikimate pathway produces kynurenine, an amino acid that is involved in the metabolism of tryptophan and the production of neurotransmitters.\n5. NADH and FADH2: The shikimate pathway produces NADH and FADH2, which are important electron carriers in cellular metabolism.\n6. Other compounds: The shikimate pathway also produces other compounds, such as 3-hydroxybenzoate and 4-hydroxybenzoate, which have been implicated in the regulation of gene expression and the detoxification of xenobiotics.\nOverall, the shikimate pathway is a critical metabolic pathway that produces a variety of important compounds in cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.\n2. The shikimate pathway is involved in the production of quinates, which contribute to the synthesis of coenzyme Q.\n3. Ergothioneine, a sulfur-containing amino acid with antioxidant properties, is a product of the shikimate pathway.\n4. The shikimate pathway produces kynurenine, an amino acid related to tryptophan metabolism and neurotransmitter production.\n5. NADH and FADH2, important electron carriers in cellular metabolism, are produced by the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.",
      "The shikimate pathway is involved in the production of quinates, which contribute to the synthesis of coenzyme Q.",
      "Ergothioneine, a sulfur-containing amino acid with antioxidant properties, is a product of the shikimate pathway.",
      "The shikimate pathway produces kynurenine, an amino acid related to tryptophan metabolism and neurotransmitter production.",
      "NADH and FADH2, important electron carriers in cellular metabolism, are produced by the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The shikimate pathway is associated with the production of chorismate, which can be a precursor for the synthesis of coenzyme Q, but quinates per se are not directly associated with the shikimate pathway.\n3. TRUE\n4. FALSE [correction]: The shikimate pathway is involved in the initial steps of tryptophan biosynthesis, but kynurenine is a metabolite produced from tryptophan by tryptophan 2,3-dioxygenase, not directly by the shikimate pathway itself.\n5. FALSE [correction]: NADH and FADH2 are produced by other metabolic pathways such as glycolysis and the citric acid cycle (Krebs cycle), not by the shikimate pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome, which is a rare condition that occurs after surgical removal of a pituitary adenoma (a tumor of the pituitary gland). Cabergoline is a dopamine receptor agonist that can help to reduce the symptoms of Nelson's syndrome, such as excessive growth of the remaining pituitary tissue, by suppressing the production of growth hormone and prolactin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after surgical removal of a pituitary adenoma.\n3. A pituitary adenoma is a tumor of the pituitary gland.\n4. Cabergoline is a dopamine receptor agonist.\n5. Cabergoline helps reduce symptoms of Nelson's syndrome by suppressing the production of growth hormone and prolactin.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after surgical removal of a pituitary adenoma.",
      "A pituitary adenoma is a tumor of the pituitary gland.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline helps reduce symptoms of Nelson's syndrome by suppressing the production of growth hormone and prolactin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used primarily for the treatment of prolactinomas, a type of pituitary adenoma that produces excess prolactin, not for Nelson's syndrome.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Cabergoline helps reduce symptoms of prolactinomas by suppressing the production of prolactin. It does not suppress growth hormone production, which is more relevant to conditions like acromegaly. Nelson's syndrome involves the overproduction of ACTH (adrenocorticotropic hormone) after removal of the adrenal glands, not growth hormone or prolactin.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the development of the nervous system, particularly the brain and spinal cord. The main manifestation of Liebenberg syndrome is intellectual disability, which is characterized by below-average intelligence, learning difficulties, and cognitive impairments.\nOther symptoms of Liebenberg syndrome may include:\n* Delayed motor development and coordination problems\n* Distinctive facial features, such as a small head, narrow eyes, and a thin upper lip\n* Vision and hearing impairments\n* Seizures and other neurological problems\n* Short stature and delayed pubertal development\n* Increased risk of infections and autoimmune disorders\nIt is important to note that the severity of Liebenberg syndrome can vary widely among individuals, and some people may have a more mild or severe form of the disorder. A diagnosis of Liebenberg syndrome is typically made through a combination of clinical evaluation, genetic testing, and imaging studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that affects the development of the nervous system.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Symptoms of Liebenberg syndrome can include delayed motor development and coordination problems.\n4. Individuals with Liebenberg syndrome may have distinctive facial features such as a small head, narrow eyes, and a thin upper lip.\n5. A diagnosis of Liebenberg syndrome can be made through clinical evaluation, genetic testing, and imaging studies.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that affects the development of the nervous system.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Symptoms of Liebenberg syndrome can include delayed motor development and coordination problems.",
      "Individuals with Liebenberg syndrome may have distinctive facial features such as a small head, narrow eyes, and a thin upper lip.",
      "A diagnosis of Liebenberg syndrome can be made through clinical evaluation, genetic testing, and imaging studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific and verifiable information provided about Liebenberg syndrome, it is not possible to confirm the accuracy of these statements. Liebenberg syndrome is not a widely recognized or well-known genetic disorder in medical literature, and it may be that the condition has been provided a fictional name or is known by another name in professional healthcare resources. Without additional context or a reliable source, the veracity of these statements regarding symptoms, diagnosis, and the disorder itself cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some orally bioavailable MPS1 kinase inhibitors:\n1. GSK-860693: A potent and selective MPS1 inhibitor that has shown promise in preclinical models of cancer and neurodegenerative diseases.\n2. BAY-80-6946: A small molecule inhibitor of MPS1 that has been shown to have antitumor activity in various cancer models.\n3. R7700007: A highly selective MPS1 inhibitor that has been shown to have antitumor activity in preclinical models of breast cancer.\n4. S63845: A potent and selective MPS1 inhibitor that has been shown to have antitumor activity in preclinical models of colon cancer.\n5. MLN0127: A small molecule inhibitor of MPS1 that has been shown to have antitumor activity in preclinical models of breast cancer.\nNote: These are just a few examples of orally bioavailable MPS1 kinase inhibitors, and there may be other compounds in various stages of development.",
    "llama-2-7b-chat-hf_fact_raw": "1. GSK-860693 is an orally bioavailable MPS1 kinase inhibitor.\n2. BAY-80-6946 is a small molecule inhibitor of MPS1 with antitumor activity in various cancer models.\n3. R7700007 is an MPS1 inhibitor that has been shown to have antitumor activity in preclinical models of breast cancer.\n4. S63845 is an MPS1 inhibitor with antitumor activity in preclinical models of colon cancer.\n5. MLN0127 is a small molecule inhibitor of MPS1 with antitumor activity in preclinical models of breast cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GSK-860693 is an orally bioavailable MPS1 kinase inhibitor.",
      "BAY-80-6946 is a small molecule inhibitor of MPS1 with antitumor activity in various cancer models.",
      "R7700007 is an MPS1 inhibitor that has been shown to have antitumor activity in preclinical models of breast cancer.",
      "S63845 is an MPS1 inhibitor with antitumor activity in preclinical models of colon cancer.",
      "MLN0127 is a small molecule inhibitor of MPS1 with antitumor activity in preclinical models of breast cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: BAY-80-6946 is a small molecule inhibitor of PI3K (phosphoinositide 3-kinase), not MPS1.\n3. UNKNOWN\n4. FALSE [correction]: S63845 is not an MPS1 inhibitor, it is a selective MCL1 inhibitor.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Yes, golimumab has been tested for diabetes. Golimumab is a tumor necrosis factor (TNF) inhibitor, which is a class of drugs used to treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.\nSeveral clinical trials have investigated the efficacy and safety of golimumab in patients with type 1 diabetes, type 2 diabetes, and other related conditions. For example, a phase IIb trial published in the Journal of Clinical Endocrinology and Metabolism in 2013 found that golimumab significantly improved glycemic control and reduced the frequency of severe hypoglycemic episodes in patients with type 1 diabetes.\nAnother study published in the journal Diabetes, Obesity and Metabolism in 2018 found that golimumab improved glycemic control and reduced body weight in patients with type 2 diabetes.\nWhile these findings are promising, it is important to note that golimumab is not currently approved by the US Food and Drug Administration (FDA) for the treatment of diabetes. Further research is needed to fully understand the potential benefits and risks of golimumab in this indication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a tumor necrosis factor (TNF) inhibitor used to treat various autoimmune diseases.\n2. Clinical trials have been conducted to investigate golimumab's efficacy and safety in patients with type 1 diabetes and type 2 diabetes.\n3. A phase IIb trial published in the Journal of Clinical Endocrinology and Metabolism in 2013 reported that golimumab significantly improved glycemic control in patients with type 1 diabetes.\n4. The same phase IIb trial mentioned above found that golimumab reduced the frequency of severe hypoglycemic episodes in type 1 diabetes patients.\n5. A study published in the journal Diabetes, Obesity and Metabolism in 2018 reported that golimumab improved glycemic control and reduced body weight in patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a tumor necrosis factor (TNF) inhibitor used to treat various autoimmune diseases.",
      "Clinical trials have been conducted to investigate golimumab's efficacy and safety in patients with type 1 diabetes and type 2 diabetes.",
      "A phase IIb trial published in the Journal of Clinical Endocrinology and Metabolism in 2013 reported that golimumab significantly improved glycemic control in patients with type 1 diabetes.",
      "The same phase IIb trial mentioned above found that golimumab reduced the frequency of severe hypoglycemic episodes in type 1 diabetes patients.",
      "A study published in the journal Diabetes, Obesity and Metabolism in 2018 reported that golimumab improved glycemic control and reduced body weight in patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true; golimumab is indeed a TNF inhibitor used in the treatment of autoimmune diseases. However, without specific information on the clinical trials, it's not possible to confirm the veracity of statements regarding the studies' findings (statements 2 to 5) without access to the actual articles or data from those trials. Therefore, the truthfulness of statements 2 through 5 would require further research into the mentioned publications and trials.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria is caused by an autosomal recessive gene. Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare genetic disorder that causes accelerated aging in children. It is caused by mutations in the LMNA gene, which encodes the protein lamin A/C. The LMNA gene is located on chromosome 1 and is inherited in an autosomal recessive pattern, meaning that a child must inherit two copies of the mutated gene, one from each parent, to develop the condition. The mutations lead to the production of a truncated form of lamin A/C, which accumulates in the nucleus of cells and disrupts the normal functioning of the cell's machinery, leading to the rapid aging and degeneration of tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare genetic disorder that causes accelerated aging in children.\n2. Progeria is caused by mutations in the LMNA gene.\n3. The LMNA gene encodes the protein lamin A/C.\n4. The LMNA gene is located on chromosome 1.\n5. To develop progeria, a child must inherit two copies of the mutated gene, one from each parent, in an autosomal recessive pattern.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome, is a rare genetic disorder that causes accelerated aging in children.",
      "Progeria is caused by mutations in the LMNA gene.",
      "The LMNA gene encodes the protein lamin A/C.",
      "The LMNA gene is located on chromosome 1.",
      "To develop progeria, a child must inherit two copies of the mutated gene, one from each parent, in an autosomal recessive pattern."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Progeria is not inherited in an autosomal recessive pattern. It is usually caused by a new (de novo) mutation and is typically not inherited from a child's parents. Most cases of progeria are sporadic, meaning they occur randomly and are not passed down through families.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The 12q14 and 12q24 regions of the human genome have been associated with several complex diseases and traits, including:\n12q14:\n* Bipolar disorder: Variants in the BDNF (brain-derived neurotrophic factor) gene at 12q14 have been implicated in the risk of developing bipolar disorder.\n* Schizophrenia: Some studies have found an increased risk of schizophrenia in individuals with variants in the genes at 12q14, including the BDNF gene.\n* Autism spectrum disorder: Some studies have found an increased risk of autism spectrum disorder in individuals with variants in the genes at 12q14, including the BDNF gene.\n12q24:\n* Prostate cancer: Variants in the CHRNA7 (cholinergic receptor nicotinic alpha 7) gene at 12q24 have been associated with an increased risk of prostate cancer.\n* Breast cancer: Some studies have found an increased risk of breast cancer in individuals with variants in the genes at 12q24, including the CHRNA7 gene.\n* Type 2 diabetes: Variants in the KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11) gene at 12q24 have been associated with an increased risk of type 2 diabetes.\nIt's important to note that the exact mechanisms by which these genetic variants contribute to disease risk are not yet fully understood and are the subject of ongoing research.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants in the BDNF gene at 12q14 have been implicated in the risk of developing bipolar disorder.\n2. An increased risk of schizophrenia has been associated with genetic variants in 12q14.\n3. An increased risk of autism spectrum disorder has been associated with genetic variants in 12q14.\n4. Variants in the CHRNA7 gene at 12q24 have been associated with an increased risk of prostate cancer.\n5. Variants in the KCNJ11 gene at 12q24 have been associated with an increased risk of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Variants in the BDNF gene at 12q14 have been implicated in the risk of developing bipolar disorder.",
      "An increased risk of schizophrenia has been associated with genetic variants in 12q14.",
      "An increased risk of autism spectrum disorder has been associated with genetic variants in 12q14.",
      "Variants in the CHRNA7 gene at 12q24 have been associated with an increased risk of prostate cancer.",
      "Variants in the KCNJ11 gene at 12q24 have been associated with an increased risk of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Variants in the BDNF gene (Brain-Derived Neurotrophic Factor), located on chromosome 12q14, have been implicated in the risk of developing several neuropsychiatric disorders, including bipolar disorder.\n\n2. TRUE: There is evidence that genetic variations in the region of chromosome 12q14 have been associated with an increased risk of schizophrenia, among other psychiatric conditions.\n\n3. UNKNOWN: While there have been associations between various genetic factors and autism spectrum disorder (ASD), the specificity of variants in 12q14 in increasing the risk of ASD cannot be confirmed without additional context about the research or findings supporting this statement.\n\n4. FALSE [correction]: The CHRNA7 gene is indeed located on chromosome 15, not 12q24, and it has been associated with neurological and psychiatric disorders, not specifically with an increased risk of prostate cancer. I don't have information about a direct link between CHRNA7 gene variants at 12q24 and prostate cancer risk.\n\n5. TRUE: Variants in the KCNJ11 gene, located at 12q24, have been linked to an increased risk of developing type 2 diabetes, as the gene plays a role in the regulation of insulin secretion.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cellular behavior, including cell migration, differentiation, and survival. The ligands that bind to Robo receptors are:\n1. Slit: Slit is a secreted protein that functions as a ligand for Robo1 and Robo2 receptors. Slit proteins are expressed in the extracellular space and bind to Robo receptors on the cell surface, initiating intracellular signaling pathways that regulate cell behavior.\n2. Robo-negative (Robo-N): Robo-N is a secreted protein that functions as a decoy ligand for Robo1 receptors. Robo-N binds to Robo1 receptors, preventing them from binding to their normal ligands, Slit, and inhibiting the downstream signaling pathways.\n3. Ephrin: Ephrin is a secreted protein that functions as a ligand for Robo2 receptors. Ephrin proteins are expressed in the extracellular space and bind to Robo2 receptors on the cell surface, initiating intracellular signaling pathways that regulate cell behavior.\nThese ligands play important roles in regulating various cellular processes, including cell migration, differentiation, and survival, and their dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Slit proteins function as ligands for Robo1 and Robo2 receptors.\n2. Slit is a secreted protein expressed in the extracellular space and binds to Robo receptors on the cell surface.\n3. Robo-N is a secreted protein that acts as a decoy ligand for Robo1 receptors.\n4. Ephrin functions as a ligand for Robo2 receptors.\n5. Dysregulation of the ligands of Robo receptors has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Slit proteins function as ligands for Robo1 and Robo2 receptors.",
      "Slit is a secreted protein expressed in the extracellular space and binds to Robo receptors on the cell surface.",
      "Robo-N is a secreted protein that acts as a decoy ligand for Robo1 receptors.",
      "Ephrin functions as a ligand for Robo2 receptors.",
      "Dysregulation of the ligands of Robo receptors has been implicated in various diseases, including cancer and neurological disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Robo-N is not a secreted protein; the statement seems to confuse Robo-N with another molecule or concept. Robo-N typically refers to a part of the Robo protein (the N-terminal), not a separate secreted protein.\n4. FALSE [correction]: Ephrin functions as a ligand for Eph receptors, not Robo receptors.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I (Transcription Factor IIA, Subunit I) is a transcriptional activator that plays a crucial role in the regulation of gene expression during various cellular processes, including cell growth, differentiation, and survival. While TFII-I has been implicated in various biological processes, there is limited evidence to suggest a direct role for this transcription factor in megakaryopoiesis, the process by which megakaryocytes (blood cells that give rise to platelets) develop from hematopoietic stem cells.\nMegakaryopoiesis is a complex process that involves the coordinated regulation of multiple transcription factors, including GATA1, GATA2, and IRF3. These transcription factors regulate the expression of genes involved in platelet-specific functions, such as thrombocytopenia, platelet shape, and signaling. While TFII-I has been shown to interact with some of these transcription factors, there is no direct evidence to suggest that it plays a direct role in megakaryopoiesis.\nHowever, TFII-I has been implicated in the regulation of genes involved in platelet function and survival, such as the platelet-specific gene, PF4. TFII-I has also been shown to regulate the expression of genes involved in the response to oxidative stress, which can affect platelet function and survival.\nIn summary, while TFII-I does not appear to play a direct role in megakaryopoiesis, it may play a role in the regulation of genes involved in platelet function and survival, and may contribute to the response to oxidative stress in platelets.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (Transcription Factor IIA, Subunit I) is a transcriptional activator involved in cell growth, differentiation, and survival.\n2. There is limited evidence to suggest a direct role for TFII-I in the process of megakaryopoiesis.\n3. Megakaryopoiesis involves the development of megakaryocytes (blood cells that give rise to platelets) from hematopoietic stem cells.\n4. Transcription factors GATA1, GATA2, and IRF3 are involved in the regulation of genes during megakaryopoiesis.\n5. TFII-I has been implicated in the regulation of the platelet-specific gene PF4 and genes involved in oxidative stress response.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (Transcription Factor IIA, Subunit I) is a transcriptional activator involved in cell growth, differentiation, and survival.",
      "There is limited evidence to suggest a direct role for TFII-I in the process of megakaryopoiesis.",
      "Megakaryopoiesis involves the development of megakaryocytes (blood cells that give rise to platelets) from hematopoietic stem cells.",
      "Transcription factors GATA1, GATA2, and IRF3 are involved in the regulation of genes during megakaryopoiesis.",
      "TFII-I has been implicated in the regulation of the platelet-specific gene PF4 and genes involved in oxidative stress response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is evidence to suggest a role for TFII-I in the process of megakaryopoiesis.\n3. TRUE\n4. UNKNOWN (while GATA1 and GATA2 are known regulators of megakaryopoiesis, the role of IRF3 in this process is not well-established or widely recognized without specific evidence)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by CYP2D6.\nAtenolol, a beta-adrenergic receptor antagonist, is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is responsible for the metabolism of approximately 20-30% of clinically used drugs, including atenolol, and plays a crucial role in the clearance of this drug from the body. The CYP2D6 enzyme is highly polymorphic, with multiple alleles that can result in varying levels of enzyme activity. This can lead to inter-individual differences in drug metabolism and response, which can have important implications for drug therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the enzyme CYP2D6.\n2. CYP2D6 metabolizes approximately 20-30% of clinically used drugs.\n3. CYP2D6 is involved in the clearance of atenolol from the body.\n4. The CYP2D6 enzyme is highly polymorphic.\n5. The polymorphism of CYP2D6 can cause inter-individual differences in drug metabolism and response.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the enzyme CYP2D6.",
      "CYP2D6 metabolizes approximately 20-30% of clinically used drugs.",
      "CYP2D6 is involved in the clearance of atenolol from the body.",
      "The CYP2D6 enzyme is highly polymorphic.",
      "The polymorphism of CYP2D6 can cause inter-individual differences in drug metabolism and response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and is more reliant on renal function for its excretion. It is not metabolized by the enzyme CYP2D6.\n2. TRUE\n3. FALSE [correction]: CYP2D6 is not involved in the clearance of atenolol from the body; atenolol's clearance is primarily renal.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Of course, I'd be happy to help! Please provide the questions related to biomedicine, and I will do my best to provide accurate and informative answers.\nAs for the last question, \"LY294002 inhibits the PI3K signaling pathway,\" here are some versions of ExpansionHunter that may be relevant:\n1. LY294002 is a small molecule inhibitor of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. It binds to the p85 subunit of PI3K and prevents the activation of the pathway, leading to the inhibition of downstream signaling events.\n2. LY294002 is a specific inhibitor of the p110α isoform of PI3K, which is primarily involved in the regulation of cell survival and growth. By inhibiting the activity of p110α, LY294002 can suppress the activation of downstream signaling pathways, including the PI3K/Akt and PI3K/mTOR pathways.\n3. LY294002 has been shown to inhibit the growth of various cancer cell lines, including those derived from breast, lung, and colon cancers, by targeting the PI3K signaling pathway. By blocking the activation of this pathway, LY294002 can reduce the proliferation of cancer cells and inhibit their ability to migrate and invade surrounding tissues.\nI hope this helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\nAdamts18 (aggrecan-like EGF-legume factor 1, or ALEF1) is a secreted protein that plays a role in hormone receptor signaling. Specifically, Adamts18 has been shown to interact with the estrogen receptor (ER) and modulate its activity.\nAdamts18 acts as a decoy for the ER, binding to the receptor and preventing it from binding to its ligands, such as estrogen. This can inhibit the activation of downstream signaling pathways that are involved in a variety of cellular processes, including cell proliferation, differentiation, and survival.\nIn addition, Adamts18 has been shown to play a role in the regulation of ER activity in certain tissues, such as the uterus and breast. For example, in the uterus, Adamts18 has been shown to be involved in the regulation of ER-mediated gene expression during the estrous cycle.\nOverall, the role of Adamts18 in hormone receptor signaling is complex and multifaceted, and further research is needed to fully understand its mechanisms of action.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a secreted protein involved in hormone receptor signaling.\n2. It has been shown to interact with the estrogen receptor (ER).\n3. Adamts18 can act as a decoy for the ER, preventing it from binding to its ligands, such as estrogen.\n4. This interaction can inhibit the activation of downstream signaling pathways involved in cell proliferation, differentiation, and survival.\n5. Adamts18 is involved in the regulation of ER-mediated gene expression in the uterus during the estrous cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a secreted protein involved in hormone receptor signaling.",
      "It has been shown to interact with the estrogen receptor (ER).",
      "Adamts18 can act as a decoy for the ER, preventing it from binding to its ligands, such as estrogen.",
      "This interaction can inhibit the activation of downstream signaling pathways involved in cell proliferation, differentiation, and survival.",
      "Adamts18 is involved in the regulation of ER-mediated gene expression in the uterus during the estrous cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: While \"Adamts\" refers to a family of proteins known as A Disintegrin and Metalloproteinase with Thrombospondin Motifs, without specific scientific context or reference it is not possible to confirm whether Adamts18 is involved in hormone receptor signaling or not.\n2. UNKNOWN: The interaction between Adamts18 and estrogen receptor (ER) cannot be confirmed without specific literature references that discuss this interaction.\n3. UNKNOWN: Without any specific scientific studies or data given, it cannot be determined if Adamts18 can act as a decoy for the estrogen receptor (ER).\n4. UNKNOWN: Since the interaction between Adamts18 and the estrogen receptor is not established in the provided statements, the impact on downstream signaling pathways remains undetermined.\n5. UNKNOWN: Again, without specific references to scientific literature, this statement about Adamts18's involvement in regulating ER-mediated gene expression in the uterus during the estrous cycle cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme histone deacetylase (HDAC). It works by binding to the HDAC enzyme and preventing it from deacetylating histone proteins, which are essential components of chromatin. By inhibiting HDAC, thiazovivin increases the acetylation of histones, leading to changes in chromatin structure and gene expression. Specifically, it has been shown to activate the expression of genes involved in cell cycle arrest, apoptosis, and DNA damage repair. In addition, thiazovivin has been shown to inhibit the activity of histone-modifying enzymes, such as histone acetyltransferases (HATs) and histone deacetylases (HDACs), which are involved in regulating chromatin structure and gene expression. Overall, the mode of action of thiazovivin is to alter chromatin structure and gene expression by inhibiting the activity of HDAC enzymes, leading to changes in cellular processes such as cell cycle progression and apoptosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an inhibitor of the enzyme histone deacetylase (HDAC).\n2. Thiazovivin inhibits the deacetylation of histone proteins by binding to the HDAC enzyme.\n3. The inhibition of HDAC by thiazovivin leads to increased acetylation of histones.\n4. Thiazovivin activates the expression of genes involved in cell cycle arrest, apoptosis, and DNA damage repair.\n5. Thiazovivin has been shown to inhibit the activity of histone-modifying enzymes including histone acetyltransferases (HATs) and histone deacetylases (HDACs).",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an inhibitor of the enzyme histone deacetylase (HDAC).",
      "Thiazovivin inhibits the deacetylation of histone proteins by binding to the HDAC enzyme.",
      "The inhibition of HDAC by thiazovivin leads to increased acetylation of histones.",
      "Thiazovivin activates the expression of genes involved in cell cycle arrest, apoptosis, and DNA damage repair.",
      "Thiazovivin has been shown to inhibit the activity of histone-modifying enzymes including histone acetyltransferases (HATs) and histone deacetylases (HDACs)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of histone deacetylase (HDAC), it is actually a ROCK inhibitor (Rho-associated protein kinase inhibitor).\n2. FALSE [correction]: Thiazovivin does not inhibit the deacetylation of histone proteins, as it does not bind to the HDAC enzyme.\n3. FALSE [correction]: Since thiazovivin is not an HDAC inhibitor, it does not lead to increased acetylation of histones due to HDAC inhibition.\n4. UNKNOWN: The effect of thiazovivin on the expression of genes involved in cell cycle arrest, apoptosis, and DNA damage repair may be part of broader cellular effects due to its role as a ROCK inhibitor, but this statement requires specific references to be verified.\n5. FALSE [correction]: Thiazovivin has been shown to be a ROCK inhibitor, not an inhibitor of histone-modifying enzymes such as histone acetyltransferases (HATs) and histone deacetylases (HDACs).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  }
]